Anti-migraine spirocycles

ABSTRACT

The present invention relates to compounds of Formula (I)  
                 
as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is one of several divisional applications that claimspriority to continuation-in-part application Ser. No. 10/729,155 filedDec. 5, 2003, which claims priority from nonprovisional application Ser.No. 10/445,523 filed May 27, 2003, now abandoned, which claims priorityfrom provisional application U.S. Ser. No. 60/386,138 filed Jun. 5,2002, from provisional application U.S. Ser. No. 60/388,617 filed Jun.13, 2002, from provisional application U.S. Ser. No. 60/389,870 filedJun. 19, 2002, from provisional application U.S. Ser. No. 60/393,200filed Jul. 1, 2002, and from provisional application U.S. Ser. No.60/413,534 filed Sep. 25, 2002.

FIELD OF THE INVENTION

The present invention relates to novel small molecule antagonists ofcalcitonin gene-related peptide receptors (“CGRP-receptor”),pharmaceutical compositions comprising them, methods for identifyingthem, methods of treatment using them and their use in therapy fortreatment of neurogenic vasodilation, neurogenic inflammation, migraine,cluster headache and other headaches, thermal injury, circulatory shock,flushing associated with menopause, airway inflammatory diseases, suchas asthma and chronic obstructive pulmonary disease (COPD), and otherconditions the treatment of which can be effected by the antagonism ofCGRP-receptors.

BACKGROUND OF THE INVENTION

Calcitonin gene-related peptide (CGRP) is a naturally occurring37-amino-acid peptide first identified in 1982 (Amara, S. G. et al,Science 1982, 298, 240-244). Two forms of the peptide are expressed(αCGRP and βCGRP) which differ by one and three amino acids in rats andhumans, respectively. The peptide is widely distributed in both theperipheral (PNS) and central nervous system (CNS), principally localizedin sensory afferent and central neurons, and displays a number ofbiological effects, including vasodilation.

When released from the cell, CGRP binds to specific cell surface Gprotein-coupled receptors and exerts its biological action predominantlyby activation of intracellular adenylate cyclase (Poyner, D. R. et al,Br J Pharmacol 1992, 105, 441-7; Van Valen, F. et al, Neurosci Lett1990, 119, 195-8.). Two classes of CGRP receptors, CGRP₁ and CGRP₂, havebeen proposed based on the antagonist properties of the peptide fragmentCGRP(8-37) and the ability of linear analogues of CGRP to activate CGRP₂receptors (Juaneda, C. et al. TiPS 2000, 21, 432-438). However, there islack of molecular evidence for the CGRP₂ receptor (Brain, S. D. et al,TiPS 2002, 23, 51-53). The CGRP₁ receptor has three components: (i) a 7transmembrane calcitonin receptor-like receptor (CRLR); (ii) the singletransmembrane receptor activity modifying protein type one (RAMP 1); and(iii) the intracellular receptor component protein (RCP) (Evans B. N. etal., J Biol. Chem. 2000, 275, 31438-43). RAMP1 is required for transportof CRLR to the plasma membrane and for ligand binding to theCGRP-receptor (McLatchie, L. M. et al, Nature 1998, 393, 333-339). RCPis required for signal transduction (Evans B. N. et al., J Biol. Chem.2000, 275, 31438-43). There are known species-specific differences inbinding of small molecule antagonists to the CGRP-receptor withtypically greater affinity seen for antagonism of the human receptorthan for other species (Brain, S. D. et al, TiPS 2002, 23, 51-53). Theamino acid sequence of RAMP1 determines the species selectivity, inparticular, the amino acid residue Trp74 is responsible for thephenotype of the human receptor (Mallee et al. J Biol Chem 2002, 277,14294-8).

Inhibitors at the receptor level to CGRP are postulated to be useful inpathophysiologic conditions where excessive CGRP receptor activation hasoccurred. Some of these include neurogenic vasodilation, neurogenicinflammation, migraine, cluster headache and other headaches, thermalinjury, circulatory shock, menopausal flushing, and asthma. CGRPreceptor activation has been implicated in the pathogenesis of migraineheadache (Edvinsson L. CNS Drugs 2001; 15(10):745-53; Williamson, D. J.Microsc. Res. Tech. 2001, 53, 167-178; Grant, A. D. Brit. J. Pharmacol.2002, 135, 356-362.). Serum levels of CGRP are elevated during migraine(Goadsby P J, et al. Ann Neurol 1990; 28:183-7) and treatment withanti-migraine drugs returns CGRP levels to normal coincident withalleviation of headache (Gallai V. et al. Cephalalgia 1995; 15: 384-90).Migraineurs exhibit elevated basal CGRP levels compared to controls(Ashina M, et al., Pain. 2000; 86(1-2):133-8.2000). Intravenous CGRPinfusion produces lasting headache in migraineurs (Lassen L H, et al.Cephalalgia. 2002 February; 22(1):54-61). Preclinical studies in dog andrat report that systemic CGRP blockade with the peptide antagonistCGRP(8-37) does not alter resting systemic hemodynamics nor regionalblood flow (Shen, Y-T. et al, J Pharmacol Exp Ther 2001, 298, 551-8).Thus, CGRP-receptor antagonists may present a novel treatment formigraine that avoids the cardiovascular liabilities of activevasoconstriction associated with non-selective 5-HT_(1B/1D) agonists,‘triptans’ (e.g., sumatriptan).

There are various in vivo migraine models known in the literature (seeDe Vries, P. et al, Eur J Pharmacol 1999, 375, 61-74). Some electricallystimulate the trigeminal ganglion and measure dilation of theintracranial vessels which they innervate (e.g., Williamson et al.Cephalalgia 1997 17:518-24). Since facial arteries are also innervatedby the trigeminal nerve, other models study changes in facial blood flowinduced by electrical trigeminal activation (e.g., Escott et al. BrainRes 1995 669:93). Alternatively, other peripheral nerves (e.g.,saphenous) and vascular beds (e.g., abdominal blood flow) are alsostudied (e.g., Escott et al. Br J Pharmacol 1993 110, 772-6). All modelshave been shown to be blocked by pretreatment with the peptideantagonist CGPR(8-37) a peptide fragment that is absent the 1^(st) sevenresidues, or by a small molecule CGRP-receptor antagonist. In someinstances, exogenous CGRP has been used as a stimulus. However, thesemodels are all invasive terminal procedures, and none have shown theclinically important abortive effect of reversing an establishedincrease in artery dilation or increased blood flow using post-treatmentof a CGRP-receptor antagonist. Williamson et al. Cephalalgia 199717:518-24, and Williamson et al. Cephalalgia. 1997 17:525-31: used interalia i.v. CGRP as a stimulus to increase intracranial dural arterydiameter in sodium pentobarb anesthetized rats employing a terminal‘intravital’ procedure that involved drilling to thin the skull and thecreation of a closed cranial window to visualize dural arteries. Theeffect was blocked by pretreatment with i.v. CGRP(8-37). Escott et al.Brain Res 1995 669:93; inter alia drilled into the rat skull and usedbrain electrodes to electrically stimulate the trigeminal ganglion andmeasured laser Doppler facial blood flow in a terminal procedure insodium pentobarb anesthetized rats involving neuromuscular blockade,tracheal intubation and artificial ventilation. The effect was blockedby pretreatment with CGRP(8-37). Escott et al. Br J Pharmacol 1993 110,772-6; inter alia used intradermal (i.d.) CGRP as the stimulus toincrease blood flow in rat abdominal skin of sodium pentobarbanesthetized animals outfitted with cannulated jugular veins foranesthetic and drug delivery. The effect was blocked by pretreatmentwith i.v. CGRP(8-37). Chu et al. Neurosci Lett 2001 310, 169-72 usedinter alia i.d. CGRP as the stimulus in rats and measured laser Dopplerchanges in blood flow in the skin of the back in a terminal method usingsodium pentobarb anesthetized and tracheal cannulated animals; andshowed pretreatment blockade by continuous release of CGRP(8-37) fromsubcutaneously (s.c.) implanted osmotic pumps. Hall et al Br J Pharmacol1995 114, 592-7 and Hall et al Br J Pharmacol 1999 126, 280-4 inter aliaused topical CGRP to increase hamster cheek pouch arteriole diameter,and i.d. CGRP to increase blood flow in rat dorsal skin of sodiumpentobarb anesthetized animals outfitted with cannulated jugular veinsfor anesthetic and drug delivery. The effect was blocked by pretreatmentwith i.v. CGRP(8-37). Doods et al. Br J Pharmacol. 2000February;129(3):420-3 inter alia drilled into the skull of the marmoset(new world monkey) and used brain electrodes to produce electricalstimulation of the trigeminal ganglion and measured facial blood flow inan invasive terminal procedure involving neuromuscular blockade andartificial ventilation of sodium pentobarbital anesthetized primates.Increase in flow was blocked by pre-treatment of a small molecule CGRPantagonist. See also WO 03/272252 Isolated DNA Molecules EncodingHumanized Calcitonin Gene-Related Peptide Receptor, Related Non-HumanTransgenic Animals and Assay Methods. Thus A compound of the presentinvention procedure being inter alia a non-invasive survival model inprimates measuring exogenous CGRP-induced changes in facial blood flowand demonstrating pre- and post-treatment effects of peptide and smallmolecule CGRP antagonists in spontaneously breathing isofluraneanesthetized marmosets who recover from the procedure offers significantadvantages.

A number of non-peptidic, small molecule CGRP-receptor antagonists havebeen recently reported. WO 97/09046 and equivalents disclose inter aliaquinine and quinidine related compounds which are ligands, in particularantagonists, of CGRP-receptor. WO 98/09630 and WO 98/56779 andequivalents disclose inter alia variously substituted, nitrobenzamidecompounds as CGRP-receptor antagonists. WO 01/32649, WO 01/49676, and WO01/32648 and equivalents disclose inter alia a series of4-oxobutanamides and related cyclopropane derivatives as CGRP-receptorantagonists. WO 00/18764, WO 98/11128 and WO 00/55154 and equivalentsdisclose inter alia benzimidazolinyl piperidines as antagonists toCGRP-receptor. Unrelated to CGRP, a series of somatostatin antagonistshave been disclosed in WO 99/52875 and WO 01/25228 and equivalents. Seealso U.S. Pat. No. 6,344,449, U.S. Pat. No. 6,313,097, U.S. Pat. No.6,521,609, U.S. Pat. No. 6,552,043, US 20030181462, US20030191068 and WO03/076432 and related applications. Thus, novel CGRP-receptorantagonists effective for the treatment of neurogenic inflammation,migraine and other disorders would be greatly advantageous.

SUMMARY OF THE INVENTION

Thus according to a first embodiment of the first aspect of the presentinvention are provided compounds of Formula (I)

and pharmaceutically acceptable salts and solvates thereofwherein

V is —N(R¹)(R²) or OR⁴;

-   -   R⁴ is H, C₁₋₆alkyl, C₁₋₄haloalkyl or (C₁₋₄alkylene)₀₋₁R^(4′)    -   R⁴ is C₃₋₇cycloalkyl, phenyl, adamantyl, quinuclidyl,        azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl,        dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl,        pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,        pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl,        thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl,        pyranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,        triazinyl, piperidinyl, piperazinyl, morpholino, thiomorpholino        or dioxolanyl; and        -   R^(4′) is optionally substituted with 1 or 2 of the same or            different substituents selected from the group consisting of            halo, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy,            amino, C₃₋₇cycloalkyl, C₁₋₃alkylamino, C₁₋₃dialkylamino,            (C₁₋₃alkyl)₀₋₂ureido, phenyl and benzyl; and        -   R^(4′) optionally contains 1 or 2 carbonyls wherein the            carbon atom of said carbonyl is a member of the ring            structure of R^(4′);    -   R¹ and R² are each independently L¹, wherein L¹ is selected from        the group consisting of H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,        —C₁₋₆alkylene-amino(C₁₋₃alkyl)₂, C₃₋₇cycloalkyl, phenyl,        azetidinyl, adamantyl, tetrahydrofuranyl, furanyl, dioxolanyl,        thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,        imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,        pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,        isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,        pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,        piperidinyl, piperazinyl, morpholino, thiomorpholino and        dioxolanyl; and        -   R¹ and R² are each optionally and independently substituted            with 1 or 2 of the same or different substituents selected            from the group consisting of halo, cyano, C₁₋₄alkyl,            C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy, amino, C₃₋₇cycloalkyl,            C₁₋₃alkylamino, C₁₋₃dialkylamino, (C₁₋₃alkyl)₀₋₂ureido,            phenyl and benzyl;        -   R¹ and R² optionally and independently contain 1 or 2            carbonyls wherein the carbon atom of said carbonyl is a            member of the heterocycles comprising R¹ and R²;        -   wherein L¹ is optionally and independently interrupted from            the nitrogen to which it is attached by L², wherein L² is            independently C₁₋₃alkylene or C₁₋₃alkylidene; or    -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is azetidinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,            imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl,            azepinyl, diazepinyl, piperazinyl, piperidinyl, morpholino            or thiomorpholino;            -   wherein X is optionally substituted with Y, wherein Y is                dioxolanyl, C₁₋₉alkyl, C₂₋₉alkenyl, C₂₋₉alkynyl,                C₁₋₄alkylamino, C₁₋₄dialkylamino, C₁₋₄alkoxy,                C₃₋₇cycloalkyl, phenyl, azetidinyl, furanyl, thienyl,                pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrrolidinonyl,                imidazolyl, imidazolinyl, imidazolidinyl,                imidazolidinonyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,                azepinyl, diazepinyl, pyridyl, pyrimidinyl,                dihydrobenzimidazolonyl, piperazinyl, piperidinyl,                morpholino, benzothiazolyl, benzisothiazolyl or                thiomorpholino; and wherein X and Y are                -   optionally interrupted with Z, wherein Z is                    —NHC(O)O—, —NHC(O)NH—, NC(O)NH₂, v-NH—,                    —C₁₋₃alkylene-, —C₁₋₃alkylene-,                    —C₁₋₃alkenylene-NHC(O)O—C₁₋₃alkylene-; and                -   optionally and independently substituted with 1 or 2                    of the same or different substituents selected from                    the group consisting of C₁₋₄alkyl, amino,                    C₁₋₃alkylamino, —C₁₋₆alkylene-amino (C₁₋₃alkyl)₂,                    (C₁₋₃alkyl)₀₋₂ureido, phenyl and benzyl;                -   X and Y optionally and independently contain 1 or 2                    carbonyls wherein the carbon atom of said carbonyl                    is a member of the heterocycles comprising X and Y;            -   provided that if X is substituted with Y, and if X and Y                are not interrupted with Z, then                -   X and Y optionally share one carbon atom and                    together form a spirocyclic moiety;

Q is Q′ or Q″;

-   -   wherein        -   Q′ is (S^(y))_(s)R³; and        -   Q″ is NH(S^(y))_(s)R³, NHC(O)(S^(y))_(s)R³,            NHC(O)O(S^(y))_(s)R³, NHC(O)NH(S^(y))_(s)R³, O(S^(y))_(s)R³,            (S^(y))_(s)NHR³, (S^(y))_(s)NHC(O)R³, (S^(y))_(s)NHC(O)OR³,            (S^(y))_(s)NHC(O)NHR³ or (S^(y))_(s)OR³;            -   wherein S^(y) is C₁₋₃alkylene or C₁₋₃alkylidene and s is                0 or 1;

U is CH₂ or NH;

-   -   provided that if Q is Q″, then U is CH₂;

R³ is R^(3a) or R^(3b)

-   -   wherein        -   R^(3a) is        -   (i) a heterocycle having two fused rings with 5 to 7 members            in each of said rings, said heterocycle containing one to            five of the same or different heteroatoms selected from the            group consisting of O, N and S and said heterocycle            optionally containing 1 or 2 carbonyls wherein the carbon            atom of said carbonyl is a member of said fused rings;        -   (ii) a 4 to 6 membered heterocycle containing one to three            of the same or different heteroatoms selected from the group            consisting of O, N and S, optionally containing 1 to 2            carbonyls, wherein the carbon atom of said carbonyl is a            member of said 4 to 6 membered heterocycle;        -   (iii) C₃₋₇cycloalkyl;        -   (iv) carbazolyl, fluorenyl, phenyl, —O-phenyl,            —O—C₁₋₄alklylene-phenyl, or napthyl; or        -   (v) C₁₋₈alkyl, C₂₋₇alkenyl, —C(O)R^(3′), CHC(O)O—R^(3′),            CH(CH₃)C(O)O—R^(3′), —C(O)O—R^(3′) or C₂₋₇alkynyl; and        -   wherein R^(3a) is optionally substituted with 1 to 3 of the            same or different substituents selected from the group            consisting of benzyl, phenyl, —O-phenyl,            —O—C₁₋₃alkylenephenyl, —C₁₋₃alkylene-OC(O)-phenyl, cyano,            amino, nitro, halo, C₁₋₆alkyl, C₁₋₃mono-bi-tri-haloalkyl,            C₁₋₃mono-bi-tri-haloalkyloxy, (C₁₋₃alkyl)₁₋₂amine,            -   —OR^(3′), —C(O)R^(3′), —C(O)O—R^(3′), —O—C(O)R^(3′),                —N(R^(3′))₂, —C(O)N(R^(3′))₂, —N(R^(3′))C(O)(R^(3′))₂,                —N(R^(3′))C(O)N(R^(3′))₂, —N(R^(3′))C(O)OR^(3′),                —O—-C(O)N(R^(3′))₂, —N(R^(3′))SO₂R^(3′), —SO₂N(R^(3′))₂                and —SO₂R^(3′);            -   R^(3′) is H or —C₁₋₆alkyl;            -   provided that if R^(3a) is, —C(O)R^(3′), CHC(O)O—R^(3′),                CH(CH₃)C(O)O—R^(3′) or —C(O)O—R^(3′), then said                -   —C(O)R^(3′), CHC(O)O—R^(3′), CH(CH₃)C(O)O—R^(3′) or                    —C(O)O—R^(3′) are unsubstituted;        -   R^(3b) is R^(3a) but is not phenyl, 1-naphthyl, 2-naphthyl,            1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl,            1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl,            1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl,            1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl,            1H-indazol-3-yl, 1-methyl-1H-indazol-3-yl, benzo[b]fur-3-yl,            benzo[b]thien-3-yl, pyridinyl, quinolinyl or isoquinolinyl;            optionally substituted in the carbon skeleton with mono-,            di- or trisubstituted by fluorine, chlorine or bromine atoms            or by branched or unbranched alkyl groups, C₃₋₈-cycloalkyl            groups, phenylalkyl groups, alkenyl, alkoxy, phenyl,            phenylalkoxy, trifluoromethyl, alkoxycarbonylalkyl,            carboxyalkyl, alkoxycarbonyl, carboxy, dialkylaminoalkyl,            dialkylaminoalkoxy, hydroxy, nitro, amino, acetylamino,            propionylamino, benzoyl, benzoylamino, benzoylmethylamino,            methylsulphonyloxy, aminocarbonyl, alkylaminocarbonyl,            dialkylaminocarbonyl, alkanoyl, cyano, tetrazolyl, phenyl,            pyridinyl, thiazolyl, furyl, trifluoromethoxy,            trifluoromethylthio, trifluoromethylsulphinyl- or            trifluoromethylsulphonyl groups;            -   wherein said substituents may be the same or different                and the above-mentioned benzoyl, benzoylamino- and                benzoylmethylamino groups may in turn additionally be                substituted in the phenyl moiety by a fluorine, chlorine                or bromine atom, or by an alkyl, trifluoromethyl, amino                or acetylamino group;

D is O, NCN or NSO₂C₁₋₃alkyl;

A is C, N or CH;

m and n are independently 0, 1 or 2;

-   -   provided that        -   if m and n are 0, then A is not N;        -   if m is 2, then n is not 2; or        -   if n is 2, then m is not 2;

E is N, CH or C;

p is 0 or 1;

-   -   if p is 1, then G, J and E together form A^(x) or A^(y);        -   A^(x) is a fused heterocycle having two fused rings with 5            to 7 members in each of said rings, said heterocycle            containing one to four of the same or different heteroatoms            selected from the group consisting of O, N and S; and            -   optionally containing 1 or 2 carbonyls wherein the                carbon atom of said carbonyl is a member of said fused                heterocycle;        -   A^(y) is a 4 to 6 membered heterocycle containing one to            three heteroatoms selected from the group consisting of O, N            and S; and            -   optionally containing 1 to 2 carbonyls, wherein the                carbon atom of said carbonyl is a member of said 4 to 6                membered heterocycle;            -   wherein A^(x) and A^(y) are optionally substituted with                C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkyl, cyano,                C₃₋₇cycloalkyl, phenyl, halophenyl, halo, furanyl,                pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl,                imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl,                pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl,                piperazinyl or morpholino; or    -   if p is 0 such that G and J are each attached to A, then A is C,        and G, J and A together form a spirocyclic ring system with said        rings of said system containing A and wherein G, J and A        together are GJA′ or GJA″;        -   wherein            -   GJA′ is A^(x) or A^(y); and            -   GJA″ is A^(x) or A^(y);                -   provided that                -    A^(x) is not a 1,3-diaza-fused heterocycle; and                -    A^(y) is not a 1,3-diaza-heterocycle;

and further provided that

-   -   if Q is Q″, then R³ is R^(3a); and    -   if Q is Q′, then        -   R³ is R^(3b); or        -   R³ is R^(3a), p is 0 and G, J and A together form GJA″.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and R³ isR^(3b).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, R³ is R^(3a)and p is 0 such that G, J and A together form GJA″.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and Q′ is(S^(y))_(s)R³ and s is 0.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and Q′ is(S^(y))_(s)R³, S^(y) is C₁₋₃alkylene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and Q′ is(S^(y))_(s)R³, S^(y) is C₁₋₃alkylidene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and U is CH₂.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, Q′ is(S^(y))_(s)R³, s is 0 and U is CH₂.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, Q′ is(S^(y))_(s)R³, S^(y) is C₁₋₃alkylene, s is land U is CH₂.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, Q′ is(S^(y))_(s)R³, S^(y) is C₁₋₃alkylidene, s is land U is CH₂.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and U is NH.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, Q′ is(S^(y))_(s)R³, s is 0 and U is NH.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, Q′ is(S^(y))_(s)R³, S^(y) is C₁₋₃alkylene, s is land U is NH.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′, Q′ is(S^(y))_(s)R³, S^(y) is C₁₋₃alkylidene, s is land U is NH.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNH(S^(y))_(s)R³.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNH(S^(y))_(s)R³ and s is 0.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNH(S^(y))_(s)R³, S^(y) is C₁₋₃alkylene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNH(S^(y))_(s)R³, S^(y) is C₁₋₃ alkylidene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)(S^(y))_(s)R³.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)(S^(y))_(s)R³ and s is 0.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)(S^(y))_(s)R³, S^(y) is C₁₋₃alkylene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)(S^(y))_(s)R³, S^(y) is C₁₋₃alkylidene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)O(S^(y))_(s)R³.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)O(S^(y))_(s)R³ and s is 0.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)O(S^(y))_(s)R³, S^(y) is C₁₋₃alkylene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)O(S^(y))_(s)R³, S^(y) is C₁₋₃alkylidene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)NH(S^(y))_(s)R³.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)NH(S^(y))_(s)R³ and s is 0.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)NH(S^(y))_(s)R³, Sy is C₁₋₃alkylene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and Q″ isNHC(O)NH(S^(y))_(s)R³, Sy is C₁₋₃alkylidene and s is 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is OR⁴.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is OR⁴ and R⁴ isC₁₋₆alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein

V is —N(R¹)(R²) or OR⁴;

-   -   R⁴ is H, C₁₋₆alkyl, C₁₋₄haloalkyl, (C₁₋₄alkylene)₀₋₁R^(4′)    -   R^(4′) is C₃₋₇cycloalkyl, phenyl, adamantyl, quinuclidyl,        azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl,        dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl,        pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,        pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl,        thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl,        pyranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,        triazinyl, piperidinyl, piperazinyl, morpholino, thiomorpholino        or dioxolanyl; and        -   R^(4′) is optionally substituted with 1 or 2 of the same or            different substituents selected from the group consisting of            halo, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy,            amino, C₃₋₇cycloalkyl, C₁₋₃alkylamino, C₁₋₃dialkylamino,            (C₁₋₃alkyl)₀₋₂ ureido, phenyl and benzyl;        -   R^(4′) optionally contains 1 or 2 carbonyls wherein the            carbon atom of said carbonyl is a member of the ring            structure of R^(4′);    -   R¹ and R² are each independently L¹, wherein L¹ is selected from        the group consisting of H, C₁₋₆alkyl,        —C₁₋₆alkylene-amino(C₁₋₃alkyl)₂, C₃₋₇cycloalkyl, phenyl,        adamantyl, azetidinyl, tetrahydrofuranyl, furanyl, dioxolanyl,        thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,        imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,        pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,        isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,        pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,        piperidinyl, piperazinyl, morpholino, thiomorpholino and        dioxolanyl; and        -   R¹ and R² are each optionally and independently substituted            with 1 or 2 of the same or different substituents selected            from the group consisting of halo, cyano, C₁₋₄alkyl,            C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy, amino, C₃₋₇cycloalkyl,            C₁₋₃alkylamino, C₁₋₃dialkylamino, (C₁₋₃alkyl)₀₋₂ureido,            phenyl and benzyl;        -   R¹ and R² optionally and independently contain 1 or 2            carbonyls wherein the carbon atom of said carbonyl is a            member of the heterocycles comprising R¹ and R²;        -   wherein L¹ is optionally interrupted from the nitrogen to            which it is attached by L², wherein L² is C₁₋₃alkylene; or    -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is azetidinyl, pyrrolinyl, pyrrolidinyl,            imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl,            azepinyl, diazepinyl, piperazinyl, piperidinyl, morpholino            or thiomorpholino;            -   wherein X is optionally substituted with Y, wherein Y is                dioxolanyl, C₁₋₄alkyl, C₁₋₄alkylamino, C₁₋₄dialkylamino,                C₁₋₄alkoxy, C₃₋₇ cycloalkyl, phenyl, azetidinyl,                pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrrolidinonyl,                imidazolyl, imidazolinyl, imidazolidinyl,                imidazolidinonyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,                azepinyl, diazepinyl, pyridyl, pyrimidinyl,                dihydrobenzimidazolonyl, piperazinyl, piperidinyl,                morpholino, benzothiazolyl, benzisothiazolyl or                thiomorpholino;                -   and wherein X and Y are                -    optionally interrupted with Z, wherein Z is                    —NHC(O)O—, —NHC(O)NH—, NC(O)NH₂, —NH—,                    —C₁₋₃alkylene-, —C₁₋₃alkylene-NHC(O)O—C₁₋₃                    alkylene-; and                -    optionally and independently substituted with 1 or                    2 of the same or different substituents selected                    from the group consisting of C₁₋₄alkyl, amino,                    C₁₋₃alkylamino, —C₁₋₆alkylene-amino (C₁₋₃alkyl)₂,                    (C₁₋₃alkyl)₀₋₂ureido, phenyl and benzyl;                -    X and Y optionally and independently contain 1 or 2                    carbonyls wherein the carbon atom of said carbonyl                    is a member of the heterocycles comprising X and Y;                -   provided that if X is substituted with Y, and if X                    and Y are not interrupted with Z, then                -    X and Y optionally share one carbon atom and                    together form a spirocyclic moiety.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R⁴ is H, C₁₋₆alkyl,C₁₋₄haloalkyl or (C₁₋₄alkylene)₀₋₁R^(4′); R^(4′) is C₃₋₇cycloalkyl,phenyl, adamantyl, quinuclidyl, azabicyclo[2.2.1]heptyl, azetidinyl,tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl,pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl,imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl,triazolyl, pyranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,triazinyl, piperidinyl, piperazinyl, morpholino, thiomorpholino ordioxolanyl; and R^(4′) is optionally substituted with 1 or 2 of the sameor different substituents selected from the group consisting of halo,cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy, amino,C₃₋₇cycloalkyl, C₁₋₃alkylamino, C₁₋₃dialkylamino, (C₁₋₃alkyl)₀₋₂ureido,phenyl and benzyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R⁴ is H, C₁₋₆alkyl,C₁₋₄haloalkyl or (C₁₋₄alkylene)₀₋₁R^(4′); R^(4′) is C₃₋₇cycloalkyl,phenyl, adamantyl, quinuclidyl, azabicyclo[2.2.1]heptyl, azetidinyl,tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl,pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl,imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl,triazolyl, pyranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,triazinyl, piperidinyl, piperazinyl, morpholino, thiomorpholino ordioxolanyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R⁴ is H, C₁₋₆alkyl or(C₁₋₄alkylene)₀₋₁R^(4′); R⁴ is C₃₋₇cycloalkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) and

-   -   R¹ and R² are each independently L¹, wherein L¹ is selected from        the group consisting of H, C₁₋₆alkyl,        —C₁₋₆alkylene-amino(C₁₋₃alkyl)₂, C₃₋₇cycloalkyl, phenyl,        azetidinyl, adamantyl, tetrahydrofuranyl, furanyl, dioxolanyl,        thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,        imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,        pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,        isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,        pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,        piperidinyl, piperazinyl, morpholino, thiomorpholino and        dioxolanyl; or    -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is azetidinyl, pyrrolinyl, pyrrolidinyl,            imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl,            azepinyl, diazepinyl, piperazinyl, piperidinyl, morpholino            or thiomorpholino;            -   wherein X is substituted with Y, wherein Y is                dioxolanyl, C₁₋₄alkyl, C₁₋₄alkoxy, C₃₋₇cycloalkyl,                phenyl, azetidinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,                pyrrolidinonyl, imidazolyl, imidazolinyl,                imidazolidinyl, imidazolidinonyl, pyrazolyl,                pyrazolinyl, pyrazolidinyl, azepinyl, diazepinyl,                pyridyl, pyrimidinyl, dihydrobenzimidazolonyl,                piperazinyl, piperidinyl, morpholino, benzothiazolyl,                benzisothiazolyl or thiomorpholino;                -   and wherein X and Y optionally share one carbon atom                    and together form a spirocyclic moiety.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) and

-   -   R¹ and R² are each independently L¹, wherein L¹ is selected from        the group consisting of H, C₁₋₆alkyl, or    -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is piperidinyl or morpholino;            -   wherein X is substituted with Y, wherein Y is                dioxolanyl, C₁₋₄alkyl or piperidinyl;                -   and wherein X and Y optionally share one carbon atom                    and together form a spirocyclic moiety.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) andwherein R¹ and R² are each independently L¹, wherein L¹ is selected fromthe group consisting of H, C₁₋₆alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) andwherein

-   -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is piperidinyl or morpholino;            -   wherein X is substituted with Y, wherein Y is                dioxolanyl, C₁₋₄alkyl or piperidinyl;                -   and wherein X and Y optionally share one carbon atom                    and together form a spirocyclic moiety.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) andwherein

-   -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is piperidinyl;            -   wherein X is substituted with Y, wherein Y is                piperidinyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) andwherein

-   -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is morpholino;            -   wherein X is substituted with Y, wherein Y is C₁₋₄alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) andwherein

-   -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is piperidinyl;            -   wherein X is substituted with Y, wherein Y is C₁₋₄alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein V is —N(R¹)(R²) andwherein

-   -   R¹ and R² together with the nitrogen to which they are attached        form X,        -   wherein X is piperidinyl;            -   wherein X is substituted with Y, wherein Y is                dioxolanyl;            -   and wherein X and Y share one carbon atom and together                form a spirocyclic moiety.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein X and Y are notinterrupted with Z.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein X and Y are notinterrupted with Z; and X and Y share one carbon atom and together forma spirocyclic moiety

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3a).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is aheterocycle having two fused rings with 5 to 7 members in each of saidrings, said heterocycle containing one to five of the same or differentheteroatoms selected from the group consisting of O, N and S.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is aheterocycle having two fused rings with 5 to 7 members in each of saidrings, said heterocycle containing one to five of the same or differentheteroatoms selected from the group consisting of O, N and S and saidheterocycle optionally containing 1 or 2 carbonyls wherein the carbonatom of said carbonyl is a member of said fused rings.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is aheterocycle having two fused rings with 5 to 7 members in each of saidrings, said heterocycle containing one to five of the same or differentheteroatoms selected from the group consisting of O, N and S and saidheterocycle optionally containing 1 or 2 carbonyls wherein the carbonatom of said carbonyl is a member of said fused rings; wherein R^(3a) isoptionally substituted with 1 to 3 of the same or different substituentsselected from the group consisting of benzyl, phenyl, —O-phenyl,—O—C₁₋₃alkylphenyl, —C₁₋₃ alkylene-OC(O)-phenyl, cyano, amino, nitro,halo, C₁₋₃mono-bi-tri-haloalkyl, C₁₋₃ mono-bi-tri-haloalkyloxy,C₁₋₆alkoxy, (C₁₋₃alkyl)₁₋₂amine, —OR^(3′), —C(O)R^(3′), —C(O)O—R^(3′),—O—C(O)R^(3′), —N(R^(3′))₂, —C(O)N(R^(3′))₂, —N(R^(3′))C(O)(R^(3′))₂,—N(R^(3′))C(O)N(R^(3′))₂, —N(R^(3′))C(O)OR^(3′), —O—C(O)N(R^(3′))₂,—N(R^(3′))SO₂R^(3′), —SO₂N(R^(3′))₂ and —SO₂R^(3′); R^(3′) is H or—C₁₋₆alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is a 4 to 6membered heterocycle containing one to three of the same or differentheteroatoms selected from the group consisting of O, N and S.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is a 4 to 6membered heterocycle containing one to three of the same or differentheteroatoms selected from the group consisting of O, N and S, optionallycontaining 1 to 2 carbonyls, wherein the carbon atom of said carbonyl isa member of said 4 to 6 membered heterocycle.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is a 4 to 6membered heterocycle containing one to three of the same or differentheteroatoms selected from the group consisting of O, N and S, optionallycontaining 1 to 2 carbonyls, wherein the carbon atom of said carbonyl isa member of said 4 to 6 membered heterocycle; wherein R^(3a) isoptionally substituted with 1 to 3 of the same or different substituentsselected from the group consisting of benzyl, phenyl, —O-phenyl,—O—C₁₋₃alkylphenyl, —C₁₋₃alkylene-OC(O)-phenyl, cyano, amino, nitro,halo, C₁₋₃mono-bi-tri-haloalkyl, C₁₋₃mono-bi-tri-haloalkyloxy,C₁₋₆alkoxy, (C₁₋₃alkyl)₁₋₂amine, —OR^(3′), —C(O)R^(3′), —C(O)O—R^(3′),—O—C(O)R^(3′), —N(R^(3′))₂, —C(O)N(R^(3′))₂, —N(R^(3′))C(O)(R^(3′))₂,—N(R^(3′))C(O)N(R^(3′))₂, —N(R^(3′))C(O)OR^(3′), —O—C(O)N(R^(3′))₂,—N(R^(3′))SO₂R^(3′), —SO₂N(R^(3′))₂ and —SO₂R^(3′); R^(3′) is H or—C₁₋₆alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) isC₃₋₇cycloalkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) isC₃₋₇cycloalkyl; wherein R^(3a) is optionally substituted with 1 to 3 ofthe same or different substituents selected from the group consisting ofbenzyl, phenyl, —O-phenyl, —O—C₁₋₃alkylphenyl,—C₁₋₃alkylene-OC(O)-phenyl, cyano, amino, nitro, halo,C₁₋₃mono-bi-tri-haloalkyl, C₁₋₃mono-bi-tri-haloalkyloxy, C₁₋₆alkoxy,(C₁₋₃alkyl)₁₋₂amine, —R^(3′), —C(O)R^(3′), —C(O)O—R^(3′), —O—C(O)R^(3′),—N(R^(3′))₂, —C(O)N(R^(3′))₂, —N(R^(3′))C(O)(R^(3′))₂,—N(R^(3′))C(O)N(R^(3′))₂, —N(R^(3′))C(O)OR^(3′), —O—C(O)N(R^(3′))₂,—N(R^(3′))SO₂R^(3′), —SO₂N(R^(3′))₂ and —SO₂R^(3′); R^(3′) is H or—C₁₋₆alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is carbazolyl,fluorenyl, phenyl, —O—phenyl, —O—C₁₋₄alklylene-phenyl, or napthyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is carbazolyl,fluorenyl, phenyl, —O-phenyl, —O—C₁₋₄alklylene-phenyl, or napthyl;wherein R^(3a) is optionally substituted with 1 to 3 of the same ordifferent substituents selected from the group consisting of benzyl,phenyl, —O-phenyl, —O—C₁₋₃alkylphenyl, —C₁₋₃alkylene-OC(O)-phenyl,cyano, amino, nitro, halo, C₁₋₃mono-bi-tri-haloalkyl,C₁₋₃mono-bi-tri-haloalkyloxy, C₁₋₆alkoxy, (C₁₋₃alkyl)₁₋₂amine, —OR^(3′),—C(O)R^(3′), —C(O)O—R^(3′), —O—C(O)R^(3′), —N(R^(3′))₂, —C(O)N(R^(3′))₂,—N(R^(3′))C(O)(R^(3′))₂, —N(R^(3′))C(O)N(R^(3′))₂,—N(R^(3′))C(O)OR^(3′), —O—C(O)N(R^(3′))₂, —N(R^(3′))SO₂R^(3′),—SO₂N(R^(3′))₂ and —SO₂R^(3′); R^(3′) is H or —C₁₋₆alkyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is C₁₋₈alkyl,C₂₋₇alkenyl, —C(O)R^(3′), —C(O)O—R^(3′) or C₂₋₇alkynyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R^(3a) is C₁₋₈alkyl,C₂₋₇alkenyl, —C(O)R^(3′), —C(O)O—R^(3′) or C₂₋₇alkynyl; wherein R^(3a)is optionally substituted with 1 to 3 of the same or differentsubstituents selected from the group consisting of benzyl, phenyl,—O-phenyl, —O—C₁₋₃alkylphenyl, —C₁₋₃alkylene-OC(O)-phenyl, cyano, amino,nitro, halo, C₁₋₃mono-bi-tri-haloalkyl, C₁₋₃mono-bi-tri-haloalkyloxy, 3′C₁₋₆alkoxy, (C₁₋₃alkyl)₁₋₂amine, —OR^(3′), —C(O)R^(3′), —C(O)O—R^(3′),—O—C(O)R^(3′), —N(R^(3′))₂, —C(O)N(R^(3′))₂, —N(R^(3′))C(O)(R^(3′))₂,—N(R^(3′))C(O)N(R^(3′))₂, —N(R^(3′))C(O)OR^(3′), —O—C(O)N(R^(3′))₂,—N(R^(3′))SO₂R^(3′), —SO₂N(R^(3′))₂ and —SO₂R^(3′); R^(3′) is H or—C₁₋₆alkyl; provided that if R^(3a) is —C(O)R^(3′), CHC(O)O—R^(3′),CH(CH₃)C(O)O—R^(3′) or —C(O)O—R^(3′), then said —C(O)R^(3′),CHC(O)O—R^(3′), CH(CH₃)C(O)O—R^(3′) or —C(O)O—R^(3′) are unsubstituted.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3a) andR^(3a) is phenyl, hydroxyphenyl, azetidinyl, napthyl, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynl, dihydroquinolinonyl, hydroquinolinonyl,quinolinyl, dihydroisoquinolinonyl, hydroisoquinolinonyl, isoquinolinyl,dihydroquinazolinonyl, hydroquinazolinonyl, quinazolinyl,dihydroquinoxalinonyl, hydroquinoxalinonyl, quinoxalinyl,benzimidazolyl, indazolyl, dihydrobenzimidazolonyl,hydrobenzimidazolonyl, benzimidazolinyl, dihydro-benzthiazolonyl,hydrobenzthiazolonyl, benzthiazolyl, dihydrobenzoxazolyl,benzotriazolyl, dihydrobenzothiophenonyl, hydrobenzothiophenonyl,benzothienyl, dihydrobenzofuranonyl, hydrobenzofuranonyl, benzofuranyl,benzdioxolanyl, dihydroindolonyl, hydroindolonyl, indolyl, indolizinyl,isoindolyl, indolinyl, indazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,furanyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl,imidazolinyl, imidazolidinyl, pyridyl, purinyl, carbazolyl, pyrimidinyl,piperidinyl, triazolopyrimidinyl, tetrahydropyrazolopyridinyl,piperazinyl or morpholino; optionally substituted as provided in thefirst embodiment of the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3a) andR^(3a) is phenyl, napthyl, indazolyl, benzimidazolinyl,dihydrobenzoxazolyl, benzotriazolyl, benzothienyl, benzdioxolanyl,dihydroindolonyl, indolyl, furanyl, thienyl, pyridyl, purinyl,carbazolyl, piperidinyl, triazolopyrimidinyl,tetrahydropyrazolopyridinyl; optionally substituted as provided in thefirst embodiment of the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3a) andR^(3a) is dihydro-benzthiazolonyl, hydrobenzthiazolonyl, benzthiazolyl,dihydrobenzothiophenonyl, hydrobenzothiophenonyl, benzothienyl,dihydrobenzofuranonyl, hydrobenzofuranonyl, benzofuranyl,dihydroindolonyl, hydroindolonyl, indolyl, indolizinyl, isoindolyl,indolinyl or indazolyl; optionally substituted as provided in the firstembodiment of the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3a) andR^(3a) is dihydrobenzoxazolyl, benzotriazolyl, indolyl, halonitrophenyl,halopyrimidine, halopurinyl, C₁₋₃alkyl-nitroaminopyrimidine,triazolopyrimidinyl, pyridyl, indazolyl, phenyl or benzdioxolanyl;optionally substituted as provided in the first embodiment of the firstaspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3a) andR^(3a) is naphthyl, phenyl-O-phenyl, or thienyl; optionally substitutedas provided in the first embodiment of the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is

1H-Indol-5-yl

1H-Indazol-5-yl

1H-Benzotriazol-5-yl

1,3-Dihydro-indol-2-on-5-yl

3H-Benzooxazol-2-on-6-yl

1,3-Dihydro-benzoimidazol-2-on-5-yl

1-Methyl-1,3-dihydro-benzoimidazol-2-on-6-yl

3,4-Dihydro-1H-quinolin-2-on-6-yl

1,4-Dihydro-benzo[d][1,3]oxazin-2-on-6-yl

3,4-Dihydro-1H-quinazolin-2-on-6-yl

3-Methyl-3,4-dihydro-1H-quinazolin-2-on-6-yl

4H-Benzo[1,4]oxazin-3-on-7-yl

wherein T^(y) is H, C₁₋₄alkyl, F, Cl, Br or nitrile.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is azetidinyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynl,dihydroquinolinonyl, hydroquinolinonyl, dihydroisoquinolinonyl,hydroisoquinolinonyl, dihydroquinazolinonyl, hydroquinazolinonyl,quinazolinyl, dihydroquinoxalinonyl, hydroquinoxalinonyl, quinoxalinyl,benzimidazolyl, 1H-indazol-5-yl, dihydrobenzimidazolonyl,hydrobenzimidazolonyl, benzimidazolinyl, dihydro-benzthiazolonyl,hydrobenzthiazolonyl, benzthiazolyl, dihydrobenzothiophenonyl,hydrobenzothiophenonyl, dihydrobenzofuranonyl, hydrobenzofuranonyl,benzdioxolanyl, dihydrobenzoxazolyl, benzotriazolyl, dihydroindolonyl,hydroindolonyl, indolizinyl, isoindolyl, indolinyl, pyrazolyl,pyrazolinyl, pyrazolidinyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,imidazolinyl, imidazolidinyl, purinyl, carbazolyl, pyrimidinyl,piperidinyl, piperazinyl or morpholino; optionally substituted asprovided in the first embodiment of the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is dihydrobenzimidazolonyl, hydrobenzimidazolonyl,benzimidazolinyl, dihydro-benzthiazolonyl, hydrobenzthiazolonyl,benzthiazolyl, dihydrobenzothiophenonyl, hydrobenzothiophenonyl,dihydrobenzofuranonyl, hydrobenzofuranonyl, 1H-indazol-5-yl,benzdioxolanyl, dihydrobenzoxazolyl, benzotriazolyl, dihydroindolonyl,hydroindolonyl, indolizinyl, isoindolyl, indolinyl, pyrazolyl,pyrazolinyl, pyrazolidinyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,imidazolinyl, imidazolidinyl, purinyl, carbazolyl, pyrimidinyl,piperidinyl, piperazinyl or morpholino; optionally substituted asprovided in the first embodiment of the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is azetidinyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynl,dihydroquinolinonyl, hydroquinolinonyl, dihydroisoquinolinonyl,hydroisoquinolinonyl, dihydroquinazolinonyl, hydroquinazolinonyl,quinazolinyl, dihydroquinoxalinonyl, hydroquinoxalinonyl, quinoxalinyl,benzimidazolyl, 1H-indazol-5-yl, dihydrobenzimidazolonyl,hydrobenzimidazolonyl, benzimidazolinyl, dihydro-benzthiazolonyl,hydrobenzthiazolonyl, benzthiazolyl, dihydrobenzothiophenonyl,hydrobenzothiophenonyl, dihydrobenzofuranonyl, hydrobenzofuranonyl,benzdioxolanyl, dihydrobenzoxazolyl, benzotriazolyl, purinyl,carbazolyl, pyrimidinyl, piperidinyl, piperazinyl or morpholino;optionally substituted as provided in the first embodiment of the firstaspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is azetidinyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynl,dihydroquinolinonyl, hydroquinolinonyl, dihydroisoquinolinonyl,hydroisoquinolinonyl, dihydroquinazolinonyl, hydroquinazolinonyl,quinazolinyl, dihydroquinoxalinonyl, hydroquinoxalinonyl, quinoxalinyl,benzimidazolyl, benzdioxolanyl, dihydrobenzoxazolyl, benzotriazolyl,dihydroindolonyl, hydroindolonyl, 1H-indazol-5-yl, indolizinyl,isoindolyl, indolinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, furanyl,pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl,purinyl, carbazolyl, pyrimidinyl, piperidinyl, piperazinyl ormorpholino; optionally substituted as provided in the first embodimentof the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is benzdioxolanyl, dihydrobenzoxazolyl, benzotriazolyl, purinyl,carbazolyl; optionally substituted as provided in the first embodimentof the first aspect.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein R³ is R^(3b) andR^(3b) is dihydrobenzoxazolyl, benzotriazolyl, indolyl, halonitrophenyl,halopyrimidinyl, halopurinyl, C₁₋₃alkyl-nitroaminopyrimidinyl,triazolopyrimidinyl, pyridyl, 1H-indazol-5-yl, phenyl or benzdioxolanyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and whereinsaid compounds have an absolute configuration of R.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q′ and whereinsaid compounds have an absolute configuration of S.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and whereinsaid compounds have an absolute configuration of R.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein Q is Q″ and whereinsaid compounds have an absolute configuration of S.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein m and n are each 1.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein D is O.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A is C.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A is C.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A is N.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein E is N.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein E is CH.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein E is C.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein said compounds exhibitas described herein a CGRP Binding IC₅₀ of less than 10 nM.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein said compounds exhibitas described herein a CGRP Binding IC₅₀ of less than 100 nM.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein said compounds exhibitas described herein a CGRP Binding IC₅₀ of less than 1000 nM.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 1; and G, J and Etogether form A^(x) or A^(y).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 1; and G, J and Etogether form A.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 1; and G, J and Etogether form A^(y).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(x) is a fusedheterocycle having two fused rings with 5 to 7 members in each of saidrings, said heterocycle containing one to four of the same or differentheteroatoms selected from the group consisting of O, N and S; andoptionally containing 1 or 2 carbonyls wherein the carbon atom of saidcarbonyl is a member of said fused heterocycle.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(x) is a fusedheterocycle having two fused rings with 5 to 7 members in each of saidrings, said heterocycle containing one to four of the same or differentheteroatoms selected from the group consisting of O, N and S.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(x) is a fusedheterocycle having two fused rings with 5 to 7 members in each of saidrings, said heterocycle containing one to four of the same or differentheteroatoms selected from the group consisting of O, N and S and whereinA^(x) is substituted with phenyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(x) is a fusedheterocycle described herein.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(y) is a 4 to 6membered heterocycle containing one to three heteroatoms selected fromthe group consisting of O, N and S; and optionally containing 1 to 2carbonyls, wherein the carbon atom of said carbonyl is a member of said4 to 6 membered heterocycle.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(y) is a 4 to 6membered heterocycle containing one to three heteroatoms selected fromthe group consisting of O, N and S.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(y) is a 4 to 6membered heterocycle containing one to three heteroatoms selected fromthe group consisting of O, N and S; and optionally containing 1 to 2carbonyls, wherein the carbon atom of said carbonyl is a member of said4 to 6 membered heterocycle; and wherein A^(y) is substituted withphenyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein A^(y) is a 4 to 6membered heterocycle described herein.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA′ or GJA″.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA′.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA″.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA′ and GJA′ is A^(x).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA′ and GJA′ is A^(y).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA″ and GJA″ is A^(x).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are GJA″ and GJA″ is A^(y).

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are form a heterocycle selected from the group consistingof imidazolinonyl, imidazolidinonyl, dihydroquinolinonyl,dihydroisoquinolinonyl, dihydroquinazolinonyl, dihydroquinoxalinonyl,dihydrobenzoxazinyl, hydrobenzoxazinyl, dihydrobenzoxazinonyl,dihydrobenzimidazolonyl, dihydrobenzimidazolyl, dihydro-benzthiazolonyl,dihydrobenzthiazolyl, dihydrobenzothiophenonyl, dihydrobenzofuranonyl,dihydroindolonyl, indolinyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl,pyrrolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl andmorpholino; wherein said heterocycle is optionally substituted withC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkyl, cyano, C₃₋₇cycloalkyl, phenyl,halophenyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl,imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,pyridyl, pyrimidinyl, piperidinyl, piperazinyl or morpholino.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are form a heterocycle selected from the group consistingof imidazolinonyl, imidazolidinonyl, dihydroquinolinonyl,dihydroisoquinolinonyl, dihydroquinazolinonyl, dihydroquinoxalinonyl,dihydrobenzoxazinyl, hydrobenzoxazinyl, dihydrobenzoxazinonyl,dihydrobenzimidazolonyl, dihydrobenzimidazolyl, dihydro-benzthiazolonyl,dihydrobenzthiazolyl, dihydrobenzothiophenonyl, dihydrobenzofuranonyl,dihydroindolonyl, indolinyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl,pyrrolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl andmorpholino; wherein said heterocycle is optionally substituted withC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkyl, cyano, C₃₋₇cycloalkyl, phenyl,halophenyl, furanyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl,pyrimidinyl, piperidinyl, piperazinyl or morpholino.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are form a heterocycle selected from the group consistingof imidazolinonyl, imidazolidinonyl, dihydroquinolinonyl,dihydroisoquinolinonyl, dihydroquinazolinonyl, dihydrobenzofuranonyl,dihydroindolonyl, indolinyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl,pyrrolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl andmorpholino; wherein said heterocycle is optionally substituted withC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄haloalkyl, cyano, C₃₋₇cycloalkyl, phenyl,halophenyl, piperazinyl or morpholino.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are form a heterocycle selected from the group consistingof imidazolinonyl, imidazolidinonyl, dihydroquinolinonyl,dihydroisoquinolinonyl, dihydroquinazolinonyl, dihydroquinoxalinonyl,dihydrobenzoxazinyl, hydrobenzoxazinyl, dihydrobenzoxazinonyl,dihydrobenzimidazolonyl, dihydrobenzimidazolyl, dihydro-benzthiazolonyl,dihydrobenzthiazolyl, dihydrobenzothiophenonyl, dihydrobenzofuranonyl,dihydroindolonyl, indolinyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl,pyrrolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl andmorpholino.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are form a heterocycle selected from the group consistingof imidazolinonyl, imidazolidinonyl, dihydroquinolinonyl,dihydroisoquinolinonyl, dihydroquinazolinonyl, dihydroquinoxalinonyl,dihydrobenzoxazinyl, hydrobenzoxazinyl and dihydrobenzoxazinonyl.

According to another embodiment of the first aspect of the presentinvention are provided compounds according to the first embodiment ofthe first aspect of the present invention wherein p is 0 such that G andJ are each attached to A, then G, J and A together form a spirocyclicring system with said rings of said system containing A and wherein G, Jand A together are form a heterocycle selected from the group consistingof imidazolinonyl, imidazolidinonyl, dihydroquinolinonyl,dihydroisoquinolinonyl, dihydroquinazolinonyl, dihydroquinoxalinonyl anddihydrobenzoxazinyl.

According to various embodiments of a second aspect of the presentinvention are provided pharmaceutical compositions comprising compoundsof Formula (I) as defined herein.

According to various embodiments of a third aspect of the presentinvention are provided methods of treating inflammation (particularlyneurogenic inflammation), headache (particularly migraine), pain,thermal injury, circulatory shock, diabetes, Reynaud's syndrome,peripheral arterial insufficiency, subarachnoid/cranial hemorrhage,tumor growth, flushing associated with menopause and other conditionsthe treatment of which can be effected by the antagonism of the CGRPreceptor by the administration of pharmaceutical compositions comprisingcompounds of Formula (I) as defined herein.

According to various embodiments of a fourth aspect of the presentinvention are uses of the compounds of the present invention selectedfrom the group consisting of (a) immune regulation in gut mucosa (b)protective effect against cardiac anaphylactic injury (c) stimulating orpreventing interleukin-1b(IL-1b)-stimulation of bone resorption (d)modulating expression of NK1 receptors in spinal neurons and (e) airwayinflammatory diseases and chronic obstructive pulmonary diseaseincluding asthma. See (a) Calcitonin Receptor-Like Receptor Is Expressedon Gastrointestinal Immune Cells. Hagner, Stefanie; Knauer, Jens;Haberberger, Rainer; Goeke, Burkhard; Voigt, Karlheinz; McGregor, GerardPatrick. Institute of Physiology, Philipps University, Marburg, Germany.Digestion (2002), 66(4), 197-203; (b) Protective effects of calcitoningene-related peptide-mediated evodiamine on guinea-pig cardiacanaphylaxis. Rang, Wei-Qing; Du, Yan-Hua; Hu, Chang-Ping; Ye, Feng; Tan,Gui-Shan; Deng, Han-Wu; Li, Yuan-Jian. School of PharmaceuticalSciences, Department of Pharmacology, Central South University, Xiang-YaRoad 88, Changsha, Hunan, Naunyn-Schmiedeberg's Archives of Pharmacology(2003), 367(3), 306-311; (c) The experimental study on the effectcalcitonin gene-related peptide on bone resorption mediated byinterleukin-1. Lian, Kai; Du, Jingyuan; Rao, Zhenyu; Luo, Huaican.Department of Orthopedics, Xiehe Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Peop. Rep. China.Journal of Tongji Medical University (2001), 21(4), 304-307, (d)Calcitonin gene-related Peptide regulates expression of neurokinin1receptors by rat spinal neurons. Seybold V S, McCarson K E, MermelsteinP G, Groth R D, Abrahams L G. J. Neurosci. 2003 23 (5): 1816-1824.epartment of Neuroscience, University of Minnesota, Minneapolis, Minn.55455, and Department of Pharmacology, Toxicology, and Therapeutics,University of Kansas Medical Center, Kansas City, Kans. 66160 (e)Attenuation of antigen-induced airway hyperresponsiveness inCGRP-deficient mice. Aoki-Nagase, Tomoko; Nagase, Takahide; Oh-Hashi,Yoshio; Shindo, Takayuki; Kurihara, Yukiko; Yamaguchi, Yasuhiro;Yamamoto, Hiroshi; Tomita, Tetsuji; Ohga, Eijiro; Nagai, Ryozo;Kurihara, Hiroki; Ouchi, Yasuyoshi. Department of Geriatric Medicine,Graduate School of Medicine, University of Tokyo, Tokyo, Japan. AmericanJournal of Physiology (2002), 283(5,Pt. 1), L963-L970; (f) Calcitoningene-related peptide as inflammatory mediator. Springer, Jochen;Geppetti, Pierangelo; Fischer, Axel; Groneberg, David A. ChariteCampus-Virchow, Department of Pediatric Pneumology and Immunology,Division of Allergy Research, Humboldt-University Berlin, Berlin,Germany. Pulmonary Pharmacology & Therapeutics (2003), 16(3), 121-130;and (g) Pharmacological targets for the inhibition of neurogenicinflammation. Helyes, Zsuzsanna; Pinter, Erika; Nemeth, Jozsef,Szolcsanyi, Janos. Department of Pharmacology and Pharmacotherapy,Faculty of Medicine, University of Pecs, Pecs, Hung. Current MedicinalChemistry: Anti-Inflammatory & Anti-Allergy Agents (2003), 2(2), 191-218all incorporated by reference herein.

According to various embodiments of a fifth aspect of the presentinvention are provided combinations of the compounds of the presentinvention with one or more agents selected from the group consisting ofCOX-2 inhibitors, NSAIDS, aspirin, acetaminophen, triptans, ergotamineand caffeine for the treatment of migraine.

According to a sixth aspect of the present invention are provided invivo non-terminal methods of identifying anti-migraine compounds.

According to the first embodiment of the sixth aspect of the presentinvention is provided an in vivo non-terminal method of identifyinganti-migraine compounds comprising administering a CGRP-receptor agonistto a mammal in an amount capable of inducing an increase in blood flow,followed by administering a test compound in an amount capable ofreversing said CGRP-induced increase in blood flow, wherein said mammalis a transgenic mammal with humanized RAMP1 having Trp74 or a mammalendogenously expressing RAMP1 having Trp74.

According to another embodiment of the sixth aspect of the presentinvention is provided an in vivo non-terminal method of identifyinganti-migraine compounds comprising administering to a mammal a testcompound prior to the delivery of a CGRP-receptor agonist wherein saidCGRP-receptor agonist is administered in an amount capable of inducingan increase in blood flow and wherein said test compound is administeredin an amount capable of suppressing said CGRP-induced increase in bloodflow, wherein said mammal is a transgenic mammal with humanized RAMP1having Trp74 or a mammal endogenously expressing RAMP1 having Trp74.

According to another embodiment of the sixth aspect of the presentinvention is provided an in vivo non-terminal method of identifyinganti-migraine compounds comprising administering to a mammal aCGRP-receptor agonist in an amount capable of inducing an increase inperipheral artery diameter, followed by administering a test compound inan amount capable of reversing said CGRP-induced increase in peripheralartery diameter, wherein said mammal is a transgenic mammal withhumanized RAMP1 having Trp74 or a mammal endogenously expressing RAMP1having Trp74.

According to another embodiment of the sixth aspect of the presentinvention is provided an in vivo non-terminal method of identifyinganti-migraine compounds comprising administering to a mammal a testcompound prior to the delivery of a CGRP-receptor agonist wherein saidCGRP-receptor agonist is administered in an amount capable of inducingan increase in peripheral artery diameter and wherein said test compoundis administered in an amount capable of suppressing said CGRP-inducedincrease in peripheral artery diameter, wherein said mammal is atransgenic mammal with humanized RAMP1 having Trp74 or a mammalendogenously expressing RAMP1 having Trp74.

According to other embodiments of the sixth aspect of the presentinvention are provided in vivo non-terminal methods of identifyinganti-migraine compounds as described herein wherein said blood flow isfacial blood flow.

According to other embodiments of the sixth aspect of the presentinvention are provided in vivo non-terminal methods of identifyinganti-migraine compounds as described herein wherein said mammalendogenously expressing RAMP1 having Trp74 is a non-human primate.

According to other embodiments of the sixth aspect of the presentinvention are provided in vivo non-terminal methods of identifyinganti-migraine compounds as described herein wherein said mammalendogenously expressing RAMP1 having Trp74 is man.

According to other embodiments of the sixth aspect of the presentinvention are provided in vivo non-terminal methods of identifyinganti-migraine compounds as described herein wherein said mammalendogenously expressing RAMP1 having Trp74 is a non-human primate andsaid non-human primate is a marmoset.

According to other embodiments of the sixth aspect of the presentinvention are provided in vivo non-terminal methods of identifyinganti-migraine compounds as described herein wherein said anti-migrainecompounds are CGRP-receptor antagonists.

Other embodiments of the present invention may comprise a suitablecombination of two or more of the embodiments and/or aspects disclosedherein.

Yet other embodiments of the present invention may comprise a suitablesubset of an embodiment and/or aspect disclosed herein.

Still yet other embodiments and aspects of the invention will beapparent according to the description provided below.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Schild Analysis.

Dose response of CGRP stimulated cAMP production in the absence (filledsquares) and presence (all others) of increasing concentrations(left-to-right) of the CGRP antagonist Example 2. Inset is Schild plotof log dose ratio minus 1 (Y-axis) against log concentration of theantagonist Example 2 (X-axis): Slope=0.94, K_(b)=0.16 nM.

FIG. 2. Direct Validation of Facial Blood Flow as Surrogate forIntracranial Artery Dilation in the Rat.

Intravenous delivery of i.v. hαCGRP induces comparable percent increases(100-120% of baseline) in rat middle meningeal artery diameter and ratfacial blood flow (left and right striped bars, respectively).Pretreatment with the peptide antagonist CGRP(8-37) produces a 50%inhibition of subsequent i.v. hαCGRP administration for both measures(filled bars). Intracranial artery diameter and facial blood flow weremeasured concurrently in each animal (n=5 rats). Data are mean±sem *p<0.05, ** p<0.01 vs corresponding hαCGRP alone.

FIG. 3. Dose-Response for hαCGRP in Non-Human-Primate Laser DopplerFacial Blood Flow.

Delivery of hαCGRP induces dose-dependent increase in laser Dopplerfacial blood flow in non-human primates (e.g., common marmoset). Animals(n=6) received increasing doses of hαCGRP at 30 min intervals. Data arepeak % change from baseline±sem, with each animal serving as its owncontrol.

FIG. 4. Inhibitition of CGRP-Induced Changes in Non-Human Primate FacialBlood Flow.

The novel CGRP antagonist Example 2 (filled bars) delivered prior tohαCGRP (striped bar), dose-dependently inhibits the CGRP-inducedincrease in laser Doppler facial blood flow. Vehicle (open bar) waswithout effect. Data are mean±sem (n=5-6 primates per group). *p<0.05compared CGRP alone.

FIG. 5. Effect of CGRP Antagonist on Non-Human Primate Blood Pressure.

In contrast to the dose-dependent inhibition of primate facial bloodflow (see FIG. 4.), Example 2 has negligible effect on blood pressure(parallel studies in separate animals, n=6). Animals received repeatdoses of Example 2 at 20 min intervals. BP data are mean±sem over 20 minperiod measured by arm cuff

DETAILED DESCRIPTION OF THE INVENTION

The description of the invention herein should be construed in congruitywith the laws and principals of chemical bonding. For example, it may benecessary to remove a hydrogen atom in order accommodate a substitutentat any given location.

As used herein, “heterocyclic” or “heterocycle” includes cyclic moietiescontaining one or more heteroatoms, (e.g., O, N or S) said heterocyclesinclude those that are aromatic and those that are not, i.e.,“alicyclic”, unless otherwise specified.

As used herein, the term “fused bicyclic system” when describing forexample a 5.6-fused bicyclic system containing 1 to 4 nitrogen atomsincludes aromatic and alicyclic systems, e.g. indolizine, indole,isoindole, 3H-indole, indoline, indazole or benzimidazole.

If a substitutent is named generically, then any and all species of thatgenus comprise that aspect of the invention. For example, a substituentgenerically named as “pyrrolonyl” (the radical of “pyrrolone”, a pyrrolehaving a carbonyl) includes pyrrol-2-onyls wherein the carbonyl isadjacent to the nitrogen and pyrrol-3-onyls wherein the carbonyl andnitrogen have an intervening methylene.

Similarly, the present invention comprises that a substituent may beattached at any and all suitable points of attachment on saidsubstituent unless otherwise specified.

However, it is also understood that the compounds encompassed by thepresent invention are those that are chemically stable, i.e.,heteroalicyclic substituents of the present invention should not beattached in such a way that a heteroatom in said heteroalicyclicsubstituent is alpha to a point of attachment wherein said point ofattachment is also a heteroatom.

An embodiment or aspect which depends from another embodiment or aspect,will describe only the variables having values or provisos that differfrom the embodiment or aspect from which it depends. If for example adependent embodiment only addresses R², then the variables and provisosnot related to R² should reflect that of the embodiment from which itdepends.

If a variable is quantified with a value of zero, then a bond attachingsaid variable should no longer be represented.

As used herein, “alkylene” means a divalent alkane, i.e., an alkanehaving two hydrogen atoms removed from said alkane (said hydrogenremoved from two different carbon atoms when said alkane contains morethan one carbon atom), e.g.,

—CH₂CH₂CH₂—.

As used herein, “alkylidene” means an alkane having two hydrogen atomsremoved from one carbon atom in said alkane, e.g.,

It should be understood that the alternating double bond designations inthe six-membered ring of the 5,6-membered fused structure represented inFormula (I) are relative and represent the delocalized π orbitalelectrons of said ring.

As used herein, “aryl” or “ar-” includes phenyl or napthyl.

As used herein, “heterocyclic” or “heterocyclo” includes both heteroaryland heteroalicyclic.

As used herein, “halo” or “halogen” includes fluoro, chloro, bromo andiodo and further means one or more of the same or different halogens maybe substituted on a respective moiety.

Unless specificied otherwise, acyclic hydrocarbons such as alkyl,alkoxy, alkenyl and alkynyl may be branched or straight chained.

It is to be understood that the present invention may include any andall possible stereoisomers, geometric isomers, diastereoisomers,enantiomers, anomers and optical isomers, unless a particulardescription specifies otherwise.

As used herein, “Trp74”, means that the 74^(th) residue in RAMP1 istryptophan (Mallee et al. J Biol Chem 2002, 277, 14294-8) incorporatedby reference herein.

As used herein “anti-migraine compound” includes any compound, peptideor peptide fragment (modified or unmodified) capable of reversing orattenuating CGRP-receptor mediated vasodilation, (e.g., CGRP-receptorantagonists).

As used herein “test compound” includes any compound, peptide or peptidefragment (modified or unmodified) being tested to determine if it iscapable of reversing or attenuating CGRP-receptor mediated vasodilation,(e.g., putative CGRP-receptor antagonists).

As used herein, “CGRP-receptor agonist” includes any compound, peptideor peptide fragment (modified or unmodified) capable of inducingCGRP-receptor mediated vasodilation particularly by example αCGRP orβCGRP; other members of the calcitonin family, e.g, adrenomedullin;N-terminal CGRP fragments, e.g, CGRP(1-12) CGRP(1-15) and CGRP(1-22);C-terminal amide (NH2) versions of CGRP e.g., CGRP(1-8+NH2),CGRP(1-13+NH2) or CGRP(1-14+NH2); and non-naturally occurring CGRPanalogues e.g., [Ala¹ψ(CH2NH)Cys²]hCGRP which contains a pseudopeptidebond between Ala¹ and Cys². See Maggi C A, Rovero P, Giuliani S,Evangelista S, Regoli D, Meli A. Biological activity of N-terminalfragments of calcitonin gene-related peptide. Eur J Pharmacol. 1990 Apr.10; 179(1-2):217-9; Qing X, Wimalawansa S J, Keith I M. SpecificN-terminal CGRP fragments mitigate chronic hypoxic pulmonaryhypertension in rats. Regul Pept. 2003 Jan. 31; 110(2):93-9; and DennisT, Fournier A, St Pierre S, Quirion R. Structure-activity profile ofcalcitonin gene-related peptide in peripheral and brain tissues.Evidence for receptor multiplicity. J Pharmacol Exp Ther. 1989 November;251(2):718-25 incorporated by reference herein.

The compounds of this invention may exist in the form ofpharmaceutically acceptable salts. Such salts may include addition saltswith inorganic acids such as, for example, hydrochloric acid andsulfuric acid, and with organic acids such as, for example, acetic acid,citric acid, methanesulfonic acid, toluenesulfonic acid, tartaric acidand maleic acid. Further, in case the compounds of this inventioncontain an acidic group, the acidic group may exist in the form ofalkali metal salts such as, for example, a potassium salt and a sodiumsalt; alkaline earth metal salts such as, for example, a magnesium saltand a calcium salt; and salts with organic bases such as atriethylammonium salt and an arginine salt. In the case of a sublingualformulation a saccharin salt or maleate salt may be of particularbenefit. The compounds of the present invention may be hydrated ornon-hydrated.

The compounds of this invention can be administered in such oral dosageforms as tablets, capsules (each of which includes sustained release ortimed release formulations), pills, powders, granules, elixirs,tinctures, suspensions, syrups and emulsions. The compounds of thisinvention may also be administered intravenously, intraperitoneally,subcutaneously, or intramuscularly, all using dosage forms well known tothose skilled in the pharmaceutical arts. The compounds can beadministered alone, but generally will be administered with apharmaceutical carrier selected upon the basis of the chosen route ofadministration and standard pharmaceutical practice. Compounds of thisinvention can also be administered in intranasal form by topical use ofsuitable intranasal vehicles, or by transdermal routes, usingtransdermal skin patches. When compounds of this invention areadministered transdermally the dosage will be continuous throughout thedosage regimen.

While dosing from 0.01 mg/kg to 30 mg/kg is envisaged for compounds ofthe present invention, the dosage and dosage regimen and scheduling of acompounds of the present invention must in each case be carefullyadjusted, utilizing sound professional judgment and considering the age,weight and condition of the recipient, the route of administration andthe nature and extent of the disease condition. In accordance with goodclinical practice, it is preferred to administer the instant compoundsat a concentration level which will produce effective beneficial effectswithout causing any harmful or untoward side effects.

Synthesis

Compounds of the present invention may be synthesized according to thegeneral schemas provided below. Variables provided in the schema beloware defined in accordance with the description of compounds of the aboveFormula unless otherwise specified. The compounds of the presentinvention may be prepared according to Scheme 1 or Scheme 2. It may alsobe possible to use variations of said schemes to prepare the compoundsof the present inventions, said variations known to those of ordinaryskill in the art.

The synthesis described in Scheme 1 begins with a compound of FormulaII, which is an amino acid with a protected amino terminus. Common aminoprotecting groups (PG) include BOC, CBZ, and FMOC and their addition andremoval are well known in the field. The carboxylic acid moiety of aFormula II compound is coupled with an amine of formula HNR¹R² usingstandard peptide coupling reagents to form an amide of Formula III. Theamino protecting group is removed resulting in a Formula IV compound.This compound is then coupled with an amine of Formula V (see below) ina mixed urea or urea isostere reaction, generating a Formula I compound.Mixed urea formation is conveniently carried using phosgene,disuccinimidyl carbonate, carbonyl diimidazole or other equivalents.Formation of urea isosteres, such as cyanoguanidines andsulfonylguanidines, are known in the literature.

The synthesis described by Scheme 2 begins with a compound of Formula V,which is an amino acid with a protected carboxylate terminus. Theprotection is generally a methlyl ester, but other protecting groupssuch as ethyl, t-butyl, and benzyl esters may also be used. The FormulaV compound is coupled with an amine of Formula VIII (see below) in amixed urea or urea isostere reaction, as above, to generate a Formula VIcompound. The Formula VI compound is converted to a free acid compoundof Formula VII which is then coupled with an amine of Formula HNR¹R² togenerate a Formula I compound.

The synthesis described by Scheme 3 begins with a compound of FormulaVII from Scheme 2. The Formula V compound is coupled with an alcohol,R⁴—OH. Such ester-forming reactions are well known in the art and can becarried out, for example, with carbodiimide coupling agents such asN,N-dicyclohexylcarbodiimide. In addition, it is often advantageous,especially for esters of secondary and tertiary alcohols, to includeadditives that accelerate acylations such as 4-dimethylaminopyridne.

Preparation of HNR¹R² and Formula VIII Amines

Formula VIII and HNR¹R² amines are commercially available, made byliterature methods or described herein.

Preparation of Formula II and Formula V Amino Acids

Formula II and Formula V amino acids may be commercially available ormade as described in Scheme 4.

The synthesis described in Scheme 4 begins with an aldehyde of FormulaIX, which is reacted with a glycine phosphonate of Formula X in aWadsworth-Emmons coupling reaction. The compound of Formula X isdeprotonated with a base such as diazabicycloundecene ortetramethylguanidine or other organic or inorganic bases well known inthe art. The double bond of the resulting Formula XI compound is reducedto give compounds of Formula XII. Reduction can be carried out to giveeither a racemate or by use of a stereoselective catalyst to give eitherenantiomer of Formula XII. Such reductions can result from transferhydrogenation from hydrogen donors such as formic acid orcyclohexadiene, or hydrogenation using gaseous hydrogen, both in thepresence of a suitable catalyst. Compounds of Formula II are prepared byacid or base hydrolysis of the ester. Compounds of Formula V areprepared by removal of the protecting group (PG) using methods wellknown in the art.

Other amino acid derivatives of Formula XII may be prepared as shown inScheme 5.

Where, for the purposes of Scheme 5, compounds of Formula XIV arenucleophilic compounds such as amines or alcohols that are able toparticipate in a Michael Reaction with a compound of Formula XIII asshown.

Other compounds of Formula I may be prepared according to Scheme 6 orScheme 7. It may also be possible to use variations of said schemes toprepare the compounds of the present inventions, said variations knownto those of ordinary skill in the art.

The synthesis described in Scheme 6 begins with commercially availableor synthesized aldehydes. The two-carbon homologation and double-bondreduction which are well-known in the literature and lead to compoundsof Formula XV. Some Formula XV compounds are also commercially availableand others may be prepared by other methods well known in the art.Preparation of compounds of Formula XVI and XVII are known in theliterature as substartes and products of the Evans chiral asymmetricsynthesis. Hydrolysis leads to compounds of Formula XVIII. As withcompounds of Formula VII in Scheme 2, these carboxylic acids can reactwith amines of formula R¹R²NH to afford compounds of Formula XIX usingwell known amide coupling protocols. Hydrolysis of the tert-butyl esterleads to compounds of Formula XX, which can be further coupled withcompounds of Formula VIII to afford Formula I compounds.

Scheme 7 also starts with commercially available or synthesizedaldehydes. These are reacted with dimethyl succinate in the presence ofbases to give compounds of Formula XXI. The double bond of the FormulaXXI compound is reduced to give compounds of Formula XXII. Reduction canbe carried out to give either a racemate or by use of a stereoselectivecatalyst to give either enantiomer of Formula XXII. Such reductions canresult from transfer hydrogenation from hydrogen donors such as formicacid or cyclohexadiene, or hydrogenation using gaseous hydrogen, both inthe presence of a suitable catalyst. Amide coupling with amines ofFormula VIII lead to compounds of Formula XXIII using well known amidesynthesis protocols. Hydrolysis of methyl ester leads to Formula XXIVcompounds, which are further coupleded with various amines or alcoholsto give amides of Formula I and esters of Formula I, respectively.

Compounds of Formula I may also be prepared according to Scheme 8.

The synthesis described in Scheme 8 begins with a commercially availableN-tert-butyloxycarbonyl-L-aspartic acid benzyl ester. Differentlyprotected aspartic acid derivatives may also be used for syntheticconvenience. The beta carboxyl group is coupled with amines of FormulaVIII using standard peptide coupling protocols. Thealpha-carboxylprotecting group of the Formula XXV compound is removed byhydrogenolysis giving compounds of Formula XXVI. These are furthercoupled with amines of the formula HNR¹R² to give compounds of formulaXXVII. The amino protecting group is removed by treatment with strongacids such as trifluoroacetic acid or hydrogen chloride in organicsolvents. The resulting compounds of Formula XXVIII are then reactedwith a variety of electrophilic reagents to generate Formula Icompounds. For example, they can be coupled with halo-aromatic compoundsusing known methods involving heating at various temperatures or bycatalysis with transition metals such as palladium or copper, either instoichiometric amounts or as catalysts. They can also react with variousaldehydes or ketones under reductive alkylation conditions, welldescribed in the art. They can also react with isocyanates, acylchlorides, or carbamoyl chlorides to generate urea, amide or carbamatederivatives, respectively. It is understood that the sequence of themodifications described above can be changed depending on the selectionof protecting groups and the order of their removal.

Compounds of Formula I may also be prepared according to Scheme 9.

The synthesis described in Scheme 9 begins with an imine of FormulaXXIX, prepared by condensation of ethyl glyoxalate and amines of formulaR³—NH₂. These are reacted with 2-tert-butoxy-2-oxoethylzinc chloride togive compounds of Formula XXX. Treatment with strong acids removes thetert-butyl ester protecting group to give free acids of Formula XXXIwhich are coupled to amines of Formula VIII to yield compounds ofFormula XXXII. The ethyl ester is hydrolyzed with a metal hydroxide saltor aqueous base to give free alpha-acids of Formula XXXIII. These, inturn are coupled with amines of the formula HNR¹R² to give compounds offormula I.

Ureidoamide Intermediates and Examples

General. ¹H- and ¹³C-NMR spectra were run on a Bruker 500 or 300 MHzinstrument and chemical shifts were reported in ppm (δ) with referenceto tetramethylsilane (δ=0.0). All evaporations were carried out underreduced pressure. Unless otherwise stated, LC/MS analyses were carriedout on a Shimadzu instrument using a YMC C18 column (3×50 mm) employinga 2 min linear gradient of 0% to 100% solvent B in A in a 3 min run. ForLC/MS and for Shimadzu Preparative HPLC system, Solvent A-was: 10%methanol/90% water/0.1% trifluoroacetic acid, and solvent B was 90%methanol/10% water/0.1% trifluoroacetic acid with a UV detector set at220 nm.

1-Benzyl-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′(1′H)-quinazoline

Polyphosphoric acid (113 g) was heated to 100-110° C. and stirred while1-benzyl-piperidin-4-one (9.27 ml, 50 mmol) was added. Immediatelyafterwards, phenyl urea (9.55 g, 70. mmol) was added in portions smallenough to avoid excessive foaming. The mixture was heated at 150-160° C.overnight. Water (200 mL) was then added slowly to the mixture which hadbeen allowed to cool to 100-110° C. (at lower temperatures the mixturebecomes too viscous to stir). The resulting solution was neutralizedwith ION NaOH to ca. pH 8, and then extracted wth chloroform. Theorganic phase was dried over magnesium sulfate and then concentrated togive the crude product which was purified by flash column chromatographyon silica gel (6:4 ethyl acetate/hexanes) to give the desired product(9.0 g, 58%). Mass spec.: 308.25 (MH)⁺.

2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′(1 ′H)-quinazoline

To a solution of1-benzyl-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′(1′H)-quinazoline(1.00 g) in degassed methanol (50 ml) and 6N hydrochloric acid (2.0 ml)was added 10% palladized charcoal (150 mg). The mixture was shaken on aParr apparatus under an atmosphere of hydrogen at 60 psi overnight.LC/MS showed incomplete reaction. More 10% palladized charcoal (200 mg)was added, and the mixture was shaken for 2 more days. At that point,all starting material was consumed. The mixture was filtered and thefiltrate concentrated to give 531 mg of the desired compound (64%). Massspec.: 218.12 (MH)⁺.

4-Amino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester

To a well stirred solution of 4-oxo-piperidine-1-carboxylic acidtert-butyl ester (9.0 g, 45.3 mmol) in methanol was added ammoniumchloride (2.66 g, 49.8 mmol) at room temperature and stirred for 1 h.Sodium cyanide (2.44 g, 49.8 mmol) was added and stirring was continuedfor additional 16 h. The reaction mixture was quenched with 5% aqueoussodium hydrogencarbonate (50 mL), diluted with water, and the methanolremoved by rotary evaporation. The cyanoamine was extracted withmethylene chloride (3×100 mL), dried over sodium sulfate, and thesolvents evaporated to give the desired compound as an oil in 91% yield.¹H-NMR (300 MHz, CDCl₃): δ 3.95-3.90 (m, 1H), 3.80-3.71 (m, 1H),3.42-3.06 (m, 2H), 2.04-1.94 (m, 1H), 1.71-1.50 (m, 3H). Mass spec.: 226(MH)⁺.

2-Phenyl-1,3,8-triaza-spiro[4.5]dec-1-en-4-one, hydrochloride

To a solution of 4-amino-4-cyano-piperidine-1-carboxylic acid tert-butylester (1.0 g, 4.44 mmol) in methylene chloride (30 mL) was addedtriethylamine (1.24 mL, 8.88 mol), followed by benzoyl chloride (936 mg,6.66 mmol). After 30 min, 4-(dimethylamino)pyridine (40 mg, 0.33 mmol)was added and stirring continued for additional 12 h. The reactionmixture was then quenched with 1M sodium hydroxide (10 mL), diluted withethyl acetate (100 mL), and separated. The organic layer was washedsequentially with 1M sodium hydroxide (40 mL), aqueous sodiumhydrogencarbonate (50 mL), and brine (50 mL) then dried over sodiumsulfate. The desired product,4-benzoylamino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester wasobtained in 90% yield through crystallization using 30% ethyl acetate inhexane as a solvent.

To a solution of 4-benzoylamino-4-cyano-piperidine-1-carboxylic acidtert-butyl ester (1.3 g, 4 mmol) in ethanol (10 mL) was added 6M sodiumhydroxide (1.5 mL) followed by 30% hydrogen peroxide. The reactionmixture was then refluxed for 3 h. The reaction mixture was then dilutedwith water (30 mL), and the ethanol removed. The residue was dilutedwith ethyl acetate (100 mL). The organic phase was washed with brine (30mL) and dried over sodium sulfate. The desired product,4-oxo-2-phenyl-1,3,8-triaza-spiro[4.5]dec-1-ene-8-carboxylic acidtert-butyl ester was obtained in 80% yield through crystallization from30% ethyl acetate in hexane. The tert-butyl ester was then dissolved inmethylene chloride (5 mL) and a saturated solution of hydrogen chloridein dioxane (25 mL) was added. After 2 h, the solvent was removed to give2-phenyl-1,3,8-triaza-spiro[4.5]dec-1-en-4-one, hydrochloride as whitepowder in 95% yield. ¹H-NMR (500 MHz, CD₃OD): δ 8.23-8.21 (m, 2H),7.96-7.92 (m, 1H), 7.79-7.76 (m, 2H), 3.68-3.64 (m, 3H), 3.31-3.30 (m,1H), 2.47-2.44 (m, 4H). Mass spec.: 230 (MH)⁺.

5-Formyl-indazole-1-carboxylic acid tert-butyl ester

A methylene chloride (2 mL) solution of di-tert-butyldicarbonate (388mg, 1.78 mmol) was added dropwise at room temperature to a solution of1H-indazole-5-carbaldehyde (273 mg, 1.87 mmol), 4-dimethylaminopyridine(114 mg, 0.94 mmol), and triethylamine (0.26 mL, 1.87 mmol) in methylenechloride (10 mL). The resulting bright yellow solution was stirred atroom temperature for 16 h. Solvents were removed in vacuo and theresidue was subjected to flash chromatography with silica gel (25 g) andethyl acetate/hexanes (1:1) containing 1% triethylamine as eluent toafford the title compound as a brownish yellow liquid (414 mg, 90%).¹H-NMR (CDCl₃, 500 MHz) δ 10.08 (s, 1H), 8.38 (s, 1H), 8.34 (s, 1H),8.25 (d, J=8.5 Hz, 1H), 8.04 (d, J=8.8 Hz, 1H), 1.71 (s, 9H). ¹³CNMR(CDCl₃, 125 MHz) δ 191.8, 149.0, 142.5, 140.6, 133.0, 128.3, 126.4,125.8, 115.3, 85.7, 27.8.

5-(2-Benzyloxycarbonylamino-2-methoxycarbonyl-vinyl)-indazole-1-carboxylicacid tert-butyl ester

A solution of N-(benzyloxycarbonyl)-α-phosphonoglycine trimethyl ester(5.50 g, 16.6 mmol) and tetramethylguanidine (1.99 mL, 15.9 mmol) inanhydrous tetrahydrofuran (50 mL) was stirred at −78° C. for 20 min. Tothis was added a solution of 5-formyl-indazole-1-carboxylic acidtert-butyl ester (3.72 g, 15.1 mmol) in tetrahydrofuran (25 mL) slowlyvia syringe over 10 min. The reaction mixture was stirred at −78° C. for4 h and then allowed to warm to room temperature overnight. The solventwas evaporated and the resulting residue subjected to flash columnchromatography on silica gel (1:2 ethyl acetate/hexane) giving the titlecompound as a white foam (5.77 g, 85%). ¹H-NMR (CDCl₃, 500 MHz) δ 8.09(d, J=9.0 Hz, 1H), 8.08 (s, 1H), 7.84 (s, 1H), 7.67 (d, J=9.0 Hz, 1H),7.47 (s, 1H), 7.30 (br s, 5H), 6.43 (br s, 1H), 5.09 (s, 2H), 3.84 (s,3H), 1.72 (s, 9H). Mass spec.: 452 (MH)⁺.

(±)-5-(2-Amino-2-methoxycarbonyl-ethyl)-indazole-1-carboxylic acidtert-butyl ester

A mixture of5-(2-benzyloxycarbonylamino-2-methoxycarbonyl-vinyl)-indazole-1-carboxylicacid tert-butyl ester (524 mg, 1.16 mmol) and 10% palladium on carbon(60 mg) in methanol (20 mL) was shaken for 4.5 h under 50 psi hydrogengas using a Parr hydrogenator. The reaction mixture was evacuated andpurged with nitrogen. Then, the reaction mixture was filtered through apad of celite and the pad was rinsed with several portions of methanol.The methanol filtrate was evaporated to give the title compound (351 mg,95%). ¹H-NMR (CDCl₃, 500 MHz) δ 8.12-8.10 (m, 2H), 7.55 (br s, 1H), 7.37(dd, J=8.9, 1.5 Hz, 1H), 3.77-3.75 (m, 1H), 3.70 (s, 3H), 3.19 (dd,J=13.7, 5.5 Hz, 1H), 2.99 (dd, J=13.7, 8.0 Hz, 1H), 1.72 (s, 9H). Massspec.: 320 (MH)⁺.

(±)-5-(2-Methoxycarbonyl-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-ethyl)-indazole-1-carboxylicacid tert-butyl ester

A solution of 5-(2-amino-2-methoxycarbonyl-ethyl)-indazole-1-carboxylicacid tert-butyl ester (307 mg, 0.96 mmol), N,N-disuccinimidyl carbonate(246 mg, 0.961 mmol), and N,N-diisopropylethylamine (0.67 mL, 3.84 mmol)in methylene chloride was stirred for 30 min at room temperature.3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (238 mg, 1.03 mmol) wasadded and the reaction mixture was stirred at room temperature for 16 h.The solvent was evaporated and the residue subjected to flashchromatography using methylene chloride/methanol/triethylamine (93:5:2)as eluent, giving the product (259 mg, 47%). ¹H-NMR (CDCl₃, 300 MHz) δ8.13-8.10 (m, 2H), 7.48 (br s, 1H), 7.31 (dd, J=8.8, 1.6 Hz, 1H), 7.16(t, J=8.0 Hz, 1H), 7.05 (d, J=7.0 Hz, 1H), 6.94 (t, J=7.7 Hz, 1H), 6.82(s, 1H), 6.66 (d, J=8.0 Hz, 1H), 4.98 (d, J=7.7 Hz, 1H), 4.87-4.81 (m,1H), 4.58-4.49 (m, 1H), 4.26 (s, 2H), 4.05-3.97 (m, 2H), 3.74-3.67 (m,4H), 3.29-3.23 (m, 2H), 2.93-2.84 (m, 2H), 1.76-1.62 (m, 1H), 1.70 (s,9H), 1.48-1.42 (m, 1H). Mass spec.: 577 (MH)⁺.

2-Trimethylsilanyl-ethanesulfonyl chloride

Sulfuryl chloride (43 ml, 539 mmol) was added in 3 min to a clearsolution of triphenylphosphine (129 g, 490 mmol) in methylene chloride(200 mL) at 0° C. in a flame-dried three-neck round bottom flask. Afterstirring at 0° C. for 5 min, the ice-water bath was removed and sodium2-trimethylsilylethanesulfonate (50 g, 245 mmol) was added in portionsover 10 min. The resulting white suspension was stirred at roomtemperature for 16 h, then it was filtered through a pad of celite. Thefiltrate was concentrated to ca 50 mL, ethyl acetate/hexanes (1:3, 1000mL) and celite (40 g) were added. The mixture was stirred at roomtemperature for 15 min and filtered through a pad of celite. Solventswere removed in vacuo and the residue was loaded onto a pre-wettedcolumn with silica gel (300 mL) using 1:3 ethyl acetate/hexanes as theeluent. Solvents were removed and the title compound was obtained as alight tan liquid (41.9 g, 85%). If not used immediately, the finalproduct should be stored under nitrogen in the freezer or refrigeratorto minimize decomposition. ¹H-NMR (CDCl₃, 500 MHz) δ 3.61-3.57 (m, 2H),1.32-1.27 (m, 2H), 0.10 (s, 9H).

1-(2-Trimethylsilanyl-ethanesulfonyl)-1H-indole-5-carboxylic acid ethylester

A solution of 1H-indole-5-carboxylic acid ethyl ester (10.31 g, 58.8mmol) in dimethylformamide (50 mL) was added dropwise at 0° C. to amixture of sodium hydride (1.83 g, 76.4 mmol) in dimethylformamide (150mL). The resulting mixture was stirred at 0° C. for 30 min, then asolution of 2-trimethylsilanyl-ethanesulfonyl chloride (17.7 g, 88.2mmol) in dimethylformamide (100 mL) was added slowly at 0° C. to theabove mixture. After 2 h, sat. aqueous ammonium chloride (200 mL) wasadded, and the mixture was extracted with ethyl acetate (300 mL). Afterseparation, the aqueous layer was extracted with ethyl acetate (2×150mL). The combined organic layers were washed with brine (3×150 mL), anddried over anhydrous sodium sulfate. Solvents were removed in vacuo andthe residue was subjected to flash chromatography on silica gel using1:1.5 methylene chloride/hexanes as eluent to afford the title compoundas a white solid (15.8 g, 79%). ¹H-NMR (CDCl₃, 500 MHz) δ 8.36 (d, J=1.5Hz, 1H), 8.03 (dd, J=9.0, 2.0 Hz, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.50 (d,J=3.5 Hz, 1H), 6.75 (d, J=3.5 Hz, 1H), 3.94 (s, 3H), 3.21-3.18 (m, 2H),0.84-0.80 (m, 2H), −0.06 (s, 9H). ¹³C-NMR (CDCl₃, 125 MHz) δ 167.3,137.7, 130.3, 128.3, 125.9, 125.5, 124.0, 112.8, 108.3, 52.2, 51.2,10.1, −2.1. Mass spec. 354.12 (MH)⁺.

Similarly Prepared:

1-(2-Trimethylsilanyl-ethanesulfonyl)-1H-indazole-5-carboxylic acidethyl ester

¹H-NMR (CDCl₃, 500 MHz) δ 8.51 (s, 1H), 8.34 (s, 1H), 8.21 (dd, J=8.9,1.5 Hz, 1H), 8.12 (d, J=9.2 Hz, 1H), 3.96 (s, 3H), 3.42-3.39 (m, 2H),0.86-0.82 (m, 2H), −0.02 (s, 9H). ¹³C-NMR (CDCl₃, 125 MHz) δ 166.4,143.1, 141.2, 130.1, 126.5, 125.0, 124.2, 112.9, 52.5, 51.3, 9.8, −2.1.Mass spec. 355.13 (MH)⁺.

[1-(2-Trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-methanol

A solution of diisobutylaluminum hydride (82.9 mL, 1M in toluene, 82.9mmol) was added slowly at 0° C. to the solution of1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indole-5-carboxylic acid ethylester (8.81 g, 25.9 mmol) in toluene (200 mL). After it was stirred at0° C. for 45 min, the reaction was quenched by the addition of methanol(26 mL), pulverized sodium sulfate decahydrate (194 g) and celite (26mL). The mixture was warmed up to room temperature in 1 h and filteredthrough a pad of celite. Solvents were removed in vacuo to afford thetitle compound as a very viscous liquid, which solidified upon cooling.A white solid (8.08 g, 100% yield). ¹H-NMR (CDCl₃, 500 MHz) δ 7.87 (d,J=8.5 Hz, 1H), 7.62 (s, 1H), 7.44 (d, J=3.7 Hz, 1H), 7.35 (dd, J=8.6,1.5 Hz, 1H), 6.66 (d, J=3.7 Hz, 1H), 4.79 (s, 2H), 3.18-3.14 (m, 2H),1.73 (s, 1H), 0.85-0.82 (m, 2H), −0.06 (s, 9H). Mass spec. 312.14 (MH)⁺.

[1-(2-Trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-methanol

A solution of1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazole-5-carboxylic acidethyl ester (azeotropically dried with toluene (2×), 5.77 g, 16.9 mmol)in tetrahydrofuran (50 mL) was added at 0° C. to a mixture of lithiumborohydride (3.68 g, 169 mmol) in tetrahydrofuran (100 mL). The mixturewas warmed up to room temperature and stirred for 14 h. It was cooled to0° C. and lithium borohydride (3.5 g) was added. The mixture was warmedup to room temperature and stirred for 14 h. It was re-cooled to 0° C.and sat. aqueous ammonium chloride (25 mL) was added slowly. Theresulted white suspension was filtered through a pad of celite, solventswere removed and the residue was subjected to flash chromatography usingethyl acetate/hexanes (1:1.5) with 1% triethylamine to afford the titlecompound as a white solid (3.8 g, 72%). ¹H-NMR (CD₃OD, 500 MHz) δ 8.41(s, 1H), 8.04 (d, J=8.5 Hz, 1H), 7.85 (s, 1H), 7.61 (dd, J=8.5, 1.2 Hz,1H), 4.76 (s, 2H), 3.49-3.46 (m, 2H), 0.76-0.72 (m, 2H), −0.03 (s, 9H);¹³C-NMR (CD₃OD, 125 MHz) δ 141.2, 140.9, 138.3, 129.2, 125.8, 119.6,112.7, 63.8, 50.8, 9.9, −3.2. Mass spec. 313.12 (MH)⁺.

1-(2-Trimethylsilanyl-ethanesulfonyl)-1H-indole-5-carbaldehyde

A solution of[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-methanol (2.1 g,6.74 mmol) in methylene chloride (30 mL) was added at 0° C. to a mixtureof activated manganese dioxide (22 g, azeotropically dried with toluene(2×)) and methylene chloride (70 mL) in a 500 mL round bottom flask. Thereaction mixture was stirred at 0° C. for 30 min and filtered through apad of celite. Solvents were removed in vacuo to afford the titlecompound as a white solid (1.8 g, 80%). ¹H-NMR (CDCl₃, 500 MHz) δ 10.06(s, 1H), 8.15 (s, 1H), 8.01 (d, J=8.6 Hz, 1H), 7.87 (dd, J=8.6, 1.5 Hz,1H), 7.54 (d, J=3.4 Hz, 1H), 6.80 (d, J=3.6 Hz, 1H), 3.24-3.20 (m, 2H),0.86-0.82 (m, 2H), −0.06 (s, 9H). ¹³C-NMR (CDCl₃, 125 MHz) δ 191.9,138.5, 132.3, 130.7, 128.8, 125.3, 125.1, 1134.6, 108.4, 51.4, 10.2,−2.1. Mass spec. 310.12 (MH)⁺.

Similarly Prepared:

1-(2-Trimethylsilanyl-ethanesulfonyl)-1H-indazole-5-carbaldehyde

Mass spec. 311.10 (MH)⁺.

2-Benzyloxycarbonylamino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-acrylicacid methyl ester

1,1,3,3-Tetramethylguanidine (0.68 mL, 5.43 mmol) was added at roomtemperature to a solution of N-(benzyloxycarbonyl)-α-phophonoglycinetrimethyl ester (1.88 g, 5.69 mmol) in tetrahydrofuran (40 mL). Themixture was stirred at room temperature for 15 min and cooled to −78°C., and a solution of1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indole-5-carbaldehyde (1.6 g,5.17 mmol) in tetrahydrofuran (15 mL) was added slowly. The resultingreaction mixture was stirred at −78° C. for 2 h and then warmed to roomtemperature in 3 h. Solvents were removed in vacuo and the residue wassubjected to flash chromatography on silica gel using methylenechloride/hexanes (1:1.5) with 1% triethylamine as eluent to afford thetitle compound as a 92:8 Z/E mixture (determined by integration ofCO₂CH₃, for Z isomer at 3.79 ppm, and E isomer at 3.65 ppm). For the Zisomer: ¹H-NMR (CD₃CN, 500 MHz) δ 7.96 (s, 1H), 7.91 (d, J=8.5 Hz, 1H),7.66 (d, J=8.5 Hz, 1H), 7.56 (d, J=3.7 Hz, 1H), 7.51 (s, 1H), 7.43-7.35(m, 5H), 7.67 (d, J=3.7 Hz, 1H), 5.16 (s, 2H), 3.79 (s, 3H), 3.42-3.38(m, 2H), 0.87-0.83 (m, 2H), −0.04 (s, 9H). Mass spec. 515.20 (MH)⁺.

Similarly Prepared:

2-Benzyloxycarbonylamino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-acrylicacid methyl ester

Flash chromatography on silica gel using methylene chloride containing1% triethylamine as eluent afforded the title compound as a 95:5 Z/Emixture (determined by the integration of —CH═C(CO₂Me)(NHCBz), 3.72 g,92%). For the Z isomer: ¹H-NMR (CD₃CN, 500 MHz) δ 8.39 (s, 1H), 8.12 (s,1H), 8.03 (d, J=8.8 Hz, 1H), 7.84 (dd, J=8.8, 1.2 Hz, 1H), 7.51 (s, 1H),7.43-7.35 (m, 5H), 5.14 (s, 2H), 3.81 (s, 3H), 3.51-3.47 (m, 2H),0.83-0.79 (m, 2H), −0.02 (s, 9H). Mass spec. 516.18 (MH)⁺.

(±)-2-Amino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-propionicacid methyl ester

To a flame dried 500 mL of round bottom flask was added2-benzyloxycarbonylamino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-acrylicacid methyl ester (2.24 h, 4.36 mmol), methanol (100 mL) and 10%palladium on charcoal (0.52 g). The mixture was degassed and purged withhydrogen five times. It was stirred at room temperature for 1 h andfiltered through a pad of celite. Solvents were removed and the residuewas subjected to flash chromatography using ethyl acetate/hexanes (1:1and 2:1) containing 1% triethylamine to afford the tile compound as acolorless viscous liquid (1.27 g, 76%), which solidified upon cooling.¹H-NMR (CD₃CN, 500 MHz) δ 7.82 (d, J=8.2 Hz, 1H), 7.51-7.49 (m, 2H),7.22 (dd, J=8.6, 1.5 Hz, 1H), 6.72 (d, J=3.7 Hz, 1H), 3.70 (dd, J=7.3,6.1 Hz, 1H), 3.65 (s, 3H), 3.38-3.34 (m, 2H), 3.08 (dd, J=13.4, 5.8 Hz,1H), 2.95 (dd, J=13.4, 7.3 Hz, 1H), 0.82-0.79 (m, 2H), −0.05 (s, 9H).¹³C-NMR(CDCl₃, 125 MHz) δ 176.0, 134.4, 133.4, 131.1, 127.9, 126.4,122.4, 113.1, 107.7, 56.6, 51.7, 50.8, 41.3, 10.1, −2.7. Mass spec.383.16 (MH)⁺.

Similarly Prepared:

(±)-2-Amino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester

¹H-NMR (CD₃CN, 500 MHz) δ 8.34 (s, 1H), 7.98 (d, J=8.6 Hz, 1H), 7.69 (s,1H), 7.46 (dd, J=8.6, 1.5 Hz, 1H), 3.71 (dd, J=7.3, 5.8 Hz, 1H), 3.65(s, 3H), 3.48-3.44 (m, 2H), 3.12 (dd, J=13.7, 5.8 Hz, 1H), 2.97 (dd,J=13.7, 7.6 Hz, 1H), 0.83-0.79 (m, 2H), −0.02 (s, 9H). ¹³C-NMR (CDCl₃,125 MHz) δ 175.9, 141.1, 140.5, 134.6, 131.5, 126.0, 122.2, 112.7, 56.4,51.8, 51.1, 40.9, 9.8, −2.6. Mass spec. 384.15 (MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester

In a glove bag that was subjected to 3 vacuum/nitrogen purge cycles, anAIRFREE® (Schlenk) reaction flask equipped with stir bar was chargedwith (−)-1,2-bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium (I) trifluoromethylsulfonate (123 mg, 0.17 mmol, 5 mol %),sealed with a rubber septum, and removed from the glove bag. The2-benzyloxycarbonylamino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-acrylicacid methyl ester (1.75 g, 3.40 mmol) was weighed into a second AIRFREE®(Schlenk) reaction flask equipped with stir bar and sealed with a rubberseptum. After 3 vacuum/nitrogen purge cycles, it was dissolved in amixture of anhydrous methanol (75 mL) and anhydrous methylene chloride(15 mL). Both solvents were deoxygenated prior to addition by spargingwith nitrogen for at least 1 h. Once in solution, the mixture was againsubjected to 3 vacuum/nitrogen purge cycles. The dehydroamino acidsolution was introduced into the AIRFREE® (Schlenk) reaction flaskcontaining the catalyst via cannula. The reaction mixture was subjectedto 5 vacuum/hyrogen purge cycles before opening the flask to 1 atm. ofhydrogen (balloon). After 16 h, the reaction mixture was purged with 3vacuum/nitrogen purge cycles. The solvent was evaporated and the residuewas subjected to column chromatography (gradient 1:4 ethylacetate/hexanes to 1:2 ethyl acetate/hexanes) to give 1.5 g (85%) of thetitle compound as a white solid with 98.4% ee as determined by HPLCanalysis using a Chirocel OD column with 80% hexane/20% ethanol aseluent (retention times: 13.9 min for title compound and 11.2 min forS-enantiomer). ¹H-NMR (CDCl₃, 300 MHz) δ 8.17 (s, 1H), 7.98 (d, J=8.8Hz, 1H), 7.47 (s, 1H), 7.35-7.25 (m, 6H), 5.29-5.24 (m, 1H), 5.08 (dd,J=19.0, 12.1 Hz, 2H), 4.73-4.67 (m, 1H), 3.73 (s, 3H), 3.38-3.32 (m,2H), 3.29 (dd, J=14.2, 5.6 Hz, 1H), 3.19 (dd, J=13.9, 5.6 Hz, 1H),0.91-0.85 (m, 2H), −0.02 (s, 9H). Mass spec.: 518 (MH)⁺.

(R)-2-Amino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester

A mixture of(R)-2-Benzyloxycarbonylamino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester (1.24 g, 2.40 mmol) and 10% palladium on carbon (124mg) in methanol (50 mL) was agitated for 2 h under 50 psi hydrogen usinga Parr hydrogenator. The reaction mixture was purged with 3vacuum/nitrogen purge cycles. The reaction mixture was then filteredthrough a pad of celite and the pad was rinsed with several portions ofmethanol. The methanol filtrate was evaporated to give 879 mg (96%) ofthe title compound as a sticky gum. ¹H-NMR (CDCl₃, 300 MHz) δ 8.21 (s,1H), 8.02 (d, J=8.8 Hz, 1H), 7.59 (s, 1H), 7.38 (d, J=8.8 Hz, 1H), 3.72(s, 3H), 3.38-3.32 (m, 2H), 3.21 (dd, J=13.9, 5.1 Hz, 1H), 2.98 (dd,J=13.9, 7.9 Hz, 1H), 0.91-0.85 (m, 2H), −0.02 (s, 9H). Mass spec.: 384(MH)⁺

7-Methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazole-5-carbaldehyde

To a suspension of 7-methylindazole 5-aldehyde (3.0 g, 18.7 mmol) inmethylene chloride (150 mL) was added triethylamine (7.83 mL, 56.2 mL, 3equiv) followed by dropwise addition of neat2-trimethylsilanyl-ethanesulfonyl chloride (5.60 g, 28.1 mmol, 1.5equiv). The mixture gradually became homogeneous and was allowed to stirat room temperature for 16 h. The solution was concentrated to a minimumamount of methylene chloride and then subjected to flash columnchromatography on silica gel (1:4 ethyl acetate/hexanes) to give 4.7 g(77%) of the product as a pale yellow solid. ¹H-NMR (CDCl₃, 300 MHz) δ9.98 (s, 1H), 8.77 (s, 1H), 8.09 (s, 1H), 7.64 (s, 1H), 3.64-3.58 (m,2H), 2.65 (s, 3H), 0.88-0.82 (m, 2H), 0.01 (s, 9H).

2-Benzyloxycarbonylamino-3-[7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-acrylicacid methyl ester

To a solution of N-(benzyloxycarbonyl)-α-phosphonoglycine trimethylester (4.93 g, 14.9 mmol, 1.1 equiv) in anhydrous tetrahydrofuran (75mL) was added tetramethylguanidine (1.78 mL, 1.05 equiv). The mixturewas stirred at room temperature under nitrogen for 5 min and was thencooled to −78° C. After stirring for 15 min at −78° C., a solution of7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazole-5-carbaldehydein tetrahydrofuran (25 mL) was added. The reaction mixture was allowedto slowly warm to room temperature overnight. Although the reaction wasincomplete, the solvent was evaporated. The resulting residue wasdissolved in ethyl acetate and washed with 1M sulfuric acid. The organiclayer was separated, dried over magnesium sulfate, filtered andevaporated. Flash column chromatography (1:4 ethyl acetate/hexanes) gave2.66 g (37%) of the product as white glass foam. ¹H-NMR (CDCl₃, 300 MHz)δ 8.48 (s, 1H), 7.62 (s, 1H), 7.38-7.25 (m, 7H), 6.48 (bs, 1H), 5.10 (s,2H), 3.83 (s, 3H), 3.58-3.52 (m, 2H), 2.51 (s, 3H), 0.89-0.83 (m, 2H),0.02 (s, 9H). Mass spec.: 530 (MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-[7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-propionicacid methyl ester

In a glove bag that was subjected to 3 vacuum/nitrogen purge cycles, anAIRFREE® (Schlenk) reaction flask equipped with stir bar was chargedwith (−)-1,2-bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium (I) trifluoromethylsulfonate (259 mg, 0.36 mmol, 9 mol-%),sealed with a rubber septum, and removed from the glove bag. The2-benzyloxycarbonylamino-3-[7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-acrylicacid methyl ester (2.03 g, 3.83 mmol) was weighed into a second AIRFREE®(Schlenk) reaction flask equipped with stir bar and sealed with a rubberseptum. After 3 vacuum/nitrogen purge cycles, it was dissolved inanhydrous methanol (80 mL, deoxygenated prior to addition by spargingwith nitrogen for at least 1 h). Once in solution, it was againsubjected to 3 vacuum/nitrogen purge cycles. The dehydroamino acidsolution was transferred via cannula to the AIRFREE® (Schlenk) reactionflask containing the catalyst. The reaction mixture was purged with 5vacuum/hydrogen purge cycles before opening the flask to a balloon ofhydrogen (1 atm). After 2.5 h, the reaction mixture was purged with 3vacuum/nitrogen purge cycles. The solvent was evaporated and the residuewas subjected to column chromatography (gradient 1:4 ethylacetate/hexanes to 1:2 ethyl acetate/hexanes) to give 1.4 g (68%;ee=99.2%) of the title compound as a white solid. ¹H-NMR (CDCl₃, 300MHz) δ 8.43 (s, 1H), 7.34 (s, 5H), 7.19 (s, 1H), 6.87 (s, 1H), 5.24 (d,J=8.1 Hz, 1H), 5.08 (dd, J=18.3, 12.1 Hz, 2H), 4.67 (dd, J=13.9, 6.2 Hz,1H), 3.73 (s, 3H), 3.57-3.51 (m, 2H), 3.16 (dd, J=14.0, 5.9 Hz, 1H).3.06 (dd, J=13.9, 6.6 Hz, 1H), 2.55 (s, 3H), 0.89-0.83 (m, 2H), 0.01 (s,9H). ¹³C-NMR (CDCl₃, 75 MHz) δ 172.0, 155.7, 151.7, 136.2, 132.2, 129.8,129.5, 128.6, 128.4, 128.2, 125.1, 121.1, 118.1, 67.1, 54.7, 52.5, 51.1,38.6, 17.1, 9.7, −2.0. Mass spec.: 532 (MH)⁺.

(R)-2-Amino-3-[7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-propionicacid methyl ester

2-Benzyloxycarbonylamino-3-[7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-propionicacid methyl ester, (1.35 g, 2.54 mmol) and 10% palladium on carbon (135mg) in methanol (40 mL) were agitated for 3.0 h under 55 psi hydrogenusing a Parr apparatus. The reaction mixture was purged with 3vacuum/nitrogen purge cycles. The reaction mixture was then filteredthrough a pad of celite and the pad was rinsed with several portions ofmethanol. The methanol filtrate was evaporated to give the titlecompound (1.01 g, quantitative yield) as a sticky gum. ¹H-NMR (CDCl₃,300 MHz) δ 8.45 (s, 1H), 7.29 (s, 1H), 6.97 (s, 1H), 3.79-3.73 (m, 1H),3.73 (s, 3H), 3.56-3.50 (m, 2H), 5.12 (dd, J=13.5, 5.12 Hz, 1H), 4.85(dd, J=13.5, 8.1 Hz, 1H), 2.58 (s, 3H), 0.87-0.81 (m, 2H), 0.01 (s, 9H).¹³C-NMR (CDCl₃, 75 MHz) δ 175.5, 151.8, 133.7, 129.9, 129.4, 125.0,121.3, 117.9, 55.5, 52.1, 51.1, 41.4, 17.1, 9.8, −2.1. Mass spec.: 398(MH)⁺.

(R)-3-[7-Methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

A mixture of2-amino-3-[7-methyl-2-(2-trimethylsilanyl-ethanesulfonyl)-2H-indazol-5-yl]-propionicacid methyl ester (500 mg, 1.26 mmol), N,N-diisopropylethylamine (0.66mL, 3.77 mmol) and disuccinimidylcarbonate (322 mg, 1.26 mmol) werestirred together in methylene chloride (20 mL) for 30 min at roomtemperature. Then, 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (444mg, 1.35 mmol) was added and the reaction mixture was allowed to stirovernight at room temperature. The solvent was evaporated and theresidue was subjected to flash column chromatography (1:4 acetone/ethylacetate) to give 490 mg (60% yield) of the title compound as a whitesolid. ¹H-NMR (CDCl₃, 300 MHz) δ 8.47 (s, 1H), 7.23 (s, 1H), 7.19-7.14(m, 1H), 7.04 (d, J=7.3 Hz, 1H), 6.97-6.93 (m, 2H), 6.77 (s, 1H), 6.65(d, J=7.7 Hz, 1H), 4.99 (d, J=7.3 Hz, 1H), 4.81 (dd, J=13.5, 6.2 Hz,1H), 4.58-4.46 (m, 1H), 4.27 (s, 2H), 4.10-3.98 (m, 2H), 3.73 (s, 2H),3.57-3.51 (m, 2H), 3.14-3.11 (m, 2H), 2.95-2.83 (m, 2H), 2.58 (s, 3H),1.77-1.65 (m, 4H), 0.92-0.84 (m, 2H), −0.01 (s, 9H). Mass spec.: 655(MH)⁺.

Similarly Prepared:

(±)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-propionicacid methyl ester

¹H-NMR (CD₃OD, 500 MHz) δ 7.85 (d, J=8.2 Hz, 1H), 7.55 (s, 1H), 7.51 (d,J=3.7 Hz, 1H), 7.27 (dd, J=8.6, 1.5 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H),7.10 (d, J=7.6 Hz,1H), 6.95 (t, J=7.6 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H),6.73 (d, J=3.7 Hz, 1H), 4.44-4.38 (m, 1H), 4.26 (s, 2H), 4.13-4.08 (m,2H), 3.73 (s, 3H), 3.34-3.29 (m, 4H), 3.13 (dd, J=13.5, 9.4 Hz, 1H),2.89-2.79 (m, 2H), 1.76-1.70 (m, 1H), 1.63-1.59 (m, 3H), 0.76-0.72 (m,2H), −0.07 (s, 9H); Mass spec.: 640.40 (MH)⁺.

(R)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester

A solution of(R)-2-Amino-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester (764 mg, 1.99 mmol), N,N-diisopropylethylamine (1.10mL, 5.97 mmol) and disuccinimidylcarbonate (509 mg, 1.99 mmol) inmethylene chloride (20 mL) was stirred for 40 min at room temperature.Then, 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (70% pure, 703mg, 2.13 mmol) was added and the reaction mixture was allowed to stirovernight at room temperature. The solvent was evaporated in vacuo andthe residue was subjected to flash column chromatography (1:4acetone/ethyl acetate) to give 1.15 g (90%) of the title compound.¹H-NMR (CDCl₃, 300 MHz) δ 8.21 (s, 1H), 8.01 (d, J=8.5 Hz, 1H), 7.53 (s,1H), 7.32 (d, J=8.5 Hz, 1H), 7.16 (t, J=7.8 Hz, 1H), 7.06 (d, J=7.6 Hz,1H), 6.95 (d, J=7.6 Hz, 1H) 1, 6.76 (s, 1H), 6.65 (d, J=7.9 Hz, 1H),5.01 (d, J=7.6 Hz, 1H), 4.84 (dd, J=13.1, 6.0 Hz, 1H), 4.56-4.49 (m,1H), 4.28 (s, 2H), 4.13-3.98 (m, 2H), 3.73 (s, 3H), 3.39-3.35 (m, 2H),3.28 (dd, J=14.0, 6.1 Hz, 1H), 3.24 (dd, J=13.7, 5.8 Hz, 1H), 2.94-2.87(m, 2H), 1.75-1.67 (m, 4H), 0.91-0.87 (m, 2H), −0.02 (s, 9H). Massspec.: 641 (MH)⁺.

Similarly Prepared:

(±)-2-{[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-propionicacid methyl ester

¹H-NMR (CD₃CN, 500 MHz) δ 9.78 (s, 1H), 7.86 (d, J=8.5 Hz, 1H), 7.56 (s,1H), 7.49 (d, J=3.7 Hz, 1H), 7.28 (dd, J=8.5, 1.5 Hz, 1H), 7.10-7.08 (m,1H), 7.05-7.03 (m, 1H), 6.99-6.97 (m, 2H), 6.70 (d, J=3.7 Hz, 1H), 5.91(d J=7.9 Hz, 1H), 4.66 (q, J=8.2 Hz, 1H), 4.45-4.39 (m, 1H), 4.14 (br s,1 h), 3.68 (s, 3H), 3.36-3.32 (m, 2H), 3.27 (dd, J=14.0, 5.5 Hz, 1H),3.18 (dd, J=13.7, 8.5 Hz, 1H), 2.90-2.84 (m, 2H), 2.55 (br s, 1H),2.36-2.21 (m, 2H), 1.74-1.70 (m, 2H), 0.82-0.78 (m, 2H), −0.09 (s, 9H).Mass spec. 626.26 (MH)⁺.

(±)-2-{[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester

¹H-NMR (CD₃CN, 500 MHz) δ 9.61 (br s, 1H), 8.35 (s, 1H), 8.00 (d, J=8.5Hz, 1H), 7.74 (s, 1H), 7.51 (dd, J=8.8, 1.5 Hz, 1H), 7.10-7.06 (m, 1H),7.05-7.02 (m, 1H), 7.00-6.97 (m, 2H), 5.90n(d, J=7.9 Hz, 1H), 4.67 4.62(m, 1H), 4.42-4.36 (m, 1H), 4.13-4.07 (br s, 1H), 3.68 (s, 3H),3.45-3.42 (m, 2H), 3.30 (dd, J=14.0, 5.8 Hz, 1H), 3.20 (dd, J=13.7, 8.8Hz, 1H), 2.89-2.84 (m, 2H), 2.52 (br s, 1H), 2.33-2.23 (m, 2H),1.72-1.69 (m, 2H), 0.80-0.76 (m, 2H), −0.07 (s, 9H). Mass spec. 627.25(MH)⁺.

(±)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-propionicacid methyl ester

¹H-NMR (CD₃OD, 500 MHz) δ 7.85 (d, J=8.2 Hz, 1H), 7.55 (s, 1H), 7.51 (d,J=3.7 Hz, 1H), 7.27 (dd, J=8.6, 1.5 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H),7.10 (d, J=7.6 Hz,1H), 6.95 (t, J=7.6 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H),6.73 (d, J=3.7 Hz, 1H), 4.44-4.38 (m, 1H), 4.26 (s, 2H), 4.13-4.08 (m,2H), 3.73 (s, 3H), 3.34-3.29 (m, 4H), 3.13 (dd, J=13.5, 9.4 Hz, 1H),2.89-2.79 (m, 2H), 1.76-1.70 (m, 1H), 1.63-1.59 (m, 3H), 0.76-0.72 (m,2H), −0.07 (s, 9H). Mass spec. 640.40 (MH)⁺.

(±)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester

¹H-NMR (CD₃OD, 500 MHz) δ 8.39 (d, J=0.5 Hz, 1H), 8.02 (d, J=8.5 Hz,1H), 7.75 (s, 1H), 7.52 (dd, J=8.5, 1.5 Hz, 1H), 7.14-7.10 (m, 2H), 6.94(t, J=7.5 Hz, 1H), 6.78 (d, J=7.5 Hz, 1H), 4.63-4.60 (m, 1 h), 4.43-4.37(m, 1H), 4.27 (s, 2H), 4.11 (br s, 1H), 4.08 (br s, 1H), 3.71 (s, 3H),3.47-3.43 (m, 2H), 3.37-3.33 (m, 1H), 3.18 (dd, j=13.5, 10.0 Hz, 1H),2.87-2.79 (m, 2H), 1.73-1.59 (m, 4H), 0.80-0.75 (m, 2H), −0.05 (s, 9H);¹³C-NMR (CD₃OD, 125 MHz) δ 173.7, 155.5, 158.1, 141.0, 140.6, 137.2,134.4, 131.3, 128.2, 126.1, 125.8, 122.2, 121.9, 118.3, 113.4, 112.6,55.9, 52.1, 51.7, 50.8, 48.9, 48.6, 48.4, 48.2, 48.0, 47.9, 47.7, 47.5,43.8, 43.7, 43.1, 37.2, 28.5, 9.8, −3.2. Mass spec.: 641.40 (MH)⁺.

EXAMPLE 1(±)-3-(1H-Indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

A solution of5-(2-methoxycarbonyl-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-ethyl)-indazole-1-carboxylicacid tert-butyl ester (168 mg, 0.29 mmol) was dissolved intetrahydrofuran (5 mL) in methanol (5 mL) was cooled to 0° C. A solutionof lithium hydroxide monohydrate (49 mg, 2.04 mmol) in water (5 mL) wasadded. The reaction mixture was stirred at 0° C. for 6 h and then placedin the freezer for a further 16 h. The solvents were removed in vacuoand the residue dissolved in water (15 mL). The pH of the aqueoussolution was adjusted to ca. 1 with 1N hydrochloric acid. The resultingwhite solid precipitated was collected by filtration. The solid wasdried under vacuum to give the title compound (108 mg, 80%). ¹H-NMR(DMSO-d₆, 300 MHz) δ 12.94 (bs, 1H), 9.19 (s, 1H), 8.01 (s, 1H), 7.61(s, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.28 (dd, J=8.5, 1.5 Hz, 1H), 7.13-7.06(m, 2H), 6.86 (t, J=7.0 Hz, 1H), 6.76-6.72 (m, 2H), 4.32-4.24 (m, 2H),4.09-4.02 (m, 4H), 3.17-2.97 (m, 2H), 2.72-2.59 (m, 2H), 1.57-1.35 (m,4H). IR (KBr, cm⁻¹) 3424, 2963, 2930, 1660, 1628, 1505, 1474, 1446, 753.Mass spec.: 463 (MH)⁺.

(R)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid

A solution of(R)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester (775 mg, 1.21 mmol) in tetrahydrofuran (9 mL) andmethanol (3 mL) was cooled to 0° C. A solution of lithium hydroxidemonohydrate (115 mg, 4.84 mmol) in water (3 mL) was added. The reactionmixture was stirred at 0° C. for 2 h and then placed in the freezer at−15° C. for 16 h. While cooling the reaction mixture with an ice bath,the pH was increased to ca. 7 by addition of 1N hydrochloric acid (3.8mL). Organic solvents were removed under vacuum. The resulting aqueoussolution was extracted with ethyl acetate after additon of more 1Nhydrochloric acid (0.5 mL). The combined extracts were dried overmagnesium sulfate, filtered and evaporated to give 684 mg (90%) of thetitle compound as a white solid. ¹H-NMR (DMSO-d₆, 300 MHz) δ 9.21 (s,1H), 8.58 (s, 1H), 7.90 (d, J=8.4 Hz, 1H), 7.78 (s, 1H), 7.56 (d, J=8.1Hz, 1H), 7.13-7.09 (m, 2H), 6.88-6.83 (m, 1H), 6.76-6.74 (m, 2H),4.33-4.27 (m, 2H), 4.18 (s, 2H), 4.09-3.96 (m, 3H), 3.57-3.51 (m, 2H),3.25-3.04 (m, 2H), 2.74-2.60 (m, 2H), 1.54-1.43 (m, 4H), 0.70-0.64 (m,2H), −0.08 (s, 9H). Mass spec.: 627 (MH)⁺.

Similarly Prepared:

(±)-2-{[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-yl]-propionicacid

Mass spec. 612.25 (MH)⁺.

(±)-2-{[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid

Mass spec. 613.26 (MH)⁺.

(±)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid

¹H-NMR (CD₃CN, 500 MHz) δ 8.37 (s, 1H), 8.08 (s, 1H), 8.01 (d, J=8.5 Hz,1H), 7.77 (s, 1H), 7.53 (dd, J=8.5, 1.5 Hz, 1H), 7.19 (t, J=7.3 Hz, 1H),7.14 (d, J=7.3 Hz, 1H), 6.98 (td, j=7.6, 1.2 Hz, 1H), 6.79 (d, j=8.0 Hz,1H), 6.28 (br s, 3H), 4.54-4.49 (m, 1H), 4.37-4.32 (m, 1H), 4.30 (s,2H), 3.98-3.92 (m, 2H), 3.45-3.41 (m, 2H), 3.37 (dd, j=14.0, 4.9 Hz,1H), 3.20 (dd, J=14.0, 9.7 Hz, 1H), 2.84-2.77 (m, 2H), 1.65-1.57 (m,4H), 0.79-0.76 (m, 2H), −0.05 (s, 9H). Mass spec.: 627.30 (MH)⁺.

(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide

To a solution of(R)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid (554 mg, 0.88 mmol) and N,N-diisopropylethylamine (0.62 mL, 3.54mmol) in methylene chloride (20 mL) was added a solution of4-piperidinopiperidine (164 mg, 0.97 mmol) and PyBOP® (460 mg, 0.88mmol) in methylene chloride (15 mL). The reaction mixture was stirredfor 16 h at room temperature. It was then concentrated to approximately2 mL and subjected to flash column chromatography using methylenechloride/methanol/triethylamine (94:5:1) as eluent to give 599 mg (87%)of the title compound as a white solid. ¹H-NMR (CD₃CN, 300 MHz) δ 8.37(s, 0.5H), 8.36 (s, 0.5H), 8.02-7.96 (m, 1H), 7.74 (s, 0.5H), 7.71 (s,0.5H), 7.55-7.46 (m, 1H), 7.21-7.12 (m, 2H), 6.97-6.92 (m, 1H), 6.79 (d,J=8.1 Hz, 1H), 5.71 (t, J=8.1 Hz, 1H), 5.00 (dd, J=15.0, 8.1 Hz, 1H),4.63-4.51 (m, 1H), 4.39-4.29 (m, 1H), 4.29 (s, 2H), 4.10-3.96 (m, 3H),3.46-3.40 (m, 2H), 2.92-2.70 (m, 8H), 2.58-2.37 (m, 5H), 1.74-1.40 (m,13H), 0.80-0.74 (m, 2H), −0.04 (s, 9H). Mass spec.: 778 (MH)⁺.

Similarly Prepared:

(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 9.42 (br s, 1H), 7.80 (d, J=8.5 Hz, 0.6H),7.78 (d, J=8.2 Hz, 0.4H), 7.50 (s, 1H), 7.43 (t, J=3.0 Hz, 1H), 7.27 (d,J=8.5 Hz, 0.6H), 7.23 (d, J=8.5 Hz, 0.4H), 7.10-7.07 (m, 1H), 7.02-6.95(m, 3H), 6.69 (s, 0.4H), 6.68 (s, 0.6H), 5.88 (d, J=8.5 Hz, 0.6H), 5.85(d, J=8.4 Hz, 0.4H), 5.04-4.98 (m, 1H), 4.49 (s, 0.4H), 4.46 (s, 0.6H),4.36-4.30 (m, 1H), 4.11-4.07 (m, 1H), 3.97-3.91 (m, 1H), 3.31-3.28 (m,2H), 3.11-3.05 (m, 6H), 2.87-2.80 (m, 2H), 2.43-2.07 (m, 8H), 1.78-1.74(m, 4H), 1.71-1.65 (m, 2H), 1.46-1.40 (m, 2H), 1.37-1.31 (m, 2H),0.80-74 (m, 2H), −0.10 (s, 9H). LC/MS: t_(R)=2.47 min, 762.37 (MH)⁺.

(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 9.67 (s, 1H), 8.32 (s, 1H), 7.96 (d, J=8.7 Hz,0.55H), 7.93 (d, J=8.6 Hz, 0.45H), 7.70 (s, 1H), 7.51 (d, J=8.6 Hz,0.55H), 7.47 (d, J=8.8 Hz, 0.45H), 7.08-7.05 (m, 1H), 7.03-6.99 (m, 1H),6.98-6.94 (m, 2H), 6.01 (d, J=7.9 Hz, 0.45H), 5.96 (d, J=7.9 Hz, 0.55h), 5.05-5.00 (m, 1H), 4.49-4.46 (m, 1H), 4.35-4.29 (m, 1H), 4.10-4.05(m, 1H), 4.00-3.93 (m, 1H), 3.40-3.36 (m, 2H), 3.17-3.30 (m, 6H),2.91-2.71 (m, 2H), 2.52-2.13 (m, 8H), 1.76 9br s, 4H), 1.69-1.65 (m,2H), 1.44-1.41 (m, 2H), 1.34-1.30 (m, 2H), 0.77-0.71 (m, 2H), −0.08 (s,9H). LC/MS: t_(R)=2.35 min, 763.35 (MH)⁺.

(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 8.17 (s, 0.6H), 8.16 (s, 0.4H), 7.84 (d, J=8.5Hz, 0.6H), 7.81 (d, J=8.5 Hz, 0.4H), 7.54 (s, 0.4H), 7.53 (s, 0.6H),7.48 (t, J=4.1 Hz, 1H), 7.31 (dd, J=8.5, 1.5 Hz, 0.6H), 7.28 (dd, J=8.5,1.5 Hz, 0.4H), 7.18 (t, j=7.4 Hz, 1H), 7.09-7.06 (m, 1H), 6.93 (t, J=7.3Hz, 1H), 6.83 (d, J=7.9 Hz, 1H), 6.72 (d, J=3.6 Hz, 1H), 6.09 (d, J=8.2Hz, 1H), 5.05-4.99 (m, 1H), 4.53-4.50 (m, 1H), 4.40-4.34 (m, 1H), 4.26(s, 1.2H)<4.24 (s, 0.8H), 3.99-3.94 (m, 1H), 3.35-3.30 (m, 2H),3.15-3.07 (m, 3H), 3.08-3.03 (m, 1H), 2.81-2.73 (m, 3H), 2.55-2.37 (m,6H), 2.21-2.16 (m, 1H), 2.13-2.08 (m, 1H), 1.69-1.57 (m, 4H), 1.51-1.45(m, 4H), 1.41-1.35 (m, 4H), 0.83-0.74 (m, 2H), −0.06 (s, 9H). Massspec.: 776.44 (MH)⁺.

(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide

Purified by silica gel chromatography using methylenechloride:methanol/triethylamine (90:10:0.5) as eluent. ¹H-NMR (CD₃CN,500 MHz) δ 8.36 (s, 1H), 8.04 (s, 1H), 8.01 (d, J=8.8 Hz, 0.6H), 7.97(dd, J=8.8 Hz, 0.4H), 7.74 (s, 1H), 7.54 (dd, J=8.5, 1.5 Hz, 0.6H), 7.51(dd, J=8.5, 1.5 Hz, 0.4H), 7.18 (t, J=7.4 Hz, 1H), 7.11 (t, J=7.3 Hz,1H), 6.94 (t, J=7.3 Hz, 1H), 6.83 (d, J=7.9 Hz, 1H), 6.05 (d, J=8.5 Hz,0.4H), 6.02 (d, J=8.5 Hz, 0.6H), 5.06-5.01 (m, 1H), 4.52-4.50 (m, 1H),4.39-4.34 (m, 1H), 4.27 (s, 1.2H), 4.25 (s, 0.8H), 4.00-3.97 (m, 2H),3.45-3.40 (m, 2H), 3.20-3.08 (m, 2H), 2.81-2.74 (m, 2H), 2.56-2.39 (m,8H), 2.27-2.24 (m, 1H), 2.20-2.16 (m, 1H), 1.68-1.57 (m, 4H), 1.52-1.45(m, 4H), 1.41-1.34 (m, 4H), 1.06-1.01 (m, 1H), 0.80-0.75 (m, 2H), −0.07(s, 9H). Mass spec.: 777.40 (MH)⁺.

(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid{2-(4-isobutyl-piperazin-1-yl)-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 9.75 (s, 1H), 7.82 (d, J=8.2 Hz, 1H), 7.54 (s,1H), 7.48 (d, J=3.6 Hz, 1H), 7.28 (d, J=8.5 Hz, 1H), 7.12-7.09 (m, 1H),7.04-7.02 (m, 1H), 7.00-6.97 (m, 2H), 6.72 (d, J=3.7 Hz, 1H), 5.97 (d,J=8.2 Hz, 1H), 5.01 (dd, J=14.6, 7.2 Hz, 1H), 4.40-4.34 (m, 1H),4.15-4.08 (m, 2H), 3.58-3.54 (m, 1H), 3.50-3.45 (m, 2H), 3.39-3.35 (m,1H), 3.36-3.32 (m, 2H), 3.14-3.10 (m, 8H), 2.89-2.83 (m, 2H), 2.34-2.23(m, 4H), 2.17-2.13 (m, 1H), 0.85 (d, J=6.7 Hz, 6H), 0.83-0.80 (m, 2H),−0.06 (s, 9H). Mass spec.: 736.40 (MH)⁺.

(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid{2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 9.27 (s, 1H), 7.82 (d, J=8.5 Hz, 1H), 7.55 (s,1H), 7.48(d, J=3.6 Hz, 1H), 7.28(dd, J=8.5, 1.5 Hz, 1H), 7.13-7.10(m,1H), 7.06-7.03 (m, 1H), 7.01-6.98 (m, 2H), 6.72 (d, J=3.6 Hz, 1H), 5.95(d, J=8.0 Hz, 1H), 5.05 (dd, J=15.0, 7.3 Hz, 1H), 4.41-4.34 (m, 1H),4.14-4.08 (m, 2H), 3.90-3.86 (m, 3H), 3.68-3.64 (m, 1H), 3.60-3.56 (m,2H), 3.45-3.40 (m, 1H), 3.35-3.31 (m, 2H), 3.15 (dd, J=13.4, 7.1 Hz,1H), 3.05 (dd, J=13.4, 7.0 Hz, 1H), 2.89-2.83 (m, 2H), 2.34-2.19 (m,3H), 1.73-1.70 (m, 2H), 1.64-1.56 (m, 2H), 1.53-1.49 (m, 1H), 1.29-1.26(m, 1H), 0.84-0.80 (m, 2H), −0.05 (s, 9H). Mass spec.: 737.37 (MH)⁺.

(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1′-carboxylicacid{2-(4-isobutyl-piperazin-1-yl)-2-oxo-1′-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 9.84 (s, 1H), 8.37 (s, 1H), 7.98 (d, J=8.5 Hz,1H), 7.74 (s, 1H), 7.52 (dd, J=8.8, 1.5 Hz, 1H), 7.11-7.09 (m, 1H),7.06-7.03 (m, 1H), 7.02-6.98 (m, 2H), 5.97 (d, J=8.2 Hz, 1H), 5.02(dd,J=14.3, 7.3 hz, 1H), 4.39-4.33 (m, 1H), 4.14-4.07 (m, 2H), 3.53-3.50(m, 3H), 3.46-3.42 (m, 2H), 3.45-3.39 (m, 1H), 3.20-3.06 (m, 5H),2.89-2.83 (m, 2H), 2.30-2.27 (m, 4H), 2.21-2.17 (m, 1H), 1.74-1.70 (m,3H), 0.86 (d, J=6.7 Hz, 6H), 0.81-0.77 (m, 2H), −0.04 (s, 9H). Massspec.: 737.40 (MH)⁺.

(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid{2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide

¹H-NMR (CD₃CN, 500 MHz) δ 9.34 (s, 1H), 8.36 (s, 1H), 7.97 (d, J=8.5 Hz,1H), 7.74 (s, 1H), 7.52 (dd, J=8.5, 1.5 Hz, 1H), 7.11-7.08 (m, 1H),7.06-7.03 (m, 1H), 7.02-6.98 (m, 2H), 5.98 (d, J=8.2 Hz, 1H), 5.06 (dd,J=14.6, 7.3 Hz, 1H), 4.39-4.32 (m, 1H), 4.13-4.03 (m, 2H), 3.92-3.88 (m,2H), 3.71-3.66 (m, 1H), 3.63-3.53 (m, 2H), 3.48-3.45 (m, 1H), 3.44-3.40(m, 2H), 3.19 (dd, j=13.4, 6.5 Hz,1H), 3.08 (dd, J=13.7, 7.3 Hz, 1H),2.85 (t, J=12.8 Hz, 2H), 2.32-2.20 (m, 4H), 1.73-1.70 (m, 2H), 1.67-1.51(m, 3H), 1.38-1.33 (m, 1H), 0.81-0.77 (m, 2H), −0.04 (s, 9H). Massspec.: 738.32 (MH)⁺.

EXAMPLE 2(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

A solution of(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide(568 mg, 0.73 mmol) and cesium fluoride (1.11 g, 7.31 mmol) was heatedat 80° C. in acetonitrile (50 mL) for 4.5 h. The reaction mixture wasconcentrated and the residue was subjected to flash columnchromatography (methylene chloride/methanol/triethylamine, 94:5:1) togive 280 mg (63% yield) of the title compound as a white solid with98.2% ee as determined by HPLC analysis using a Chirocel OD column with20% B (A=ethanol, B=0.05% diethylamine in hexanes) as eluent (Retentiontimes: 9.51 min for title compound and 15.9 min for S-enantiomer).¹H-NMR (CD₃OD, 500 MHz) δ 8.04 (s, 0.75H), 8.03 (s, 0.25H), 7.67 (s,0.75H), 7.65 (s, 0.25H), 7.56 (d, J=8.5 Hz, 0.75H), 7.51 (d, J=8.5 Hz,0.25H), 7.41 (d, J=8.5 Hz, 0.75H), 7.31 (d, J=8.5 Hz, 0.25H), 7.19-7.12(m, 2H), 6.97-6.94 (m, 1H), 6.80 (d, J=7.9 Hz, 1H), 5.08-5.05 (m, 1H),4.60-4.53 (m, 1H), 4.48-4.40 (m, 1H), 4.37 (s, 1.5H), 4.26 (s, 0.5H),4.24-4.14 (m, 2H), 4.06-3.97 (m, 1H), 3.15 (d, J=7.9 Hz, 1.5H),3.12-3.05 (m, 0.5H), 2.94-2.86 (m, 3H), 2.57-2.51 (m, 1.5H), 2.47-2.42(m, 1H), 2.37-2.33 (m, 0.75H), 2.03-2.02 (m, 1.5H), 1.87-1.75 (m,3.75H), 1.73-1.68 (m, 2H), 1.67-1.54 (m, 3H), 1.53-1.44 (m, 4H),1.43-1.34 (m, 2H), 1.30-1.26 (m, 1H), 0.83-0.77 (m, 0.75H), −0.16 to−0.24 (m, 0.75H). Mass spec.: 613 (MH)⁺.

Similarly Prepared:

EXAMPLE 3(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide

¹H-NMR (DMSO-d₆, 500 MHz) δ 10.99 (s, 0.6H), 10.96 (s, 0.4H), 10.85 (s,1H), 7.41 (s, 0.4H), 7.36 (s, 0.6H), 7.33 (d, J=8.0 Hz, 0.6H), 7.29-7.26(m, 1H), 7.16-7.14 (m, 1H), 7.10 (d, J=7.6 Hz, 0.4H), 7.02-6.96 (m, 4H),6.81 (br s, 1H), 6.37-6.35 (m, 1H), 4.86 (q, J=8.0 Hz, 0.6H), 4.80 (q,J=7.5 Hz, 0.4H), 4.45 (br s, 1H), 4.38-4.32 (m, 1H), 4.21-4.16 (m, 1H),3.98 (br s, 1H), 3.18 (d, J=5.2 Hz, 0.6H), 3.04-2.92 (m, 2.4H),2.82-2.74 (m, 4H), 2.37-2.33 (m, 2H), 2.25-2.08 (m, 4H), 2.04-1.90 (m,2H), 1.47-1.24 (m, 10H), 0.75-0.71 (m, 1H). LC/MS: t_(R)=1.90 min,598.42 (MH)⁺.

EXAMPLE 4(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

¹H-NMR (DMSO-d₆, 500 MHz) δ 10.70 (s, 1H), 8.22 (d, J=8.2 Hz, 0.6H),8.11 (s, 0.4H), 8.00 (s, 0.6H), 7.89 (d, J=9.1 Hz, 0.4H), 7.62-7.57 (m,1H), 7.50-7.43 (m, 1H), 7.30-7.26 (m, 1H), 7.14-7.08 (m, 1H), 6.99-6.95(m, 2H), 6.85 (br s, 1H), 4.89-4.80 (m, 1H), 4.45-4.31 (m, 2H),4.18-4.00 (m, 2H), 3.26-3.16 (m, 1H), 3.09-2.96 (m, 2H), 2.82-2.73 (m,4H), 2.38-2.34 (m, 2H), 2.24-2.08 (m, 4H), 2.03-1.88 (m, 2H), 1.47-1.22(m, 10H), 0.90-0.84 (m, 1H). LC/MS: t_(R)=1.73 min, 599.32 (MH)⁺.

EXAMPLE 5(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide

A mixture of4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-ylmethyl]-ethyl}-amide(52 mg, 0.067 mmol), cesium fluoride (51 mg, 0.33 mmol) in acetonitrile(5 mL) was heated at 80° C. for 4 h. The solvents were removed in vacuoand the residue was subjected to chromatography on silica gel usingmethylene chloride/methanol/triethylamine (93:5:2) as eluent to affordthe title compound as a white solid (70% yield). ¹H-NMR (CD₃CN, 500 MHz)δ 9.30 (s, 1H), 7.48 (s, 1H), 7.42 (s, 1H), 7.39 (d, J=8.2 Hz, 0.6H),7.36 (d, J=8.2 Hz, 0.4H), 7.24-7.21 (m, 1H), 7.19 (t, J=7.9 Hz, 1H),7.12-7.09 (m, 1H), 7.06 (d, J=8.2 Hz, 0.6H), 7.02 (d, J=8.2 Hz, 0.4H),6.95 (t, J=7.4 Hz, 1, 4.04-3.93 (m, 1H), 3.07-3.02 (m, 1.6H), 2.95 (dd,J=13.7, 7.1 Hz, 0.4H), 2.85-2.72 (m, 3H), 2.56-2.37 (m, 3H), 2.42-2.37(m, 1H), 1.99-1.95 (m, 7H), 1.76-1.51 (m, 8H), 1.45-1.40 (m, 3H). LC/MS:t_(R)=1.91 min, 612.44 (MH)⁺.

EXAMPLE 6(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

Purified by silica gel chromatography using methylenechloride:methanol:triethylamine (93:5:2) as eluent to afford the titlecompound as a white solid (90% yield). ¹H-NMR (CD₃OD, 500 MHz) δ 8.04(s, 0.7H), 8.02 (s, 0.3H), 7.67 (s, 0.7H), 7.65 (s, 0.3H), 7.56 (d,J=8.5 Hz, 0.7H), 7.51 (d, J=8.5 Hz, 0.3H), 7.40 (d, J=8.5 Hz, 0.7H),7.33 (d, J=8.5 Hz, 0.3H), 7.19-7.12 (m, 2H), 6.97-6.94 (m, 1H), 6.80 (d,J=8.0 Hz, 1H), 5.08-5.05 (m, 1H), 4.59-4.54 (m, 1H), 4.48-4.42 (m, 1H),4.37 (s, 1H), 4.27-4.20 (m, 2H), 4.04 (d, J=13.4 Hz, 0.3H), 3.99 (d,J=13.4 Hz, 0.7H), 3.19-3.08 (m, 2H), 2.94-2.86 (m, 3H), 2.57 (br s, 2H),2.51-2.36 (m, 2H), 2.07-2.05 (m 1H), 1.90-1.31 (m, 16H). LC/MS:t_(R)=1.85 min, 613.44 (MH)⁺. The (R)-enantiomer, whose discretesynthesis is described above (Example 1), was obtained by chiralseparation of the racemate by employing the following conditions:Chiracel OD prep column, 50×500 mm, 20 um; A=EtOH, B=0.05%diethylamine/hexane; 20% B@ 65 ml/min for 45 min; retention times: 20.5min for R and 32.8 min for S enantiomers.

EXAMPLE 7(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[1-(1H-indol-5-ylmethyl)-2-(4-isobutyl-piperazin-1-yl)-2-oxo-ethyl]-amide

LC/MS: t_(R)=2.05 min, 572.31 (MH)⁺.

EXAMPLE 8(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide

LC/MS: t_(R)=2.35 min, 573.26 (MH)⁺.

EXAMPLE 9(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[1-(1H-indazol-5-ylmethyl)-2-(4-isobutyl-piperazin-1-yl)-2-oxo-ethyl]-amide

LC/MS: t_(R)=1.86 min, 573.28 (MH)⁺.

EXAMPLE 10(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

LC/MS: t_(R)=2.18 min, 574.23 (MH)⁺.

EXAMPLE 11(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

To a solution of the3-(1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid (95 mg, 0.21 mmol) and N,N-diisopropylethylamine (0.14 mL, 0.82mmol) in dimethylformamide (5 mL) was added a solution of1,4-dioxa-8-azaspiro[4,5]decane (32 mg, 0.23 mmol) and PyBOP® (107 mg,0.21 mmol) in methylene chloride (5 mL). The reaction mixture wasstirred for 16 h at room temperature. All solvent was removed using highvacuum. The residue was subjected to flash column chromatography usingmethylene chloride/methanol/triethylamine (93:5:2) to give the titlecompound as a white solid (67 mg, 56% yield). ¹H-NMR (CDCl₃, 500 MHz) δ10.52 (s, 1H), 7.97 (s, 1H), 7.54 (s, 1H), 7.37 (d, J=8.6 Hz, 1H), 7.20(d, J=10.7 Hz, 1H), 7.16 (t, J=7.2 Hz, 1H), 7.04 (d, J=7.6 Hz, 1H), 7.01(s, 1H), 6.94 (t, J=8.6 Hz, 1H), 6.67 (d, J=7.6 Hz, 1H), 5.64 (d, J=7.9Hz, 1H), 5.16 (dd, J=15.0, 6.7 Hz, 1H), 4.56-4.49 (m, 1H), 4.25 (s, 2H),4.11 (br t, J=15.6 Hz, 2H), 3.92-3.84 (m, 4H), 3.73-3.69 (m, 1H),3.60-3.56 (m, 1H), 3.48-3.43 (m, 1H), 3.22-3.17 (m, 1H), 3.11 (d, J=6.7Hz, 2H), 2.90-2.85 (m, 2H), 2.68-2.60 (m, 4H), 1.67-1.61 (m, 2H),1.54-1.49 (m, 2H). Mass spec.: 588 (MH)⁺.

4-Bromo-2,6-dimethylphenyldiazo-t-butyl sulfide

4-Bromo-2,6-dimethylaniline (20.00 g, 100 mmol) was ground to a powderwith a mortar and pestle and then suspended in 24% hydrochloric acid (41mL). The stirred mixture was cooled to −20° C. and treated with sodiumnitrite (7.24 g, 1.05 equiv) in water (16 mL), dropwise over 40 minwhile the temperature was maintained below −5° C. After a further 30 minat −5° C. to −20° C., the mixture was buffered to ca. pH 5 with solidsodium acetate. This mixture (kept at ca. −10° C.) was added in portionsto a stirred solution of t-butyl thiol (11.3 mL, 1 equiv) in ethanol(100 mL) at 0° C. over ca. 10 min. Following addition, the mixture wasstirred at 0° C. for 30 min and then crushed ice (ca. 150 mL) was added.The mixture was stored in the refrigerator overnight. The resultinglight-brown solid was collected by filtration, washed with water, anddried under high vacuum for several h.

(26.90 g, 89%). The compound appeared to be stable as a solid butunderwent significant decomposition when recrystallization from ethanolwas attempted. ¹H-NMR (CDCl₃, 500 MHz) δ 1.58 (9H, s), 1.99 (6H, s),7.21 (2H, s). Mass spec.: 303.05 (MH)⁺.

5-Bromo-7-methylindazole

Into a flame-dried round bottom flask,4-bromo-2,6-dimethylphenyldiazo-t-butyl sulfide (12.50 g, 41.5 mmol) andpotassium t-butoxide (46.56 g, 10 equiv) were combined. A stir bar wasadded and the mixture placed under nitrogen. To this was added dry DMSO(120 mL). The mixture was stirred vigorously overnight at rt. Thereaction mixture was then carefully poured into a mixture of crushed ice(400 mL) and 10% hydrochloric acid (200 mL). The resulting suspensionwas left to stand at 4° C. overnight and the solid was collected byfiltration and washed with water. The crude solid was dissolved in 5:1methylene chloride/methanol and the solution dried over magnesiumsulfate and evaporated to give the product as an off-white solid (7.60g, 87%). ¹H-NMR (CDCl₃/CD₃OD, 500 MHz) δ 2.51 (3H, s), 7.22 (1H, s),7.69 (1H, s), 7.94 (1H, s). Mass spec.: 211.03 (MH)⁺.

7-methylindazole-5-carboxaldehyde

5-Bromo-7-methylindazole (6.10 g, 28.9 mmol) and sodium hydride (60% inmineral oil, 1.27 g, 1.1 equiv) were weighed into a flame-driedround-bottom flask containing a magnetic stir bar. Under a nitrogenatmosphere at room temperature, dry tetrahydrofuran (30 mL) was added.The mixture was stirred at room temperature for 15 min, during whichtime it became homogeneous. The stirred mixture was cooled to −70° C.and a solution of sec-butyllithium in cyclohexane (1.4M, 45 mL, 2.2equiv) was added over several minutes. After 1 h at −70° C.,dimethylformamide (10 mL) was added over several minutes. The mixturewas allowed to warm to room temperature and was stirred overnight. Itwas then cooled to 0° C. and carefully treated with 1N hydrochloric acid(60 mL). After a few minutes, solid sodium bicarbonate was added tobasify the mixture to pH 9-10. The layers were separated and the aqueousphase washed twice with ethyl acetate. The combined organic phases wereextracted with 0.8M sodium hydrogen sulfate (3×125 mL). The combinedaqueous phases were washed with ethyl acetate (100 mL) and then the pHwas adjusted to ca. 10 with solid sodium hydroxide. The resultingsuspension was extracted with ethyl acetate (3×150 mL). The combinedorganic phases were washed with brine, dried (magnesium sulfate) andevaporated to give the product as a light-tan solid (3.01 g, 65%).¹H-NMR (CDCl₃, 500 MHz) δ 2.63 (3H, s), 7.73 (1H, s), 8.12 (1H, s), 8.25(1H, s), 10.03 (1H, s). Mass spec.: 161.06 (MH)⁺.

2-Benzyloxycarbonylamino-3-(7-methyl-1H-indazol-5-yl)-acrylic acidmethyl ester

A stirred solution of N-benzyloxycarbonyl-α-phosphonoglycine trimethylester (5.51 g, 1.2 equiv.) in tetrahydrofuran (30 mL) at roomtemperature was treated with tetramethylguanidine (1.91 mL, 1.1 equiv).After 10 min, 7-methylindazole-5-carboxaldehyde (2.22 g, 13.86 mmol) intetrahydrofuran (20 mL) was added. Disappearance of starting materialwas monitored by TLC and LC/MS. After 5 days at room temperature, thesolvent was evaporated and the residue dissolved in ethyl acetate. Thesolution was washed with 2% phosphoric acid and brine, dried (magnesiumsulfate) and evaporated. The residue was purified by flashchromatography on silica gel, eluting with 1) 1:1 and 2) 2:1 ethylacetate/hexane, to give the product as a colorless foam (4.93 g, 97%).¹H-NMR (CDCl₃, 500 MHz) δ 2.43 (3H, s), 3.80 (3H, s), 5.12 (2H, s), 6.66(1H, s), 7.28 (5H, brs), 7.33 (1H, s), 7.47 (1H, s), 7.74 (1H, s), 7.96(1H, s). Mass spec.: 366.16 (MH)⁺.

(±)-2-Amino-3-(7-methyl-1H-indazol-5-yl)-propionic acid methyl ester

A solution of2-benzyloxycarbonylamino-3-(7-methyl-1H-indazol-5-yl)-acrylic acidmethyl ester (4.93 g, 13.49 mmol) in methanol (125 mL) was degassed bybubbling nitrogen through it for 30 min and then 10% palladium oncharcoal (0.6 g) was carefully added. The mixture was hydrogenated at 40psi in a Parr shaker apparatus overnight. The catalyst was removed byfiltration through a pad of celite and the filtrate was concentrated invacuo to give the product as a colorless foam (3.62 g, quant.). ¹H-NMR(CD₃OD, 500 MHz) δ 2.45 (3H, s), 2.99 (1H, Abq), 3.22 (1H, Abq), 3.74(3H, s), 3.89 (1H, m), 6.91 (1H, s), 7.31 (1H, s), 7.73 (1H, s). Massspec.: 234.11 (MH)⁺.

EXAMPLE 12(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

A stirred solution of (±)-2-amino-3-(7-methyl-1H-indazol-5-yl)-propionicacid methyl ester (162.9 mg, 0.698 mmol) in methylene chloride (3 mL) atroom temperature was treated with carbonyl diimidazole (113.2 mg, 1equiv). After 1.5 h at room temperature,3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (161.5 mg, 1 equiv.)was added. The mixture was stirred at room temperature overnight. Awhite precipitate had formed that was shown to be the desired product.The solvent was evaporated and the residue triturated with methylenechloride. The product was collected by filtration, washed with methylenechloride and dried in vacuo to give a white solid (241.5 mg, 71%). Someproduct remained in the mother liquors. ¹H-NMR (dimethylformamide-d₇,500 MHz) δ 1.75 (4H, m), 2.78 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, m),3.86 (3H, s), 4.44 (2H, s), 4.57 (1H, m), 4.72 (1H, m), 7.11 (3H, m),7.31 (1H, s), 7.34 (2H, m), 7.72 (1H, s), 9.34 (1H, s). Mass spec.:491.13 (MH)⁺.

Similarly Prepared:

EXAMPLE 133-(7-Methyl-1H-indazol-5-yl)-2-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinazoline)carbonylamino]-propionic acid methyl ester

¹H-NMR (DMSO-d₆) δ 1.59 (4H, m), 2.46 (3H, s), 3.00-3.08 (4H, m), 3.6(3H, s), 3.78-3.81 (2H, m), 4.30-4.32 (1H, m), 6.78-6.88 (4H, m), 7.03(1H, s), 7.10 (1H, m), 7.13 (1H, s), 7.41 (1H,s), 7.96 (1H, s), 9.12(1H, s). Mass spec.: 477.11 (MH)⁺.

EXAMPLE 143-(7-Methyl-1H-indazol-5-yl)-2-(1,2-dihydro-2-oxospiro-4H-3,1-dihydro-benzoxazine-4′4-piperidine-carbonylamino)-propionicacid methyl ester

Mass spec.: 478.15 (MH)⁺.

3-(7-Methyl-1H-indazol-5-yl)-2{3′,4′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinolinecarbonylamino}-propionic acid methyl ester

¹H-NMR (DMSO-d₆) δ 1.42-1.56 (4H, m), 2.47 (3H, s), 2.50-2.54 (1H, d),2.60-2.64 (1H, d), 2.98-3.06 4H, m), 3.60 (3H, s) 3.80 (2H, m), 4.30(1H, m), 6.86 (2H, d), 6.95 (2H, m), 7.15 (1H, m), 7.40 (1H, s), 7.95(1H, s), 8.32 (1H, s), 10.14 (1H, s), 13.05 (1H, s). Mass spec.: 476.17(MH)⁺.

3-(7-Methyl-1H-indazol-5-yl)-2-[2′-phenyl-1′,3′,8′-triaza-spiro(4′,5′)deo-1-ene-8-carbonylamino]-propionic acid methyl ester

¹H-NMR (DMSO-d₆) δ 1.50 (2H, m), 1.68 (2H, m), 2.46 (3H, s wasoverlapped with DMSO), 3.05 (2H, m), 3.30 (2H, m), 3.60 (3H, s), 3.86(2H, m), 4.28 (1H, m), 6.98 (1H, d), 7.04 (1H, s), 7.40 (1H, s), 7.58(2H, m), 7.65 (1H, m), 8.00 (1H, s), 8.04 (2H, m). Mass spec.: 489.15(MH)⁺.

EXAMPLE 15(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

A suspension of(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (240.0 mg, 0.489 mmol) in 1:1 tetrahydrofuran/methanol(20 mL) at room temperature was treated with a solution of lithiumhydroxide (140.5 mg, 7 equiv) in water (10 mL). Within 1 min, themixture became homogeneous and it was left to stand at 4° C. overnight.The solvents were evaporated at ca. 30° C. and the pH was adjusted toca. 1 with 1N hydrochloric acid. The resulting white suspension wasstored at 4° C. for several hours and the product was collected byfiltration, washed with a small amount of water, and dried in vacuo(169.0 mg, 73%). Solid sodium chloride was added to the filtrateresulting in precipitation of more product (5.2 mg, total yield 75%).¹H-NMR (CD₃OD, 500 MHz) δ 1.2-1.7 (4H, m), 2.58 (3H, s), 2.5-3.2 (4H,m), 3.35 (2H, m), 4.15 (2H, m), 4.36 (1H, m), 4.60 (1H, m), 6.79 (1H,d), 6.96 (1H, t), 7.18 (3H, m), 7.49 (1H, s), 8.00 (1H, s). Mass spec.:477.13 (MH)⁺.

Similarly Prepared:

3-(7-Methyl-1H-indazol-5-yl)-2-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinazolinecarbonylamino]-propionic acid

¹H-NMR (DMSO-d₆) δ 1.58 (4H, m), 2.46 (3H, s), 3.00-3.23 (3H, m),3.78-3.91 (3H, m), 3.88 (2H, m) 4.28 (1H, s), 6.70 (1H, d), 6.75-6.85(3H, m), 7.04 (1H, d), 7.11 (1H, m) 7.18 (1H, s), 7.96 (1H, s), 13.02(1H, m). Mass spec.: 463.09 (MH)⁺.

3-(7-Methyl-1H-indazol-5-yl)-2-(1,2-dihydro-2-oxospiro-4H-3,1-dihydro-benzoxazine-4′4-piperidine-carbonylamino)-propionicacid methyl ester

¹H-NMR (DMSO-d₆) δ 1.63-1.98 (4H, m), 2.46 (3H, s, 7-Me was overlappedwith DMSO), 2.98-3.32 (4H, m), 3.90 (2H, m), 4.28 (1H, m), 6.78 (1H, d),6.87 (2H, m), 6.96 (1H, m), 7.05 (1H, s), 7.24 (1H, m), 7.41 (1H, s),7.96 (1H, s), 10.22 (1H, s) 12.42 (1H, br.) 13.02 (1H, m). Mass spec.:464.07 (MH)⁺.

3-(7-Methyl-1H-indazol-5-yl)-2{3′,4′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinoline-carbonylamino}-propionic acid

¹H-NMR (DMSO-d₆) δ 1.39-1.45 (2H, m), 1.53-1.56 (2H, m), 2.46 (3H, s),2.50-2.54 (1H, d), 2.60-2.63 (1H, d), 2.88-3.00(3H, m), 3.09-3.11 (1H,m), 3.78-3.81 (2H, m), 4.27 (1H, m), 6.69-6.70 (1H, d), 6.86-6.87 (1H,d), 6.93-6.94 (1H, m) 6.99-7.00 (1H, m), 7.05 (1H, m), 7.41 (1H, s),7.95 (1H, s), 10.13 (1H, s), 12.50 (1H, m), 13.03 (1H, m). Mass spec.:462 (MH)⁺.

3-(7-Methyl-1H-indazol-5-yl)-2-[2′-phenyl-1′,3′,8′-triaza-spiro(4′,5′)deo-1-ene-8-carbonylamino]-propionic acid

¹H-NMR (DMSO-d₆) δ 1.36 (2H, m), 1.63 (2H, m), 2.46 (3H, s wasoverlapped with DMSO), 2.98-3.03 (2H,m), 3.09-3.11 (2H, m), 3.86 (2H,m), 4.21 (1H, m), 6.69 (1H, m), 7.04 (1H, s), 7.40 (1H, s), 7.52-7.58(3H, m), 7.99 (3H, m), 11.55 (1H, m), 13.00 (1H, m). Mass spec.: 475.08(MH)⁺.

EXAMPLE 16(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

A stirred solution of(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid (65.7 mg, 0.138 mmol) in 2:1 dimethylformamide/methylene chloride(1.5 mL) at 0° C. was treated with 4-(1-piperidyl)-piperidne (46.5 mg, 2equiv), diisopropylethylamine (0.048 mL, 2 equiv) and PyBOP® (75.5 mg,1.05 equiv). The ice bath was allowed to melt and the mixture wasstirred at room temperature overnight. The solvents were removed underhigh vacuum and the residue was purified by flash chromatography onsilica gel, eluting with 18:1 methylene chloride/methanol containing 1%triethylamine, to give the product as a pale-yellow solid (80.4 mg,93%). ¹H-NMR (CD₃OD, 500 MHz) δ −0.28 (1H, m), 0.75 (1H, m), 1.2-2.0(12H, m), 2.08 (2H, m), 2.4-2.5 (3H, m), 2.59 (3H, s), 2.68 (2H, m),2.90 (4H, m), 3.08 (4H, m), 3.9-5.1 (4H, several m), 6.81 (1H, d), 6.96(1H, t), 7.16 (3H, m), 7.49 (1H, s), 8.03 (1H, s). Mass spec.: 627.29(MH)⁺.

Similarly Prepared:

EXAMPLE 17(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-2-piperidin-1-yl-ethyl]-amide

¹H-NMR (CD₃OD, 500 MHz) δ 0.87 (1H, m), 1.33 (1H, m), 1.47 (2H, m), 1.80(6H, m), 2.57 (3H, s), 2.89 (2H, m), 3.06 (2H, m), 3.18 (4H, m), 3.40(2H, m), 3.61 (1H, m), 4.16 (1H, m), 4.28 (1H, Abq), 4.43 (1H, m), 5.02(1H, m), 6.51 (1H, d), 6.79 (1H, d), 6.96 (1H, t), 7.11 (1H, d), 7.15(1H, t), 7.48 (1H, s), 8.01 (1H, s). Mass spec.: 544.24 (MH)⁺.

EXAMPLE 18(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-dimethylcarbamoyl-2-(7-methyl-1H-indazol-5-yl)-ethyl]-amide

¹H-NMR (CD₃OD, 500 MHz) δ 1.12 (2H, d), 1.64 (2H, m), 2.57 (3H, s), 2.74(1H, m), 2.87 (3H, s), 2.89 (3H, s), 2.86 (2H, m), 3.07 (2H, m), 3.20(1H, m), 4.17 (1H, m), 4.25 (1H, Abq), 4.43 (1H, m), 4.97 (1H, m), 6.79(1H, d), 6.95 (1H, t), 7.0-7.4 (3H, m), 7.48 (1H, d), 8.01 (1H, s). Massspec.: 504.15 (MH)⁺.

EXAMPLE 19(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-amide

¹H-NMR (CD₃OD, 500 MHz) δ 1.30 (2H, m), 1.66 (2H, m), 1.78 (1H, m), 1.90(1H, m), 2.00 (3H, s), 2.19 (1H, m), 2.35 (1H, m), 2.58 (3H, s), 2.88(2H, m), 3.09 (2H, d), 3.10-3.45 (3H, m), 3.66 (1H, m), 4.19 (2H, d),4.20 (2H, s), 4.43 (1H, m), 4.98 (1H, t), 6.80 (1H, d), 6.95 (1H, t),7.11 (2H, m), 7.16 (1H, t), 7.47 (1H, s), 8.02 (1H, s). Mass spec.:559.23 (MH)⁺.

EXAMPLE 20(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-2-pyrrolidin-1-yl-ethyl]-amide

¹H-NMR (CD₃OD, 500 MHz) δ 1.40-1.90 (5H, m), 2.02 (3H, brs), 2.57 (3H,s), 2.86 (1H, m), 2.89 (2H, q), 309 (2H, m), 3.16 (1H, m), 3.25 (2H, m),3.40 (1H, m), 3.56 (1H, m), 4.17 (2H, d), 4.27 (2H, s), 4.40 (1H, m),4.69 (1H, t), 6.80 (1H, d), 6.95 (1H, t), 7.10 (1H, s), 7.16 (1H, m),7.48 (1H, s), 7.53 (1H, m), 8.01 (1H, s). Mass spec.: 530.19 (MH)⁺.

EXAMPLE 21(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide

¹H-NMR (CD₃OD, 500 MHz) δ 1.38 (1H, t), 1.68 (2H, m), 1.81 (1H, m), 2.30(1H, m), 2.53 (3H, s), 2.95 (4H, m), 3.13 (2H, d), 3.22 (1H, m),3.35-3.65 (4H, m), 3.79 (1H, m), 4.18 (2H, d), 4.31 (2H, s), 4.42 (1H,m), 4.99 (1H, t), 6.64 (2H, d), 6.80 (1H, d), 6.89 (1H, m), 6.96 (1H,t), 7.14 (3H, m), 7.51 (1H, s), 7.99 (1H, s), 8.10 (2H, d), 8.16 (1H,m). Mass spec.: 622.26 (MH)⁺.

EXAMPLE 22(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-2-(4-pyridin-2-yl-piperazin-1-yl)-ethyl]-amide

¹H-NMR (CD₃OD, 500 MHz) δ 1.27 (1H, m), 1.38 (1H, m), 1.67 (2H, m), 1.84(1H, m), 2.54 (3H, s), 2.65 (1H, m), 2.88 (2H, m), 3.15 (4H, m), 3.35(1H, m), 3.58 (3H, m), 3.77 (1H, m), 4.18 (2H, d), 4.30 (2H, s), 4.42(1H, m), 5.01 (1H, t), 6.62 (1H, d), 6.70 (1H, t), 6.80 (1H, d), 6.95(1H, t), 7.10 3H, m), 7.50 (1H, s), 7.54 (1H, t), 7.99 (1H, s), 8.05(1H, 7). Mass spec.: 622.25 (MH)⁺.

EXAMPLE 23(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.2-1.73 (14H, m), 2.46 (3H, s), 2.75-3.24(12H, m), 3.87 (2H, m), 4.45 (1H, m), 4.78-4.85 (1H, m), 6.80 (1H,m),6.86 (1H, m), 7.05 (1H, m), 7.12 (1H, m), 7.21 (1H, m), 7.27 (2H, m),7.98 (1H, m), 9.23 (1H, m). Mass spec.: 613.25 (MH)⁺

EXAMPLE 24(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-(1-piperidinyl)-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide

¹H-NMR (CD₃OD, 500 MHz) δ 0.87 (1H, m), 1.28-1.47 (5H, m), 1.74-1.85(4H, m), 2.53 (3H, s), 3.02-3.38 (8H, m), 3.92 (2H, m), 5.02 (1H, m),6.82 (1H, d), 6.99 (1H, d), 7.04-7.09 (2H, m), 7.17 (1H, m), 7.32 (2H,s), 7.45 (1H, s), 7.96 (1H, s). Mass spec.: 530.17 (MH)⁺.

EXAMPLE 25(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide

¹H-(DMSO-d₆, 500 MHz) δ 1.88 (14H, m), 2.64 (3H, s), 2.78 (12H,m), 4.0(2H, m), 4.4 (1H, m), 4.85 (1H, m), 6.80-6.88 (2H, m), 7.03 (2H, m),7.11 (1H, m), 7.23 (1H, m), 7.36 (2H, m), 7.97 (1H, m). Mass spec.:614.73 (MH)⁺.

EXAMPLE 26(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-(1-piperidinyl)-2-oxoethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.15-1.91 (10H, m), 2.47 (3H, s), 2.95-3.05(6H, m) 3.40 (4H, m) 3.95 (2H, d), 4.81(1H, m), 6.81 (1H, d), 6.88 (1H,d), 6.94 (1H, m), 6.99 (1H, m), 7.04 (1H, s), 7.24 (1H, m), 7.37 (1H,s), 7.96 (1H, s). Mass spec.: 531.23 (MH)⁺.

EXAMPLE 27(±)-[1-Dimethylcarbamoyl-2-(7-methyl-1H-indazol-5-yl)-ethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.68-1.88 (4H, m), 2.47 (3H, m), 2.79 (6H,s), 2.89-3.04 (4H, m), 3.96 (2H, d), 4.75 (1H, m), 6.81 (1H, d), 6.88(1H, m), 6.93 (1H, m), 6.98 (1H, m), 7.05 (1H, s), 7.24 (1H, m), 7.43(1H, s), 7.97 (1H, m), 8.32 (1H, s). Mass spec.: 491.14 (MH)⁺.

EXAMPLE 28(±)-[1-(2-adamantyl-carbamoyl)-2-(7-methyl-1H-indazol-5-yl)-ethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.40-1.95 (15H, m), 2.46 (3H, m), 2.89-3.07(4H, m), 3.81 (1H, m), 3.90 (2H, m), 4.48 (1H, m), 6.74 (2H, m), 6.86(1H, d), 6.97 (1H, m), 7.11 (1H, s), 7.24 (1H, m), 7.36 (1H, s), 7.44(1H, s), 7.96 (1H, s). Mass Spec.: 597.27 (MH)⁺.

EXAMPLE 29(±)-1′,2′-Dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide

LC/MS: t_(R)=1.56 min, 609.14 (MH)⁺.

EXAMPLE 30(±)-1′,2′-Dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine-1-carboxylicacid{2-(7-methyl-1H-indazol-5-yl)-1-[(pyridin-4-ylmethyl)-carbamoyl]-ethyl}-amide

LC/MS: t_(R)=1.49 min, 553.12 (MH)⁺.

EXAMPLE 31(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]3′,4′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinoline]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.20-2.00 (14H, m), 2.46 (3H, s), 2.38-3.03(12H, m), 3.87 (2H, m), 4.34 (1H, m), 4.76-4.87 (1H, m), 6.65 (1H, m),6.82-7.64 (3H, m), 7.13-7.23 (2H, m), 7.36 (3 h, m), 7.96 (1H, s). Massspec.: 612.32 (MH)⁺.

EXAMPLE 32(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1-piperidinyl]-2-oxoethyl]3′,4′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinoline]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.10-1.68 (10H, m), 2.46 (3H, s), 2.50-2.60(2H, m), 2.82-2.97 (4H, m), 3.39 (2H, m), 3.85 (2H, m), 4.80 (1H, m),6.68 (1H, m), 6.87 (1H, d), 6.94 (1H, m), 7.03 (1H, s), 7.06 (1H, m),7.15 (1H, m), 7.37 (1H, s), 7.40 (1H, s), 7.96 (1H, s). Mass spec.:529.25 (MH)⁺.

EXAMPLE 33(±)-[1-Dimethylcarbmoyl-2-(7-methyl-1H-indazol-5-yl)-ethy]1-3′,4′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinoline]-1-carboxamide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.43 (2H, m), 1.56 (2H, m), 2.46 (3H, s),2.56 (2H, m), 2.79 (3H, s), 2.90 (5H, m), 3.84 (2H, m), 4.73 1H, m),6.69 (1H, d), 2.69 (1H, d), 6.94 (1H, m), 7.05 (2H, m), 7.14 (1H, m),7.37 (1H, s), 7.42 (1H, s), 7.96 (1H, s). Mass spec.: 489.2 (MH)⁺.

EXAMPLE 34(±)-4-Oxo-2-phenyl-1,3,8-triaza-spiro[4,5]dec-1-ene-8-carboxylic acid{1-(7-methyl-1H-indazol-5-ylmethyl)-2-[1,4]bipiperidinyl-1′-yl-2-oxo-ethyl}-amide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.34-2.00 (14H, m), 2.48 (3H, s overlappedwith DMSO), 2.70-3.30 (12H, m), 3.90 (2H, m), 4.40 (1H, m), 4.82 (1H,m), 6.82 (1H, m), 7.04 (1H, s), 7.37 (2H, m), 7.56 (3H, m), 7.98 (3H,m). Mass spec.: 625.29 (MH)⁺.

EXAMPLE 35(±)-4-Oxo-2-phenyl-1,3,8-triaza-spiro[4,5]dec-1-ene-8-carboxylic acid{1-(7-methyl-1H-indazol-5-ylmethyl)-2-[1-piperidinylyl]-2-oxo-ethyl}-amide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.10-1.62 (6H, m), 1.73 (4H, m), 2.48 (3H,s), 3.00 (6H,m), 3.39 (2H, m), 3.93 (2H, m), 4.82 (1H, m), 6.78 (1H, m),7.05 (1H, s), 7.37 (2H, s), 7.40 (1H, s), 7.53 (2H, m), 7.98 (2H, m).Mass spec.: 543.26 (MH)⁺.

EXAMPLE 36(±)-4-Oxo-2-phenyl-1,3,8-triaza-spiro[4,5]dec-1-ene-8-carboxylicacid[1-dimethylcarbamoyl-2-(7-methyl-1H-indazol-5-yl)-ethyl]amide

¹H-NMR (DMSO-d₆, 500 MHz) δ 1.28-1.61 (4H, m), 2.78 (4H, m), 2.90 (6H,m), 3.94 (2H, m), 4.74 (1H, m), 6.77 (1H, m), 7.05 (1H, s), 7.37 (4H,s), 7.42 (1H, s), 7.52 (2H, m), 7.98 (2H, m). Mass spec.: 502.21 (MH)⁺.

EXAMPLE 374-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{1-(1H-indazol-5-ylmethyl)-2-oxo-2-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-ethyl}-amide

LC/MS: t_(R)=1.51 min, 674 (MH)⁻.

EXAMPLE 384-(3-(1H-Indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionyl)-piperazine-1-carboxylicacid benzyl ester

LC/MS: t_(R)=1.74 min, 665 (MH)⁺.

EXAMPLE 394-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(1H-indazol-5-ylmethyl)-2-oxo-2-piperazin-1-yl-ethyl]-amide

To a degassed solution of4-(3-(1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionyl)-piperazine-1-carboxylicacid benzyl ester (280 mg, 0.42 mmol) in methanol (50 ml) was added 10%palladized charcoal (50 mg). The mixture was shaken in a Parr apparatusunder an atmosphere of hydrogen at 50 psi for 3 h. The mixture wasfiltered through celite. The filtrate was concentrated under reducedpressure to give the desired product in 91% yield. LC/MS: t_(R)=1.22min, 531 (MH)⁺.

EXAMPLE 40a4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{1-(1H-indazol-5-ylmethyl)-2-[4-(2-methyl-butyl)-piperazin-1-yl]-2-oxo-ethyl}-amide

A stirred solution of4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(1H-indazol-5-ylmethyl)-2-oxo-2-piperazin-1-yl-ethyl]-amide (100mg, 0.188 mmol) in methanol (25 mL) was treated with2-methyl-butyraldehyde (0.03 ml, 0.376 mmol). After 1 h at roomtemperature, sodium triacetoxyborohydride (80 mg, 0.316 mmol) was added.The mixture was allowed to stir overnight. The solution was filteredthrough an SCX cartridge. The cartridge was eluted first with methanoland then with a 1M solution of ammonia in methanol. The solvent wasremoved in vacuo to give the desired product in 50% yield. LC/MS:t_(R)=1.31 min, 601(MH)⁺.

General Experimental Procedure for the Preparation of Examples 40b-40k.

The appropriate aldehyde (0.04 mmol) was added to a solution of Example39 piperazine (0.02 mmol) in methanol (2.0 mL) and the resultingsolution was shaken at room temperature for 1 h. Sodiumtriacetoxyborohydride (0.2 mmol) was then added and the solution allowedstir overnight at room temperature. The solution was then filteredthrough a SCX cartridge and the cartridge washed with methanol and anammonia/methanol solution. The ammonia/methanol solution wasconcentrated in vacuo and the crude products were purified bypreparative HPLC to the afford the products listed in Table 1. TABLE 1Examples 40b-40k. HPLC Retention Mass spec Example No. Structure time(min) (MH)⁺ 40b

2.62 629 40c

1.41 587 40d

1.27 573 40e

1.74 611 40f

1.89 643 40g

1.48 610 40h

2.19 614 40i

2.36 629 40j

1.66 647 40k

2.61 545

EXAMPLE 41A3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid cyclohexyl ester

To a stirred solution of(±)-2-amino-3-(7-methyl-1H-indazol-5-yl)-propinic acid (20 mg, 0.042mmoles), 4-(dimethylamino)pyridine (2.5 mg, 0.02 mmoles), and1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (33 mg,0.17 mmoles) in methylene chloride (2 mL) and dimethylforamide (1 mL),was added cyclohexanol (13.3 μL, 0.126 mmoles). The reaction mixture wasstirred at 50-55° C. for 4 h. The solvent was removed under reducedpressure, the residue purified by preparative TLC on silica gel (9:1chloroform/methanol) to give the desired product as white solid (9.4 mg,40%). ¹H-NMR (CD₃OD, 500 MHz) δ 1.32-1.87 (14H, m), 2.57 (3H, s), 2.86(2H, m), 3.11-3.26 (2H, m), 4.13-4.22 (3H, m), 4.46 (1H, m), 4.55 (1H,m), 4.80 (1H, m), 6.79 (1H, d), 6.97 (1H, m), 7.08-7.18 (2H, m), 7.35(1H, s), 7.47 (1H, s), 8.01-8.02 (1H, m). Mass spec.: 559.22 (MH)⁺.

Similarly Prepared:

EXAMPLE 41b3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-benzyl-piperidin-4-yl ester

LC/MS: t_(R)=1.76 min, 650.30 (MH)⁺.

EXAMPLE 41c3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-methyl-piperidin-4-yl ester

LC/MS: t_(R)=1.59 min, 574.27 (MH)⁺.

EXAMPLE 41 d3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 4-phenyl-cyclohexyl ester

LC/MS: t_(R)=2.69 min, 635.29 (MH)⁺.

EXAMPLE 41 e3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid (R)-1-pyridin-4-yl-ethyl ester

LC/MS: t_(R)=1.66 min, 582.22 (MH)⁺.

EXAMPLE 41f3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid(S)-1-pyridin-4-yl-ethyl ester

LC/MS: t_(R)=1.65 min, 582.23 (MH)⁺.

4-Bromo-2-chloro-6-methylphenyldiazo-t-butyl sulfide

4-Bromo-2-chloro-6-methylaniline (4.0 g, 18.3 mmol) was suspended in 24%hydrochloric acid (5 mL). The stirred mixture was cooled to −20° C. andtreated with sodium nitrite (1.32 g, 1.05 equiv.) in water (2 mL),dropwise over 10 min while the temperature was maintained below −5° C.After a further 30 min at −5° C. to −20° C., the mixture was buffered toca. pH 5 with solid sodium acetate. This mixture (kept at ca. −10° C.)was added in portions to a stirred solution of t-butyl thiol (2.06 mL, 1equiv.) in ethanol (18.5 mL) at 0° C. over ca. 10 min. Followingaddition, the mixture was stirred at 0° C. for 30 min and then crushedice (ca. 50 mL) was added. The mixture was stored in the refrigeratorovernight. The resulting light-brown solid was collected by filtration,washed with water, and dried under high vacuum for several hours (4.60g, 78%). Mass spec.: 323.03 (MH)⁺.

5-Bromo-7-chloroindazole

Into a flame-dried round bottom flask,4-bromo-2,-chloro-6-methylphenyldiazo-t-butyl sulfide (4.60 g, 14.4mmol) and potassium t-butoxide (16.1 g, 10 equiv) were combined. A stirbar was added and the mixture placed under nitrogen. To this was addeddry DMSO (50 mL). The mixture was stirred vigorously for 10 min at roomtemperature. The reaction mixture was then carefully poured into amixture of crushed ice (150 mL) and 10% hydrochloric acid (74 mL). Theresulting suspension was left to stand at 4° C. overnight and the solidwas collected by filtration and washed with water. The solid wascollected and dried in vacuo to give 2.86 g (86%) as a beige solid.¹H-NMR (CDCl₃, 500 MHz) δ 7.52 (d, J=1.5, 1H), 7.82 (d, J=1.5, 1H), 8.08(s, 1H). Mass spec.: 230.90 (MH)⁺.

7-Chloroindazole-5-carboxaldehyde

5-Bromo-7-chloroindazole (2.0 g, 8.7 mmol) and sodium hydride (221 mg,1.1 equiv) were weighed into a flame-dried round-bottom flask containinga magnetic stir bar. Under a nitrogen atmosphere at room temperature,dry tetrahydrofuran (30 mL) was added. The mixture was stirred at roomtemperature for 15 min, during which time it became homogeneous. Thestirred mixture was cooled to −78° C. and a solution oftert-butyllithium in pentane (1.7 M, 10.5 mL, 2.0 equiv) was added overseveral minutes. After 30 min at −78° C., the reaction was graduallywarmed to −50° C., kept there for 15 min, and recooled to −78° C.Dimethylformamide (2.8 mL) was slowly added and the mixture allowed towarm to −50° C. The solution was quickly transferred to a separatoryfunnel containing diethyl ether and water. The aqueous was made acidicby the addition of 1 M potassium hydrogen sulfate and neutralized by theaddition of sodium bicarbonate. The aqueous was extracted with diethylether (3×) which was washed with water, then brine, dried over magnesiumsulfate, and concentrated to give 1.7 g (100%) of nearly pure material.An analytically pure sample was obtained by recrystallization from hotmethanol. ¹H-NMR (CDCl₃, 500 MHz) δ 7.97 (s, 1H), 8.20 (s, 1H), 8.30 (s,1H), 10.02 (s, 1H). Mass spec.: 181.09 (MH)⁺.

2-Benzyloxycarbonylamino-3-(7-chloro-1H-indazol-5-yl)-acrylic acidmethyl ester

A stirred suspension of potassium tert-butoxide (375 mg, 1.2 equiv.) inmethylene chloride (20 mL) was cooled to −20° C. and treated with asolution of N-benzyloxycarbonyl-α-phosphonoglycine trimethyl ester (1.11g, 1.2 equiv.) in methylene chloride (5 mL). After 10 min,7-chloroindazole-5-carboxaldehyde (0.50 g, 2.79 mmol) in methylenechloride (5 mL) was added. The reaction was allowed to gradually warm toroom temperature and was stirred for 3 days. The reaction was pouredinto a separatory funnel containing water and diethyl ether. The aqueouswas extracted with diethyl ether (3×) which was washed with brine, driedover magnesium sulfate, and concentrated. Column chromatography gave0.40 g (37%) of product along with 0.20 g (40%) of starting material.¹H-NMR (CDCl₃, 500 MHz) δ 3.64 (s, 3H), 5.11 (s, 2H), 6.44 (bs, 1H),7.30 (bs, 5H), 7.43 (s, 1H), 7.62 (s, 1H), 7.80 (s, 1H), 8.07 (s, 1H).Mass spec.: 386.16 (MH)⁺.

(±)-2-Amino-3-(7-chloro-1H-indazol-5-yl)-propionic acid methyl ester

A solution of2-benzyloxycarbonylamino-3-(7-chloro-1H-indazol-5-yl)-acrylic acidmethyl ester (300 mg, 0.78 mmol) in methanol (10 mL) was treated withtrifluoroacetic acid (0.2 mL), flushed with nitrogen, and treated with10% palladium on charcoal (30 mg). The flask was flushed with hydrogenand allowed to stir under an atmosphere of hydrogen. After 4 days, allstarting material had been consumed. The reaction was flushed withnitrogen, filtered through celite, and concentrated. Columnchromatography gave 78 mg (40%). ¹H-NMR (CDCl₃, 500 MHz) δ 1.31 (bs,3H), 2.95 (dd, J=13.7, 7.9, 1H), 3.18 (dd, J=13.7, 5.2, 1H), 3.48 (s,3H), 3.78 (dd, J=7.9, 5.2, 1H), 7.23 (s, 1H), 7.46 (s, 1H), 8.00 (s,1H). Mass spec.: 254.06 (MH)⁺.

EXAMPLE 42(±)-3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

A stirred solution of (±)-2-amino-3-(7-chloro-1H-indazol-5-yl)-propionicacid methyl ester (78 mg, 0.31 mmol) in tetrahydrofuran (2 mL) at 0° C.was treated with carbonyl diimidazole (50 mg, 1 equiv). The reaction wasstirred for 5 min, warmed to room temperature, stirred 10 min, andtreated with 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (78 mg,1.1 equiv). The mixture was stirred at room temperature overnight. Thesolvent was evaporated and the residue purified by column chromatographyto give 148 mg (94%) as a white powder. ¹H-NMR (DMSO-d₆, 500 MHz) δ 1.46(m, 4H), 2.55-2.80 (m, 2H), 3.05 (dd, J=13.7, 10.7, 1H), 3.15 (m, 1H),3.62 (s, 3H), 4.04 (d, J=13.4, 2H), 4.11 (s, 2H), 4.22-4.39 (m, 2H),6.76 (d, J=7.9, 1H), 6.87 (dd, J=7.3, 7.3, 1H), 6.90 (d, J=8.2, 1H),7.08 (d, J=7.6, 1H), 7.12 (dd, J=7.6, 7.6, 1H), 7.40 (s, 1H), 7.60 (s,1H), 8.15 (s, 1H), 9.18 (s, 1H), 13.48 (s, 1H). Mass spec.: 511.18(MH)⁺.

EXAMPLE 43(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-chloro-1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

A suspension of(±)-3-(7-chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (15 mg, 0.029 mmol) in 1:1 tetrahydrofuran/methanol (1mL) at room temperature was treated with a solution of lithium hydroxide(3.0 mg, 2.5 equiv) in water (0.25 mL), and the resulting solution wasstirred for 1.5 h. The solution was cooled to 0° C., treated withaqueous 1 M potassium hydrogen sulfate (60 μL, 2.0 equiv), andconcentrated to give the crude acid which was immediately used withoutpurification. The crude acid was dissolved in dimethylformamide (0.3 mL)and sequentially treated with methylene chloride (0.15 mL),4-piperidyl-piperidine (10.1 mg, 2 equiv), diisopropylethylamine (10 μL,2 equiv), and PyBOP® (16.5 mg, 1.1 equiv). The solution was stirred 30min and concentrated. The product was purified by column chromatographyto give 14.7 mg (77%, 2 steps). ¹H-NMR (CDCl₃, 500 MHz) δ 1.30-1.60 (m,8H), 1.65-1.88 (m, 5H), 2.14 (m, 1H), 2.23 (m, 1H), 2.30-2.70 (m, 7H),2.80-3.20 (m, 5H), 3.94 (d, J=13.4, 13.1, 1H), 4.10-4.30 (m, 4H), 4.55(m, 1H), 4.62 (dd, J=13.1, 12.8, 1H), 5.19 (m, 1H), 5.91 (dd, J=30.2,22.3, 1H), 6.70 (d, J=7.6, 1H), 6.92 (dd, J=7.6, 7.3, 1H), 7.01 (dd, J,7.9, 7.6, 1H), 7.13 (s, 0.4H), 7.15 (dd, J=7.9, 7.6, 1H), 7.24 (s,0.6H), 7.33 (s, 0.4H), 7.43 (s, 0.6H), 7.49 (bs, 1H), 7.91 (s, 0.4H),7.95 (s, 0.6H), 11.25 (bd, J=50.7, 1H). Mass spec.: 647.37 (MH)⁺.

4-Bromo-2-ethyl-6-methyl-phenylamine

2-Ethyl-6-methyl-phenylamine (14 mL, 100 mmol) was dissolved inconcentrated hydrochloric acid (30 mL) and water (220 mL) and cooled to0° C. To this was added bromine (5.1 mL, 1 equiv.) dropwise. There wasrapid formation of a white precipitate. The precipitate was filtered andwashed with diethyl ether. The precipitate was suspended in water andneutralized with aqueous potassium carbonate. An oil formed which wasextracted into diethyl ether. The ethereal was dried over potassiumcarbonate, filtered, and concentrated to give 7.0 g (33%) as a purpleoil which was used without purification. Mass spec.: 214.01 (MH)⁺.

4-Bromo-2-ethyl-6-methylphenyldiazo-t-butyl sulfide

4-Bromo-2-ethyl-6-methylaniline (7.0 g, 33 mmol) was suspended in 7.8 Mhydrochloric acid (30 mL). The stirred mixture was cooled to −20° C. andtreated with sodium nitrite (2.27 g, 1.05 equiv.) in water (5 mL),dropwise over 10 min while the temperature was maintained below −5° C.After a further 30 min at −5° C. to −20° C., the mixture was buffered toca. pH 5 with solid sodium acetate. This mixture (kept at ca. −10° C.)was added in portions to a stirred solution of t-butyl thiol (3.7 mL, 1equiv.) in ethanol (50 mL) at 0° C. over ca. 10 min. Following addition,the mixture was stirred at 0° C. for 30 min and then crushed ice (ca. 50mL) was added. The mixture was stored in the refrigerator for 2 h. Theresulting light-brown solid was collected by filtration, washed withwater, and dried under high vacuum for several hours (9.47 g, 92%). Massspec.: 315.05 (MH)⁺.

5-Bromo-7-ethyl-1H-indazole

To a stirred solution of potassium t-butoxide (33.6 g, 10 equiv.) inDMSO (200 mL) was added a solution of4-bromo-2-ethyl-6-methylphenyldiazo-t-butyl sulfide (9.4 g, 30 mmol) inDMSO (100 mL) via cannula. The mixture was stirred vigorously for 1 h.The reaction mixture was then carefully poured into a mixture of crushedice (500 mL), concentrated hydrochloric acid (25 mL), and water (100mL). The resulting precipitate was filtered, washed with water,dissolved in methanol, and concentrated to give 5.7 g (85%) as a tansolid. ¹H-NMR (CDCl₃, 500 MHz) δ 1.39 (t, J=7.6, 3H), 2.92 (q, J=7.6,2H), 7.30 (s, 1H), 7.75 (s, 1H), 8.04 (s, 1H). Mass spec.: 225.00 (MH)⁺.

7-Ethyl-1H-indazole-5-carbaldehyde

5-Bromo-7-ethyl-1H-indazole (2.0 g, 8.9 mmol) and sodium hydride (226mg, 1.1 equiv.) were weighed into a flame-dried round-bottom flaskcontaining a magnetic stir bar. Under a nitrogen atmosphere at roomtemperature, dry tetrahydrofuran (60 mL) was added. The mixture wasstirred at room temperature for 15 min. The stirred mixture was cooledto −78° C. and a solution of tert-butyllithium in pentane (1.7 M, 10.5mL, 2.0 equiv.) was added over several minutes. After 15 min at −78° C.,the reaction was gradually warmed to −50° C., and recooled to −78° C.Dimethylformamide (2.8 mL) was slowly added and the mixture allowed towarm to −50° C. The solution was quickly transferred to a stirredsolution of water 300 mL and 1 M potassium hydrogen sulfate (25 mL). Theresulting suspension was extracted with diethyl ether, washed withwater, then brine, dried over magnesium sulfate, and concentrated.Column chromatography gave 160 mg (10%) as a white solid. ¹H-NMR (CD₃OD,500 MHz) δ 1.38 (t, J=7.6, 3H), 2.98 (q, J=7.6, 2H), 7.71 (s, 1H), 8.22(s, 1H), 8.24 (s, 1H), 9.96 (s, 1H). Mass spec.: 175.08 (MH)⁺.

2-Benzyloxycarbonylamino-3-(7-ethyl-1H-indazol-5-yl)-acrylic acid methylester

To a stirred solution of N-benzyloxycarbonyl-α-phosphonoglycinetrimethyl ester (0.61 g, 2.0 equiv.) and7-ethyl-1H-indazole-5-carbaldehyde (160 mg, 0.92 mmol) intetrahydrofuran (5 mL) at 0° C. was added tetramethylguanidine (0.22 mL,1.9 equiv.). The reaction was allowed to slowly warm to room temperatureovernight. The reaction was concentrated, dissolved in diethyl ether,washed with water, then brine, dried (magnesium sulfate), andconcentrated. The residue was purified by column chromatography to give333 mg (95%) as an oil. ¹H-NMR (CDCl₃, 500 MHz) δ 1.33 (t, J=7.6, 3H),2.86 (q, J=7.3, 2H), 3.83 (s, 3H), 5.11 (s, 2H), 6.39 (bs, 1H), 7.29(bs, 5H), 7.43 (s, 1H), 7.50 (s, 1H), 7.78 (s, 1H), 8.04 (s, 1H). Massspec.: 380.17 (MH)⁺.

(±)-2-Amino-3-(7-ethyl-1H-indazol-5-yl)-propionic acid methyl ester

To a solution of2-benzyloxycarbonylamino-3-(7-ethyl-1H-indazol-5-yl)-acrylic acid methylester (330 mg, 0.78 mmol) in methanol (5 mL) under nitrogen was addedpalladium on charcoal (10%, 33 mg). The flask was flushed with hydrogenand allowed to stir under an atmosphere of hydrogen overnight. Thereaction was flushed with nitrogen, filtered through celite, andconcentrated to give 210 mg (98%) which was used without purification.¹H-NMR (CDCl₃, 500 MHz) δ 1.34 (t, J=7.6, 3H), 2.85 (q, J=7.6, 2H), 2.96(dd, J=13.7, 7.6, 1H), 3.19 (dd, J=13.7, 8.6, 1H), 3.48 (s, 2H), 3.73(s, 3H), 3.80 (dd, J=7.6, 5.2, 1H), 6.99 (s, 1H), 7.38 (s, 1H), 7.97 (s,1H). Mass spec.: 248.15 (MH)⁺.

EXAMPLE 44(±)-3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

A stirred solution of (±)-2-amino-3-(7-ethyl-1H-indazol-5-yl)-propionicacid methyl ester (100 mg, 0.41 mmol) in tetrahydrofuran (2 mL) at 0° C.was treated with carbonyl diimidazole (66 mg, 1 equiv). The reaction wasstirred for 5 min, warmed to room temperature, stirred for 15 min, andthen treated with 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (103mg, 1.1 equiv). The mixture was stirred at room temperature overnight.The solvent was evaporated and the residue purified by columnchromatography to give 188 mg (92%) as a white solid. ¹H-NMR (CDCl₃, 500MHz) δ 1.36 (t, J=7.6, 3H), 1.69 (m, 4H), 2.86 (m, 2H), 2.90 (q, J=7.6,2H), 3.22 (dd, J=5.5, 4.9, 2H), 3.75 (s, 3H), 4.03 (dd, J=44.0, 13.7,2H), 4.26 (s, 2H), 4.51 (m, 1H), 4.84 (m, 1H), 5.02 (m, 1H), 6.70 (d,J=7.9, 1H), 6.90-7.05 (m, 4H), 7.16 (dd, J=7.6, 7.6, 1H), 7.34 (s, 1H),8.03 (s, 1H). Mass spec.: 505.29 (MH)⁺.

EXAMPLE 45(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-ethyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

To a solution of(±)-3-(7-ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (15 mg, 0.03 mmol) in methanol (0.6 mL) was added asolution of lithium hydroxide monohydrate (3.0 mg, 2.5 equiv) in water(0.1 mL), and the resulting solution was stirred for 6 h. The solutionwas cooled to 0° C., treated with aqueous 1 M potassium hydrogen sulfate(60 μL, 2.0 equiv), and concentrated to give the crude acid which wasimmediately used without purification. The crude acid was dissolved indimethylformamide (0.4 mL), cooled to 0° C., and sequentially treatedwith methylene chloride (0.2 mL), 4-piperidyl-piperidine (11 mg, 2.2equiv), diisopropylethylamine (12 μL, 2.3 equiv.), and PyBOP® (19 mg,1.2 equiv). The solution was stirred for 15 min at 0° C., warmed to roomtemperature, stirred 1.5 h, and concentrated. The product was purifiedby column chromatography to give 14.5 mg (76%, 2 steps). ¹H-NMR (CDCl₃,500 MHz) δ 1.28-1.48 (m, 10H), 1.52 (m, 2H), 1.60-1.82 (m, 6H), 1.95 (m,1.4H), 2.06 (m, 1.6H), 2.20-2.50 (m, 5H), 2.77-2.93 (m, 5H), 2.96-3.17(m, 2H), 3.76 (d, J=13.4, 0.4H), 3.86 (d, J=13.7, 0.6H), 4.10-4.20 (m,2H), 4.26 (s, 2H), 4.57 (m, 2H), 5.10-5.24 (m, 1H), 5.67 (d, J=8.2,0.6H), 5.74 (d, J=7.9, 0.4H), 6.67 (d, J=7.9, 1H), 5.67 (d, J=8.2,0.6H), 5.74 (d, J=7.9, 0.4H), 6.67 (d, J=7.9, 1H), 6.93 (dd, J=7.6, 7.3,1H), 6.96 (s, 0.4H), 7.03 (dd, J=7.0, 6.7, 1H), 7.09 (m, 1.6H), 7.15(dd, J=7.0, 6.7, 1H), 7.31 (s, 0.4H), 7.38 (s, 0.6H), 7.94 (s, 0.4H),7.95 (s, 0.6H). Mass spec.: 641.50 (MH)⁺.

(3,4-Dinitro-phenyl)-methanol

Borane-tetrahydrofuran complex (1M in tetrahydrofuran, 800 mL, 800 mmol)was added at −20° C. over 45 min to a solution of 3,4-dinitrobenzoicacid (93.5 g, 441 mmol) in tetrahydrofuran (300 mL). The resultingmixture was stirred at −20° C. for 1 h and then warmed to roomtemperature and stirred overnight. It was quenched by the addition of 32mL of 1:1 acetic acid/water. Solvents were removed in vacuo and theresidue was poured into an ice-cold 1000 mL of sat. sodium bicarbonatewith vigorous stirring over 15 min. The mixture was extracted with ethylacetate (3×500 mL). The combined organic layers were washed with sat.sodium bicarbonate, brine and dried over sodium sulfate. Afterfiltration, solvents were removed to afford the title compound as alight yellow solid (100%). ¹H-NMR (CDCl₃, 500 MHz) δ 7.91(d, J=8.0 Hz,1H), 7.89 (s, 1H), 7.71 (dd, J=8.5, 1.0 Hz, 1H), 4.87 (s, 2H), 2.30 (s,1H).

3,4-Dinitro-benzaldehyde

A solution of (3,4-dinitro-phenyl)-methanol (95.3 g, 481 mmol) inmethylene chloride (500 mL) was added all at once to a suspension ofpyridinium chlorochromate (156 g, 722 mmol) in methylene chloride (900mL). The mixture was stirred at room temperature for 1.5 h and thenether (1500 mL) was added. The supernatant was decanted from theresulting black gum, and the insoluble residue was washed thoroughlywith methylene chloride (3×250 mL). The combined organic solution werefiltered through a pad of florisil to afford a light bright yellow clearsolution. Solvents were removed in vacuo and the residue was purified bysilica gel chromatography using methylene chloride as eluent to affordthe title compound as a yellow solid (71%). ¹H-NMR (CDCl₃, 300 MHz) δ8.45 (d, J=1.5 Hz, 1H), 8.28 (dd, J=8.1, 1.5 Hz, 1H), 8.07 (d, J=8.1 Hz,1H). ¹³CNMR (CD₃OD, 125 MHz) δ 187.7, 139.2, 134.2, 126.2, 125.7.

2-Benzyloxycarbonylamino-3-(3,4-dinitro-phenyl)-acrylic acid methylester

1,1,3,3-Tetramethylguanidine (41.2 mL, 329 mmol) was added at roomtemperature to a solution of N-(benzyloxycarbonyl)-alpha-phophonoglycinetrimethyl ester (114.1 g, 344 mmol) in tetrahydrofuran (800 mL). Themixture was stirred at room temperature for 15 min and cooled to −78° C.A solution 3,4-dinitro-benzaldehyde (61.4 g, 313 mmol) intetrahydrofuran (200 mL) was slowly added via cannula. The resultingmixture was stirred at −78° C. for 2 h and then allowed to warm to roomtemperature overnight. Solvents were removed in vacuo, and the yellowresidue was dissolved in 4.5 L of ethyl acetate. The solution was washedwith 1.5 L of 1N sulfuric acid, water twice, brine and dried over sodiumsulfate. After filtration, solvents were removed in vacuo and theresidue was crystallized from ethyl acetate (20 g crude product/100 mLof ethyl acetate). The yellow crystals were collected and furtherpurified by chromatography on silica gel using methylene chloride aseluent. The title compound was obtained a s yellow crystals (77%).¹H-NMR (CDCl₃, 500 MHz) δ 7.85 (d, J=1.5 Hz, 1H), 7.74 (d, J=8.0 Hz,1H), 7.62 (dd, J=8.5, 1.5 Hz, 1H), 7.35-7.34 (m, 3H), 7.34 (br s, 2H),7.23 (s, 1H), 6.95 (br s, 1H), 5.07 (s, 2H), 3.90 (s, 3H).

Similarly Prepared:

2-Benzyloxycarbonylamino-3-(3-hydroxy-4-nitro-phenyl)-acrylic acidmethyl ester

¹H-NMR (CDCl₃, 500 MHz) δ 7.93 (d, J=9.0 Hz, 1H), 7.32 (br s, sH), 7.28(br s, 2H), 7.17 (s, 1H), 7.16 (d, J=2.0 Hz, 1H), 7.01 (dd, J=9.0, 2.0Hz, 1H), 6.74 (br s, 1H), 5.06 (s, 2H), 3.86 (s, 3H).

(R)-2-Benzyloxycarbonylamino-3-(3,4-dinitro-phenyl)-propionic acidmethyl ester

An oven-dried 500 mL Shlenck flask was put into a glove-bag filled withnitrogen. After the glove-bag was evacuated and filled with nitrogen(3×), the flask was sealed and taken out of the glove-bag and weighed.It was put back into the glove-bag and evacuated and filled withnitrogen (3×), then it was charged with(−)-1,2-bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadienene)rhodium(I) trifluoromethanesulfonate. The flask was sealed and taken out of theglove-bag and weighed (784 mg, 1.08 mmol).2-Benzyloxycarbonylamino-3-(3,4-dinitro-phenyl)-acrylic acid methylester (8.72 g, 21.7 mmol) was added to another 500 mL of Schlenck flaskand was evacuated and filled with nitrogen (3×). Methylene chloride (350mL, degassed with nitrogen for 2 h) was added and the resulting solutionwas transferred to the catalyst flask via cannula. The flask was purgedand filled with hydrogen (4×) and the mixture was stirred at roomtemperature for 4 h. The solvents were removed in vacuo and the residuewas purified by silica gel chromatography using ethyl acetate/hexanes(1:1) as eluent to afford the title compound as a light tan gummy solid(99% yield and 99.2% ee determined by HPLC analysis using the followingconditions: Chiralpak AD column (4.6×250 mm, 10 um; A=ethanol, B=hexane;40% B @ 1.0 mL/min for 14 min; retention times: 10.9 min for R enatiomerand 6.9 min for S enatiomer). ¹H-NMR (CDCl₃, 500 MHz) δ 7.80 (d, J=8.0Hz, 1H), 7.63 (s, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.38-7.31 (m, 5H), 5.37(d, J=6.0 Hz, 1H), 5.13-5.05 (m, 2H), 4.68 (d, J=6.0 Hz, 1H), 3.71 (s,3H), 3.36 (dd, J=13.5, 5.0 Hz, 1H), 3.17 (dd, J=13.5, 6.0 Hz, 1H).

Similarly Prepared:

(R)-2-Benzyloxycarbonylamino-3-(3-hydroxy-4-nitro-phenyl)-propionic acidmethyl ester

¹H-NMR (CDCl₃, 500 MHz) δ 7.97 (d, J=9.0 Hz, 1H), 7.36-7.30 (m, 5H),6.90 (s, 1H), 6.71 (d, J=8.5 Hz, 1H), 5.29 (d, j=7.0 Hz, 1H), 5.11 (d,J=12.5 Hz, 1H), 5.07 (d, J=12.0 Hz, 1H), 4.68 (dd, j=13.0, 6.0 Hz, 1H),3.74 (s, 3H), 3.20 (dd, j=13.5, 5.0 Hz, 1H), 3.05 (dd, J=13.5, 6.0 Hz,1H).

(R)-2-Benzyloxycarbonylamino-3-(3,4-diamino-phenyl)-propionic acidmethyl ester

Solid ammonium formate (2.27 g, 36 mmol) was added in small portions at0° C. to a methanol (50 mL, degassed with nitrogen for 2 h) suspensionof (R)-2-benzyloxycarbonylamino-3-(3,4-dinitro-phenyl)-propionic acidmethyl ester (1.45 g, 3.6 mmol) and zinc powder (1.41 g, 21.6 mmol). Theresulting mixture was stirred at room temperature overnight. Thesolvents were removed in vacuo and then toluene (30 mL, degassed) andethyl acetate (30 mL, degassed) were added, followed by acetic acid (3mL). The mixture was further diluted until all organic solids dissolved,then it was washed with water, brine and dried over sodium sulfate.After filtration, solvents were removed in vacuo to afford the titlecompound containing 1 equivalent of acetic acid as a reddish gummy solid(85%). Mass Spec.: 344.18 (MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-benzoimidazol-5-yl)-propionicacid methyl ester

A solution of(R)-2-benzyloxycarbonylamino-3-(3,4-diamino-phenyl)-propionic acidmethyl ester-acetic acid (640 mg) in acetic acid (8 mL) was heated at130° C. for 4 h. The mixture was then poured into water and cooled to 0°C. The pH was adjusted to 8 by gradual addition of solid sodiumbicarbonate. The mixture was then extracted with ethyl acetate (3×100mL), and the combined organic layers were washed with water, brine anddried over sodium sulfate. After filtration, solvents were removed toafford the title compound as a brownish foamy solid (95%). ¹H-NMR(CDCl₃, 500 MHz) δ 7.39 (d, J=8.5 Hz, 1H), 7.35 (s, 1H), 7.26-7.22 (m,5H), 7.06 (d, J=8.0 Hz, 1H), 5.03 (d, J=12.5 Hz, 1H), 4.99 (d, J=13.0hz, 1H), 4.51 (dd, J=8.5, 5.5 Hz, 1H), 3.70 (s, 3H), 3.27 (dd, J=13.5,5.0 Hz, 1H), 3.03 (dd, J=14.0, 9.0 Hz, 1H), 2.55 (s, 3H). Mass spec.:368.19 (MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-[2-methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-propionicacid methyl ester and(R)-2-Benzyloxycarbonylamino-3-[2-methyl-1-(2-trimethylsilanyl-ethanesulfonyl)-1H-benzoimidazol-5-yl]-propionicacid methyl ester

To a suspension of(R)-2-benzyloxycarbonylamino-3-(2-methyl-1H-benzoimidazol-5-yl)-propionicacid methyl ester (533 mg, 1.96 mmol), and sodium carbonate inacetonitrile (20 mL) was added neat 2-trimethylsilanyl-ethanesulfonylchloride all at once. The mixture was stirred at room temperatureovernight. Solvents were removed and the residue was purified bychromatography on silica gel using ethyl acetate/hexanes (1:2) as eluentto afford the title compound as a waxy solid (1:1 mixture of N1 and N3isomers, 66%).

¹H-NMR (CDCl₃, 500 MHz) δ 7.68 (d, J=8.5 hz, 0.5H), 7.55 (d, J=8.5 Hz,0.5H), 7.53 (s, 0.5H), 7.41 (s, 0.5H), 7.34-7.29 (m, 5H), 7.06-7.04 (m,1H), 5.22 (d, J=8.0 Hz, 0.5H), 5.17 (d, J=7.5 Hz, 0.5H), 5.11-5.07 (m,2H), 4.72-4.69 (m, 1H), 3.75 (s, 1.5H), 3.72 (s, 1.5H), 3.24-3.17 (m,2H), 2.79 (s, 3H), 0.92-0.83 (m, 2H), −0.02 (s, 4.5H), −0.05 (s, 4.5H).Mass spec.: 532.26 (MH)⁺.

(R)-2-Amino-3-[2-methyl-1-(2-trimethylsilanyl-ethanesulfonyl)-1H-benzoimidazol-5-yl]-propionicacid methyl ester and(R)-2-Amino-3-[2-methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-propionicacid methyl ester

A methanol (50 mL) suspension of(R)-2-benzyloxycarbonylamino-3-[2-methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-propionicacid methyl ester and(R)-2-Benzyloxycarbonylamino-3-[2-methyl-1-(2-trimethylsilanyl-ethanesulfonyl)-1H-benzoimidazol-5-yl]-propionicacid methyl ester (1:1 mixture, 600 mg), and 10% palladium on charcoal(180 mg) was agitated on a Parr apparatus overnight under 40 psi ofhydrogen at room temperature. After replacing the hydrogen atmospherewith nitrogen, the mixture was filtered through a pad of celite.Solvents were removed in vacuo to afford the title compound as a tansolid (80%). ¹H-NMR (CD₃OD, 500 MHz) δ 7.81 (d, J=8.5, 0.5 Hz, 0.5H),7.70 (s, 0.5H), 7.58 (d, J=8.5 Hz, 0.5H), 7.49 (s, 0.5H), 7.25 (d, J=9.0Hz, 1H), 3.89 (dd, J=14.0, 6.5 Hz, 1H), 3.75 (s, 1.5H), 3.72 (s, 1.5H),3.55-3.51 (m, 2H), 3.18 (d, J=6.0 Hz, 1H), 3.22-3.18 (m, 0.5H),3.14-3.09 (m, 0.5H), 2.81 (s, 1.5H), 2.80 (s, 1.5H), 0.92-0.88 (m, 2H),0.02 (s, 4.5H), 0.01 (s, 4.5H); ¹³CNMR (CD₃OD, 125 MHz) δ 174.3, 174.1,153.5, 153.3, 141.7, 140.6, 133.9, 133.82, 133.78, 132.7, 126.5, 126.3,119.7, 119.0, 114.1, 113.4, 55.6, 51.8, 51.7, 51.6, 40.2, 39.8, 15.83,15.77, 9.9, −3.07, −3.11. Mass spec.: 398.20 (MH)⁺.

(R)-3-[2-Methyl-1-(2-trimethylsilanyl-ethanesulfonyl)-1H-benzoimidazol-5-yl]-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester and(R)-3-[2-Methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for(R)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester. Purified by silica gel chromatography using ethylacetate with 1% triethylamine as eluent to afford the title compound asan off-white solid (87%). ¹H-NMR (CD₃OD, 500 MHz) δ 7.82 (d, J=8.5 Hz,0.5H), 7.80 (s, 0.5H), 7.59 (d, J=8.0 Hz, 0.5H), 7.55 (s, 0.5H),7.33-7.30 (m, 1H), 7.16 (t, J=8.0 Hz, 1H), 7.12 (t, J=7.5 Hz, 1H), 6.95(t, J=7.5 Hz, 1H), 6.79 (d, J=7.5 Hz, 1H), 4.60-4.55 (m, 1H), 4.45-4.40(m, 1H), 4.29-4.27 (m, 2H), 4.15-4.10 (m, 2H), 3.77 (s, 1.5H), 3.74 (s,1.5H), 3.56-3.51 (m, 2H), 3.35-3.31 (m, 2H), 3.21-3.15 (m, 1H),2.91-2.80 (m, 2H), 2.78 (s, 1.5H), 2.77 (s, 1.5H), 1.76-1.73 (m, 1H),1.66-1.61 (m, 2H), 0.92-0.87 (m, 2H), 0.009 (s, 4.5H), −0.007 (s, 4.5H).¹³CNMR (CD₃OD, 125 MHz) 173.8, 173.7, 158.2, 158.1, 155.6, 153.4, 153.2,141.6, 140.3, 137.2, 135.3, 135.1, 133.7, 132.5, 128.2, 126.4, 126.3,125.7, 122.13, 122.10, 119.6, 118.8, 118.4, 114.0, 113.4, 113.2, 57.3,56.2, 51.9, 51.7, 51.5, 43.8, 43.7, 42.9, 37.6, 37.2, 28.4, 17.4, 15.7,15.6, 9.9, −3.1, −3.2. Mass spec.: 655.36 (MH)⁺.

(R)-3-(2-Methyl-1H-benzoimidazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

The 1:1 mixture of(R)-3-[2-Methyl-1-(2-trimethylsilanyl-ethanesulfonyl)-1H-benzoimidazol-5-yl]-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester and(R)-3-[2-Methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester was treated as described above for(R)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid. The hydrolysis conditions (lithiumhydroxide/methanol-tetrahydrofuran-water (1:1:1) at −15° C. overnightwere used. The title compound was obtained as a white solid (25%). Massspec.: 477.24 (MH)⁺.

EXAMPLE 46(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(2-methyl-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for(R)-4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide.Purified by silica gel chromatography using methylenechloride:methanol:triethylamine (93:5:2) as eluent to give a whitesolid. This was dissolved in ethyl acetate (60 mL) and washed with a 1:1sat. sodium bicarbonate/brine twice and dried over sodium sulfate. Afterfiltration, solvents were removed to afford the title compound as awhite solid (11% yield). LC/MS: t_(R)=1.59 min, 627.34 (MH)⁺.

(R)-3-(4-Amino-3-hydroxy-phenyl)-2-benzyloxycarbonylamino-propionic acidmethyl ester hydochloride

Powdered iron (3.7 g, 66.4 mmol) and ammonium chloride (5.9 g, 111 mmol)were added at 0° C. to a solution of(R)-2-benzyloxycarbonylamino-3-(3-hydroxy-4-nitro-phenyl)-propionic acidmethyl ester (2.07 g, 5.53 mmol) in degassed 1:1 methanol/water (400mL). The resulting mixture was stirred at room temperature for 48 h.Trifluoroacetic acid (7 mL) was added, and the mixture was swirled untilit was a clear dark red solution containing a suspension of unreactediron powder. The mixture was filtered and the filtrate was concentratedin vacuo. The residue was extracted with ethyl acetate (2×150 mL), thecombined organic layers were washed with brine and dried over sodiumsulfate. After filtration, hydrochloric acid (4.2 mL, 4M in dioxane) wasadded. Solvents were removed in vacuo, and the title compound wasobtained as a tan foamy solid (80%). ¹H-NMR (CD₃OD, 500 MHz) δ 7.34-7.28(m, 5H), 7.20 (d, J=8.0 hz, 1H), 6.88 (s, 1H), 6.78 (d, J=7.5 Hz, 1H),5.05-5.00 (m, 2H), 4.42 (dd, J=8.5, 5.0 Hz, 1H), 3.70 (s, 3H), 3.65 (s,1H), 3.33 (br s, 2H), 3.11 (dd, J=14.0, 5.0 hz, 1H), 2.90 (dd, J=13.5,9.0 Hz, 1H). ¹³CNMR (CD₃OD, 125 MHz) 172.5, 157.4, 151.2, 140.2, 137.0,128.5, 128.0, 127.7, 123.8, 120.9, 117.0, 116.9, 67.2, 55.7, 52.0, 37.2.Mass spec.: 345.20 (MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

A methylene chloride (15 mL) solution of carbonyl diimidazole (498 mg,3.07 mmol) was added at 0° C. to a solution of(R)-3-(4-amino-3-hydroxy-phenyl)-2-benzyloxycarbonylamino-propionic acidmethyl ester (1.17 g, 3.07 mmol), diisopropylethylamine (1.60 mL, 9.21mmol), and methylene chloride (85 mL). The mixture was stirred at 0° C.for 4 h. The solvents were removed in vacuo and the residue was purifiedby silica gel chromatography using ethyl acetate/hexanes as eluent toafford the title compound as a white solid (51%). ¹H-NMR (CDCl₃, 500MHz) δ 9.07 (s, 1H), 7.37-7.29 (m, 5H), 6.96 (s, 1H), 6.90 (d, J=8.0 Hz,1H), 6.87 (d, J=8.0 Hz, 1H), 5.36 (d, J=8.0 Hz, 1H), 5.11 (d, J=12.0 Hz,1H), 5.07 (d, J=12.5 Hz, 1H), 4.65 (dd, J=13.5, 5.5 Hz, 1H), 3.74 (s,3H), 3.17 (dd, J=14.0, 5.5 Hz, 1H), 3.07 (dd, J=14.0, 6.0 Hz, 1H).¹³CNMR (CDCl₃, 125 MHz) δ 171.9, 155.7, 155.5, 144.1, 136.2, 130.8,128.6, 128.42, 128.38, 128.2, 125.1, 111.1, 109.8, 67.2, 55.1, 52.6,38.3. Mass spec.: 371.18 (MH)⁺.

(R)-2-Amino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionic acid methylester

A solution of(R)-2-benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (310 mg) in 4.4% formic acid in methanol (20 ml,freshly prepared in degassed methanol) was added via cannula to asuspension of 10% palladium on charcoal in 4.4% formic acid in methanol(20 ml, freshly prepared in degassed methanol). The resulting mixturewas stirred at room temperature for 4 h. After filtration through a padof celite, the solvents were removed in vacuo giving a tan solid. Thesolid was dissolved in a mixture of ethyl acetate (50 mL), toluene (10mL) and ethanol (40 ml), and solid sodium bicarbonate (3.1 g) was added.The mixture was stirred at room temperature for 2 h and filtered.Solvents were removed in vacuo to afford the title compound.

¹H-NMR (CD₃OD, 500 MHz) δ 8.41 (br s, 2H), 7.17 (s, 1H), 7.09 (br s,2H), 4.32 (s, 1H), 3.83 (s, 3H), 3.33 (s, 1H), 3.30 (s, 1H), 3.22 (s,1H). Mass spec.: 237.20 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for(R)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester. Purified by silica gel chromatography using methylenechloride:methanol:triethylamine (93:5:2) as eluent to afford the titlecompound as a white solid (33%). ¹H-NMR (CD₃OD, 500 MHz) δ 7.17-7.13 (m,3H), 7.08 (d, J=7.9 hz, 1H), 7.03 (d, J=8.0 Hz, 1H), 6.95 (t, J=7.0 Hz,1H), 6.79 (d, J=8.0 Hz, 1H), 4.55-4.51 (m, 1H), 4.44-4.41 (m, 1H), 4.33(s, 2H), 4.14-4.10 (m,2H), 3.74 (s, 3H), 3.33 (br s, 2H), 3.23 (dd,j=13.7, 5.2 Hz, 1H), 3.03 (dd, J=14.0, 9.7 Hz, 1H), 2.92-2.82 (m, 2H),1.79-1.63 (m, 4H). ¹³CNMR (CD₃OD, 125 MHz) 173.8, 158.2, 156.2, 155.6,144.4, 137.1, 132.7, 129.3, 128.2, 125.7, 125.0, 122.2, 118.4, 113.4,110.6, 109.6, 56.2, 52.0, 51.7, 43.8, 42.9, 37.3, 28.4. Mass spec.:494.30 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid. The hydrolysis conditions (lithiumhydroxide/methanol-tetrahydrofuran-water (1:1:1) at −15° C. overnightwere used. The title compound was obtained as a white solid (95%). Massspec.: 480.30 (MH)⁺.

EXAMPLE 47(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-ethyl]-amide

Prepared as described above for(R)-4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide.The crude product was purified by silica gel chromatography usingmethylene chloride:methanol:triethylamine (93:5:2) as eluent to give awhite solid. This was dissolved in ethyl acetate (60 mL) and washed witha 1:1 sat. sodium bicarbonate/brine twice and dried over sodium sulfate.After filtration, solvents were removed to afford the title compound asa white solid (70%). ¹H-NMR (CD₃OD, 500 MHz) δ 7.20-7.14 (m 4H), 7.08(d, J=9.0 Hz, 1H), 6.96 (td, J=7.5, 1.0 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H),4.99-4.94 (m, 1H), 4.61-4.58 (m, 1H), 4.47-4.43 (m, 1H), 4.39 (s, 1H),4.23-4.16 (m, 2H), 4.08-4.04 (m, 1H), 3.06-2.88 (m, 5H), 2.74-2.69 (m,2H), 2.59-2.52 (m, 2H), 2.41-2.33 (m, 2H), 1.96-1.89 (m, 1H), 1.88-1.47(m, 16H). LC/MS: t_(R)=1.86 min, 630.31 (MH)⁺.

(R)-3-(1H-Benzotriazol-5-yl)-2-benzyloxycarbonylamino-propionic acidmethyl ester

To a solution of(R)-2-benzyloxycarbonylamino-3-(3,4-diamino-phenyl)-propionic acidmethyl ester mono acetate (2.68 g, 6.65 mmol) in acetic acid (30 mL) andwater (40 mL), at room temperature was added a solution of sodiumnitrite (0.46 g, 6.65 mmol) in water (8 mL), dropwise over severalminutes. The resulting mixture was stirred at room temperature for 20min, then cooled to 0° C., concentrated ammonium hydroxide was added toadjust pH to 11. The mixture was extracted with ethyl acetate twice inthe presence of solid sodium chloride, and the organic layers were driedover sodium sulfate. After filtration, solvents were removed in vacuoand the residue was purified by chromatography on silica gel using ethylacetate/hexanes (6:4) as eluent to afford the title compound as a tansolid (94% yield). ¹H-NMR (CD₃OD, 500 MHz) δ 7.75 (d, J=8.5 Hz, 1H),7.58 (s, 1H), 7.31-7.25 (m, 5H), 7.18 (d, J=8.5 Hz, 1H), 5.39 (d, J=8.0Hz, 1H), 5.10 (d, J=12.0 Hz, 1H), 5.05 (d, J=12.0 Hz, 1H), 4.74 (dd,j=13.5, 6.0 Hz, 1H), 3.73 (s, 3H), 3.34 (dd, J=14.0, 5.5 Hz,1H), 3.22(dd, J=13.5, 6.0 Hz, 1H). ¹³CNMR (CD₃OD, 125 MHz) δ 172.1, 156.0, 136.1,128.6, 128.3, 128.1, 67.2, 55.2, 52.7, 38.5. Mass spec. 355.18 (MH)⁺.

(R)-2-Amino-3-(1H-benzotriazol-5-yl)-propionic acid methyl ester

Prepared as described above for(R)-2-amino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionic acid methylester. ¹H-NMR (CD₃OD, 500 MHz) δ 8.38 (br s, 2H), 7.89 (d, J=7.5 Hz,1H), 7.81 (s, 1H), 7.40 (d, J=7.5 Hz, 1H), 4.44 (s, 1H), 3.81 (s, 3H),3.48-3.45 (m, 1H), 3.40-3.37 (m, 1H), 3.33 (br s, 1H). ¹³CNMR (CD₃OD,125 MHz) δ 169.8, 139.4, 138.9, 133.0, 127.6, 115.52, 115.47, 54.3,52.6, 36.7. Mass spec. 221.15 (MH)⁺.

EXAMPLE 48(R)-3-(1H-Benzotriazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for(R)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-yl]-propionicacid methyl ester except that carbonyl diimidazole was used in place ofN,N-disuccinimidyl carbonate (DSC). ¹H-NMR (CD₃OD, 300 MHz) δ 7.82 (d,J=8.4 Hz, 1H), 7.24 (s, 1H), 7.39 (dd, J=8.7, 1.2 Hz, 1H), 7.15-7.08 (m,2H), 6.94 (td, J=7.5, 0.9 Hz, 1H), 6.75 (d, J=7.8 Hz,1H), 4.67-4.60 (m,1H), 4.39-4.31 (m, 1H), 4.15 (s, 2H), 4.08-4.03 (m, 2H), 3.72 (s, 3H),3.38 (dd, J=13.9, 5.5 Hz, 1H), 3.32-3.29 (m, 1H), 3.17 (dd, J=13.9, 10.3Hz, 1H), 2.87-2.71 (m, 2H), 1.64-1.48 (m, 4H). Mass spec. 478.30 (MH)⁺.

EXAMPLE 49(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(1H-benzotriazol-5-ylmethyl)-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl]-amide

Prepared as described above for(R)-4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide.Purified by silica gel chromatography using methylenechloride/methanol/triethylamine (93:5:2) as eluent. ¹H-NMR (CD₃OD, 500MHz) δ 7.83 d, J=8.2 Hz, 0.75H), 7.79 (d, J=8.5 Hz, 0.25H), 7.71 (s,0.25H), 7.69 (s, 0.75H), 7.33 (d, J=9.2 Hz, 1H), 7.16-7.12 (m, 2H),6.96-6.91 (m, 1H), 6.78 (d, J=8.0 Hz, 0.75H), 6.77 (d, J=8.0 Hz, 0.25H),5.07-5.03 (m, 1H), 4.58-4.55 (m, 1H), 4.45-4.40 (m, 1H), 4.34 (s,1.25H), 4.24 (s, 0.75H), 4.20-4.05 (m, 2.25H), 4.00-3.96 (m, 0.75H),3.24-3.09 (m, 2H), 2.91-2.78 (m, 4H), 2.64-2.61 (m, 2H), 2.56-2.42 (m,2H), 2.15-2.10 (m, 1.25H), 2.02-1.98 (m, 1.75H), 1.95-1.90 (m, 1H),1.68-1.60 (m, 8H), 1.54-1.46 (m, 6H). LC/MS: t_(R)=1.86 min, 614.28(MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-1H-indol-5-yl)-propionicacid methyl ester

PyHBr₃ (1.28 g, 4.02 mmol) was added in small portions over 30 min to asolution of (R)-2-benzyloxycarbonylamino-3-(1H-indol-5-yl)-propionicacid methyl ester (0.47 g, 1.34 mmol) in t-butanol (10 mL) while thereaction temperature was maintained between 25-30° C. The resultingmixture was stirred at room temperature for 3.5 h. The solvent wasremoved in vacuo, and the residue was extracted with ethyl acetate (2×).The combined organic phases were washed with brine and dried over sodiumsulfate. After filtration, solvents were removed and the residue wasazeotropically dried with anhydrous ethanol. The residue was dissolvedin glacial acetic acid (10 mL) and zinc powder (0.88 g, 13.4 mmol) wasadded. The mixture was stirred at room temperature overnight. After theacetic acid was removed in vacuo, the residue was purified by flashchromatography on silica gel using ethyl acetate/hexanes [(1:3) firstand then (3:2)] as eluent to afford the title compound as a white solid(41% for 2 steps). ¹H-NMR (CDCl₃, 500 MHz) δ 8.03 (s, 1H), 7.36-7.31 (m,5H), 6.94 (s, 1H), 6.91 (d, J=8.0 Hz, 1H), 6.73 (d, J=7.5 Hz, 1H), 5.26(d, J=8.0 Hz, 1H), 5.11 (d, J=12.0 Hz, 1H), 5.05 (d, j=12.5 Hz, 1H),4.61 (dd, J=13.5, 6.0 hz, 1H), 3.72 (s, 3H), 3.45 (s, 2H), 3.10 (dd,J=14.0, 5.5 Hz, 1H), 3.00 (dd, J=14.0, 6.0 Hz, 1H). ¹³CNMR (CDCl₃, 125MHz) δ 177.7, 172.2, 155.7, 141.7, 136.3, 129.8, 128.9, 128.6, 128.3,128.2, 125.8, 125.6, 109.8, 67.1, 55.1, 52.5, 38.0, 36. Mass spec.369.20 (MH)⁺.

(R)-2-Amino-3-(2-oxo-2,3-dihydro-1H-indol-5-yl)-propionic acid methylester

Prepared as described above for(R)-2-amino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionic acid methylester. ¹H-NMR (CD₃OD, 500 MHz) δ 8.48 (br s, 2H), 7.16 (s, 1H), 7.10 (s,1H), 6.89 (s, 1H), 4.21 (s, 1H), 3.81 (s, 3H), 3.54 (s, 1H), 3.33 (s,2H), 3.20 (s, 1H), 3.12 (s, 1H). ¹³CNMR (CD₃OD, 125 MHz) δ 178.9, 170.7,143.3, 129.0, 128.6, 126.9, 125.6, 110.0, 57.3, 54.6, 52.3, 37.0. Massspec. 235.30 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

A solution of phosgene in toluene (2M, 0.158 mL, 0.30 mmol) was added toa vigorously stirred mixture of(R)-2-amino-3-(2-oxo-2,3-dihydro-1H-indol-5-yl)-propionic acid methylester (70 mg, 0.25 mmol) in methylene chloride (15 mL) and saturatedsodium bicarbonate (7.5 mL). After the mixture was stirred at roomtemperature for 30 min, 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one(58 mg, 0.25 mmol) was added. The resulting mixture was stirred at roomtemperature for 1.5 h, diluted with ethyl acetate, and washed with 0.25N hydrochloric acid that had been saturated with solid sodium chloride.The organic layers were dried over sodium sulfate. After filtration,solvents were removed to afford the title compound as a tan viscous oil.LC/MS: t_(R)=2.01 min, 492.10 (MH)⁺.

EXAMPLE 50(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-(2-oxo-2,3-dihydro-1H-indol-5-ylmethyl)-ethyl]-amide

Prepared as described above for(R)-4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid{2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indazol-5-ylmethyl]-ethyl}-amide.Purified by flash chromatography on silica gel using methylenechloride/methanol/triethylamine (93:5:2) as eluent. ¹H-NMR (CD₃OD, 500MHz) δ 7.20-7.09 (m, 4H), 6.97 (t, J=7.3 Hz, 1H), 6.88 (d, J=7.9 Hz,0.65H), 6.84 (d, J=7.6 Hz, 0.35H), 6.80 (d, J=7.7 Hz, 1H), 5.51 (s,0.65H), 5.23 (s, 0.35H), 4.99-4.95 (m, 0.65H), 4.92-4.88 (m, 0.35H),4.60-4.56 (m, 1.65H), 4.46-4.41 (m, 1.35H), 4.39 (s, 1.3H), 4.36 (s,0.7H), 4.24-4.17 (m, 2H), 4.05-4.02 (m, 1H), 3.65-3.61 (m, 2H),3.52-3.47 (m, 1H), 3.20-3.16 (m, 1H), 3.00-2.88 (m, 2H), 2.70-2.64 (m,2H), 2.53-2.46 (m, 2H), 2.40-2.34 (m, 2H), 1.94-1.46 (m, 15H), 1.39-1.36(m, 2H). LC/MS: t_(R)=1.83 min, 628.40 (MH)⁺.

2-(Di-tert-butoxycarbonylamino)-acrylic acid methyl ester

To a solution of 2-tert-butoxycarbonylamino-3-hydroxy-propionic acidmethyl ester (10.0 g, 39 mmol) and di-tert-butyl-dicarbonate (21.8 g,2.6 equiv.) in acetonitrile (40 mL) was added 4-dimethylaminopyridine(0.48 g, 0.1 equiv) at room temperature. The solution was stirredovernight and concentrated. The residue was dissolved in diethyl ether,washed sequentially with 1 M potassium hydrogen sulfate (2×), saturatedsodium bicarbonate, brine, dried over magnesium sulfate, andconcentrated to give 15.6 g (quant.) as an oil. Inspection of the ¹H NMRshowed a mixture of the title compound and2-(di-tert-butoxycarbonylamino)-3-tert-butoxycarbonyloxy-propionic acidmethyl ester. As it was later found that both react with secondaryamines to give the same products, the mixture was used withoutseparation. 2-(Di-tert-butoxycarbonylamino)-acrylic acid methyl ester:¹H-NMR (CDCl₃) δ 1.45 (s, 18H), 3.78 (s, 3H), 5.63 (s, 1H), 6.33 (s,1H). Mass spec.: 324.14 (M+Na)⁺.2-(Di-tert-butoxycarbonylamino)-3-tert-butoxycarbonyloxy-propionic acidmethyl ester: ¹H-NMR (CDCl₃, 500 MHz) δ 1.46 (s, 9H), 1.49 (s, 18H),3.72 (s, 3H), 4.42 (dd, J=11.6, 9.2, 1H), 4.75 (dd, J=11.3, 4.6, 1H),5.30 (dd, J=9.2, 4.6, 1H). Mass spec.: 442.21 (M+Na)⁺.

(±)-3-(4-Benzyloxy-2-oxo-2H-pyridin-1-yl)-2-(di-tert-butoxycarbonylamino)-propionicacid methyl ester

To a solution of 2-(di-tert-butoxycarbonylamino)-acrylic acid methylester (900 mg, 3.0 mmol), and 4-benzyloxy-1H-pyridin-2-one (630 mg, 1.03equiv) in acetonitrile (2.5 mL) was added cesium carbonate (100 mg, 0.10equiv). The resulting suspension was heated to 80° C. via microwave for2 h. The reaction was concentrated, dissolved in water, and extractedwith methylene chloride (3×). The combined organic phases were washedwith brine, dried over magnesium sulfate, and concentrated to give 1.47g (97%) which was used without purification. Mass spec.: 503.56 (MH)⁺.

(±)-4-Benzyloxy-1-[3-[1,4′]bipiperidinyl-1′-yl-2-(di-tert-butoxycarbonylamino)-3-oxo-propyl]-1H-pyridin-2-one

To a stirred solution of3-(4-benzyloxy-2-oxo-2H-pyridin-1-yl)-2-(di-tert-butoxycarbonylamino)-propionicacid methyl ester (1.47 g, 2.9 mmol) in methanol (17 mL) was added asolution of lithium hydroxide monohydrate (0.50 g, 4 equiv) in water(2.85 mL). The reaction mixture was stirred for 3 h at room temperature,cooled to 0° C., treated with concentrated hydrochloric acid (0.99 mL),and concentrated to afford the crude acid, half of which was taken on inthe following step. The crude acid was dissolved in methylene chloride(6 mL), cooled to 0° C. and treated sequentially with4-piperidyl-piperidine (0.25 g, 1 equiv), triethylamine (0.31 mL, 2.5equiv), and bis-2-oxo-3-oxazolidinyl)phoshinic chloride (0.38 g, 1equiv). The reaction was allowed to warm to room temperature and stirredovernight. The reaction was concentrated, and purified by Prep HPLC toafford 489 mg (52%, 2 steps). Mass spec.: 639.41 (MH)⁺.

EXAMPLE 51(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(4-benzyloxy-2-oxo-2Hpyridin-1-ylmethyl)-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl]-amide

To a stirred solution of4-benzyloxy-1-[3-[1,4′]bipiperidinyl-1′-yl-2-(di-tert-butoxycarbonylamino)-3-oxo-propyl]-1H-pyridin-2-onein methylene chloride (3 mL) was added trifluoroacetic acid (1 mL) at 0°C. After 2 h, the reaction was concentrated to afford the crude amine(151 mg, 97%) as its trifluoroacetic acid salt [Mass spec.: 439.61(MH)⁺] which was split into two portions, using half in the followingprocedure. To a solution of the crude amine (75 mg, 0.11 mmol) anddiisopropylethylamine (80 μL, 4 equiv) in methylene chloride (3 mL) at0° C. was added carbonyl diimidazole (29 mg, 1.6 equiv, in 2 portions).After stirring for 10 min, the solution was treated with3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-acetic acid (40 mg, 1.15equiv). The reaction was warmed to room temperature and stirredovernight. The reaction was concentrated and purified by prep TLC togive 40.8 mg (53%). ¹H-NMR (CD₃OD, 500 MHz) δ 1.25-1.56 (m, 4H),1.56-1.84 (m, 9H), 1.90-2.08 (m, 2H), 2.60-2.95 (m, 8H), 3.11 (dd,J=24.1, 12.8, 1H), 3.89 (ddd, J=22.0, 13.2, 9.2, 1H), 4.10 (dd, J=14.3,14.1, 2H), 4.27-4.54 (m, 5H), 4.60 (bd, J=11.9, 1H), 5.08 (dd, J=13.2,12.2, 2H), 5.26 (ddd, J=9.4, 9.4, 4.8, 1H), 6.05 (dd, J=13.7, 2.7, 1H),6.16 (m, 1H), 6.77 (d, J=8.0, 1H), 6.84 (ddd, J=7.6, 7.6, 2.1, 1H), 7.04(d, J=7.6, 1H), 7.12 (dd, J=7.6, 7.4, 1H), 7.28-7.43 (m, 5H), 7.48 (d,J=7.6, 1H). Mass spec.: 696.85 (MH)⁺.

EXAMPLE 52(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-hydroxy-2-oxo-2H-pyridin-1-ylmethyl)-2-oxo-ethyl]-amide

A stirred solution of4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(4-benzyloxy-2-oxo-2H-pyridin-1-ylmethyl)-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl]-amide(29 mg) and 10% palladium on charcoal (5 mg) in methanol (1 mL) wasplaced under an atmosphere of hydrogen. After 1 h at room temperature,the reaction was flushed with nitrogen, filtered through celite, andconcentrated to give the product. ¹H-NMR (CD₃OD, 500 MHz) δ 1.40-1.85(m, 12H), 2.04 (dd, J=27.4, 17.0, 2H), 2.66 (dd, J=21.1, 11.0, 1H),2.80-3.19 (m, 8H), 3.95 (ddd, J=49.8, 12.5, 7.9, 1H), 4.07-4.28 (m, 3H),4.34 (bs, 2H), 4.36-4.59 (m, 2H), 4.63 (bd, J=12.8, 1H), 5.20 (m, 1H),5.75 (dd, J=7.3, 2.1, 1H), 5.97 (dd, J=8.9, 7.6, 1H), 6.78 (d, J=7.6,1H), 6.93 (dd, J=7.6, 7.3, 1H), 7.08-7.18 (m, 2H), 7.33 (dd, J=18.3,11.0, 1H). Mass spec.: 606.32 (MH)⁺.

(±)-2-(Di-tert-butoxycarbonylamino)-3-(4-hydroxy-piperidin-1-yl)-propionicacid methyl ester

To a solution of 2-(di-tert-butoxycarbonylamino)-acrylic acid methylester (1.0 g, 3.0 mmol) in acetonitrile (10 mL) was added piperidin-4-ol(0.33 g, 1.1 equiv). A gentle stream of nitrogen was placed over thereaction while it stirred overnight. The crude oil which resulted wasdissolved in ethyl acetate, washed with water, then brine, dried overmagnesium sulfate, and concentrated to give 1.38 g (quant.) as an oilwhich was used without purification. Mass spec.: 403.42 (MH)⁺.

(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(di-tert-butoxycarbonylamino)-3-(4-hydroxy-piperidin-1-yl)-propan-1-one

To a solution of2-(di-tert-butoxycarbonylamino)-3-(4-hydroxy-piperidin-1-yl)-propionicacid methyl ester (1.0 g, 2.5 mmol) in methanol (6 mL) was added asolution of lithium hydroxide monohydrate (400 mg, 3.9 equiv) in water(1 mL). The reaction was stirred 6 h, cooled to 0° C., neutralized withconcentrated hydrochloric acid, and concentrated. The crude acid wasused without purification. The crude acid was suspended in methylenechloride (25 mL), treated with a few drops of methanol to aid indissolving the acid, and cooled to 0° C. The resulting suspension wastreated sequentially with 4-piperidyl-piperidine (0.53 g, 1.25 equiv),triethylamine (0.70 mL, 2. equiv), andbis-2-oxo-3-oxazolidinyl)phoshinic chloride (0.80 g, 1.25 equiv). Thereaction was allowed to warm to room temperature overnight. The reactionwas concentrated and then purified by Prep HPLC to afford 310 mg (23%, 2steps). Mass spec.: 539.49 (MH)⁺.

(±)-2-Amino-1-[1,4′]bipiperidinyl-1′-yl-3-(4-hydroxy-piperidin-1-yl)-propan-1-one

To a solution of1-[1,4′]bipiperidinyl-1′-yl-2-(di-tert-butoxycarbonylamino)-3-(4-hydroxy-piperidin-1-yl)-propan-1-one(310 mg, 0.58 mmol) in methylene chloride (5 mL) at 0° C. was addedtrifluoroacetic acid (2.0 mL). The ice bath was removed and the reactionstirred for 30 min. The reaction was concentrated to afford the productas its trifluoroacetic acid salt (400 mg, quant.) which was used withoutpurification. Mass spec.: 339.46 (MH)⁺.

(±)-[2-[1,4′]Bipiperidinyl-1′-yl-1-(4-hydroxy-piperidin-1-ylmethyl)-2-oxo-ethyl]-carbamicacid tert-butyl ester

To a solution2-amino-1-[1,4′]bipiperidinyl-1′-yl-3-(4-hydroxy-piperidin-1-yl)-propan-1-one(trifluoroacetic acid salt, 300 mg, 0.58 mmol) and diisopropylethylamine(0.30 mL, 4 equiv) in tetrahydrofuran (5 mL) was addeddi-tert-butyl-dicarbonate (128 mg, 1 equiv). The resulting solution wasstirred at room temperature for 1 h, and concentrated. The residue wasdissolved in ethyl acetate, washed with water, then brine, dried overmagnesium sulfate, and concentrated to afford to 248 mg (98%) which wasused without purification. Mass spec.: 439.65 (MH)⁺.

(±)-[2-[1,4′]Bipiperidinyl-1′-yl-2-oxo-1-(4-oxo-piperidin-1-ylmethyl)-ethyl]-carbamicacid tert-butyl ester

To a solution of1-[1,4′]bipiperidinyl-1′-yl-2-(di-tert-butoxycarbonylamino)-3-(4-hydroxy-piperidin-1-yl)-propan-1-one(200 mg, 0.37 mmol) in methylene chloride (4 mL) was added Dess-Martinperiodinane (316 mg, 2 equiv) in two portions. After 1 h, the reactionwas quenched by the addition of saturated sodium bicarbonate, andextracted into methylene chloride (3×). The combined organic phases werewashed with brine, dried over magnesium sulfate, and concentrated togive 187 mg (94%) which was used without purification. Mass spec.:437.63 (MH)⁺.

(±)-1-(2-Amino-3-[1,4′]bipiperidinyl-1′-yl-3-oxo-propyl)-piperidin-4-one

To a solution of[2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-(4-oxo-piperidin-1-ylmethyl)-ethyl]-carbamicacid tert-butyl ester (100 mg, 0.23 mmol) in methylene chloride (5 mL)at 0° C. was added trifluoroacetic acid. The ice bath was removed,stirring continued for 1 h, and the reaction concentrated to give 150 mg(96%) as its trifluoroacetic acid salt which was used withoutpurification. Mass spec.: 337.64 (MH)⁺.

EXAMPLE 53(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-hydroxy-piperidin-1-ylmethyl)-2-oxo-ethyl]-amide

To a solution of4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-hydroxy-piperidin-1-ylmethyl)-2-oxo-ethyl]-amide(3 trifluoroacetic acid salt, 200 mg, 0.39 mmol) in methylene chloride(5 mL) at 0° C. was added diisopropylethylamine (0.27 mL, 3.9 equiv),and carbonyl diimidazole (63 mg, 1 equiv). After stirring for 15 min,the solution was treated with3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (acetic acid salt, 142mg, 1.25 equiv). The solution was warmed to room temperature and stirredovernight. The reaction was concentrated and purified by Prep TLC togive 130 mg (56%) as an oil. LC/MS: t_(R)=1.17 min, 596.44 (MH)⁺.

3-Dimethylaminomethylene-4-oxo-piperidine-1-carboxylic acid tert-butylester

4-Oxo-piperidine-1-carboxylic acid tert-butyl ester (10 g, 50 mmol) wasdissolved in dimethyl formamide dimethylacetal (50 mL) and heated toreflux for 1.25 h. The solution was cooled, concentrated, and purifiedby flash chromatography to give 2.55 g (19%). Mass spec.: 255.16 (MH)⁺.

1,4,6,7-Tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butylester

To a solution of 3-dimethylaminomethylene-4-oxo-piperidine-1-carboxylicacid tert-butyl ester (2.55 g, 10 mmol) in methanol (50 mL) was addedhydrazine hydrate (0.61 mL, 1.25 equiv). The solution was heated toreflux, immediately allowed to cool to room temperature, andconcentrated to give 1.4 g (63%) which was used without purification.Mass spec.: 224.11 (MH)⁺.

4,5,6,7-Tetrahydro-1H-pyrazolo[4,3-c]pyridine

1,4,6,7-Tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butylester (0.70 g, 3.1 mmol) was dissolved in trifluoroacetic acid (10 mL)at 0° C., stirred for 1 h, and was concentrated. The residue wasdissolved in ethanol and treated with concentrated hydrochloric acid (1mL). The bis-hydrochloride salt precipitated out as a white solid whichwas filtered to give 510 mg (83%). The free base was prepared as neededby dissolving the salt in water, loading it onto an SCX column, flushingwith methanol, and then eluting with 2 M ammonia in methanol.

(±)-2-(Di-tert-butoxycarbonylamino)-3-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester

To a solution of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (160 mg)in 2.5 mL methanol was added 2-(di-tert-butoxycarbonylamino)-acrylicacid methyl ester (400 mg). The reaction was concentrated toapproximately 1.5 mL by application of a gentle stream of nitrogen. Thesolution was stirred at room temperature overnight. The reaction wasconcentrated, dissolved in ethyl acetate, washed with brine, dried overmagnesium sulfate, and concentrated. The resulting residue was pureenough to use without purification. ¹H-NMR (CDCl₃, 500 MHz) δ 1.44 (s,9H), 2.73 (m, 3H), 2.91 (m, 1H), 3.06 (dd, J=13.4, 8.6, 1H), 3.22 (dd,J=13.4, 8.2, 1H), 3.54 (d, J=13.4, 1H), 3.63 (d, J=13.4, 1H), 3.71 (s,3H), 5.11 (dd, J=8.5, 5.2, 1H), 7.25 (s, 1H). Mass spec.: 425.23 (MH)⁺.

(±)-2-Amino-3-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester

To a solution of2-(di-tert-butoxycarbonylamino)-3-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester (0.55 g, 1 equiv.) in methylene chloride (5 mL, 0° C.)was added trifluoroacetic acid (1.5 mL). The ice bath was removed andstirring continued for 2 h. The solution was concentrated, redissolvedin methanol, and passed onto a column of strong cation exchange resin.After flushing with methanol, the product was removed from the column byeluting with 2 M ammonia in methanol to afford the product as its freebase (275 mg, 95%). ¹H-NMR (CDCl₃, 500 MHz) δ 2.71 (dd, J=12.8, 8.6,1H), 2.74-2.91 (m, 6H), 3.48 (s, 2H), 3.54 (d, J=13.4, 1H), 3.62 (d,J=13.4, 1H), 3.69 (dd, J=8.2, 4.9, 1H), 3.73 (s, 3H), 7.27 (s, 1H). Massspec.: 225.16 (MH)⁺.

3,3-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester

To a solution of 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (16g, 80 mmol) in tetrahydrofuran (400 mL) at 0° C. was added sodiumhydride (4.1 g, 2.1 equiv) in 4 portions. To this was added iodomethane(12.5 mL, 2.5 equiv) dropwise. The reaction was allowed to graduallywarm to room temperature and stirred overnight. The reaction wasconcentrated, dissolved in diethyl ether, washed with brine, dried overmagnesium sulfate, and concentrated. The product was crystallized fromhot pentane (2×) to give 5.9 g (32%). ¹H-NMR (CDCl₃, 500 MHz) δ 1.09 (s,6H), 1.47 (s, 9H), 2.47 (dd, J=6.4, 6.4, 2H), 3.41 (m, 2H), 3.70 (m,2H). Mass spec.: 250.12 (M+Na)⁺.

5-Dimethylaminomethylene-3,3-dimethyl-4-oxo-piperidine-1-carboxylic acidtert-butyl ester

3,3-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester (5 g,22 mmol) was dissolved in dimethyl formamide dimethylacetal (25 mL) andheated at reflux for 2 h. The reaction mixture was then heated to 130°C. for 1 h via microwave, and concentrated to give 6.43 g (quant.) as anoil which used without purification. ¹H-NMR (CDCl₃, 500 MHz) δ 1.07 (s,6H), 1.45 (s, 9H), 3.06 (s, 6H), 3.37 (m, 2H), 4.57 (m, 2H), 7.41 (bs,1H).

7,7-Dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylicacid tert-butyl ester

To a solution of5-dimethylaminomethylene-3,3-dimethyl-4-oxo-piperidine-1-carboxylic acidtert-butyl ester (6.35 g, 22 mmol) in methanol (15 mL) was addedhydrazine hydrate (1.2 mL, 1.1 equiv). The solution was stirred at roomtemperature overnight and concentrated to give 5.3 g (94%) which wasused without purification. Mass spec.: 252.19 (MH)⁺.

7,7-Dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine

To a solution of7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylicacid tert-butyl ester (5.3 g, 21 mmol) in methylene chloride (10 mL) at0° C. was added trifluoroacetic acid (5 mL). The reaction was allowed towarm to room temperature, stirred 15 min, and treated with additionaltrifluoroacetic acid (5 mL). After 1 h, the reaction was concentrated,dissolved in ethanol (10 mL), cooled to 0° C., treated with concentratedhydrochloric acid (3 mL), and concentrated. The resulting solid wastriturated with ethanol, and filtered to give 3.02 g (64%) as itsbis-hydrochloride salt. The free base was prepared as needed bydissolving the salt in water, loading it onto an SCX column, flushingwith methanol, and then eluting with 2M ammonia in methanol. ¹H-NMR(D₂O, 500 MHz) δ 1.49 (s, 6H), 3.46 (s, 2H), 4.39 (s, 2H), 7.86 (s, 1H).Mass spec.: 152.14 (MH)⁺.

(±)-2-(Di-tert-butoxycarbonylamino)-3-(7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester

To a solution of7,7-dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (160 mg) inmethanol (3 mL) was added 2-(di-tert-butoxycarbonylamino)-acrylic acidmethyl ester (331 mg). A gentle stream of nitrogen was applied and thereaction stirred overnight. In the morning, the volume was greatlyreduced. The last traces of solvent were removed under high vacuum togive 490 mg (quant.) which was used without purification. ¹H-NMR (CDCl₃,500 MHz) δ 1.24 (s, 3H), 1.26 (s, 3H), 1.38 (s, 18H), 2.33 (d, J=11.3,1H), 2.57 (d, J=11.3, 1H), 3.09 (dd, J=13.1, 5.5, 1H), 3.15 (dd, J=13.4,9.5, 1H), 3.35 (d, J=12.8, 1H), 3.57 (d, J=12.8, 1H), 3.68 (s, 3H), 5.13(dd, J=9.5, 3.7, 1H), 7.16 (s, 1H). Mass spec.: 453.30 (MH)⁺.

(±)-2-Amino-3-(7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester

To a solution of2-(di-tert-butoxycarbonylamino)-3-(7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester (0.49 g, 1 equiv) in methylene chloride (5 mL, 0° C.)was added trifluoroacetic acid (1.5 mL). The ice bath was removed andstirring continued for 2 h. The solution was concentrated, redissolvedin methanol, and loaded onto a column of strong cation exchange resin.After flushing with methanol, the product was removed from the column byeluting with 2M ammonia in methanol to afford the product as its freebase (250 mg, 94%). ¹H-NMR (CDCl₃, 500 MHz) δ 1.27 (s, 3H), 1.28 (s,3H), 2.41 (d, J=11.3, 1H), 2.50 (d, J=11.3, 1H), 2.69 (dd, J=12.5, 7.9,1H), 2.82 (dd, J=12.5, 5.2, 1H), 3.45 (d, J=12.8, 1H), 3.52 (d, J=12.8,1H), 3.67 (m, 1H), 3.69 (s, 3H), 7.19 (s, 1H). Mass spec.: 253.16 (MH)⁺.

(±)-2-{[4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester

To a solution of2-amino-3-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester (260 mg, 1 equiv) in methylene chloride (2 mL, 0° C.)was added carbonyl diimidazole (188 mg, 1 equiv). After 15 min,3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (295 mg, 1.1 equiv) wasadded in one portion. The ice bath was removed and stirring continuedovernight. The reaction was concentrated and purified by columnchromatography to give 118 mg (21%). ¹H-NMR (CDCl₃, 500 MHz) δ 1.60-1.80(m, 4H), 2.70-3.05 (m, 8H), 3.45 (s, 2H), 3.56 (d, J=13.4, 1H), 3.62 (d,J=13.4, 1H), 3.75 (s, 3H), 4.02 (d, J=13.1, 1H), 4.10 (d, J=12.5, 1H),4.24 (s, 2H), 4.45-4.57 (m, 2H), 5.79 (bs, 1H), 6.68 (d, J=7.94, 1H),6.90 (dd, J=7.3, 7.3, 1H), 7.00 (d, J=7.3, 1H), 7.13 (dd, J=7.6, 7.3,1H), 7.25 (s, 1H), 7.82 (s, 1H). Mass spec.: 482.27 (MH)⁺.

EXAMPLE 54(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-ylmethyl)-ethyl]-amide

To a solution of2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-3-(1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester (16 mg, 1 equiv) in methanol (0.6 mL) was addedlithium hydroxide monohydrate (3 mg, 2.2 equiv) in water (0.1 mL) andstirred for 4 h at room temperature. The solution was cooled to 0° C.,treated with aqueous 1 M potassium hydrogen sulfate (60 μl, 1.8 equiv),and concentrated to give the crude acid which was immediately usedwithout purification. The crude acid was dissolved in dimethylformamide(0.3 mL) and sequentially treated with methylene chloride (0.15 mL),4-piperidyl-piperidine (11 mg, 2 equiv), diisopropylethylamine (12 μL, 2equiv), and PyBOP® (19 mg, 1.1 equiv). The solution was stirred 30 minand concentrated. The product was purified by column chromatography togive 17.6 mg (85%, 2 steps). ¹H-NMR (CDCl₃, 500 MHz) δ 1.30-1.60 (m,9H), 1.62-1.78 (m, 5H), 1.81 (bd, J=11.0, 2H), 2.23-2.49 (m, 6H),2.55-3.10 (m, 11H), 3.59 (d, J=7.3, 2H), 4.00-4.20 (m, 3H), 4.23 (s,2H), 4.50 (m, 1H), 4.63 (m, 1H), 5.03 (m, 1H), 5.71 (d, J=7.3, 1H), 6.67(d, J=7.9, 1H), 6.91 (dd, J=7.6, 7.3, 1H), 7.02 (dd, J=7.9, 7.3, 1H),7.14 (dd, J=7.6, 7.6, 1H), 7.24 (s, 1H), 7.39 (s, 1H), 10.76 (bs, 1H).Mass spec.: 618.34 (MH)⁺.

EXAMPLE 55(±)-3-(7,7-Dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

To a solution of2-amino-3-(7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-propionicacid methyl ester (250 mg, 1 equiv) in tetrahydrofuran (4 mL, 0° C.) wasadded carbonyl diimidazole (162 mg, 1 equiv). After 5 min, the ice bathwas removed and the reaction stirred at room temperature for 30 min. Tothis was added 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (250 mg,1.1 equiv) in one portion, and the reaction stirred overnight. Thereaction was concentrated and purified by column chromatography to give228 mg (45%). ¹H-NMR (CDCl₃, 500 MHz) δ 1.30 (s, 3H), 1.31 (s, 3H),1.60-1.80 (m, 4H), 2.43 (d, J=11.6, 1H), 2.53 (d, J=11.3, 1H), 2.80-2.95(m, 4H), 3.51 (dd, J=20.4, 13.1, 2H), 3.74 (s, 3H), 4.00 (d, J=13.7,1H), 4.10 (d, J=12.2, 1H), 4.25 (dd, J=16.2, 14.4, 2H), 4.86 (m, 2H),6.66 (d, J=7.6, 1H), 6.92 (dd, J=7.6, 7.3, 1H), 7.02 (d, J=7.3, 1H),7.14 (dd, J=7.6, 7.6, 1H), 7.24 (s, 1H). Mass spec.: 510.27 (MH)⁺.

EXAMPLE 56(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-ylmethyl)-2-oxo-ethyl]-amide

To a solution of3-(7,7-dimethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (20 mg, 1.0 equiv) in methanol (0.6 mL) was addedlithium hydroxide monohydrate (4 mg, 2.2 equiv) in water (0.1 mL) andstirred for 4 h at room temperature. The solution was cooled to 0° C.,treated with aqueous 1M potassium hydrogen sulfate (75 μl, 1.8 equiv),and concentrated to give the crude acid which was immediately usedwithout purification. The crude acid was dissolved in dimethylformamide(0.3 mL) and sequentially treated with methylene chloride (0.15 mL),4-piperidyl-piperidine (13 mg, 2 equiv), diisopropylethylamine (14 μL, 2equiv), and PyBOP® (22 mg, 1.1 equiv). The solution was stirred 1.5 hand concentrated. The product was purified by column chromatography togive a product which was tainted with HOBT. The HOBT was removed bypassing the product through a plug of basic alumina, eluting with 10%methanol in methylene chloride. Concentration gave 18.3 mg (72%, 2steps). ¹H-NMR (CDCl₃, 500 MHz) δ 1.25-1.32 (m, 6H), 1.40 (m, 4H), 1.54(m, 5H), 1.65 (m, 4H), 1.83 (m, 2H), 2.30-2.56 (m, 8H), 2.81 (m, 4H),3.04 (dt, J=57.1, 12.2, 1H), 3.43-3.60 (m, 2H), 4.00-4.17 (m, 2H),4.18-4.26 (m, 3H), 4.49 (m, 1H), 4.62 (m, 1H), 5.03 (m, 1H), 5.80 (dd,J=16.8, 9.8, 1H), 6.69 (d, J=7.9, 1H), 6.90 (dd, J=7.3, 7.3, 1H), 6.99(dd, J=7.6, 7.3, 1H), 7.13 (dd, J=7.6, 7.6, 1H), 7.19 (s, 1H), 7.66 (bd,J=12.8, 1H). Mass spec.: 646.43 (MH)⁺.

2-Benzyloxycarbonylamino-3-(6-methoxy-pyridin-3-yl)-acrylic acid methylester

To a suspension of potassium tert-butoxide (1.23 g, 1.5 equiv) inmethylene chloride (70 mL, −20° C.) was added a solution ofN-benzyloxycarbonyl-α-phosphonoglycine trimethyl ester (3.63 g, 1.5equiv) in methylene chloride (15 mL). The resulting solution was stirred5 min and treated with the 6-methoxy-pyridine-3-carbaldehyde (1.0 g, 7.3mmol) in methylene chloride (15 mL). After stirring for 1.5 h, thereaction was warmed to 0° C. and stirred 1 h. The reaction was quicklypoured into a separatory funnel containing ethyl acetate and water.Brine was added to aid in separation of the layers. The aqueous wasextracted with ethyl acetate (3×) which were in turn washed with brine,dried over magnesium sulfate, and concentrated to give 2.63 g (quant.)which was used without purification. Mass spec.: 343.08 (MH)⁺.

(±)-2-Amino-3-(6-methoxy-pyridin-3-yl)-propionic acid methyl ester

A flask containing2-benzyloxycarbonylamino-3-(6-methoxy-pyridin-3-yl)-acrylic acid methylester (620 mg), palladium on charcoal (10%, 100 mg), ethyl acetate (10mL) and methanol (20 mL) was flushed with nitrogen, then hydrogen,before finally affixing a balloon of hydrogen. The reaction was allowedto stir overnight. The flask was flushed with nitrogen, filtered throughcelite, and concentrated to give 390 mg (quant.) which was used withoutpurification. Mass spec.: 211.11 (MH)⁺.

(±)-3-(6-Methoxy-pyridin-3-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

To a solution of 2-amino-3-(6-methoxy-pyridin-3-yl)-propionic acidmethyl ester (130 mg) and diisopropylethylamine (0.3 mL) in methylenechloride (2 mL, 0° C.) was added N,N′-disuccinimidyl carbonate (158 mg).After 30 min, 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (120 mg)in methylene chloride (1 mL) was added via canula. The reaction waswarmed to room temperature and stirred overnight. The reaction wasconcentrated and purified by prep HPLC to give 160 mg (55%). Mass spec.:468.19 (MH)⁺.

EXAMPLE 57(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(6-methoxy-pyridin-3-ylmethyl)-2-oxo-ethyl]-amide

To a solution of3-(6-methoxy-pyridin-3-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (160 mg) in methanol (6 mL) was added a solution oflithium hydroxide monohydrate (29 mg) in water (1 mL). The reaction wasstirred at room temperature for 4 h and cooled to 0° C. The reaction wastreated with 1N hydrochloric acid (0.6 mL), concentrated. The residueobtained was dissolved in methylene chloride (5 mL), and treatedsequentially with 4-piperidyl-piperidine (75 mg), triethylamine (0.14mL), and bis-2-oxo-3-oxazolidinyl)phoshinic chloride (104 mg). Thereaction was stirred overnight, concentrated, and purified by prep HPLCto give 94 mg (45%). LC/MS: t_(R)=1.86 min, 604.51 (MH)⁺.

2-Benzyloxycarbonylamino-3-(2-methoxy-pyrimidin-5-yl)-acrylic acidmethyl ester

To a suspension of potassium t-butoxide (1.23 g) in methylene chloride(70 mL, −30° C.) was added a solution ofN-benzyloxycarbonyl-α-phosphonoglycine trimethyl ester (3.63 g) inmethylene chloride (15 mL). The resulting solution was stirred 5 min andtreated with the 2-methoxy-pyrimidine-5-carbaldehyde (1.0 g) inmethylene chloride (15 mL). After stirring for 1.5 h, the reaction waswarmed to 0° C. and stirred 1 h. The reaction was quickly poured into asep funnel containing ethyl acetate and water. Brine was added to aid inseparation of the layers. The aqueous was extracted with ethyl acetate(3×) which were in turn washed with brine, dried over magnesium sulfate,and concentrated. The crude product was recrystallized from hot methanolto give 1.4 g of pure material. Mass spec.: 344.10 (MH)⁺.

(±)-2-Amino-3-(2-methoxy-pyrimidin-5-yl)-propionic acid methyl ester

A flask containing amino ester (700 mg), palladium on charcoal (10%, 100mg) and methanol (20 mL) was flushed with nitrogen, then hydrogen,before finally affixing a balloon of hydrogen. The reaction was allowedto stir overnight. The flask was flushed with nitrogen, filtered throughcelite, and concentrated to give 379 mg (88%) which was used withoutpurification. Mass spec.: 212.08 (MH)⁺.

(±)-3-(2-Methoxy-pyrimidin-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

To a solution of 2-Amino-3-(2-methoxy-pyrimidin-5-yl)-propionic acidmethyl ester (125 mg) and diisopropylethylamine (0.3 mL) in methylenechloride (2 mL, 0° C.) was added N,N′-disuccinimidyl carbonate (155 mg).After 30 min, 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (120 mg)in methylene chloride (2 mL) was added via canula. The reaction waswarmed to room temperature and stirred overnight. The reaction wasconcentrated and purified by prep HPLC to give 99 mg (36%). Mass spec.:469.10 (MH)⁺.

EXAMPLE 58(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(2-methoxy-pyrimidin-5-ylmethyl)-2-oxo-ethyl]-amide

To a solution of3-(2-methoxy-pyrimidin-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (99 mg) in methanol (6 mL) was added a solution oflithium hydroxide monohydrate (18 mg) in water (1 mL). The reaction wasstirred at room temperature for 4 h and cooled to 0° C. The reaction wastreated with 1N hydrochloric acid (0.4 mL), concentrated. The residueobtained was dissolved in methylene chloride (3 mL), and treatedsequentially with 4-piperidyl-piperidine (50 mg), triethylamine (88 μL),and bis-2-oxo-3-oxazolidinyl)phoshinic chloride (71 mg). The reactionwas stirred overnight, concentrated, and purified by prep HPLC to give103 mg (45%). LC/MS: t_(R)=1.23 min, 605.54 (MH)⁺.

2-Benzyloxy-5-bromo-pyridine

A suspension of 2,5-dibromopyridine (2.0 g, 8.4 mmol),dibenzo-18-crown-6 (0.14 g, 0.05 equiv), benzyl alcohol (1.1 mL, 1.3equiv), and potassium hydroxide (1.1 g, 2.4 equiv) in toluene (30 mL)were heated at reflux for 3 h in an apparatus fitted with a Dean-Starktrap. The suspension was cooled, concentrated, suspended in water, andextracted into methylene chloride. The combined organic phases werewashed with water, then brine, dried over magnesium sulfate, andconcentrated to give 1.9 g (85%) which was used without purification.Mass spec.: 264.25 (MH)⁺.

6-Benzyloxy-pyridine-3-carbaldehyde

To a solution of 2-benzyloxy-5-bromo-pyridine (1.64 g, 6.2 mmol) intetrahydrofuran (25 mL, −78° C.) was added n-butyllithium (2.5 M inhexane, 2.61 mL, 1.05 equiv). After 1 h at −78° C., dimethylformamide(0.97 mL, 2 equiv) was added and the mixture stirred for 30 min. Thereaction was quickly poured into a stirred solution of 5% aqueous sodiumbicarbonate (50 mL) and extracted with diethyl ether (3×). The etherealwas washed with brine, dried over magnesium sulfate, and concentrated togive 1.16 g (quant.) which was used without purification. Mass spec.:186.34 (MH)⁺.

2-Benzyloxycarbonylamino-3-(6-benzyloxy-pyridin-3-yl)-acrylic acidmethyl ester

To a stirred suspension of potassium tert-butoxide (0.440 g, 1.7 equiv)in methylene chloride (25 mL) at −20° C. was addedN-benzyloxycarbonyl-α-phosphonoglycine trimethyl ester (1.3 g, 1.7equiv) in methylene chloride (5 mL). The resulting solution was stirredfor 5 min and treated with the 6-benzyloxy-pyridine-3-carbaldehyde (0.49g, 2.28 mmol) in methylene chloride (5 mL). The reaction was stirred at−20° C. for 1 h, allowed to gradually warm to 0° C., and poured into aseparatory funnel containing water and diethyl ether. The reaction wasextracted with diethyl ether (2×), washed with brine, dried overmagnesium sulfate, and concentrated to give 0.98 g (quant.) as an oilwhich was used without purification. Mass spec.: 419.32 (MH)⁺.

(±)-2-Benzyloxycarbonylamino-3-(6-benzyloxy-pyridin-3-yl)-propionic acidmethyl ester

A flask was charged with2-benzyloxycarbonylamino-3-(6-benzyloxy-pyridin-3-yl)-acrylic acidmethyl ester (0.50 g, 1.2 mmol), Wilkinson's catalyst (200 mg, 0.2equiv), methanol (5 mL), and toluene (3 mL). The flask was flushed withnitrogen, then hydrogen, heated to 35° C., and allowed to stir under anatmosphere of hydrogen for 4 days. The reaction was flushed withnitrogen, diluted with methanol, filtered, and concentrated to affordthe crude product which was purified by column chromatography to give145 mg (29%).

(±)-2-Amino-3-(6-benzyloxy-pyridin-3-yl)-propionic acid methyl ester

To a stirred solution of2-benzyloxycarbonylamino-3-(6-benzyloxy-pyridin-3-yl)-propionic acidmethyl ester (130 mg, 0.31 mmol) in methylene chloride (5 mL, 0° C.) wasadded trimethylsilyl iodide (44 μL, 1.0 equiv). The ice bath was removedand stirring continued for 1 h. Reaction was poured into saturatedsodium bicarbonate, extracted with ethyl acetate (3×), washed withbrine, dried over magnesium sulfate, and concentrated to give 81 mg(91%) which was used without purification. Mass spec.: 287.37 (MH)⁺.

(±)-3-(6-Benzyloxy-pyridin-3-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

To a stirred solution of 2-amino-3-(6-benzyloxy-pyridin-3-yl)-propionicacid methyl ester (60 mg, 0.21 mmol) in methylene chloride (1 mL, 0° C.)was added carbonyl diimidazole (34 mg, 1.0 equiv.). After 15 min, asolution of 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (58 mg, 1.2equiv.) in methylene chloride (0.5 mL) was added via canula. The icebath was removed and stirring continued overnight. The reaction wasconcentrated and purified by column chromatography to give 59 mg (52%).Mass spec.: 544.49 (MH)⁺.

EXAMPLE 59(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(6-benzyloxy-pyridin-3-ylmethyl)-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl]-amide

To a stirred solution of3-(6-benzyloxy-pyridin-3-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (59 mg, 0.11 mmol) in methanol (3 mL) was added asolution of lithium hydroxide monohydrate (9.1 mg, 2 equiv) in water(0.5 mL). The reaction was stirred 2 h at room temperature, cooled to 0°C., quenched by addition of 1N hydrochloric acid (0.15 mL), andconcentrated. The crude product was used without purification. The crudeacid was dissolved in methylene chloride (2 mL, 0° C.), and treatedsequentially with 4-piperidino-piperidine (34 mg, 1.8 equiv),triethylamine (35 μL, 2.3 equiv.), andbis-2-oxo-3-oxazolidinyl)phoshinic chloride (34 mg, 1.2 equiv). The icebath was removed and the reaction allowed to stir overnight. Thereaction was concentrated and purified by Prep TLC to give 30.3 mg(41%). LC/MS: t_(R)=1.49 min, 680.29 (MH)⁺.

EXAMPLE 60(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-2-oxo-1-(6-oxo-1,6-dihydro-pyridin-3-ylmethyl)-ethyl]-amide

A flask was charged with4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(6-benzyloxy-pyridin-3-ylmethyl)-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl]-amide(27 mg, 0.04 mmol), palladium on charcoal (10%, 4 mg), and methanol (1mL). The flask was flushed with nitrogen, then hydrogen, and allowed tostir under an atmosphere of hydrogen overnight. The flask was flushedwith nitrogen, and the reaction filtered through celite to give 22.1 mg(94%). LC/MS: t_(R)=0.93 min, 590.32 (MH)⁺.

Piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester

To a solution of ethyl isonipecotate (5.00 g, 0.032 mol) andtriethylamine (4.9 mL, 0.035 mmol) in dichloromethane (25 mL) at 0° C.was slowly added a solution of di-tert-butyldicarbonate (7.2 g, 0.033mol) in dichloromethane (25 mL). The reaction mixture was stirred atroom temperature overnight, then washed with potassium hydrogen sulfatethree times and with brine once. The organic extract was dried overanhydrous sodium sulfate, filtered and concentrated in vacuum to givethe desired product (8.23 g, 100%) as colorless oil. ¹H NMR (C₆D₆, 500MHz) δ 3.88 (q, J=7.5 Hz, 2H), 2.52 (m, 1H), 1.60-1.48 (m, 8H), 1.42 (s,9H), 0.92 (t, 3H). Mass spec.: 280.44 (M+Na)⁺.

4-(2-Nitro-benzyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester4-ethyl ester

To a solution of piperidine-1,4-dicarboxylic acid 1-tert-butyl ester4-ethyl ester (8.23 g, 0.032 mol) in tetrahydrofuran (85 mL) was slowlyadded a solution of sodium bis(trimethylsilyl)amide (44 mL, 0.044 mol).After the resulting mixture had been stirred at −78° C. for 1 h, asolution of 2-nitrobenzyl bromide (8.21 g, 0.038 mol) was added. Thereaction mixture was allowed to warm up to room temperature and wasstirred overnight. It was then concentrated and the residue waspartitioned between water and ethyl acetate. The organic extract waswashed with brine, dried over anhydrous magnesium sulfate, filtered, andconcentrated under vacuum. The final product was purified from thecomplex reaction mixture by way of column chromatography on silica gel(eluent—hexanes—ethyl acetate 4:1) to give the desired product (1.61 g,13%) as brown oil. Mass spec.: 415.38 (M+Na)⁺.

4-(2-Amino-benzyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester4-ethyl ester

A mixture of 4-(2-nitro-benzyl)-piperidine-1,4-dicarboxylic acid1-tert-butyl ester 4-ethyl ester (1.61 g, 4.102 mmol) and 10% palladiumon charcoal (0.10 g) in ethanol (190 mL) was hydrogenated at 50 psiovernight. The resultant mixture was filtered through a plug of celite,and the filtrate concentrated under vacuum to provide the desiredproduct (1.29 g, 99%) as colorless oil. Mass spec.: 363.45 (MH)⁺.

4-(2-Amino-benzyl)-piperidine-4-carboxylic acid ethyl esterhydrochloride

To a solution of 4-(2-amino-benzyl)-piperidine-1,4-dicarboxylic acid1-tert-butyl ester 4-ethyl ester (1.29 g, 4.102 mmol) in dichloromethane(15 mL) was added a 4.0M solution of hydrogen chloride in dioxane (5mL). The resulting solution was stirred at room temperature overnight.The concentration of the solution under vacuum provided the titlecompound (1.23 g, 100%) as white solid, which was used in the next stepwithout purification. Mass spec.: 263.40 (MH)⁺.

3,4-Benzo-2,9-diazaspiro[5.5]undeca-1-one

A solution of 4-(2-amino-benzyl)-piperidine-4-carboxylic acid ethylester hydrochloride (1.23 g, 4.102 mmol) was dissolved in methanol andthe resulting solution was stirred at room temperature overnight. Thesolution was diluted by half with water and passed through a short plugof the hydroxide form of AG® 1-X2 ion-exchange resin (100-200 mesh),eluting with 50% aqueous methanol. The evaporation of the collectedfractions gave the desired product (0.89 g, 100%) as white solid. ¹H-NMR(CD₃OD, 500 MHz) δ 7.23 (m, 2H), 7.05 (d, J=7.5 Hz, 1H), 6.89 (d, J=8.0Hz, 1H), 3.46-3.41 (m, 2H), 3.34-3.30 (m, 2H), 2.14-2.09 (m, 2H),1.73-1.67 (m, 4H). Mass spec.: 217.46 (MH)⁺.

(R)-2-Amino-3-benzo[b]thiophen-3-yl-1-[1,4′]bipiperidinyl-1′-yl-propan-1-one,dihydrochloride

To a well stirred solution of3-benzo[b]thiophen-3-yl-(2R)-2-tert-butoxycarbonylamino-propionic acid(1.0 g, 3.1 mmol) in methylene chloride (30 mL) at room temp was added4-piperidinopiperidine (573 mg, 3.4 mmol), triethylamine (1.3 mL, 9.3mmol) followed by 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one(1.02 g, 3.4 mmol). After 3 h, the reaction mixture was treated withaqueous sodium hydrogencarbonate (15 mL), brine (20 mL) and dried(sodium sulfate). The crude mixture was purified by flash chromatographyusing 5% methanol in methylene chloride to give(1R)-1-benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-carbamicacid tert-butylester in 82% yield.(1R)-1-Benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-carbamicacid tert-butylester (1.2 g, 2.54 mmol) in methylene chloride (5 mL) wasadded to a saturated solution of hydrogen chloride in dioxane (20 mL)and stirred for 2 h. The solvents were removed to give(2R)-2-amino-3-benzo[b]thiophen-3-yl-1-[1,4′]bipiperidinyl-1′-yl-propan-1-one,dihydrochloridein 98% yield. ¹H-NMR (500 MHz, CD₃OD): δ 7.98-7.88 (m, 2H), 7.55-7.40(m, 3H), 4.85-4.83 (m, 1H), 3.66-2.68 (m, 9H), 1.92-1.44 (m, 12H). Massspec.: 372 (MH)⁺.

EXAMPLE 61(R)-1-Oxo-3,4-benzo-2,9-diaza-spiro[5.5]undec-3-ene-9-carboxylic acid(1-benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-amide

To a solution of2-amino-3-benzo[b]thiophen-3-yl-1-[1,4′]bipiperidinyl-1′-yl-propan-1-one(50.0 mg, 0.135 mmol) in 1,2-dichloroethane (1.5 mL) were addedN,N′-disuccinimidyl carbonate (34.6 mg, 0.135 mmol) and diisopropylethylamine (0.09 mL, 0.500 mmol). The resulting solution was stirred for 1 h,at which point 3,4-benzo-2,9-diazaspiro[5.5]undeca-1-one (30.4 mg, 0.140mmol) was added. The reaction mixture was stirred at room temperatureovernight and concentrated. The purification was achieved by way ofreversed-phase preparative HPLC to give the desired product (75.5 mg,77%) as brown oil. ¹H-NMR (CD₃OD, 500 MHz) δ 7.92-7.85 (m, 2H),7.44-7.34 (m, 3H), 7.21-7.16 (m, 2H), 7.00 (t, J=7.0 Hz, 1H), 6.86 (t,J=8.5 Hz, 1H), 5.15-5.02 (m, 1H), 4.72-4.45 (m, 1H), 3.95-3.20 (m, 8H),3.18-2.92 (m, 4H), 2.92-2.75 (m, 2H), 2.75-2.63 (m, 1H), 2.40-2.30 (m,1H), 2.08-1.64 (m, 8H), 1.58-1.20 (m, 6H). Mass spec.: 614.37 (MH)⁺.

EXAMPLE 62N-[(1R)-1-(Benzo[b]thien-3-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-3′,4′-dihydro-2-oxospiro-[piperidine-4,4′(1H)-quinoline]-1-carboxamide

Prepared as described for(R)-1-oxo-3,4-benzo-2,9-diaza-spiro[5.5]undec-3-ene-9-carboxylic acid(1-benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-amidefrom 3′,4′-dihydro-2-oxospiro-[piperidine-4,4′(1H)-quinoline (M. S.Chambers, et al., J. Med. Chem., 1992, 35, 2033-2039; WO-94/13696).¹H-NMR (CDCl₃, 500 MHz) δ −0.35 (1H, m), 0.79 (1H, m), 1.2-2.1 (12H, m),2.22 (5H, m), 2.38 (2H, m), 2.74 (2H, ABq), 3.19 (3H, m), 3.33 (2H, m),3.65 (1H, d), 3.80 (1H, m), 3.93 (1H, t), 4.49 (1H, d), 5.31 (1H, t),5.96 (1H, t), 6.89 (1H, d), 7.05 (1H, t), 7.18 (1H, d), 7.26 (1H, m),7.33 (1H, m), 7.40 (1H, m), 7.78 (1H, m), 7.96 (1H, Abq), 9.01 (1H,brs), 9.17 (1H, brs). Mass spec.: 614.36 (MH)⁺.

EXAMPLE 63N-[(1R)-1-(Benzo[b]thien-3-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-2′,3′-dihydro-1-oxospiro-[piperidine-4,4′(1H)-isoquinoline]-1-carboxamide

Prepared as described for(R)-1-oxo-3,4-benzo-2,9-diaza-spiro[5.5]undec-3-ene-9-carboxylic acid(1-benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-amidefrom 2′,3′-dihydro-1-oxospiro-[piperidine-4,4′(1H)-isoquinoline (M. S.Chambers, et al., J. Med. Chem., 1992, 35, 2033-2039; WO-94/13696).¹H-NMR (CDCl₃, 500 MHz) δ 0.01 (1H, m), 0.78 (1H, m), 1.1-2.0 (12H, m),2.15-2.30 (5H, m), 2.74 (1H, t), 3.0-3.6 (9H), 3.89(2H, m), 4.46 (1H,d), 5.29 (1H, m), 5.62 (1H, d), 6.47 (1H, brs), 7.38 (5H, m), 7.51 (1H,m), 7.77 (1H, m), 7.85 (1H, m), 8.11 (1H, d). Mass spec.: 614.42 (MH)⁺.

EXAMPLE 64N-[(1R)-1-(Benzo[b]thien-3-ylmethyl)-2-[1,4′-bipiperidin]-1′-yl-2-oxoethyl]-1,2-dihydro-2-oxospiro-[4H-3,1-benzoxazine-4,4′-piperidine]-1′-carboxamide

Prepared as described for(R)-1-oxo-3,4-benzo-2,9-diaza-spiro[5.5]undec-3-ene-9-carboxylic acid(1-benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-amidefrom 1,2-dihydro-2-oxospiro-[4H-3,1-benzoxazine-4,4′-piperidine(prepared as described in Takai, et al.; Chem. Pharm. Bull. 1985, 33,1129-1139) to give the title compound (76%). Mass spec.: 616 (MH)⁺.R_(f)=1.42.

Succinate Intermediates and Examples 3-Benzo[b]thiophen-3-yl-acrylicacid

A suspension of 1-benzothiophene-3-carbaldehyde (4.9 g, 0.03 mol),malonic acid (6.6 g, 0.06 mol) and piperidine (1 mL) in 100 mL anhydrouspyridine was heated at 110° C. overnight. The reaction mixture wascooled to room temperature and the solvent was removed in vacuo. Theresidue was taken up in 100 mL of water and 1 N hydrochloric acid wasadded to adjust the pH of this solution to ca. 3. The suspension wasfiltered and the yellow solid was collected, washed with water (3×50 mL)and concentrated in vacuo to give the indicated product with 95% purity(5.65 g, 91%).

3-Benzo[b]thiophen-3-yl-propionic acid

A suspension of 3-benzo[b]thiophen-3-yl-acrylic acid: (5.6 g, 0.027 mol)and 10% Pd/C (600 mg) in 1:1 methanol/ethyl acetate (50 mL) washydrogenated in a Parr apparatus at 50 psi overnight. The mixture wasfiltered and concentrated to give the crude product without furtherpurification (ca. 100% conversion). Mass spec.: 205(MH)⁻.

3-(3-Benzo[b]thiophen-3-yl-propionyl)-4(R)-benzyl-oxazolidin-2-one

To a solution of 3-benzo[b]thiophen-3-yl-propionic acid (2.1 g, 0.010mol), triethylamine (4.12 g, 0.040 mol) in anhydrous tetrahydrofuran(100 mL) at 0° C. was added pivaloyl chloride (1.38 mL, 0.011 mol).After stirring for 1.5 h at 0° C., lithium chloride (0.475 g, 0.011 mol)and (R)-4-benzyl-2-oxazolidinoe (1.988 g, 0.011 mol) were added. Thereaction mixture was allowed to warm up to room temperature and stirredovernight. Then the mixture was washed with water (3×150 mL). Theorganic layer was separated, dried, and evaporated to give the crudeproduct. The title product was obtained as a brown oil (90%) by flashchromatography on silica gel eluting with 100% methylene chloride. Thiscompound was used immediately in the following procedure.

3(S)-Benzo[b]thiophen-3-ylmethyl-4-(4-benzyl-2-oxo-oxazolidin-3-yl)-4-oxobutyric acid tert-butyl ester

To a solution of3-(3-benzo[b]thiophen-3-yl-propionyl)-4-benzyl-oxazolidin-2-one (3.35 g,9.18 mmol) in 100 mL anhydrous tetrahydrofuran at −78° C. was addedlithium diisopropyl amide in tetrahydrofuran (6.1 mL, 11.01 mmol) andthe reaction mixture was stirred for 30 min Following addition oft-butyl bromoacetate (1.62 mL, 11.01 mmol) at −78° C., the mixture wasstirred overnight while it was allowed to warm to room temperature. Thesolvent was evaporated and the residue diluted with ethyl acetate. Theorganic layer was washed with water (3×100 mL), dried, filtered, andconcentrated to give the crude product. The title product was obtainedby filtration through a pad of silica, eluting with methylene chloride(49%).

2(S)-Benzo[b]thiophen-3-ylmethyl-succinic acid, 4-tert-butyl ester

To a stirred solution of3-benzo[b]thiophen-3-ylmethyl-4-(4-benzyl-2-oxo-oxazolidin-3-yl)-4-oxobutyricacid tert-butyl ester (2.15 g, 4.49 mmol) in tetrahydrofuran (50 mL) andwater (30 mL) at 0° C. was added 30% aqueous hydrogen peroxide (1 mL)followed by lithium hydroxide (0.2155 g, 8.98 mmol). The reactionmixture was stirred overnight. Tetrahydrofuran was removed in vacuo andthe resulting solution was acidified with 10% citric acid, and extractedwith ethyl acetate (3×50 mL). The organic layer was washed with sodiumbisulfite solution, dried and concentrated to give the title product.

3(S)-Benzo[b]thiophen-3-ylmethyl-4-[1,4′]bipiperidinyl-1′-yl-4-oxo-butyricacid tert-butyl ester

A solution of 2-benzo[b]thiophen-3-ylmethyl-succinic acid 4-tert-butylester (1.8420 g, 5.76 mmol), piperidylpiperidine (1.2240 g, 7.28 mmol)and triethylamine (0.7353 g, 7.28 mmol) in 100 mL methylene chloride wastreated with 3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one(DEPBT, 1.8953 g, 6.34 mmol). The mixture was stirred overnight and thenwashed with water (3×40 mL). The organic layer was dried, filtered, andconcentrated in vacuo to give the crude product. This was furtherpurified by flash chromatography on silica gel, eluting with 0-10% 2 Mammonia in methanol/methylene chloride, to give the desired product.This product was carried on without further purification.

3(S)-Benzo[b]thiophen-3-ylmethyl-4-[1,4′]bipiperidinyl-1′-yl-4-oxo-butyricacid

A solution of3-benzo[b]thiophen-3-ylmethyl-4-[1,4′]bipiperidinyl-1′-yl-4-oxo-butyricacid tert-butyl ester in 15 mL methylene chloride was treated withtrifluoroacetic acid (3 mL) and the reaction mixture was stirredovernight at room temperature. The solvent was evaporated to give thecorresponding trifluoroacetate salt of the title product (99%).

EXAMPLE 65 1-[1,4′]Bipiperidinyl-1′-yl-2-(3(S)-Benzo[b]thiophen-3-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione

A solution of3-benzo[b]thiophen-3-ylmethyl-4-[1,4′]bipiperidinyl-1′-yl-4-oxo-butyricacid (25.0 mg, 0.060 mmol),1,2-dihydro-2-oxospiro-4H-3,1-dihydro-benzoxazine-4′4-piperidine (15.7mg, 0.072 mmol) and triethylamine (7.3 mg, 0.072 mmol) in 5 mL methylenechloride at room temperature was treated with3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 21.5 mg,0.072 mmol). The solution was stirred overnight and then washed withwater (3×5 mL). The organic layer was dried, concentrated, and the crudeproduct was purified by flash chromatography on silica gel, eluting with0-10% 2M ammonia in methanol/methylene chloride, to give the desiredproduct in 60% yield. LC/MS: t_(R)=1.34 min, 615.45 (MH)⁺.

2-(7-Methyl-1H-indazol-5-ylmethylene)-succinic acid 1-methyl ester

To a mixture of 7-methyl indazole aldehyde (0.2619 g, 1.64 mmol) andDBE-4 dibasic ester (dimethyl succinate) (0.32 mL, 2.45 mmol) int-butanol (20 mL) was added potassium t-butoxide (0.4036 g, 3.60 mmol).The reaction mixture was heated at 50° C. for 2 h under nitrogen. Aftera further 16 h at room temperature, the solvent was removed in vacuo andthe residue was taken up in water (100 mL) and extracted with ethylacetate (3×50 mL). The aqueous layer was acidified with 1 N hydrochloricacid to pH 3˜4 and extracted with ethyl acetate (3×50 mL). The combinedethyl acetate solution was dried and concentrated in vacuo to give thecrude product as a yellow solid (99%, cis/trans isomer approximately40:60). The crude mixture was carried to next step without furtherpurification. Mass spec.: 275 (MH)⁺.

(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-succinic acid 1-methyl ester

A suspension of 2-(7-methyl-1H-indazol-5-ylmethylene)-succinic acid1-methyl ester (0.4440 g, 1.62 mmol) and 10% Pd/C (0.04 g) in ethylacetate (15 mL) and methanol (5 mL) was hydrogenated in a Parr apparatusovernight at 50 psi. The reaction mixture was filtered through a pad ofcelite and the filtrate evaporated to give the desired product as ayellow solid (100%). Mass spec.: 277 (MH)⁺.

EXAMPLE 66(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid methyl ester

A solution of 2-(7-methyl-1H-indazol-5-ylmethyl)-succinic acid 1-methylester (0.2253 g, 0.82 mmol),1,2-dihydro-2-oxospiro-4H-3,1-dihydro-benzoxazine-4′4-piperidine (0.1938g, 0.89 mmol) and triethylamine (0.099 g, 0.98 mmol) in methylenechloride (15 mL) was treated with3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 0.2685 g,0.90 mmol). The mixture was stirred overnight and then washed with water(3×5 mL). The organic layer was dried, and concentrated in vacuo. Theresidue was purified by flash chromatography on silica gel, eluting with0-10% 2M ammonia in methanol/methylene chloride, to afford the desiredproduct (53%). LC/MS: t_(R)=1.40 min, 477.28 (MH)⁺.

Similarly Prepared:

EXAMPLE 67(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid methyl ester

¹H-NMR (400 MHz, CDCl₃) δ 8.02 (1H, s), 7.98(1H, m), 7.90 (1H, m),7.35-6.89 (4H, m), 6.72 (1H, m), 4.71(1H, m), 4.57(1H, m), 4.27 (1H, s),4.22 (1H, m), 3.85 (1H, m), 3.65 (3H, m), 3.30 (1H, m), 3.11(2H, m),2.83 (2H, m), 2.81-2.54 (4H, m), 2.35 (1H, m), 1.73-1.67 (4H, m). Massspec.: 490.32 (MH)⁺.

(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid

A solution of2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid methyl ester (0.1911 g, 0.40 mmol) and lithium hydroxide (19.3 mg,0.80 mmol) in tetrahydrofuran (10 mL) and water (8 mL) was stirredovernight at room temperature. The reaction mixture was acidified with1N hydrochloric acid to ca. pH 1 and concentrated to removetetrahydrofuran in vacuo to afford a white solid precipitate which wascollected by filtration. The solid was washed twice with small amountsof water and dried in vacuo overnight (100%). Mass spec.: 477 (MH)⁺.

EXAMPLE 68(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione

A solution of2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid (0.020 g, 0.04 mmol), piperidylpiperidine (0.0087 g, 0.05 mmol) andtriethylamine (0.09 g, 0.08 mmol) in methylene chloride (5 mL) at roomtemperature was treated with3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 0.0155 g,0.05 mmol). The mixture was stirred overnight and then washed with water(3×5 mL). The organic layer was dried and the solvents were removed invacuo. The crude product was purified by preparative TLC on silica gel(10% 2 M ammonium hydroxide/methanol in methylene chloride) to give thedesired product (36%). LC/MS: t_(R)=1.18 min, 613.47 (MH)⁺.

Similarly Prepared:

EXAMPLE 69(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 7.99 (1H, m), 7.62 (1H, m), 7.38 (1H, m),7.14(1H, m), 7.04-6.90 (3H, m), 6.70 (2H, d, J=8.0 Hz), 4.70-4.58 (3H,m), 4.24 (2H, m), 4.00 (2H, m), 3.70 (1H, m), 3.18-2.72 (5H, m),2.64-2.22 (8H, m), 2.18-0.82 (17H, m). Mass spec.: 626.34 (MH)⁺.

EXAMPLE 70(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 8.06 (1H, s), 7.75 (1H, m), 7.36 (1H, m), 7.14(1H, m), 7.01-6.79 (3H, m), 6.70 (1H, m), 4.70-4.49 (2H, m), 4.23 (2H,m), 3.98 (1H, m), 3.87 (3H, m), 3.65-3.44 (4H, m), 3.26 (1H, m),3.10-2.88 (3H, m), 2.75 (1H, m), 2.51 (3H, s), 2.35 (1H, m), 2.00 (1H,m), 1.70-1.00 (9H, m). Mass spec.: 601.38 (MH)⁺.

EXAMPLE 71(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 9.27 (1H, m), 8.00 (1H, s), 7.37 (1H, m), 7.23(1H, m), 7.10-6.99 (3H, m), 6.87 (1H, m), 4.54 (1H, m), 3.97-3.50 (10H,m), 3.30 (1H, m), 3.16-2.76 (4H, m), 2.53 (3H, s), 2.35 (1H, m),2.20-1.00 (9H, m). Mass spec.: 588.36 (MH)⁺.

EXAMPLE 72(±)-N,N-Dimethyl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyramide

LC/MS: t_(R)=1.36 min, 525.35 (M+Na)⁺.

EXAMPLE 73(±)-1-(2,6-Dimethyl-morpholin-4-yl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=1.41 min, 573.39 (MH)⁺.

EXAMPLE 74(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-1-(4-methyl-piperidin-1-yl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 8.06 (1H, b), 7.60-6.73 (7H, m), 4.71 (1H, m),4.54 (2H, m), 4.26 (2H, m), 4.05-3.89 (2H, m), 3.65 (1H, m), 3.09-2.81(4H, m), 2.61 (3H, s), 2.41 (2H, m), 1.76-0.51(15H, m). Mass spec.:557.38 (MH)⁺.

EXAMPLE 75(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-1-morpholin-4-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=1.32 min, 545.42 (MH)⁺.

EXAMPLE 76(±)-N,N-Dimethyl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyramide

LC/MS: t_(R)=1.27 min, 512.30 (M+Na)⁺.

EXAMPLE 77(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-1-(piperidin-1-yl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 9.26-9.01 (1H, m), 8.09 (1H, s), 7.42-6.89(7H, m), 4.56 (1H, m), 3.84 (1H, m), 3.65 (3H, m), 3.30 (2H, m), 3.05(3H, m), 2.81 (1H, m), 2.60 (3H, s), 2.39 (1H, m), 2.09 (2H, m), 1.85(1H, m), 1.43-0.79 (9H, m). Mass spec.: 530.34 (MH)⁺.

EXAMPLE 78(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-1-piperidin-1-yl-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 8.02 (1H, s), 7.82 (1H, m), 7.37 (1H, m), 7.14(1H, m), 7.04-6.90 (3H, m), 6.73 (1H, d, J=8.0 Hz), 4.69 (1H, m), 4.56(1H, m), 4.24 (2H, d, J=7.2 Hz), 4.02 (1H, m), 3.65 (2H, m), 3.33 (3H,m), 3.07 (3H, m), 2.78 (1H, m), 2.55 (3H, s), 2.36 (1H, m), 1.80-1.50(4H, m), 1.43 (4H, b), 1.26 (2H, b), 0.81 (2H, b). Mass spec.: 543.40(MH)⁺.

EXAMPLE 79(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione

¹H-NMR (400 MHz, CDCl₃) δ 8.86 (1H, m), 7.98 (1H, s), 7.54-6.85 (7H, m),4.73-4.48 (3H, m), 3.96-0.80 (3H, m), 3.73-3.58 (3H, m), 3.17-2.78 (5H,m), 2.55-2.24 (5H, m), 2.02-1.79 (6H, m), 1.70-0.79 (7H, m). Mass spec.:599.31 (M+Na)⁺.

EXAMPLE 80(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione

LC/MS: t_(R)=1.25 min, 574.25 (MH)⁺.

EXAMPLE 81(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=1.34 min, 587.38 (MH)⁺.

EXAMPLE 82(±)-2-(1H-Indazol-5-ylmethyl)-N,N-dimethyl-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyramide

LC/MS: t_(R)=1.28 min, 489.33 (MH)⁺.

EXAMPLE 83(±)-5-{2-([1,4′]Bipiperidinyl-1′-carbonyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyl}-indazole-1-carboxylicacid tert-butyl ester

LC/MS: t_(R)=1.47 min, 742.55 (M+Na)⁺.

EXAMPLE 84(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-N-prop-2-ynyl-butyramide

LC/MS: t_(R)=1.33 min, 535.32 (M+Na)⁺.

Aspartate Intermediates and Examples

(L)-2-tert-Butoxycarbonylamino-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid benzyl ester

To a stirred solution of N-tert-butyloxycarbonyl-L-asparticacid-alpha-benzyl ester (1.4 g, 4.33 mmol) and3,4-dihydro-3-(4-piperidinyl-2(1H)-quinazolinone (1.26 g, 4.33 mmol) inmethylene chloride (12 mL) was added3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 1.425 g,4.76 mmol) in one portion followed by dropwise addition of triethylamine(0.724 mL, 5.20 mmol). The resulting suspension gradually becamehomogeneous with stirring and was stirred at room temperature overnight(15 h). The mixture was diluted with methylene chloride and washed withsodium hydroxide (0.5 N) and water. The layers were separated and theorganic layer was dried with sodium sulfate, and concentrated in vacuoto give a light yellow foam. The crude product was purified by flashcolumn chromatography (10% methanol in methylene chloride) to give acolorless oil. Mass spec.: 559 (M+Na)⁺.

(L)-2-tert-Butoxycarbonylamino-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid

To a solution of2-tert-butoxycarbonylamino-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid benzyl ester (1.48 g, 2.76 mmol) in ethyl acetate/methanol (16 mL,1:1) in a Parr bottle was added 10% palladized charcoal (150 mg) in oneportion. Hydrogenation was carried out with a Parr apparatus at 52 psifor 1 h. TLC (10% methanol in methylene chloride) indicated aquantitative conversion. The mixture was filtered and concentrated invacuo to afford a glassy colorless solid (1.14 g, 93%).

EXAMPLE 85

(L)-{1-([1,4′]Bipiperidinyl-1′-carbonyl)-3-oxo-3-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-propyl}-carbamicacid tert-butyl ester

To a stirred solution of2-tert-butoxycarbonylamino-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid (1.14 g, 2.55 mmol) and 4-piperidinyl-piperidine (525 mg, 2.81mmol) in methylene chloride (20 mL) was added3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 840 mg,2.81 mmol) in one portion followed by dropwise addition of triethylamine(0.427 mL, 3.06 mmol). The resulted mixture was stirred at roomtemperature overnight (15 h). The mixture was diluted with methylenechloride and washed with sodium hydroxide (0.5 N) solution and water.The layers were separated and the organic layer was dried with sodiumsulfate and concentrated in vacuo to give a light yellow foam. The crudeproduct was purified by flash column chromatography (10% (1M ammonia inmethanol) in methylene chloride) to give a colorless foam (1.08 g, 71%).¹H-NMR (400 MHz, CDCl₃) δ 8.86-8.55 (1H, br), 7.05 (1H, br), 6.93 (1H,br), 6.82 (1H, br), 6.72 (1H, d, J=7.6 Hz), 6.10-5.68 (1H, br), 5.20(1H, m), 54.70-4.40 (2H, br), 4.20 (2H, br), 4.01-3.82 (2H, br.),3.10-2.88 (3H, br), 2.99 (3H, br), 2.53 (6H, br), 1.90-1.10 (23H, m).Mass spec.: 597 (MH)⁺.

(L)-2-Amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a stirred solution of{1-([1,4′]bipiperidinyl-1′-carbonyl)-3-oxo-3-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-propyl}-carbamicacid tert-butyl ester (1.05 g, 1.76 mmol) in methylene chloride (12 mL)was added trifluroacetic acid (2 mL). The mixture was stirred at roomtemperature until complete conversion (monitored by LCMS, ca. 15 h). Themixture was then diluted with water and sodium hydroxide (1.5 g) wasslowly added with stirring. The layers were separated and the aqueouslayer was extracted with methylene chloride. The combined organic layerswere dried over sodium sulfate and concentrated in vacuo to give a lightyellow foam (860 mg, 98%). Mass spec.: 497 (MH)⁺.

EXAMPLE 86(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(1H-indol-5-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a solution of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(52 mg, 0.105 mmol) and N-tert-BOC-5-bromo-indole (prepared as describedin Tetrahedron 2000, pp 8473-8482) (31 mg, 0.105 mmol) intetrahydrofuran (1 mL) in a 5 mL drum vial was added2-dicyclohexylphosphino-2′-(N,N-dimethylamino)-biphenyl (4.1 mg, 0.0105mmol), Pd₂(dba)₃ (4.8 mg, 0.005 mmol), and cesium carbonate (54.6 mg,0.168 mmol) under nitrogen. The vial was sealed with a teflon-lined cap.The deep orange-colored reaction mixture was heated at 80° C. withstirring. The reaction was continued at 80° C. overnight. Conversionreached approximately 50% after 17 h. The solvent was removed in vacuoand the residue dissolved in methylene chloride and filtered. Thedesired product was purified by prep arative TLC (10% methanol inmethylene chloride) to afford the tert-butyloxycarbonyl-protectedproduct (11 mg, 15%). Mass spec.: 712 (MH)⁺. This intermediate (11 mg)was dissolved in 3 mL methylene chloride and treated withtrifluoroacetic acid (1.5 mL). The colorless solution turned to a tancolor and was stirred at room temperature for 1.5 h. The mixture wasconcentrated in vacuo and dried under high vacuum to a give tan powder(15 mg, 100%). Mass spec.: 612 (MH)⁺.

EXAMPLE 87(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(5-chloro-2-nitro-phenylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a stirred solution of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(33.7 mg, 0.068 mmol) and 4-chloro-1,2-dinitrobenzene (16.8 mg, 0.075mmol) in ethanol (0.5 mL) was added a saturated sodium bicarbonatesolution (4 drops). The mixture was stirred at room temperature for 70 hto approximately 60% conversion. The product was purified by preparativeHPLC to give a yellow solid (17.7 mg, 40%). Mass spec.: 652 (MH)⁺.

EXAMPLE 88(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(6-chloro-pyrimidin-4-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

A mixture of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(22.3 mg, 0.045 mmol) and 4,6-dichloropyrimidine (16 mg, 0.095 mmol) in2-propanol (0.5 mL) in a microwavable vial was heated at 130° C. undermicrowave irradiation for 40 min. LC/MS indicated 90% conversion. Thesolvent was removed in vacuo and the residue was partitioned betweenmethylene chloride and 1 N sodium hydroxide solution. The organic layerwas separated, dried over sodium sulfate, and concentrated in vacuo. Theresidue was purified by flash column chromatography (10% (1N ammonia inmethanol) in methylene chloride) to afford a white solid (23 mg, 84%).¹H-NMR (400 MHz, CDCl₃) δ 8.36 (1H, d, J=12.8 Hz), 8.04-7.81 (1H, 2s),7.14 (1H, t, J=7.6 Hz), 7.10-6.80 (2H, m), 6.74 (1H, t, J=8.2 Hz),6.52-6.42 (1H, m), 5.90-5.50 (1H, br), 4.85-4.40 (3H, m), 4.40-4.05 (3H,m), 4.05-3.82 (1H, m), 3.20-3.00 (2H, m), 3.00-2.68 (2H, m), 2.68-2.30(8H, m), 2.05-1.90 (2H, m), 1.90-0.70 (12H, m). Mass spec.: 609 (MH)⁺.

Similarly Prepared:

EXAMPLE 89(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(2-chloro-9H-purin-6-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=1.10 min, 649 (MH)⁺.

EXAMPLE 90(L)-2-(4-Amino-6-methyl-5-nitro-pyrimidin-2-ylamino)-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=1.12 min, 649 (MH)⁺.

EXAMPLE 91(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(4,5-diamino-6-methyl-pyrimidin-2-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a solution of2-(4-amino-6-methyl-5-nitro-pyrimidin-2-ylamino)-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dionein 2:1 methanol/ethyl acetate (6 mL) in a Parr bottle was added 10%palladized charcoal (60 mg). The mixture was shaken under a hydrogenatmosphere at 55 psi for 20 h. The mixture was filtered through celiteand the filtrate was concentrated in vacuo to afford a colorless solid(41.2 mg, 49.2% for two steps). LC/MS: t_(R)=0.86 min, 619 (MH)⁺.

EXAMPLE 92(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(7-methyl-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a stirred solution of1-[1,4′]bipiperidinyl-1′-yl-2-(4,5-diamino-6-methyl-pyrimidin-2-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(10.6 mg, 0.0125 mmol) in acetic acid (1.5 mL) was added sodium nitrite(24 mg) followed by a few drops of water. The resulting light yellowsolution was stirred at room temperature for 6 h. The reaction mixturewas diluted with water and methanol and purified by preparative HPLC toafford a colorless oil/solid (3.0 mg, 28%). LC/MS: t_(R)=1.07 min, 630(MH)⁺.

General Procedure for the Synthesis of Examples 93-95:

A mixture of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(0.014 mmol), one of a series of aldehydes (0.07 mmol, 5 equiv) andsolid anhydrous magnesium sulfate (0.031 mmol, 2.2 equiv) in1,2-dichloroethane (3.0 mL) was treated with a catalytic amount ofacetic acid and was shaken overnight. Sodium cyanoborohydride (0.07mmol, 5 eq) was then added in one portion and the suspension was againshaken overnight. Purification was carried out either by filtrationthrough an SCX cartridge or by preparative HPLC.

EXAMPLE 93(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-((2′-pyridyl)-methyl-amino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=0.87 min, 588 (MH)⁺.

EXAMPLE 94(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-((5′-indazolyl)-methyl-amino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=0.92 min, 626 (MH)⁺.

EXAMPLE 95(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-((3′-methyl-phenyll)-methyl-amino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

LC/MS: t_(R)=1.08 min, 600 (MH)⁺.

EXAMPLE 96(L)-1-[1,4′]Bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-2-(pyrimidin-4-ylamino)-butane-1,4-dione

To a solution of1-[1,4′]bipiperidinyl-1′-yl-2-(6-chloro-pyrimidin-4-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(21 mg) was dissolved in 4 mL ethyl acetate/methanol (1:1) in a Parrbottle was added 10% palladized charcoal (10 mg). Hydrogenation wascarried out on a Parr apparatus at 55 psi overnight. The degassedmixture was then filtered and concentrated in vacuo. The residue waspurified by preparative HPLC to afford a yellow solid (12.4 mg, 45%).Mass spec.: 575 (MH)⁺.

EXAMPLE 97(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-(4-hydroxy-cyclohexylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a stirred mixture of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(47.9 mg, 0.096 mmol) and 4-hydroxy-cyclohexanone (Synthesis reported inCan. J. Chem. 1994, 72, 1699-1704) (11 mg, 0.096 mmol) in methanol (1.0mL) was added excess zinc chloride followed by sodium cyanoborohydride(5 equiv). The suspension was stirred at room temperature for 6 days.The methanol was removed in vacuo and the residue partitioned betweenmethylene chloride and 1 N sodium hydroxide. The aqueous layer wasextracted with methylene chloride (3×). The combined methylene chloridesolution was passed through a celite cartridge and concentrated invacuo. The residue was purified by preparative TLC (10% (1N ammonia inmethanol) in methylene chloride) to afford the desired product as awhite solid (15.3 mg, 27%). Mass spec.: 595 (MH)⁺.

EXAMPLE 98(L)-1-[1,4′]Bipiperidinyl-1′-yl-2-[(1H-imidazol-4-ylmethyl)-amino]-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a stirred solution of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(20.6 mg, 0.0415 mmol) and 4-imidazlecarboxyaldehyde (4 mg, 0.0415 mmol)in methylene chloride (1.0 mL) was added sodium cyanoborohydride (8.8mg, 0.0415 mmol) in one portion. The suspension was stirred at roomtemperature for 2 days and then partitioned between methylene chlorideand 1N sodium hydroxide. The layers were separated and the aqueous layerwas extracted with methylene chloride. The combined organic layers weredried over sodium sulfate, and concentrated in vacuo. The residue waspurified by preparative TLC (10% (1N ammonia in methanol) in methylenechloride) to afford the desired product as a colorless oil thatsolidified upon standing (6.1 mg, 26%). ¹H-NMR (400 MHz, CDCl₃) δ 7.61(1H, d, J=4.8 Hz), 7.16 (1H, t, J=7.6 Hz), 7.10-6.85 (3H, m), 6.67 (1H,d, J=8.0 Hz), 4.85-4.63 (2H, m), 4.63-4.40 (1H, m), 4.40-3.65 (7H, m),3.25-2.40 (10H, m), 2.15-0.70 (18H, m). Mass spec.: 577 (MH)⁺.

EXAMPLE 99(L)-N-{1-([1,4′]Bipiperidinyl-1′-carbonyl)-3-oxo-3-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-propyl}-4-methoxy-benzamide

To a stirred mixture of2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(91.5 mg, 0.184 mmol) and p-anisoyl chloride (34.6 mg, 0.203 mmol) inmethylene chloride was added two drops of triethylamine (35 μL). Thelight yellow solution was stirred at room temperature for 2.5 h toachieve complete conversion. The reaction mixture was washed with sodiumhydroxide (1N) and the aqueous layer was then extracted with methylenechloride. The combined organic layers were passed through a celitecartridge and concentrated in vacuo to give a glassy solid. The crudeproduct was purified by flash column chromatography (10% (1N ammonia inmethanol) in methylene chloride) to give a glassy solid (92.8 mg, 80%).¹H-NMR (400 MHz, CDCl₃) δ 8.55-8.47 (1H, d), 8.10-7.78 (3H, m), 7.09(1H, t, J=7.4 Hz), 6.96-6.74 (4H, m), 5.62-5.44 (1H, br), 4.75-4.40 (3H,m), 4.40-4.05 (3H, m), 4.05-3.82 (1H, br), 3.76 (3H, s), 3.18-2.88 (3H,m), 2.88-2.70 (1H, m), 2.70-2.30 (8H, m), 2.05-1.19 (14H, m). Massspec.: 631 (MH)⁺.

EXAMPLE 100(L)-N-{1-([1,4′]Bipiperidinyl-1′-carbonyl)-3-oxo-3-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-propyl}-4-hydroxy-benzamide

A stirred solution ofN-{1-([1,4′]bipiperidinyl-1′-carbonyl)-3-oxo-3-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-propyl}-4-methoxy-benzamidesolution in methylene chloride (69 mg) was treated with boron tribromide(1M in methylene chloride, 0.6 mL), dropwise at room temperature. Theresulting suspension was stirred at room temperature for 7 h and thenthe reaction was quenched with excess triethylamine followed bymethanol. The solvents were removed in vacuo and the residue wasdissolved in methanol and purified by preparative HPLC. LC/MS:t_(R)=1.03 min, 617 (MH)⁺.

EXAMPLE 101 (L)-1H-Pyrazole-3-carboxylicacid{1-([1,4′]bipiperidinyl-1′-carbonyl)-3-oxo-3-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-propyl}-amide

To a stirred solution of pyrrazole-3-carboxylic acid (4 mg, 0.036 mmol)and2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione(13 mg, 0.026 mmol) in methylene chloride (1 mL) was added3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 8.6 mg,0.036 mmol) in one portion followed by one drop of triethylamine. Theresulting mixture was stirred at room temperature overnight (15 h). Themixture was then partitioned between sodium hydroxide (0.5 N) andmethylene chloride. The layers were separated and the aqueous layer wasextracted with methylene chloride (3×). LCMS indicated that the productwas remained in the aqueous layer. The product was purified bypreparative HPLC to give a yellow oil (17.2 mg, 94%). Mass spec.: 591(MH)⁺.General Procedure for the Synthesis of Examples 102-134:

The starting amine,2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione,was dispersed in a 96-well mini-reactor (ca. 10 mg each) in 1 mLdichloroethane. Individual acyl chlorides (ca. 2 equiv.) were addedfollowed by a resin-bound solid-phase piperidine base (4 equiv). Theblock was shaken overnight. Approximately 4 equivalents of tris-amineresin was added to each well and the mini-reactor was shaken for another5 h. The reaction mixtures were filtered, and purified by eitherpreparative HPLC or filtration through an SCX cartridge or both. HPLCretention times and mass spectral data for each example are listed inTable 2. TABLE 2 Amides and Carbamates HPLC MS Example Structure t_(R)(min) (M+) 102

1.84 637.38 103

1.39 565.45 104

1.89 641.46 105

1.73 619.42 106

1.62 615.41 107

2.25 737.37 108

2.12 669.3 109

1.59 675.46 110

1.62 601.43 111

2.09 669.33 112

1.91 665.36 113

1.68 646.37 114

1.66 645.4 115

2.14 690.45 116

1.59 607.39 117

1.59 621.4 118

2.01 735.43 119

1.92 679.32 120

1.22 537.4 121

2.03 685.4 122

1.79 637.38 123

1.84 669.3 124

1.53 636.35 125

2.04 691.35 126

1.89 657.35 127

1.86 649.39 128

1.67 691.42 129

1.84 635.38 130

1.69 617.42 131

1.74 635.38 132

1.84 631.44 133

1.94 695.28 134

1.7 647.41General Procedure for the Synthesis of Examples 135-200:

The starting amine,2-amino-1-[1,4′]bipiperidinyl-1′-yl-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione,was dispersed in a 96-well mini-reactor (ca. 10 mg in each well) indichloroethane (1 mL). Individual isocyanates (ca. 2 equiv) were addedto individual wells. The block was shaken for 2 days. Approximately 4equivalent of tris-amine resin was added to each well and themini-reactor was shaken for another two days. The reaction mixtures werefiltered, and individual product was purified by either preparative HPLCor filtration through an SCX cartridge or both. HPLC retention times andmass spectral data for each example are listed in Table 3. TABLE 3 UreasHPLC t_(R) MS Example Structure (min) (MH)⁺ 135

1.43 665.84 136

1.56 707.88 137

1.39 665.84 138

1.3 643.83 139

1.44 657.86 140

1.42 650.22 141

1.26 629.81 142

1.41 643.83 143

1.24 615.78 144

1.53 691.88 145

1.21 629.81 146

1.52 707.88 147

1.19 657.82 148

1.44 684.67 149

1.3 645.81 150

1.24 645.81 151

1.33 643.83 152

1.56 718.22 153

1.55 683.78 154

1.37 655.84 155

1.27 675.83 156

1.26 651.76 157

1.39 643.83 158

1.43 643.83 159

1.57 684.67 160

1.46 683.78 161

1.48 684.67 162

1.5 657.86 163

1.14 651.76 164

1.34 685.66 165

1.26 675.83 166

1.28 701.87 167

1.52 718.22 168

1.35 669.75 169

1.24 649.86 170

1.11 639.8 171

1.31 633.77 172

1.34 650.22 173

1.47 684.67 174

1.27 675.83 175

1.34 659.83 176

1.41 694.68 177

1.28 633.77 178

1.39 650.22 179

1.42 694.68 180

1.26 633.77 181

1.19 645.81 182

1.34 687.84 183

1.08 581.76 184

1.31 651.76 185

1.39 643.83 186

1.33 664.25 187

1.41 680.25 188

1.48 718.22 189

1.28 659.83 190

1.41 643.83 191

1.41 664.25 192

1.41 664.25 193

1.41 668.21 194

1.45 708.71 195

1.39 647.8 196

1.27 673.82 197

1.45 691.88 198

1.26 643.83 199

1.45 693.89 200

1.4 699.78

2-(1H-Indazol-5-ylamino)-succinic acid 4-tert-butyl ester 1-ethyl ester

To a solution/suspension of 5-aminoindazole (1.01 g, 7.6 mmol) intetrahydrofuran (20 mL) was added ethyl glyoxlate solution (ca. 50% intoluene, 1.7 mL, 1.1 equiv) in one portion followed by magnesium sulfate(4.6 g). The mixture was stirred at room temperature overnight (23 h)and then filtered and concentrated in vacuo. The resulting crude imineintermediate (1.3 g, 6 mmol) was dried by azeotroping with anhydrousbenzene and further dried under high vacuum. The residue was thendissolved in tetrahydrofuran (20 mL) and cooled at 0° C. A solution of2-tert-butoxy-2-oxoethylzinc chloride (0.5 M in ether, 24 mL, 2 equiv)was then slowly added. After stirring at 0° C. for 1 h, the mixture wasstored at 4° C. overnight. The mixture was then diluted with ethylacetate and quenched with half-saturated ammonium chloride solutionalong with a minimum amount of 0.5 N HCl to dissolve the precipitatedsolids. The layers were separated and the aqueous layer was extractedwith ethyl acetate. The combined organic layers were washed with waterand saturated sodium bicarbonate solution. The organic layer was driedover sodium sulfate and concentrated in vacuo. The crude product waspurified by flash column chromatography on silica gel, eluting with 10%methanol in methylene chloride, to afford the desired product (1.3 g,65%) as a tan oil. ¹H-NMR (400 MHz, CDCl₃) δ 7.89 (1H, s), 7.40-7.27(1H, m), 6.98-6.77 (2H, m), 4.42-4.35 (1H, m), 4.30-4.12 (3H, m), 2.80(2H, d, J=4.4 Hz), 1.43 (9H, s), 1.27-1.17 (4H, m). Mass spec.: 356.24(M+Na)⁺, 278.23 (M−^(t)Bu)⁺, t_(R)=1.287 min.

2-(1H-Indazol-5-ylamino)-succinic acid 1-ethyl ester

A stirred solution of 2-(1H-indazol-5-ylamino)-succinic acid4-tert-butyl ester 1-ethyl ester (123.6 mg, 0.37 mmol) in methylenechloride (2 mL) and trifluoroacetic acid (0.5 mL) was stirred at roomtemperature overnight. The reaction mixture was then diluted with ethylacetate and washed with saturated ammonium chloride solution, water andbrine. The organic layer was dried and concentrated to give a dark greenoil: LC/MS: t_(R)=0.643 min, 278.19 (MH)⁺.

2-(1H-Indazol-5-ylamino)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid ethyl ester

To a stirred solution of 2-(1H-indazol-5-ylamino)-succinic acid 1-ethylester (84 mg, 0.215 mmol) in methylene chloride (1 mL) was added theamine (99 mg, 0.429 mmol, 2 equiv) followed by DEPBT (128 mg, 0.43 mmol,2 equiv.) and triethylamine (70 μL, 0.47 mmol, 2.2 equiv). The mixturewas stirred overnight and then diluted with ethyl acetate and washedwith half-saturated ammonium chloride solution, water and brine. Theorganic layer was dried and concentrated to a tan oil. The crude productwas purified by flash column chromatography on silica gel, eluting with10% methanol in methylene chloride, to give the desired product (36.2mg, 34.5% for two steps) as a reddish oil. ¹H-NMR (400 MHz, CDCl₃) δ7.90 (2H, d, J=4.4 Hz), 7.33 (1H, d, J=8.4 Hz), 7.20-7.14 (1H, m),7.00-6.80 (4H, m), 6.70 (1H, t, J=6.8 Hz), 4.58-4.48 (1H, m), 4.65-4.40(2H, m), 4.34-4.05 (3H, m), 4.02-3.82 (1H, m), 3.20-2.99 (2H, m),2.99-2.84 (1H, m), 2.70-2.52 (1H, m), 1.80-1.50 (5H, m), 1.35-1.12 (5H,m). LC/MS: t_(R)=1.130 min, 491.37 (MH)⁺.

2-(1H-Indazol-5-ylamino)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid

To a solution of the ethyl ester (34 mg, 0.069 mmol) in tetrahydrofuran(0.3 mL) was added lithium hydroxide in water (1M, 280 μL, 4 equiv) andthe mixture was stirred at room temperature for 17 h. The solution wasdried under a stream of nitrogen. To the residue was added 0.2 mLtettrahydrofuran and 0.2 mL anhydrous benzene and the suspension wasblown dry again with a stream of nitrogen. LC/MS: t_(R)=0.900 min,463.30 (MH)⁺.

EXAMPLE 201(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(1H-indazol-5-ylamino)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

To a solution of2-(1H-indazol-5-ylamino)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid ethyl ester (0.069 mmol) in dimethylformamide (0.5 mL) in a cappeddrum vial was added piperidinylpiperidine (14.3 mg, 0.076 mmol, 1.1equiv), DEPBT (22.8 mg, 1.1 equiv) and triethylamine (8 drops, ca. 160μL). The mixture was stirred at room temperature overnight. The finalproduct was purified by preparative HPLC to afford the desired product(15 mg, 26% for two steps) as a tan solid. LC/MS: t_(R)=0.917 min,613.54 (MH)⁺.

ADDITIONAL EXAMPLES (1-Benzyl-piperidin-4-yl)-(2-nitro-benzyl)-amine

2-Nitrobenzaldehyde (1 g, 6.61 mmol) and 4-amino-1-benzylpiperidine(1.35 mL, 6.61 mmol) were combined in ethanol (20 mL). The resultingsuspension was stirred at room temperature for 20 min before a solutionof sodium borohydride (0.25 g, 6.61 mmol) in ethanol (5 mL) was addeddropwise over 10 min. After the addition was complete, the reaction wasstirred for 1 h, cooled to 0° C. and concentrated ammonium chloride wasadded to the reaction mixture until no bubbling was observed. Thesolvents were evaporated in vacuo and the resultant crude mixture wasdissolved in water (10 mL) and methylene chloride (10 mL). The layerswere separated and the organic layer washed with water (2×) and brine(2×), dried over sodium sulfate, filtered, and concentrated to afford1.5 g (70%) of the desired product. LC/MS: t_(R)=0.7 min, 326.18 (MH)⁺.

(2-Amino-benzyl)-(1-benzyl-piperidin-4-yl)-amine

(1-Benzyl-piperidin-4-yl)-(2-nitro-benzyl)-amine (1.2 g, 3.7 mmol) andzinc dust (1 g, excess) were combined in 75% aqueous acetic acid (16 mL)and stirred at 60° C. for 2 h. After cooling to room temperature, thesolvents were removed in vacuo and the resultant crude dissolved inwater (10 mL), followed by addition of ammonium hydroxide until pH 3 wasattained. The solution was extracted with methylene chloride (3×). Theorganic layers were pooled together washed with water (2×), brine (2×),dried over sodium sulfate, filtered, and concentrated to afford 0.8 g(73%) of the desired product. ¹H-NMR (CD₃OD) δ 2.50 (m, 2H), 3.20 (m,2H), 3.49 (dd, J=7.0, 7.3, 1H), 3.62 (m, 4H), 4.20 (s, 2H), 4.36 (s,2H), 7.04 (m, 2H), 7.32 (dd, J=7.3, 7.6, 1H), 7.41 (d, J=7.9, 1H), 7.50(m, 5H). Mass spec.: 296.40 (MH)⁺.

3-(1-Benzyl-piperidin-4-yl)-3,4-dihydro-1H-benzo[1,2,6]thiadiazine-2,2-dioxide

A solution of (2-amino-benzyl)-(1-benzyl-piperidin-4-yl)-amine (1.0 g,3.39 mmol) and sulfamide (0.64 g, 6.78 mmol) in pyridine was heated atreflux for 14 h. After cooling to room temperature, the solvent wasevaporated and the crude product dissolved in water. After beingadjusted to pH 9 with 6N sodium hydroxide, the resulting mixture wasextracted with methylene chloride (2×). The extracts were washed withwater (2×), dried over sodium sulfate, filtered, and concentrated toafford an oily residue which was dissolved in ethyl acetate (4 mL). Thissolution was mixed with 4N HCl in 1,4-dioxane (2 mL) followed byaddition of diethyl ether until precipitation of product occurred. Thedesired product was obtained by filtration to afford 0.7 g (53%). LC/MS:t_(R)=0.96 min, 358.16 (MH)⁺.

3-Piperidin-4-yl-3,4-dihydro-1H-benzo[1,2,6]thiadiazine-2,2-dioxide

3-(1-Benzyl-piperidin-4-yl)-3,4-dihydro-1H-benzo[1,2,6]thiadiazine-2,2-dioxide(0.46 g, 1.29 mmol) in methanol (10 mL) was flushed with nitrogen, andtreated with palladium on charcoal (10%, 46 mg). The flask was flushedwith hydrogen and allowed to stir under an atmosphere of hydrogenovernight. The reaction was flushed with nitrogen, filtered throughcelite, and concentrated. Column chromatography gave 0.26 g (75%) of thedesired material. ¹H-NMR (CD₃OD) δ 1.53-1.61 (m, 2H), 1.80 (m, 2H), 2.55(m, 2H), 2.95-3.05 (m, 2H), 3.30 (m, 2H), 3.70 (m, 2H), 4.65 (s, 2H),6.70 (d, J=7.9, 1H), 7.40 (dd, J=8.2, 6.7, 1H), 7.10 (m, 2H). Massspec.: 268.10 (MH)⁺.

6-Bromo-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one

3-Piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (0.2 g, 0.87 mmol) wasdissolved in acetic acid (2 mL). To this solution was added a solutionof bromine (1.8 mL, 35.14 mmol) in acetic acid (0.5 mL) dropwise over 5min. After stirring for at room temperature for 1 h, the reactionmixture was diluted with methylene chloride, washed with water (2×),brine (2×), dried over sodium sulfate, filtered, and concentrated toafford 0.16 g (59%) which was used immediately without furtherpurification. LC/MS: t_(R)=0.91 min, 310.15 (MH)⁺.

2-Oxo-3-piperidin-4-yl-1,2,3,4-tetrahydro-quinazoline-6-carbonitrile

6-Bromo-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (0.16 g, 0.52mmol), zinc cyanide (37 mg, 0.31 mmol) andtetrakis(triphenylphosphine)palladium(0) (60 mg, 0.05 mmol) werecombined in dimethylformamide (4 mL). The reaction flask was connectedto high vacuum and degassed (3×) by a freeze-thawing method, beforebeing heated at 90° C. with stirring under nitrogen for 1 h. Aftercooling to room temperature, the solution was evaporated in vacuo andthe crude mixture purified by preparative HPLC to afford 50 mg (38%) ofthe desired nitrile. ¹H-NMR (CD₃OD) δ 1.99 (m, 2H), 2.08-2.23 (m, 2H),3.15 (m, 2H), 3.50 (bs, 1H), 3.55 (bs, 1H), 4.40 (m, 1H), 4.47 (s, 2H),6.93 (d, J=8.1, 1H), 4.10 (m, 2H). Mass spec.: 257.13 (MH)⁺.

N-(1-Benzyl-piperidin-4-yl)-2-(2-nitro-phenyl)-acetamide

(2-Nitro-phenyl)-acetic acid (2.0 g, 11.04 mmol),4-amino-1-benzylpiperidine (2.25 mL, 10.03 mmol), 1-hydroxybenzotriazole(1.49 g, 11.04 mmol) and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide(2.3 g, 12.03 mmol) were combined in ethyl acetate (25 mL). To thissolution was added triethylamine (4.2 mL. 30.1 mmol) and the reactionmixture stirred at 40° C. for 2 h. After cooling to room temperature,the mixture was diluted with ethyl acetate and washed with water (2×),5% sodium bicarbonate, brine (2×), dried over sodium sulfate, andconcentrated to afford 3.5 g (98%) of the desired product. LC/MS:t_(R)=1.24 min, 354.30 (MH)⁺.

[2-(2-Amino-phenyl)-ethyl]-(1-benzyl-piperidin-4-yl)-amine

Into a flame dried flask,N-(1-benzyl-piperidin-4-yl)-2-(2-nitro-phenyl)-acetamide (3.2 g, 9.06mmol) and lithium aluminium hydride (1.0 g, 18.12 mmol) were combined.1,4-Dioxane (15 mL) was added and the mixture slowly brought to refluxover 1 h and stirred at reflux for 16 h. The reaction mixture was cooledto 0° C. and excess lithium aluminium hydride destroyed by dropwiseaddition of methanol, followed by careful addition of 20% potassiumhydroxide. The aluminum salts were filtered, the filtrate concentratedand used as is for the next reaction.

3-(1-Benzyl-piperidin-4-yl)1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one

A stirred solution of[2-(2-amino-phenyl)-ethyl]-(1-benzyl-piperidin-4-yl)-amine (0.44 g, 1.42mmol) in tetrahydrofuran (5 mL) at 0° C. was treated with carbonyldiimidazole (0.23 g, 1.42 mmol). The reaction was stirred for 30 min at0° C. and at reflux for 1 h. After cooling to room temperature, thesolvent was evaporated and the residue purified by column to afford 100mg (21%) of the desired product. LC/MS: t_(R)=1.29 min, 336.34 (MH)⁺.

3-Piperidin-4-yl-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one

3-(1-Benzyl-piperidin-4-yl)1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one (100 mg, 0.3 mmol) inmethanol (5 mL) was flushed with nitrogen, and treated with palladium oncharcoal (10%, 10 mg). The flask was flushed with hydrogen and allowedto stir under an atmosphere of hydrogen overnight. The reaction wasflushed with nitrogen, filtered through celite, and concentrated. Columnchromatography gave 50 mg (68%) of the desired material. LC/MS:t_(R)=1.07 min, 246.26 (MH)⁺.

3-[(1-Benzyl-piperidin-4-yl-amino)-methyl]-4-nitro-phenol

5-Hydroxy-2-nitro-benzaldehyde (5 g, 29.9 mmol) and4-amino-1-benzylpiperidine (5.6 mL, 29.9 mmol) were combined in ethanol(30 mL). The resulting suspension was stirred at room temperature for 20min before a solution of sodium borohydride (1.13 g, 29.9 mmol) inethanol (10 mL) was added dropwise over 10 min. After the addition wascomplete, the reaction was stirred at room temperature for 1 h, cooledto 0° C. and concentrated ammonium chloride added to the reactionmixture until no bubbling was observed. The solvents were evaporated invacuo and the resultant crude mixture was dissolved in water (30 mL) andmethylene chloride (40 mL). The layers were separated and the organiclayer washed with water (2×), brine (2×), dried over sodium sulfate,filtered, and concentrated to afford 5.8 g (57%) of the desired product.LC/MS: t_(R)=0.95 min, 342.27 (MH)⁺.

4-Amino-3-[(1-benzyl-piperidin-4-yl-amino)-methyl]-phenol

(1-Benzyl-piperidin-4-yl)-(2-nitro-benzyl)-amine (0.25 g, 0.7 mmol) andzinc dust (0.2 g, excess) were combined in 75% aqueous acetic acid (8mL) and stirred at 60° C. for 2 h. After cooling to room temperature,the solvents were removed in vacuo and the resultant crude mixturedissolved in water (10 mL), followed by addition of ammonium hydroxideuntil pH 3 was attained. The solution was extracted with methylenechloride (3×). The organic layers were pooled together, washed withwater (2×), brine (2×), dried over sodium sulfate, filtered, andconcentrated to afford 0.18 g (79%) of the desired product.

3-(1-Benzyl-piperidin-4-yl)-6-hydroxy-3,4-dihydro-1H-quinazolin-2-one

A stirred solution of4-amino-3-[(1-benzyl-piperidin-4-yl-amino)-methyl]-phenol (0.16 g, 0.51mmol) in tetrahydrofuran (3 mL) at 0° C. was treated with carbonyldiimidazole (52 mg, 0.51 mmol). The reaction was stirred for 30 min at0° C. and at reflux for 1 h. After cooling to room temperature, thesolvent was evaporated and the residue purified by column to afford 100mg (57%) of the desired product. LC/MS: t_(R)=1.09 min, 338.28 (MH)⁺.

6-Hydroxy-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one

3-(1-Benzyl-piperidin-4-yl)-6-hydroxy-3,4-dihydro-1H-quinazolin-2-one(100 mg, 0.3 mmol) in methanol (5 mL) was flushed with nitrogen, andtreated with palladium on charcoal (10%, 10 mg). The flask was flushedwith hydrogen and allowed to stir under an atmosphere of hydrogenovernight. The reaction was flushed with nitrogen, filtered throughcelite, and concentrated. Column chromatography gave 60 mg (81%) of thedesired material. LC/MS: t_(R)=0.75 min, 248.22 (MH)⁺.

N-(1-Benzyl-piperidin-4-yl)-2-methoxy-6-nitro-benzamide

2-Methoxy-6-nitro-benzoic acid (2.0 g, 10.1 mmol),4-amino-1-benzylpiperidine (1.9 mL, 10.1 mmol), 1-hydroxybenzotriazole(1.43 g, 10.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide(1.9 g, 10.1 mmol) were combined in ethyl acetate (25 mL). To thissolution was added triethylamine (4.2 mL. 30.3 mmol) and the reactionmixture stirred at 40° C. for 2 h. After cooling to room temperature,the mixture was diluted with ethyl acetate and washed with water (2×),5% sodium bicarbonate, brine (2×), dried over sodium sulfate, andconcentrated to afford 3.2 g (86%) of the desired product. LC/MS:t_(R)=1.10 min, 370.28 (MH)⁺.

(2-Amino-6-methoxy-benzyl)-(1-benzyl-piperidin-4-yl)-amine

Into a flame dried flask,N-(1-benzyl-piperidin-4-yl)-2-methoxy-6-nitro-benzamide (1.0 g, 2.8mmol) and lithium aluminium hydride (0.31 g, 8.45 mmol) were combined.To the mixture was added anhydrous 1,4-dioxane (15 mL). The mixture wasslowly brought to reflux over 1 h and stirred at reflux for 16 h. Thereaction mixture was cooled to 0° C. and excess lithium aluminiumhydride destroyed by dropwise addition of methanol, followed by carefuladdition of 20% potassium hydroxide. The aluminum salts were filtered,the filtrate concentrated and used as is for the next reaction.

3-(1-Benzyl-piperidin-4-yl)-8-methoxy-3,4-dihydro-1H-quinazolin-2-one

A stirred solution of(2-amino-6-methoxy-benzyl)-(1-benzyl-piperidin-4-yl)-amine (0.2 g, 0.62mmol) in tetrahydrofuran (3 mL) at 0° C. was treated with carbonyldiimidazole (99 mg, 0.62 mmol). The reaction was stirred for 30 min at0° C. and at reflux for 1 h. After cooling to room temperature, thesolvent was evaporated and the residue purified by column to afford 150mg (68%) of the desired product. LC/MS: t_(R)=1.41 min, 352.30 (MH)⁺.

8-Methoxy-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one

3-(1-Benzyl-piperidin-4-yl)-8-methoxy-3,4-dihydro-1H-quinazolin-2-one(100 mg, 0.28 mmol) in methanol (5 mL) was flushed with nitrogen, andtreated with palladium on charcoal (10%, 10 mg). The flask was flushedwith hydrogen and allowed to stir under an atmosphere of hydrogenovernight. The reaction was flushed with nitrogen, filtered throughcelite, and concentrated. Column chromatography gave 68 mg (93%) of thedesired material. LC/MS: t_(R)=1.11 min, 262.23 (MH)⁺.

N-(1-Benzyl-piperidin-4-yl)-2-chloro-6-nitro-benzamide

2-Chloro-6-nitro-benzoic acid (1.2 g, 5.97 mmol),4-amino-1-benzylpiperidine (1.1 mL, 5.97 mmol), 1-hydroxybenzotriazole(0.84 g, 1.05 equiv) and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide(1.1 g, 1.05 equiv) were combined in ethyl acetate (20 mL). To thissolution was added triethylamine (2.5 mL. 3.0 equiv) and the reactionmixture stirred at 40° C. for 2 h. After cooling to room temperature,the mixture was diluted with ethyl acetate and washed with water (2×),5% sodium bicarbonate, brine (2×), dried over sodium sulfate, andconcentrated to afford 1.9 g (85%) of the desired product.

(2-Amino-6-chloro-benzyl)-(1-benzyl-piperidin-4-yl)-amine

Into a flame dried flask,N-(1-benzyl-piperidin-4-yl)-2-chloro-6-nitro-benzamide (1.67 g, 4.47mmol) and lithium aluminium hydride (0.51 g, 13.43 mmol) were combined.To this was added anhydrous 1,4-dioxane (15 mL). The mixture was slowlybrought to reflux and stirred for 16 h. The reaction mixture was cooledto 0° C. and excess lithium aluminium hydride destroyed by dropwiseaddition of methanol, followed by careful addition of 20% potassiumhydroxide. The aluminum salts were filtered, the filtrate concentratedand used as is for the next reaction.

3-(1-Benzyl-piperidin-4-yl)-8-chloro-3,4-dihydro-1H-quinazolin-2-one

A stirred solution of(2-amino-6-chloro-benzyl)-(1-benzyl-piperidin-4-yl)-amine (0.66 g, 2.0mmol) in tetrahydrofuran (8 mL) at 0° C. was treated with carbonyldiimidazole (0.36 g, 2.05 mmol). The reaction was stirred for 30 min at0° C. and at reflux for 1 h. After cooling to room temperature, thesolvent was evaporated and the residue purified by column to afford 0.58g (82%) of the desired product. LC/MS: t_(R)=1.40 min, 356.25 (MH)⁺.

2-Chloro-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one

3-(1-Benzyl-piperidin-4-yl)-8-chloro-3,4-dihydro-1H-quinazolin-2-one(0.17 g, 0.48 mmol) in methanol (10 mL) was flushed with nitrogen, andtreated with palladium on charcoal (10%, 17 mg). Trifluoroacetic acid(0.2 mL) was added and the mixture flushed with nitrogen then allowed tostir under an atmosphere of hydrogen overnight. The reaction was flushedwith nitrogen, filtered through celite, and concentrated. Columnchromatography gave 100 mg (79%) of the desired material. LC/MS:t_(R)=0.99 min, 266.08 (MH)⁺.

5-Bromo-1H-indole-3-carbonitrile

A mixture of 5-bromo-indole-3-carboxaldehyde (5 g, 22.3 mmol),diammonium hydrogen phosphate (15.6 g, 31.8 mmol) in 1-nitropropane (66mL) and acetic acid (22 mL) were heated at reflux for 16 h. Aftercooling to room temperature, the solvents were removed under reducedpressure and water added to the dark residue. After a short while,5-bromo-1H-indole-3-carbonitrile precipitated rapidly. The solid wasfiltered, washed severally with water and dried for several hours toafford 4.3 g (86%) of the desired product. ¹H-NMR (CD₃OD) δ 7.40 (m,2H), 7.77 (s, 1H), 7.97 (s, 1H). Mass spec.: 222.95 (MH)⁺.

5-Formyl-1H-indole-3-carbonitrile

5-Bromo-1H-indole-3-carbonitrile (4.25 g, 19.23 mmol) and sodium hydride(0.51 g, 21.2 mmol) were weighed into a flame-dried round-bottom flaskcontaining a magnetic stir bar. Under a nitrogen atmosphere at roomtemperature, dry tetrahydrofuran (24 mL) was added. The mixture wasstirred at room temperature for 15 min, during which time it becamehomogeneous. The stirred mixture was cooled to −78° C. and a solution ofsec-butyllithium in cyclohexane (1.4M, 30.2 mL, 2.2 equiv) was addedover several minutes. After 1 h at −78° C., dimethylformamide (6.0 mL)was slowly added and the mixture allowed to warm to room temperatureovernight. The solution was cooled to 0° C. and carefully treated with 1N hydrochloric acid (45 mL). After a few minutes, solid sodiumbicarbonate was added until a pH of 9-10 was attained. The two layerswere separated and the aqueous phase washed twice with ethyl acetate.The combined organic layers were washed with water (2×), brine (2×),dried over sodium sulfate, and concentrated. Column chromatography gave2.4 g (72%) of pure material. LC/MS: t_(R)=0.99 min, 171.07 (MH)⁺.

2-Benzyloxycarbonylamino-3-(3-cyano-1H-indol-5-yl)-acrylic acid methylester

A stirred solution of N-benzyloxycarbonyl-α-phosphonoglycine trimethylester (1.68 g, 5.1 mmol) in tetrahydrofuran (10 mL) at room temperaturewas treated with tetramethylguanidine (0.6 mL, 1.1 equiv). After 10 min,5-formyl-1H-indole-3-carbonitrile (0.72 g, 4.24 mmol) was added. Afterstirring at room temperature for 3 days, the solvent was evaporated andthe residue washed with water (2×), brine (2×), dried over sodiumsulfate, and concentrated. Column chromatography gave 1.3 g (82%) ofpure material. LC/MS: t_(R)=1.43 min, 376.22 (MH)⁺.

(±)-2-Amino-3-(3-cyano-1H-indol-5-yl)-propionic acid methyl ester

2-Benzyloxycarbonylamino-3-(3-cyano-1H-indol-5-yl)-acrylic acid methylester (0.5 g, 1.3 mmol) in methanol (8 mL) was flushed with nitrogen,and treated with palladium on charcoal (10%, 50 mg). The flask wasflushed with hydrogen and allowed to stir under an atmosphere ofhydrogen overnight. The reaction was flushed with nitrogen, filteredthrough celite, and concentrated. Column chromatography gave 0.3 g (92%)of the desired material. LC/MS: t_(R)=0.80 min, 244.20 (MH)⁺.

Example 202(±)-3-(3-Cyano-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

A stirred solution of 2-amino-3-(3-cyano-1H-indol-5-yl)-propionic acidmethyl ester (25 mg, 0.11 mmol) in tetrahydrofuran (3 mL) at 0° C. wastreated with carbonyl diimidazole (17.5 mg, 1.1 equiv.). The reactionwas stirred for 5 min at 0° C., warmed to room temperature, stirred 10min, and treated with 3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one(25 mg, 1.1 equiv.). The mixture was stirred at room temperatureovernight. The solvent was evaporated and the residue purified by columnchromatography to give 40 mg (75%) as a white powder. LC/MS: t_(R)=1.37min, 501.33 (MH)⁺.

Example 203(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(3-cyano-1H-indol-5-yl-methyl)-2-oxo-ethyl]-amide

A solution of3-(3-cyano-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester (15 mg, 0.03 mmol) in methanol (0.6 mL) at roomtemperature was treated with a solution of lithium hydroxide monohydrate(3.0 mg, 2.5 equiv.) in water (0.1 mL). The solution was stirred at roomtemperature for 2 h. The solution was cooled to 0° C., and treated withaqueous 1M potassium hydrogen sulfate (60 μL, 2.0 equiv.), and thesolvents evaporated to give the crude acid which was used immediatelywithout purification. The crude acid was dissolved in dimethylformamide(0.4 mL) cooled to 0° C., and sequentially treated with methylenechloride (0.2 mL), 4-piperidyl-piperidine (11 mg, 2.2 equiv),N,N-diisopropylethylamine (12 μL, 2.3 equiv) and PyBop (19 mg, 1.2equiv). The solution was stirred for 15 min at 0° C., warmed to roomtemperature, stirred 1.5 h, and concentrated. The product was purifiedby column chromatography to give 10.1 mg (52% 2 steps). ¹H-NMR (CD₃OD) δ1.60-2.10 (m, 14H), 2.53 (d, J=13.0, 1H), 2.58 (d, J=12.2, 1H),2.65-3.00 (m, 7H), 3.12 (d, J=7.0, 1H), 3.17 (d, J=7.0, 1H), 3.84 (s,1H), 3.46 (bs, 1H), 4.08-4.86 (m, 5H), 4.70 (m, 1H), 5.02 (dd, J=8.2,6.7, 1H), 6.79 (d, J=7.6, 1H), 6.9(m, 1H), 7.10 (dd, J=7.3, 7.9, 1H),9.18 (s, 1H), 7.15 (dd, J=7.3, 7.6, 1H), 7.30 (m, 1H), 7.50 (m, 1H),8.00 (s, 1H). Mass spec.: 647.41 (MH)⁺.

3-(4-Bromo-2-methyl-phenylamino)-2-methyl-acrylic acid ethyl ester

To a solution of 4-bromo-2-methyl aniline (7.0 g, 37.8 mmol) inacetonitrile (80 mL) was added, sequentially, concentrated hydrochloricacid (15 mL), water (40 mL) and a solution of sodium nitrite (2.74 g,39.7 mmol) in water (40 mL) under ice cooling to give the diazoniumsalt. The solution was transferred dropwise to a solution of 50%potassium hydroxide (16 mL) and ethyl-2-methyl acetoacetate (5.38 mL, 38mmol) in ethanol (50 mL) at 0° C. After the addition was complete, thereaction mixture was poured into ice-water (150 mL) and extracted withethyl acetate. The organic layer was washed with brine (2×), dried oversodium sulfate, filtered, and concentrated to give 7.5 g (66%) of thetitle compound which was used immediately without purification. ¹H-NMR(CD₃OD) δ 1.80 (t, J=7.0, 3H), 2.13 (s, 3H), 2.29 (s, 3H), 4.26 (dd,J=5.8, 7.0, 1H), 4.30 (dd, J=5.8, 7.0, 1H), 7.26 (m, 2H), 7.43 (m, 1H).Mass spec.: 323.07 (MNa)⁺.

5-Bromo-7-methyl-1H-indole-2-carboxylic acid ethyl ester

A solution of p-toluenesulfonic acid monohydrate (4.26 g, 75 mmol) intoluene (80 mL) was heated at reflux under a dean-stark water separatorfor 1.5 h. To this solution was added a solution of5-bromo-7-methyl-1H-indole-2-carboxylic acid ethyl ester (7.5 g, 25.0mmol) in toluene (40 mL) and the reaction mixture heated at reflux for 5h. After cooling to room temperature, the reaction mixture was poured into ice-water (120 mL) and extracted twice with ethyl acetate. Theorganic layers were pooled together and washed with sodium bicarbonate(2×), brine (2×), dried over sodium sulfate, filtered, and concentrated.Column chromatography on silica gel afforded 5.5 g (78%) of the titlecompound. ¹H-NMR (CD₃OD) δ 1.35 (t, J=7.0, 3H), 2.52 (s, 3H), 4.36 (q,J=7.0, 2H), 7.13 (s, 1H), 7.14 (s, 1H), 7.70 (s, 1H), 11.90 (s, 1H).Mass spec.: 284.09 (MH)⁺.

5-Bromo-7-methyl-1H-indole

5-Bromo-7-methyl-1H-indole-2-carboxylic acid ethyl ester (5.3 g, 18.7mmol) was added to a potassium hydroxide solution in 1:1 water/ethanolmixture (20 mL) and heated at reflux for 12 h. After cooling to roomtemperature, the solvents were removed in vacuo and the resultantresidue transferred to a 6N hydrochloric acid solution (20 mL). Thewhite precipitate that formed was filtered, washed severally with water,and dried for several hours. The crude solid was dissolved in quinoline(14 mL) and heated at reflux for 4 h. After cooling to room temperature,the crude mixture was poured into a mixture of ice water (100 mL) andconcentrated hydrochloric acid (16 mL), extracted with ethyl acetate(2×), brine (2×), dried over sodium sulfate, and concentrated. Attemptsto recrystallize the desired product from isopropanol resulted insignificant decomposition. The title compound was obtained by flashchromatography on silica get to afford 1.5 g (38%, 2 steps). LC/MS:t_(R)=1.72 min, 210.05 (MH)⁺.

5-Bromo-7-methyl-1H-indole-3-carboxaldehyde

5-Bromo-7-methyl-1H-indole (1.2 g, 5.71 mmol) was dissolved inacetonitrile (6 mL) and transferred slowly to a solution ofbromomethylene dimethyl ammonium bromide (1.36 g, 6.28 mmol) inacetonitrile (9 mL) at −10° C. to 0° C. The reaction was stirred at 0°C. for 2 h and at room temperature for 30 min. The solvents wereevaporated and the crude mixture dissolved in water and stirred at 50°C. for 4 h. After cooling to room temperature, the crude mixture wasextracted with ethyl acetate (2×). The organic layers were pooledtogether and washed with brine (2×), dried over magnesium sulfate,filtered, and concentrated. Purification by flash chromatography onsilica gel afforded 0.7 g (52%, 2 steps) of the desired compound. ¹H-NMR(CD₃OD) δ 2.50 (s, 3H), 7.24 (s, 1H), 8.34 (m, 1H), 9.93 (s, 1H). Massspec.: 238.05 (MH)⁺

5-Bromo-7-methyl-1H-indole-3-carbonitrile

A mixture of 5-bromo-indole-3-carboxaldehyde (0.7 g, 2.94 mmol),diammonium hydrogen phosphate (2.05 g, 15.5 mmol) in 1-nitropropane (9mL) and acetic acid (3 mL) were heated at reflux for 16 h. After coolingto room temperature, the solvents were removed under reduced pressureand water added to the dark residue. After a short while,5-bromo-1H-indole-3-carbonitrile precipitated rapidly, was filtered,washed severally with water and dried for several hours to afford 0.6 g(87%) of the desired nitrile. LC/MS: t_(R)=1.71 min, 235.01 (MH)⁺.

5-Formyl-7-methyl-1H-indole-3-carbonitrile

5-Bromo-7-methyl-1H-indole-3-carbonitrile (0.58 g, 2.46 mmol) and sodiumhydride (68 mg, 2.7 mmol) were weighed into a flame-dried round-bottomflask containing a magnetic stir bar. Under a nitrogen atmosphere atroom temperature, dry tetrahydrofuran (9 mL) was added. The mixture wasstirred at room temperature for 15 min, during which time it becamehomogeneous. The stirred mixture was cooled to −78° C. and a solution ofsec-butyllithium in cyclohexane (1.4M, 3.8 mL, 2.2 equiv) was added overseveral minutes. After 1 h at −78° C., dimethylformamide (0.9 mL) wasslowly added and the mixture allowed to warm to room temperatureovernight. The solution was cooled to 0° C. and carefully treated with1N hydrochloric acid. After a few minutes, solid sodium bicarbonate wasadded until a pH of 9-10 was attained. The two layers were separated andthe aqueous phase washed twice with ethyl acetate. The combined organiclayers were washed with water (2×), brine (2×), dried over sodiumsulfate, and concentrated. Column chromatography gave 60 mg (14%) ofdesired product and 0.4 g of unreacted starting material. LC/MS:t_(R)=1.21 min, 185.10 (MH)⁺.

2-Benzyloxycarbonylamino-3-(3-cyano-7-methyl-1H-indol-5-yl)-acrylic acidmethyl ester

A stirred solution of N-benzyloxycarbonyl-α-phosphonoglycine trimethylester (180 mg, 0.54 mmol) in tetrahydrofuran (3 mL) at room temperaturewas treated with tetramethylguanidine (40 μL, 1.1 equiv). After 10 min,5-formyl-7-methyl-1H-indole-3-carbonitrile (50 mg, 0.27 mmol) was added.After stirring at room temperature for 3 days, the solvent wasevaporated and the residue washed with water (2×), brine (2×), driedover sodium sulfate, and concentrated. Column chromatography gave 100 mg(95%) of pure material. LC/MS: t_(R)=1.59 min, 390.24 (MH)⁺.

(±)-2-Amino-3-(3-cyano-7-methyl-1H-indol-5-yl)-propionic acid methylester

2-Benzyloxycarbonylamino-3-(3-cyano-7-methyl-1H-indol-5-yl)-acrylic acidmethyl ester (0.1 g, 0.26 mmol) in methanol (2.5 mL) was flushed withnitrogen, and treated with palladium on charcoal (10%, 10 mg). The flaskwas flushed with hydrogen and allowed to stir under an atmosphere ofhydrogen overnight. The reaction was flushed with nitrogen, filteredthrough celite, and concentrated. Column chromatography gave 60 mg (90%)of the desired material. LC/MS: t_(R) ^(=0.93) min, 258.22 (MH)⁺.

Example 204(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-[(3-cyano-7-methyl-1H-indol-5-yl-methyl)-2-oxo-ethyl]-amide

Prepared as describe above for Example 203: ¹H-NMR (CD₃OD) δ 1.55-2.10(m, 16H), 2.50 (s, 3H), 2.80-3.20 (m, 9H), 4.10-4.40 (m, 7H), 4.90 (m,3H), 6.72 (d, J=7.9, 1H), 6.93 (dd, J=8.5, 8.5, 1H), 7.40 (s, 1H),7.88(s, 1H), 7.90 (s, 1H), 7.99 (s, 1H). Mass spec.: 651.57 (MH)⁺.

4-Bromo-2-isopropyl-6-methyl-phenylamine

2-Isopropyl-6-methyl-phenylamine (5 g, 33.5 mmol) was dissolved inacetic acid (20 mL). To this solution was added a solution of bromine(1.8 mL, 35.14 mmol) in acetic acid (5 mL) dropwise over 10 min. Afterstirring for 1 h at room temperature, the reaction mixture was dilutedwith methylene chloride, washed with water (2×), saturated sodiumthiosulfate (2×), saturated sodium bicarbonate (2×), and brine. Theorganic phase was dried over sodium sulfate, filtered, and concentrated.Purification by flash chromatography on silica gel afforded 7.6 g(quantitative) of the desired product. LC/MS: t_(R)=1.37 min, 230.07(MH)⁺.

4-Bromo-2-isopropyl-6-methyl-phenyldiazo-t-butyl sulfide

4-Bromo-2-isopropyl-6-methyl-phenylamine (7.6 g, 33.5 mmol) wassuspended in 24% hydrochloric acid (15 mL). The stirred mixture wascooled to −20° C. and treated with sodium nitrite (2.4 g, 1.05 equiv.)in water (5 mL), dropwise over 30 min while the temperature wasmaintained below −5° C. After a further 30 min at −5° C. to −20° C., themixture was buffered to ca. pH 5 with solid sodium acetate. This mixture(kept at ca. −10° C.) was added in portions to a stirred solution oft-butyl thiol (3.77 mL, 1.0 equiv.) in ethanol (25 mL) at 0° C. over ca.30 min. Following addition, the mixture was stirred at 0° C. for 30 minand then crushed ice (ca. 50 mL) was added. The resulting light-brownsolid was collected by filtration, washed with water, and dried underhigh vacuum for several hours to afford 7.9 g (72%) of the desiredproduct. ¹H-NMR (CDCl₃) δ 1.15 (t, J=6.7, 3H), 1.58 (s, 9H), 2.00 (s,3H), 2.54 (m, 1H), 7.20 (s, 1H), 7.28 (s, 1H). Mass spec.: 331.08(MNa)⁺.

5-Bromo-7-isopropyl-1H-indazole

A flame-dried round bottom flask was charged with4-bromo-2,6-diethylphenyldiazo-t-butyl sulfide (7.94 g, 24 mmol) andpotassium t-butoxide (27 g, 10 equiv). A stir bar was added and themixture placed under nitrogen. To this was added dry dimethylsulfoxide(70 mL). The mixture was stirred vigorously overnight at roomtemperature. The reaction mixture was carefully poured into a mixture ofcrushed ice (250 mL) and 10% hydrochloric acid (120 mL). The resultingsuspension was collected by filtration and washed severally with water.The solid was collected and dried in vacuo to give 4.2 g (74%) of thedesired product. LC/MS: t_(R)=1.73 min, 241.06 (MH)⁺.

7-Isopropyl-1H-indazole-5-carbaldehyde

5-Bromo-7-isopropyl-1H-indazole (3.1 g, 12.1 mmol) and sodium hydride(0.34 g, 1.1 equiv.) were weighed into a flame-dried round-bottom flaskcontaining a magnetic stir bar. Under a nitrogen atmosphere at roomtemperature, dry tetrahydrofuran (18 mL) was added. The mixture wasstirred at room temperature for 15 min, during which time it becamehomogeneous. The stirred mixture was cooled to −78° C. and a solution ofsec-butyllithium in cyclohexane (1.4M, 20 mL, 2.2 equiv.) was added overseveral minutes. After 1 h at −78° C., dimethylformamide (3.0 mL) wasslowly added and the mixture allowed to warm to room temperatureovernight. The solution was cooled to 0° C. and carefully treated with 1N hydrochloric acid (35 mL). After a few minutes, solid sodiumbicarbonate was added until a pH of 9-10 was attained. The two layerswere separated and the aqueous phase washed twice with ethyl acetate.The combined organic layers were washed with water (2×), brine (2×),dried over sodium sulfate, and concentrated. Column chromatography gave2.1 g (92%) of pure material. LC/MS: t_(R)=1.15 min, 189.12 (MH)⁺.

2-Benzyloxycarbonylamino-3-(7-isopropyl-1H-indazol-5-yl)acrylic acidmethyl ester

A stirred solution of N-benzyloxycarbonyl-α-phosphonoglycine trimethylester (0.39 g, 1.2 equiv) in tetrahydrofuran (5 mL) at room temperaturewas treated with tetramethylguanidine (0.16 mL, 1.1 equiv.). After 10min, 7-isopropyl-1H-indazole-5-carbaldehyde (0.2 g, 1.06 mmol) wasadded. After stirring at room temperature for 3 days, the solvent wasevaporated and the residue purified by flash chromatography on silicagel to give 0.35 g (84%) of product. LC/MS: t_(R)=1.61 min, 394.16(MH)⁺.

(±)-2-Amino-3-(7-isopropyl-1H-indazol-5-yl)propionic acid methyl ester

A solution of2-benzyloxycarbonylamino-3-(7-isopropyl-1H-indazol-5-yl)acrylic acidmethyl ester (0.35 g, 0.89 mmol) in methanol (7 mL) was flushed withnitrogen, and treated with palladium on charcoal (10%, 35 mg). The flaskwas flushed with hydrogen and allowed to stir under an atmosphere ofhydrogen overnight. The reaction was flushed with nitrogen, filteredthrough celite, and concentrated. Column chromatography gave 0.21 g(90%) of the desired material.

Example 205(±)-3-(7-Isopropyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for3-(3-cyano-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester. LC/MS: t_(R)=1.49 min, 519.35 (MH)⁺.

Example 206(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-[(7-isopropyl-1H-indazol-5-yl-methyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 203 from3-(7-isopropyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester: ¹H-NMR (CD₃OD) δ 1.45 (m, 6H), 1.60-2.05 (m, 14H),2.20-2.50 (m, 4H), 2.73 (d, J=13.7, 1H), 2.90 (m, 4H), 4.05 (d, J=14.0,1H), 4.20 (m, 2H), 4.35 (s, 1H), 4.65 (dd, J=12.2, 14.3, 1H), 4.95 (m,2H), 6.79 (d, J=7.9, 1H), 6.92 (dd, J=7.6, 6.1, 1H), 7.13(m, 1H), 7.80(s, 1H), 7.45 (s, 1H), 8.05(s, 1H). Mass spec.: 655.40 (MH)⁺.

4-Bromo-2,6-diethylphenyldiazo-t-butyl sulfide

4-Bromo-2,6-diethylaniline (6.3 g, 27.6 mmol) was suspended in 24%hydrochloric acid (15 mL). The stirred mixture was cooled to −20° C. andtreated with sodium nitrite (2.0 g, 1.05 equiv.) in water (5 mL),dropwise over 30 min while the temperature was maintained below −5° C.After a further 30 min at −5° C. to −20° C., the mixture was buffered toca. pH 5 with solid sodium acetate. This mixture (kept at ca. −10° C.)was added in portions to a stirred solution of t-butyl thiol (3.15 mL,1.0 equiv.) in ethanol (25 mL) at 0° C. over ca. 30 min. Followingaddition, the mixture was stirred at 0° C. for 30 min and then crushedice (ca. 50 mL) was added. The resulting light-brown solid was collectedby filtration, washed with water, and dried under high vacuum forseveral hours to afford 6.0 g (66%) of the desired product. ¹H-NMR(CDCl₃) δ 1.15 (t, J=7.6, 6H), 1.50 (s, 9H), 2.27 (m, 4H), 7.21 (s, 2H).Mass spec.: 331.08 (MH)⁺.

5-Bromo-7-ethyl-3-methylindazole

A flame-dried round bottom flask was charged with4-bromo-2,6-diethylphenyldiazo-t-butyl sulfide (4.0 g, 12.1 mmol) andpotassium t-butoxide (13.2 g, 10 equiv). A stir bar was added and themixture placed under nitrogen. To this was added dry dimethylsulfoxide(35 mL). The mixture was stirred vigorously overnight at roomtemperature. The reaction mixture was carefully poured into a mixture ofcrushed ice (130 mL) and 10% hydrochloric acid (60 mL). The resultingsuspension was collected by filtration and washed severally with water.The solid was collected and dried in vacuo to give 2.85 g (98%) as abeige solid. ¹H-NMR (CD₃OD) δ 1.32 (t, J=7.6, 3H), 2.50 (s, 3H), 2.88(m, 2H), 7.25 (s, 1H), 7.68 (s, 1H). Mass spec.: 239.26 (MH)⁺.

7-Ethyl-3-methylindazole-5-carboxaldehyde

5-Bromo-7-ethyl-3-methylindazole (2.85 g, 11.9 mmol) and sodium hydride(0.31 g, 1.1 equiv.) were weighed into a flame-dried round-bottom flaskcontaining a magnetic stir bar. Under a nitrogen atmosphere at roomtemperature, dry tetrahydrofuran (15 mL) was added. The mixture wasstirred at room temperature for 15 min, during which time it becamehomogeneous. The stirred mixture was cooled to −78° C. and a solution oftert-butyllithium in pentane (1.4M, 18.7 mL, 2.0 equiv) was added overseveral minutes. After 1 h at −78° C., dimethylformamide (2.8 mL) wasslowly added and the mixture allowed to warm to room temperatureovernight. The solution was cooled to 0° C. and carefully treated with1N hydrochloric acid (30 mL). After a few minutes, solid sodiumbicarbonate was added until a pH of 9-10 was attained. The two layerswere separated and the aqueous phase washed twice with ethyl acetate.The combined organic layers were washed with water (2×), brine (2×),dried over sodium sulfate, and concentrated. Column chromatography gave1.5 g (67%) of pure material. LC/MS: t_(R)=1.15 min, 189.12 (MH)⁺.

2-Benzyloxycarbonylamino-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-acrylicacid methyl ester

A stirred solution of N-benzyloxycarbonyl-α-phosphonoglycine trimethylester (3.17 g, 9.57 mmol, 1.2 equiv.) in tetrahydrofuran (15 mL) at roomtemperature was treated with tetramethylguanidine (1.1 mL, 1.1 equiv.).After 10 min, 7-ethyl-3-methylindazole-5-carboxaldehyde (1.5 g, 7.98mmol) was added. After stirring at room temperature for 3 days, thesolvent was evaporated and the residue purified by flash chromatographyon silica gel to give 2.5 g (80%) of product. LC/MS: t_(R)=1.61 min,394.16 (MH)⁺.

(±)-2-Amino-3-(7-ethyl-3 methyl-1H-indazol-5-yl)-propionic acid methylester

2-Benzyloxycarbonylamino-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-acrylicacid methyl ester (1.0 g, 2.54 mmol) in methanol (15 mL) was flushedwith nitrogen, and treated with palladium on charcoal (10%, 100 mg). Theflask was flushed with hydrogen and allowed to stir under an atmosphereof hydrogen overnight. The reaction was flushed with nitrogen, filteredthrough celite, and concentrated. Column chromatography gave 0.6 g (91%)of the desired material. ¹H-NMR (CD₃OD) δ 1.32 (m, 3H), 2.50 (s, 3H),2.88 (dd, J=7.3, 7.6, 1H), 2.89 (dd, J=7.6, 7.6, 1H), 3.02 (dd, J=6.4,7.0, 1H), 3.11 (dd, J=7.6, 5.8, 1H), 3.35 (s, 1H), 3.65 (m, 3H), 7.00(s, 1H), 7.33 (s, 1H). Mass spec.: 262.24 (MH)⁺.

Example 207(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-[(7-ethyl-1H-indazol-5-yl-methyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 203 from(±)-2-amino-3-(7-ethyl-3 methyl-1H-indazol-5-yl)-propionic acid methylester. ¹H-NMR (CD₃OD) δ 1.35 (m, 3H), 1.85-2.20 (m, 4H), 2.50 (s, 1H),2.70 (m, 2H), 2.85 (s, 3H), 2.88-3.25 (m, 7H), 3.35 (s, 1H), 3.47 (dd,J=7.3, 7.3, 1H), 4.00-4.40 (m, 7H), 4.70 (m, 1H), 5.00 (m, 3H), 6.79 (d,J=7.6, 1H), 6.93 (dd, J=7.3, 7.3, 1H), 7.10 (m, 1H), 7.15 (dd, J=7.3,7.6, 1H), 7.45 (m, 1H). Mass spec.: 655.50 (MH)⁺.

Example 208(±)-4-(2,2-Dioxo-1,4-dihydro-2H-2λ⁶-benzo[1,2,6]thiadiazin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-[(7-methyl-1H-indazol-5-yl-methyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 203 from3-piperidin-4-yl-3,4-dihydro-1H-benzo[1,2,6]thiadiazine-2,2-dioxide:¹H-NMR (CD₃OD) δ 1.20-2.10 (m, 12H), 2.20-2.60 (m, 6H), 2.90 (m, 6H),3.78-4.11 (m, 4H), 4.60 (s, 3H), 4.90 (m, 1H), 6.70 (d, J=8.1, 1H), 6.79(dd, J=7.67, 7.3, 1H), 7.44 (s, 1H), 7.10 (m, 1H), 7.13 (m, 3H), 8.03(s, 1H). Mass spec.: 663.60 (MH)⁺.

Example 209(±)-4-(2,2-Dioxo-1,4-dihydro-2H-2λ⁶-benzo[1,2,6]thiadiazin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1(7-ethyl-3-methyl-1H-indazol-5-yl-methyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 203 from3-piperidin-4-yl-3,4-dihydro-1H-benzo[1,2,6]thiadiazine-2,2-dioxide:¹H-NMR (CD₃OD) δ 1.35 (m, 3H), 1.42-2.05 (m, 10H), 2.40 (m, 3H), 2.55(s, 3H), 2.67-3.12 (m, 7H), 3.85 (m, 1H), 3.97 (s, 1H), 4.03 (m, 3H),4.65 (m, 4H), 4.95 (dd, J=4.9, 5.8, 1H), 6.73 (d, J=7.9, 1H), 6.98 (dd,J=7.3, 6.4, 1H), 7.20 (m, 2H), 7.88 (s, 1H). Mass spec.: 691.51 (MH)⁺.

Example 210(±)-2-[4-(6-Cyano-2-oxo-1,4-dihydro-2H-qinazolin-3-yl)-piperidine-1-carbonyl]-amino]-3-(7-methyl-1H-indazol-5-yl)-propionicacid methyl ester

Prepared as described above for3-(3-cyano-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester: LC/MS: t_(R)=1.34 min, 516.40 (MH)⁺.

Example 211(±)-4-(6-Cyano-2-oxo-1,4-dihydro-2H-qinazolin-3-yl)-piperidine-1-carboxylicacid {2-[1,4′ ]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl}-amide

Prepared as described above for Example 203 from2-oxo-3-piperidin-4-yl-1,2,3,4-tetrahydro-quinazoline-6-carbonitrile:¹H-NMR (CD₃OD) δ 1.80 (m, 12H), 2.40(m, 4H), 2.60 (s, 3H), 2.70-3.20 (m,10H), 4.00-4.30 (m, 6H), 5.00 (m, 1H), 5.50 (s, 2H), 6.90 (d, J=7.8,1H), 7.21 (s, 1H), 7.50 (m, 4H), 8.05 (s, 1H). Mass spec.: 652.64 (MH)⁺.

Example 212(±)-4-(2-Oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl-1-carboxylicacid {2-[1,4′ ]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl}-amide

Prepared as described above for Example 203 from3-piperidin-4-yl-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one: ¹H-NMR(CD₃OD) δ 1.40-2.00 (m, 12H), 2.30-2.60 (m, 8H), 2.70-3.20 (m, 10H),3.70 (m, 2H), 3.60 (d, J=9.5, 1H), 4.00-4.30 (m, 4H), 4.70 (m, 1H), 5.00(m, 1H), 6.90 (m, 2H), 7.10 (m, 3H), 7.20 (s, 1H), 7.50 (s, 1H), 8.05(s, 1H). Mass spec.: 652.64 (MH)⁺.

Example 213(±)-4-(6-Hydroxy-2-oxo-1,4-dihydro-2H-qinazolin-3-yl)-piperidine-1-carboxylicacid {2-[1,4′ ]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl}-amide

Prepared as described above for Example 203 from6-hydroxy-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one: LC/MS:t_(R)=1.24 min, 643.62 (MH)⁺.

Example 214(±)-4-(8-Methoxy-2-oxo-1,4-dihydro-2H-qinazolin-3-yl)-piperidine-1-carboxylicacid {2-[1,4′ ]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl}-amide

Prepared as described above for Example 203 from8-methoxy-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one: ¹H-NMR(CD₃OD) δ 1.40-2.00 (m, 12H), 2.40 (m, 2H), 2.50 (s, 3H), 2.80 (m, 3H),3.00-3.20 (m, 3H), 3.50 (m, 2H), 4.00-4.60 (m, 6H), 5.00 (m, 2H), 6.70(dd, J=8.5, 10.1, 1H), 6.85 (m, 2H), 7.10 (m, 1H), 7.20 (s, 1H), 7.47(s, 1H). Mass spec.: 657.41 (MH)⁺.

Example 215(±)-4-(8-Chloro-2-oxo-1,4-dihydro-2H-qinazolin-3-yl)-piperidine-1-carboxylicacid {2-[1,4′ ]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl}-amide

Prepared as described above for Example 203 from2-chloro-3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one: ¹H-NMR(CD₃OD) δ 1.40-2.00 (m, 14H), 2.30-2.60(m, 8H), 2.80 (m, 4H), 3.50 (m,3H), 3.98 (s, 1H), 4.10 (m, 4H), 4.40 (m, 2H), 4.60 (m, 1H), 4.95 (m,1H), 6.95 (dd, J=7.9, 7.9, 1H), 7.10 (m, 1H), 7.26 (dd, J=6.7, 7.6, 1H),7.47 (m, 1H), 8.04 (s, 1H). Mass spec.: 661.27 (MH)⁺.

Example 216(±)—N-(3-(7-Ethyl-3-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)-1-carboxamide

Prepared as described above for Example 203: LC/MS: t_(R)=1.51 min,641.63 (MH)⁺.

Example 217 (±)—N-(3-(7-Ethyl-3-methyl1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide

Prepared as described above for Example 203: LC/MS: t_(R)=1.48 min,642.61 (MH)⁺.

tert-Butyl 2-fluorophenylcarbamate

To a solution of di-tert-butyldicarbonate (45.2 g, 207 mmol, 1.0 equiv.)in tetrahydrofuran (210 mL) at room temperature was added2-fluoroaniline (20.0 mL, 207 mmol). The reaction was heated to refluxand held there for 6 h. It was cooled, concentrated, dissolved inpentane, washed with 5% citric acid, then 1 M potassium bisulfate (2×),then water, then 20% potassium hydroxide, then brine, dried overmagnesium sulfate, and concentrated to give 48.0 g (quant.) as an amberoil which was used without purification. ¹H-NMR (CDCl₃, 500 MHz) δ 1.52(s, 9H), 6.68 (bs, 1H), 6.85-7.20 (m, 3H), 8.07 (dd, J=8.1, 8.1, 1H).Mass spec.: 234.18 (MNa)⁺.

2-(tert-Butoxycarbonylamino)-3-fluoro-benzoic acid

To a solution of tert-butyl 2-fluorophenylcarbamate (44.0 g, 208 mmol)in tetrahydrofuran (660 mL) at −78° C. was added tert-butyllithium inpentane (1.7 M, 306 mL, 2.5 equivx) dropwise. After addition wascomplete, the reaction was stirred at −78° C. for 30 min. The solutionwas allowed to gradually reach −20° C. before being recooled to −78° C.and transferred via canula to a slurry of carbon dioxide (excess) andtetrahydrofuran (500 mL). The solution was allowed to slowly warm toroom temperature. The reaction mixture was concentrated to remove mostof the tetrahydrofuran, and poured into a sep funnel containing waterand diethyl ether. The layers were separated, and the aqueous extractedwith diethyl ether twice more. The ethereals were discarded. The aqueouswas acidified with 5% citric acid, extracted with diethyl ether (3×).The ethereal was dried over magnesium sulfate, and concentrated to givea light yellow solid which was recrystallized from hot toluene to give37.1 g (70%) as a faint yellow solid.

¹H-NMR (CDCl₃, 500 MHz) δ 1.50 (s, 9H), 6.25 (bs, 1H), 7.18 (ddd, J=7.9,7.9, 4.9, 1H), 7.33 (dd, J=9.5, 9.2, 1H), 7.79 (d, J=7.9, 1H), 7.94 (s,1H). Mass spec.: 278.21 (MNa)⁺.

tert-Butyl 2-(1-benzylpiperidin-4-ylcarbamoyl)-6-fluorophenylcarbamate

To a solution of 2-(tert-butoxycarbonylamino)-3-fluoro-benzoic acid(37.1 g, 145 mmol), 4-amino-1-benzylpiperidine (35.6 mL, 1.20 equiv.),1-hydroxybenzotriazole (21.6 g, 1.1 equiv.), and triethylamine (44.1 g,3.0 equiv.) in ethyl acetate (450 mL) was added1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30.7 g, 1.1equiv.) in one portion. Initially, everything went into solution, but aprecipitate formed very rapidly. The reaction was fitted with a refluxcondenser and heated at reflux for 5 h. The reaction was diluted withethyl acetate, washed with water (2×), then 1N sodium hydroxide (2×),then brine, dried over magnesium sulfate, and concentrated to give 67.0g (quant.) as a white solid which was used without purification. ¹H-NMR(CDCl₃, 500 MHz) δ 1.48 (s, 9H), 1.55 (m, 2H), 1.99 (bd, J=11.0, 2H),2.17 (dd, J=11.0, 11.0, 2H), 2.84 (bd, J=11.3, 2H), 3.51 (s, 2H), 3.94(m, 1H), 6.13 (bd, J=7.6, 1H), 7.10-7.28 (m, 4H), 7.31 (m, 4H), 7.59 (s,1H). Mass spec.: 428.41 (MH)⁺.

2-Amino-N-(1-benzylpiperidin-4-yl)-3-fluorobenzamide

To a solution of tert-butyl2-(1-benzylpiperidin-4-ylcarbamoyl)-6-fluorophenylcarbamate (67.0 g, 157mmol) in dichloromethane (700 mL) at 0° C. was added trifluoroaceticacid (100 mL). The ice bath was removed and the reaction stirred at roomtemperature overnight. The reaction was concentrated and partitionedbetween ethyl acetate and saturated sodium bicarbonate. The aqueous wasextracted with ethyl acetate (2×), which were washed with water (3×),then brine, dried over magnesium sulfate, and concentrated to give 47.6g (93%) as a white solid which was used without purification. Massspec.: 328.33 (MH)⁺.

N-(2-Amino-3-fluorobenzyl)-1-benzylpiperidin-4-amine

To a refluxing suspension of lithium aluminum hydride (16.1 g, 424 mmol,3.50 equiv.) in dioxane (800 mL) was added a solution of2-amino-N-(1-benzylpiperidin-4-yl)-3-fluorobenzamide (39.7 g, 121 mmol)in dioxane (250 mL) at such a rate that gas evolution was limited to asafe flow. Upon completion of the addition, the resulting suspension washeated at reflux for 4 h. The reaction was cooled to 0° C., and quenchedby the cautious addition of 20% potassium hydroxide. Upon formation of awhite, filterable precipitate, the solid was filtered through a courseglass sintered funnel, and the eluent concentrated to give 36.3 g (96%)as a light yellow oil which was used without purification. Mass spec.:314.29 (MH)⁺.

3-(1-Benzylpiperidin-4-yl)-8-fluoro-3,4-dihydroquinazolin-2(1H)-one

To a solution of N-(2-amino-3-fluorobenzyl)-1-benzylpiperidin-4-amine(36.3 g, 116 mmol) in tetrahydrofuran (600 mL) at room temperature wasadded carbonyl diimidazole (20.7 g, 1.10 equiv.) in one portion. Thereaction was stirred at room temperature for 3 h, heated at reflux for30 min, and concentrated. The resulting solid was dissolved in 1:1diethyl ether/ethyl acetate, washed with water (3×), then brine, driedover magnesium sulfate, and concentrated to give the crude product as awet, yellow solid. The solid was triturated with diethyl ether andfiltered to give 30.0 g (76%) as a white powder. ¹H-NMR (CDCl₃, 500 MHz)δ 1.68 (m, 2H), 1.86 (dddd, J=11.9, 11.9, 11.9, 3.4, 2H), 2.14 (dd,J=11.6, 10.1, 2H), 2.98 (d, J=11.6, 2H), 3.51 (s, 2H), 4.34-4.44 (m,3H), 6.71 (bs, 1H), 6.79-6.89 (m, 2H), 6.94 (dd, J=9.2, 9.2, 1H),7.21-7.34 (m, 5H). Mass spec.: 340.30 (MH)⁺.

8-Fluoro-3,4-dihydro-3-(piperidin-4-yl)quinazolin-2(1H)-one

A 250 mL flask was charged with3-(1-benzylpiperidin-4-yl)-8-fluoro-3,4-dihydroquinazolin-2(1H)-one(1.40 g, 4.12 mmol) and methanol (25.0 mL). The suspension was heatedwith a heat gun to aid in dissolution. The flask was flushed withnitrogen, treated with palladium on charcoal (141 mg, 0.032 equiv.),flushed with nitrogen, then hydrogen, and vigorously stirred under anatmosphere of hydrogen overnight. The reaction was flushed withnitrogen, filtered through celite, and concentrated to give 0.99 g (97%)as a white solid which was used without purification. ¹H-NMR (CDCl₃, 500MHz) δ 1.71 (m, 4H), 2.75 (m, 2H), 3.16 (m, 2H), 4.38 (s, 2H), 4.46 (m,1H), 6.77 (bs, 1H), 6.81-6.89 (m, 2H), 6.95 (m, 1H). Mass spec.: 250.22(MH)⁺.

3-(1-Benzylpiperidin-4-yl)-8-fluoroquinazoline-2,4(1H,3H)-dione

To a solution of 2-amino-N-(1-benzylpiperidin-4-yl)-3-fluorobenzamide(750 mg, 2.29 mmol) in dichloromethane (30.0 mL) at 0° C. was addedtriphosgene (227 mg, 0.33 equiv.) as a solution in dichloromethane (5mL). The ice bath was removed and the reaction heated at reflux for 6 h.The reaction was concentrated, dissolved in ethyl acetate, washed withsaturated sodium bicarbonate, then water, then brine, dried overmagnesium sulfate, and concentrated to give 700 mg of a white solid. Thecrude product was purified by flash chromatography to give 205 mg (25%)as a white solid. Mass spec.: 354.13 (MH)⁺.

8-Fluoro-3-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione

A flask containing a solution of3-(1-benzylpiperidin-4-yl)-8-fluoroquinazoline-2,4(1H,3H)-dione (75.0mg, 0.21 mmol) and palladium on charcoal (8.00 mg, 0.035 equiv) inmethanol (3.00 mL) was flushed first with nitrogen, then hydrogen. Thereaction was stirred under an atmosphere of hydrogen overnight. Thereaction was flushed with nitrogen, filtered through celite, andconcentrated to give 53 mg (95%) as a white solid which was used withoutpurification. Mass spec.: 264.25 (MH)⁺.

8′-Fluoro-2′,3′-dihydro-2′-oxospiro-(1-phenylmethylpiperidine)-4,4′-quinazoline

A 500 mL 3-neck flask was charged with polyphosphoric acid (110 mL) andfitted with an overhead stirrer, a nitrogen inlet, and a bubbler. Theflask was flushed with nitrogen and heated to 105° C. in an oil bath. Tothis was added 1-benzyl-4-piperidone (21.0 mL, 115 mmol). To this wasadded N-(2-Fluorophenyl)urea (21.3 g, 1.2 equiv) in many small portionsover 2 h. The reaction was heated to 160° C. with vigorous stirring.After 2 h, the reaction was quenched by pouring over crushed ice andneutralizing with 20% potassium hydroxide. The reaction mixture wasextracted with dichloromethane, washed with water, then brine, driedover magnesium sulfate, and concentrated. The whole lot was purified bypreparative HPLC (˜130 injections) to give a much purer product. Theproduct was repurified by flash chromatography to give a solid which wastriturated with diethyl ether and filtered to give 275 mg (0.7%) asawhite solid. ¹H-NMR (CDCl₃, 500 MHz) δ 1.91 (dd, J=13.7, 2.1, 2H), 2.10(ddd, J=13.1, 13.1, 4.3, 2H), 2.27 (ddd, J=12.5, 12.5, 2.1, 2H), 2.86(m, 2H), 3.57 (s, 2H), 5.40 (bs, 1H), 6.90 (bs, 1H), 6.90-7.05 (m, 3H),7.27 (m, 1H), 7.32 (m, 4H). Mass spec.: 326.13 (MH)⁺.

8′-Fluoro-2′,3′-dihydro-2′-oxospiro-piperidine-4,4′-quinazoline

To a solution of8′-fluoro-2′,3′-dihydro-2′-oxospiro-(1-phenylmethylpiperidine)-4,4′-quinazoline(250 mg, 0.77 mmol) in methanol (4 mL) and dichloromethane (4 mL) wasadded palladium on charcoal (30.0 mg, 0.037 equiv.). The reaction wasflushed with hydrogen, and stirred under an atmosphere of hydrogenovernight. The balloon was removed, the reaction flushed with nitrogen,filtered through celite, washed with additional methanol, andconcentrated to give 158 mg (87%) as a white solid which was usedwithout purification. ¹H-NMR (CDCl₃/CD₃OD, 500 MHz) δ 1.87 (d, J=12.8,2H), 2.15 (ddd, J=14.0, 14.0, 5.5, 2H), 3.10 (m, 4H), 6.84 (m, 2H), 6.93(d, J=7.0, 1H). Mass spec.: 236.11 (MH)⁺.

Example 218(±)—N-(3-(7-Ethyl-1H-indazol-5-yl)-1-(6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-oxopropan-2-yl)-4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz) δ1.24 (m, 2H), 1.55-2.07 (m, 5H), 2.57 (m, 1H), 2.82 (m, 4H), 3.08 (m,2H), 3.30 (m, 3H), 3.35 (m, 5H), 3.48 (m, 3H), 3.65 (m, 1H), 4.14 (m,2H), 4.27 (m, 2H), 4.33-4.57 (m, 2H), 5.06 (dd, J=6.7, 6.7, 1H), 5.22(d, J=1.8, 2H), 6.78 (d, J=7.6, 1H), 6.93 (m, 1H), 7.00-7.18 (m, 3.5H),7.37 (d, J=9.8, 1H), 7.46 (s, 0.5H), 7.91 (dd, J=10.1, 1.8, 1H). Massspec.: 596.43 (MH)⁺.

Example 219(±)—N-(3-(7-Ethyl-1H-indazol-5-yl)-1-(6,7-dihydro-7,7-dimethyl-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-oxopropan-2-yl)-4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz) δ1.11 (m, 3H), 1.50-1.80 (m, 4H), 2.87 (m, 4H), 3.10 (m, 2H), 3.32 (m,9H), 3.48 (m, 4H), 4.00-4.45 (m, 6H), 5.05-5.25 (m, 2H), 6.77 (d, J=6.1,1H), 6.93 (m, 1H), 7.13 (m, 3H), 7.30-7.60 (m, 2H), 7.95 (m, 1H). Massspec.: 624.49 (MH)⁺.

Example 220 (±)-Methyl2-(4-(8-fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propanoate

Prepared as described above for3-(3-cyano-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester: ¹H-NMR (CDCl₃, 500 MHz) δ 1.53-1.68 (m, 4H), 2.48 (s,3H), 2.82 (m, 2H), 3.05 (m, 6H), 3.09 (dd, J_(AB)=13.7, 6.1, 1H), 3.14(dd, J_(AB)=14.0, 6.1, 1H), 3.35 (bs, 1H), 3.68 (s, 3H), 3.88-4.02 (m,2H), 4.22 (d, J_(AB)=15.6, 1H), 4.25 (d, J_(AB)=15.3, 1H), 4.44 (m, 1H),4.71 (dd, J=6.1, 6.1, 1H), 6.78 (d, J=7.3, 1H), 6.84 (ddd, J=7.6, 7.6,4.9, 1H), 6.88-6.95 (m, 2H), 7.28 (s, 1H), 7.91 (s, 1H). Mass spec.:509.25 (MH)⁺.

Example 221(±)-4-(8-Fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz) δ−0.25 (m, 1H), 0.82 (m, 1H), 1.25-2.10 (m, 13H), 2.20-2.63 (m, 6H),2.68-2.98 (m, 4H), 3.00-3.22 (m, 3H), 3.31 (m, 2H), 3.44 (bs, 1H),4.00-4.50 (m, 6H), 4.64 (m, 1H), 4.96 (m, 1H), 6.85-7.05 (m, 3H), 7.08(s, 0.4H), 7.20 (s, 0.6H), 7.46 (d, J=7.0, 1H), 7.99 (s, 0.4H), 8.05 (d,J=2.4, 0.6H). Mass spec.: 645.58 (MH)⁺.

Example 222(±)-4-(8-Fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CDCl₃, 500 MHz) δ1.73 (m, 4H), 2.49 (m, 4H), 2.80-3.26 (m, 7H), 3.43 (m, 2H), 3.65-3.95(m, 3H), 4.14 (dd, J=21.7, 14.3, 2H), 4.32 (s, 2H), 4.51 (m, 1H), 5.15(dd, J=7.9, 6.4, 1H), 5.90 (bs, 1H), 6.80 (d, J=7.3, 1H), 6.83-7.01 (m,4H), 7.06 (dd, J=7.6, 7.3, 1H), 7.10 (s, 1H), 7.26-7.33 (m, 2H), 7.44(s, 1H), 7.87 (s, 1H), 8.06 (s, 1H). Mass spec.: 639.36 (MH)⁺.

Example 223(±)-4-(8-Fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)-N-(1-(4-(4-fluorophenyl)piperazin-1-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CDCl₃, 500 MHz) δ1.73 (m, 4H), 2.26 (dd, J=7.9, 7.6, 1H), 2.49 (s, 3H), 2.75-3.05 (m,4H), 3.09 (m, 2H), 3.19-3.45 (m, 3H), 3.63 (m, 1H), 3.78 (m, 2H), 4.13(dd, J=16.5, 15.3, 2H), 4.32 (s, 2H), 4.50 (m, 1H), 5.15 (dd, J=8.2,6.1, 1H), 5.85 (bs, 1H), 6.70-6.84 (m, 3H), 6.85-7.02 (m, 5H), 7.09 (s,1H), 7.43 (s, 1H), 7.78 (s, 1H), 8.06 (s, 1H).

Mass spec.: 657.35 (MH)⁺.

Example 224(±)-4-(8-Fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)-N-(1′-(4-(2-fluorophenyl)piperazin-1-yl)-3-(7-methyl-1H-indazol-5-yl)-1′-oxopropan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CDCl₃, 500 MHz) δ1.62-1.78 (m, 4H), 2.24 (dd, J=7.9, 8.2, 1H), 2.50 (s, 3H), 2.70-2.85(m, 2H), 2.85-2.96 (m, 2H), 2.00 (m, 1H), 3.08 (dd, J_(AB)=13.1, 8.6,1H), 3.12 (m, 1H), 3.30 (m, 1H), 3.57 (m, 1H), 3.73 (m, 2H), 4.13 (dd,J=19.8, 15.0, 2H), 4.33 (s, 2H), 4.53 (m, 1H), 5.18 (dd, J=8.2, 5 (8,1H), 5.82 (bs, 1H), 6.58 (dd, J=8.2, 8.2, 1H), 6.81 (d, J=7.6, 1H),6.85-7.05 (m, 5H), 7.09 (s, 1H), 7.44 (s, 1H), 7.58 (s, 1H), 8.05 (s,1H). Mass spec.: 657.37 (MH)⁺.

Example 225(±)-4-(8-Fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-o-tolylpiperazin-1-yl)propan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CDCl₃, 500 MHz) δ1.60-1.79 (m, 4H), 2.03 (dd, J=8.5, 8.2, 1H), 2.22 (s, 3H), 2.49 (s,3H), 2.54 (dd, J=8.6, 8.5, 1H), 2.65 (m, 1H), 2.81 (m, 1H), 2.85-2.97(m, 2H), 3.05-3.22 (m, 3H), 3.38 (m, 1H), 3.50-3.65 (m, 2H), 3.83 (m,1H), 4.15 (dd, J=15.9, 15.3, 2H), 4.31 (s, 2H), 4.53 (m, 1H), 5.19 (dd,J=7.9, 5.8, 1H), 5.84 (bs, 1H), 6.54 (d, J=7.6, 1H), 6.81 (d, J=7.6,1H), 6.89 (ddd, J=7.6, 7.6, 5.2, 1H), 6.96 (m, 2H), 7.00-7.23 (m, 4H),7.39 (s, 1H), 7.43 (s, 1H), 8.04 (s, 1H). Mass spec.: 653.38 (MH)⁺.

Example 226 (±)-Methyl2-(4-(8-fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(7-ethyl-3-methyl-1H-indazol-5-yl)propanoate

Prepared as described above for3-(3-cyano-1H-indol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester: ¹H-NMR (CD₃OD, 500 MHz) δ 1.33 (m, 3H), 1.39-1.72 (m,4H), 2.70-2.95 (m, 3H), 3.06 (m, 1H), 3.25 (m, 1H), 3.70 (m, 3H),3.95-4.30 (m 4H), 4.38 (m, 1H), 4.57 (m, 1H), 6.80-7.05 (m, 3H), 7.08(s, 1H), 7.38 (s, 1H). Mass spec.: 537.47 (MH)⁺.

Example 227(±)—N-(3-(7-Ethyl-3-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-4-(8-fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz)δ 310.36 (m, 1H), 0.70 (m, 1H), 1.21 (bd, J=11.9, 1H), 1.28-2.00 (m, 19H),2.31 (dd, J=11.6, 11.3, 1H), 2.40 (dd, J=13.1, 11.6, 1H), 2.79-3.16 (m,7H), 3.72 (m, 1H), 3.85-4.03 (m, 1H), 4.10-4.48 (m, 5H), 4.53 (bd,J=11.0, 1H), 5.05 (m, 1H), 6.85-7.03 (m, 3H), 7.08 (s, 0.2H), 7.18 (s,0.8H), 7.37 (s, 1H). Mass spec.: 673.42 (MH)⁺.

Example 228(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-4-(8-fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz) δ0.71 (m, 1H), 1.26 (m, 1H), 1.40-2.15 (m, 13H), 2.50-3.29 (m, 9H),3.32-3.64 (m, 3H), 4.14 (d, J_(AB)=12.8, 1H), 4.17 (d, J_(AB)=11.6, 1H),4.32-4.45 (m, 3H), 4.68 (bd, J=13.4, 1H), 4.92 (m, 1H), 6.87-7.22 (m,6H). Mass spec.: 648.47 (MH)⁺.

Example 229(±)—N-(3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-8′-fluoro-2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz) δ−0.23 (m, 1H), 0.85 (m, 1H), 1.20-2.10 (m, 22H), 2.25-2.55 (m, 7H), 2.58(s, 3H), 2.74 (d, J=11.3, 1H), 2.94 (dd, J=12.5, 12.2, 2H), 3.00-3.20(m, 5H), 3.40-3.65 (m, 2H), 3.80-4.15 (m, 4H), 4.55-4.73 (m, 2H), 4.96(dd, J=7.9, 7.6, 1H), 5.01 (dd, J=10.4, 5.8, 1H), 6.65-7.15 (m, 5H),7.21 (s, 1H), 7.47 (s, 1H), 7.96 (m, 1H), 8.04 (s, 1H). Mass spec.:631.29 (MH)⁺.

Example 230(±)-4-(8-Fluoro-1,2-dihydro-2,4-dioxoquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 203: ¹H-NMR (CD₃OD, 500 MHz) δ−0.26 (m, 1H), 0.81 (m, 1H), 1.20-2.10 (m, 11H), 2.20-2.80 (m, 9H), 2.90(m, 3H), 3.10 (m, 3H), 3.34 (m, 1H), 3.44 (m, 1H), 4.06 (bd, J=13.4,1H), 4.17 (d, J_(AB)=15.9, 1H), 4.22 (d, J_(AB)=13.1, 1H), 4.64 (dd,J=24.4, 13.1, 1H), 4.91-5.13 (m, 2H), 7.00-7.25 (m, 2H), 7.44 (m, 2H),7.81 (m, 1H), 7.92-8.08 (m, 1H). Mass spec.: 659.59 (MH)⁺.

(R)-Methyl2-amino-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate

A mixture of(R)-2-benzyloxycarbonylamino-3-(3,4-diamino-phenyl)-propionic acidmethyl ester (500 mg, 1.20 mmol) and trifluoroacetic acid (6 mL) washeated at 80° C. for 16 h. The reaction mixture was poured into icewater (75 mL), neutralized to pH 7 with aqueous saturated sodiumbicarbonate, and extracted with ethyl acetate (2×250 mL). The organicextracts were dried over sodium sulfate, filtered and evaporated to givethe title compound as the trifluoroacetic acid salt (459 mg, 84% yield).¹H-NMR (CDCl₃, 300 MHz) δ 7.37 (bs, 1H) 7.35 (bs, 1H), 7.17 (d, J=8.4Hz, 1H), 4.70 (s, 2H), 3.85 (dd, J=8.4, 4.8 Hz, 1H), 3.77 (s, 3H), 3.30(dd, J=13.9, 4.8 Hz, 1H), 2.97 (dd, J=13.5, 8.4 Hz, 1H). Mass spec.: 288(MH)⁺.

(R)-Methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate

A solution of the amino ester (R)-methyl2-amino-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate (230mg, 0.51 mmol), diisopropylethylamine (262 mg, 2.03 mmol), anddisuccinimidyl carbonate (129 mg, 0.51 mmol) in a mixture of methylenechloride/dimethylformamide (15:1 ratio) was stirred at room temperaturefor 30 min. To the solution was added4-(2-keto-1-benzimidazolinyl)piperidine and the reaction mixture wasallowed to stir at room temperature for 16 h. The reaction mixture wasfiltered to remove any solids and was then purified by flash columnchromatography (95:3:2 methylene chloride/methanol/triethylamine) togive the title compound (215 mg, 77% yield) as a tan solid. ¹H-NMR(CDCl₃, 300 MHz) δ 7.67 (d, J=8.4 Hz, 1H), 7.39 (s, 1H), 7.21-7.16 (m,1H), 7.05-6.94 (m, 3H), 6.70-6.68 (m, 2H), 5.11 (d, J=7.3 Hz, 1H), 4.78(dd, J=12.1, 5.5 Hz, 1H), 4.42 (d, J=4.4 Hz, 2H), 4.29 (d, J=12.1 Hz,1H), 3.82-3.72 (m, 2H), 3.74 (s, 3H), 3.44 (dd, J=13.9, 5.5 Hz, 1H),3.22 (dd, J=13.9, 5.5 Hz), 2.95-2.83 (m, 3H), 2.18-2.03 (m, 2H),1.79-1.68 (m, 2H). Mass spec.: 545 (MH)⁺.

(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoicacid

To a solution of the ester (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate(220 mg, 0.40 mmol) in tetrahydrofuran and methanol (1:1 mixture, 20 mL)at 0° C. was added lithium hydroxide (36 mg, 1.51 mmol) in water (10mL). The mixture was stirred at 0° C. for 2 h and then stored at −15° C.for 16 h. The organic solvents were evaporated. The aqueous solution wasextracted with ethyl acetate while adjusting the pH to 4 with 1N HCl (3mL). The organic extracts were dried over sodium sulfate, filtered, andevaporated to give the title compound (176 mg, 82% yield). LC/MS:t_(R)=2.01 min, 531 (MH)⁺.

Example 231N—((R)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

To a stirred solution of the acid(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid (33 mg, 0.06 mmol) anddiisopropylethylamine (33 mg, 0.25 mmol) in methylene chloride (2 mL)was added a solution of PyBOP (33 mg, 0.06 mmol) and4-piperidinopiperidine (12 mg, 0.07 mmol) in methylene chloride (1 mL).The reaction mixture was stirred at room temperature for 16 h and wassubjected to preparative thin layer chromatography for purification(1:10 2M ammonia in methanol/methylene chloride) to give the titlecompound (4.6 mg, 12% yield). ¹H-NMR (CD₃OD, 500 MHz) δ 7.73-7.71 (m,1H), 7.62 (bs, 1H), 7.39-7.36 (m, 1H), 7.19-7.11 (m, 2H), 6.96 (t, J=7.2Hz, 1H), 6.81 (d, J=7.9 Hz, 1H), 5.06-5.02 (m, 1H), 4.67-4.58 (m, 1H),4.49-4.40 (m, 1H), 4.38 (s, 1H), 4.33 (bs, 1H), 4.25-4.16 (m, 2H),4.10-4.03 (m, 1H), 3.22-3.14 (m, 3H), 3.04-2.87 (m, 4H), 2.79-2.71 (m,1H), 2.58-2.48 (m, 1H), 2.44-2.33 (m, 1H), 2.31-2.22 (m, 1H), 2.04-1.92(m, 1H), 1.86-1.43 (m, 11H), 1.33-1.29 (m, 1H), 0.94-0.84 (m, 1H),−0.04--0.12(m, 1H). LC/MS: t_(R)=1.97 min, 681 (MH)⁺.

Example 232 N—((R)-1-(dimethylcarbamoyl)-2-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)ethyl)-4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 231. ¹H-NMR (CD₃OD, 300 MHz) δ7.69-7.56 (m, 2H), 7.34 (d, J=7.7 Hz, 1H), 7.17-7.08 (m, 2H), 6.92 (t,J=7.7 Hz, 1H), 6.77 (d, J=8.4 Hz, 1H), 6.56 (d, J=7.7 Hz, 1H), 5.02-4.97(m, 1H), 4.46-4.35 (m, 1H), 4.29 (s, 2H), 4.15 (d, J=12.8 Hz, 1H),3.26-3.11 (m, 5H), 2.87 (s, 6H), 1.86-1.68 (m, 2H), 1.66-1.59 (m, 2H).LC/MS: t_(R)=2.37 min, 558 (MH)⁺.

Benzyl(R)-1-(methoxycarbonyl)-2-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)ethylcarbamate

To a dilute solution of(R)-2-benzyloxycarbonylamino-3-(3,4-diamino-phenyl)-propionic acidmethyl ester (600 mg, 1.44 mmol) in tetrahydrofuran (125 mL) was addedtriethylamine (320 mg, 3.17 mmol) followed by 1,1′-carbonyldiimidazole(280 mg, 1.73 mmol). The reaction mixture was stirred at roomtemperature for 16 h and then filtered to remove solid. The filtrate wasevaporated and subjected to flash column chromatography (1:12methanol/methylene chloride) to give the title compound (313 mg, 59%yield).

¹H-NMR (CD₃OD, 300 MHz) δ 7.28-7.21 (m, 5H), 6.94-6.83 (m, 3H),5.06-4.95 (m, 2H), 4.46-4.41 (m, 1H), 3.68 (s, 3H), 3.17-3.11 (m, 1H),2.95-2.88 (m, 1H). LC/MS: t_(R)=2.11 min, 370 (MH)⁺.

(R)-methyl 2-amino-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)propanoate

Benzyl(R)-1-(methoxycarbonyl)-2-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)ethylcarbamate(265 mg, 0.72 mmol) and 10% palladium on carbon (30 mg) in methanol (15mL) were agitated for 1.5 h under 50 psi hydrogen using a Parrapparatus. The reaction mixture was purged with 3 vacuum/nitrogen purgecycles. The reaction mixture was then filtered through a pad of Celite®and the pad was rinsed with several portions of methanol. The methanolfiltrate was evaporated to give the title compound (168 mg, quantitativeyield). ¹H-NMR (CD₃OD, 300 MHz) δ 6.97 (d, J=8.1 Hz, 1H), 6.87 (s, 1H),6.86 (d, J=8.2 Hz, 1H), 3.71-3.64 (m, 1H), 3.67 (s, 3H), 3.04-2.89 (m,2H). LC/MS: t_(R)=0.87 min, 236 (MH)⁺.

Example 233 (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)propanoate

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.¹H-NMR (CD₃OD, 300 MHz) δ 7.16-7.08 (m, 2H), 6.98-6.90 (m, 4H), 6.76 (d,J=8.1 Hz, 1H), 4.52-4.47 (m, 1H), 4.39-4.35 (m, 1H), 4.27 (s, 2H),4.13-4.05 (m, 2H), 3.70 (s, 3H), 3.21-3.14 (m, 1H), 3.04-2.96 (m, 1H),2.89-2.74 (m, 2H), 1.78-1.59 (m, 4H). LC/MS: t_(R)=1.77 min, 493 (MH)⁺.

(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)propanoicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. ¹H-NMR (CD₃OD, 300 MHz) δ 7.16-7.09 (m,2H), 6.99-6.90 (m, 4H), 6.76 (d, J=7.3 Hz, 1H), 4.53-4.48 (m, 1H), 4.28(s, 2H), 4.13-4.03 (m, 2H), 3.07-2.97 (m, 1H), 2.89-2.77 (m, 2H),1.79-1.60 (m, 4H), 1.28-1.21 (m, 1H). LC/MS: t_(R)=1.83 min, 479 (MH)⁺.

Example 234N—((R)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)-1-oxo-1(4-piperidin-1-yl)piperidine-1-yl)propan-2-yl)-4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 231. ¹H-NMR (CD₃OD, 300 MHz) δ7.17-7.10 (m, 2H), 7.01 (s, 1H), 6.95-6.90 (m, 3H), 6.78 (d, J=8.1 Hz,1H), 4.98-4.93 (m, 1H), 4.62-4.55 (m, 1H), 4.41-4.33 (m, 2H), 4.20-4.16(m, 2H), 4.04-3.96 (m, 1H), 3.05-2.85 (m, 7H), 2.71-2.57 (m, 1H),2.53-2.32 (m, 1H), 1.86-1.76 (m, 2H), 1.70-1.61 (m, 8H), 1.50-1.41 (m,2H), 1.03-0.89 (m, 1H), 0.10-0.02 (m, 1H). Mass spec.: 629.22 (MH)⁺.

Example 235 N—((R)-1-(dimethylcarbamoyl)-2-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)ethyl)-4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.96 min, 506(MH)⁺.

(R)-Methyl2-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinazoline)carbonylamino]-3-2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)propanoate

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.¹H-NMR (DMSO-d6, 500 MHz) δ 10.54 (s, 1H), 10.50 (s, 1H), 9.22 (s, 1H),7.21 (s, 1H), 7.13-7.10 (m, 1H), 6.96-6.79 (m, 7H), 4.29-4.25 (m, 1H),3.82-3.78 (m, 2H), 3.60 (s, 3H), 3.32-3.23 (m, 1H), 3.16-3.14 (m, 1H),3.00-2.90 (m, 2H), 2.08 (s, 1H), 1.67-1.55 (m, 4H). LC/MS: t_(R)=1.62min, 479 (MH)⁺.

(R)-2-[2′,3-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinazoline)carbonylamino]-3-2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)propanoicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4μl)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. ¹H-NMR (CD₃OD, 300 MHz) δ 7.19-7.14 (m,1H), 7.05-6.95 (m, 5H), 6.81 (d, J=7.7 Hz, 1H), 5.04-4.90 (m, 1H),4.57-4.52 (m, 1H), 3.96-3.84 (m, 2H), 3.24-3.14 (m, 2H), 3.07-2.95 (m,1H), 1.94-1.73 (m, 4H). LC/MS: t_(R)=1.67 min, 465 (MH)⁺

Example 236N—((R)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-6-yl)-1-oxo-1(4-piperidin-1-yl)piperidine-1-yl)propan-2-yl)-4-(2′,3′-dihydro-2′-oxospiro(piperidine-4,4′-(1H)-quinazoline)carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.55 min, 615(MH)⁺.

4-Acetamido-3-methylbenzoic acid

To a suspension of 4-amino-3-methylbenzoic acid (60 g, 0.40 mol) inmethylene chloride (800 mL) was added triethylamine (121 g, 1.19 mol).The solution became clear. Then, acetic anhydride (81 g, 0.79 mol) wasadded and the reaction mixture was stirred for 60 h at room temperature.The solvent was evaporated. The residue was diluted with water (400 mL)and extracted with ethyl acetate (3×600 mL). The combined organicextracts were dried over magnesium sulfate, filtered and evaporated togive the title compound as a tan solid (43 g, 56% yield). ¹H-NMR(d₆-DMSO, 300 MHz) δ 9.36 (s, 1H), 7.77 (s, 1H), 7.10 (s, 2H), 2.27 (s,3H), 2.10 (s, 3H). LC/MS: t_(R)=1.22 min, 194 (MH)⁺.

4-Acetamido-3-methyl-5-nitrobenzoic acid

To a solution of 60% nitric acid in sulfuric acid (410 mL) was added4-acetamido-3-methylbenzoic acid (43 g, 0.22 mol) in small portions over40 min while cooling with an ice bath. After addition of all amide wascomplete, the reaction mixture was stirred for 1 h at 0° C. and thenvery slowly poured over 1500 mL of ice. The yellow solid was collectedby filtration and washed with ice cold water to give the title compound(38 g, 72% yield). ¹H-NMR (CD₃OD, 300 MHz) δ 8.29 (s, 1H), 8.18 (s, 1H),2.39 (s, 3H), 2.16 (s, 3H). Mass spec.: 237 (MH)⁺.

4-Amino-3-methyl-5-nitrobenzoic acid

A suspension of 4-acetamido-3-methyl-5-nitrobenzoic acid (38 g, 0.16mol) in 3N hydrochloric acid (800 mL) was heated at reflux for 8 h andthen stirred at room temperature for 8 h. The yellow solid was collectedby filtration and transferred to a 2 L flask with a mixture of methylenechloride and methanol. The solvent was evaporated under high vacuum togive the title compound (23 g, 74% yield). ¹H-NMR (DMSO-d₆, 300 MHz) δ12.79 (bs, 1H), 8.46 (s, 1H), 7.79 (s, 1H), 7.61 (s, 2H), 2.34 (s, 3H).¹³C-NMR (d₆-DMSO, 75 MHz) δ 166.0, 147.0, 135.1, 130.0, 126.4, 125.9,116.7, 17.9. LC/MS: t_(R)=1.23 min, 195 (MH)⁻.

3-Methyl-4,5-dinitrobenzoic acid

To a suspension of 4-amino-3-methyl-5-nitrobenzoic acid (5.0 g, 25.5mmol) in trifluoroacetic acid (200 mL) was added hydrogen peroxide (50wt-%, 15 mL). The reaction mixture was heated at 50° C. for 2 h and thesolution eventually went from a dark orange clear solution to a paleyellow clear solution. The reaction mixture was slowly poured into icewater (800 mL). The solid was collected by filtration and dried undervacuum to give the title compound as an off-white solid (4.0 g, 70%yield). ¹H-NMR (CD₃OD, 300 MHz) δ 8.59 (s, 1H), 8.40 (s, 1H), 2.45 (s,3H). ¹³C-NMR (CD₃OD, 75 MHz) δ 165.8, 147.4, 142.0, 139.3, 134.8, 134.6,125.4, 17.2. Mass spec.: 225.14 (MH)⁻.

(3-Methyl-4,5-dinitrophenyl)methanol

A solution of 3-methyl-4,5-dinitrobenzoic acid (4.0 g, 17.7 mmol) intetrahydrofuran (200 mL) was cooled to −70° C. with a dry ice/acetonebath. To this solution was added borane-tetrahydrofuran (1M intetrahydrofuran, 35.4 mL). The reaction mixture was allowed to slowlywarm to room temperature and was stirred for 16 h. The reaction wasincomplete, was again cooled to −50° C. and additionalborane-tetrahydrofuran (1M in tetrahydrofuran, 35.4 mL) was added.Again, the reaction mixture was allowed to slowly warm to roomtemperature overnight. The reaction was quenched with a mixture ofacetic acid and water (1:1, 30 mL) while cooling at 0° C. After stirringfor 30 min, all organic solvent was evaporated and the aqueous materialwas neutralized by pouring into ice cold saturated sodium bicarbonate(350 mL) in small portions. The aqueous layer was extracted with ethylacetate. The extracts were washed with brine, dried over magnesiumsulfate, filtered and evaporated. The residue was subjected to flashcolumn chromatography (1:2 hexanes/ethyl acetate) to give the titlecompound (3.2 g, 86% yield). ¹H-NMR (CDCl₃, 300 MHz) δ 8.00(s, 1H), 7.62(s, 1H), 4.82 (s, 2H), 2.41 (s, 3H). ¹³C-NMR (CDCl₃, 75 MHz) δ 144.5,143.3, 140.9, 134.3, 132.9, 120.8, 63.0, 17.4.

3-Methyl-4,5-dinitrobenzaldehyde

In a flame-dried flask, manganese (IV) oxide (36.0 g, 414 mmol) wasazeotropically dried with toluene. Then, a solution of(3-methyl-4,5-dinitrophenyl)methanol (3.2 g, 15 mmol) in chloroform (100mL) was transferred to the flask containing the manganese dioxide. Thereaction mixture was heated at 50° C. with stirring for 3 h. Uponcompletion of the reaction, the reaction mixture was filtered through apad of Celite® to remove manganese dioxide and the Celite was washedwith chloroform several time. The filtrate was evaporated to give thetitle compound (1.4 g, 44% yield). ¹H-NMR (CDCl₃, 300 MHz) δ 10.09 (s,1H), 8.51 (s, 1H), 8.16 (s, 1H), 2.51 (s, 3H).

Benzyl(Z)-1-(methoxycarbonyl)-2-(3-methyl-4,5-dinitrophenyl)vinylcarbamate

To a solution of N-(benzyloxycarbonyl)-α-phophonoglycine trimethyl ester(2.4 g, 7.3 mmol) in tetrahydrofuran (40 mL) at −78° C. was added1,1,3,3-tetramethylguanidine (729 mg, 6.33 mmol) and the mixture wasstirred for 1 h at −78° C. To this mixture was added a solution of3-methyl-4,5-dinitrobenzaldehyde (1.4 g, 6.7 mmol) in tetrahydrofuran(15 mL). The reaction mixture was allowed to slowly warm to roomtemperature and was then stirred for 16 h at room temperature. Thesolvent was evaporated and the residue subjected to flash columnchromatography (gradient, 1:2 to 1:1 ethyl acetate/hexanes). The productwas then recrystallized from ethyl acetate/hexanes (1:1) to give thetitle compound (1.7 g, 62% yield). ¹H-NMR (CDCl₃, 300 MHz) δ 8.01 (s,1H), 7.55 (s, 1H), 7.33-7.22 (m, 6H), 6.94 (bs, 1H), 5.06 (s, 2H), 3.89(s, 3H), 2.29 (s, 3H). ¹³C-NMR (CDCl₃, 75 MHz) δ 164.7, 152.5, 143.1,140.6, 137.7, 137.0, 135.3, 132.5, 128.8, 128.7, 128.6, 127.1, 123.5,123.2, 68.3, 53.5, 17.4. Mass spec.: 414.20 (MH)⁻.

Benzyl(R)-1-(methoxycarbonyl)-2-(3-methyl-4,5-dinitrophenyl)ethylcarbamate

In a glove bag that was subjected to 3 vacuum/nitrogen purge cycles, anAIRFREE® (Schlenk) reaction flask equipped with stir bar was chargedwith (−)-1,2-bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium (I) trifluoromethylsulfonate (125 g, 0.173 mmol, 4 mol %),sealed with a rubber septum, and removed from the glove bag. Thebenzyl(Z)-1-(methoxycarbonyl)-2-(3-methyl-4,5-dinitrophenyl)vinylcarbamate(1.65 g, 3.97 mmol) was weighed into a second AIRFREE® (Schlenk)reaction flask equipped with stir bar and sealed with a rubber septum.After 3 vacuum/nitrogen purge cycles, it was dissolved in a mixture ofanhydrous methylene chloride (40 mL). The solvent was deoxygenated priorto addition by sparging with nitrogen for at least 1 h. Once insolution, the mixture was again subjected to 3 vacuum/nitrogen purgecycles. The dehydroamino acid solution was introduced into the AIRFREE®(Schlenk) reaction flask containing the catalyst via cannula. Thereaction mixture was subjected to 5 vacuum/hyrogen purge cycles beforeopening the flask to 1 atmosphere of hydrogen. After 16 h, the reactionmixture was purged with 3 vacuum/nitrogen purge cycles. The solvent wasevaporated and the residue was subjected to column chromatography (1:1ethyl acetate/hexanes) to give the title compound (1.58 g, 95%). ¹H-NMR(CDCl₃, 300 MHz) δ 7.75 (s, 1H), 7.39-7.33 (m, 6H), 5.37 (d, J=7.0 Hz,1H), 5.15-5.04 (m, 2H), 4.70-4.46 (m, 1H), 3.77 (s, 3H), 3.30 (dd,J=13.9, 5.5 Hz, 1H), 3.12 (dd, J=13.9, 6.2 Hz, 1H), 2.33 (s, 3H). LC/MS:t_(R)=2.71 min, 418 (MH)⁺.

Benzyl(R)-1-(methoxycarbonyl)-2-(3,4-diamino-5-methylphenyl)ethylcarbamate

Solid ammonium formate (755 mg, 11.9 mmol) was added in small portionsat 0° C. to suspension ofbenzyl(R)-1-(methoxycarbonyl)-2-(3-methyl-4,5-dinitrophenyl)ethylcarbamate(500 mg, 1.20 mmol) and zinc powder (470 mg, 7.19 mmol) in methanol (20mL, degassed with nitrogen for 2 h). The resulting mixture was stirredat room temperature for 60 h. Reaction was incomplete. The reactionmixture was again cooled to 0° C. and additional zinc powder (470 mg,7.19 mmol) was added. The reaction was stirred for 4 h at which time thereaction was complete. The reaction mixture was filtered to remove zinc.The filtrate was evaporated. A mixture of toluene and ethyl acetate(1:1) were added, followed by acetic acid (2 mL). The mixture wasfurther diluted until all organic solids dissolved, then it was washedwith water, brine, dried over sodium sulfate, and evaporated. Theresidue was then redissolved in ethyl acetate and 4N hydrogen chloridein dioxane (4 mL) was added. The solvent was evaporated to give thetitle compound as the dihydrochloride salt (515 mg, quantitative yield).¹H-NMR (CD₃OD, 300 MHz) δ 7.35-7.30 (m, 5H), 6.94-6.93 (m, 2H), 5.03 (s,2H), 4.42-4.37 (m, 1H), 3.70 (s, 3H), 3.09-3.03 (m, 1H), 2.87-2.79 (m,1H), 2.25 (s, 3H). LC/MS: t_(R)=1.79 min, 358 (MH)⁺.

Benzyl(R)-1-(methoxycarbonyl)-2-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)ethylcarbamate

To a solution ofbenzyl(R)-1-(methoxycarbonyl)-2-(3,4-diamino-5-methylphenyl)ethylcarbamate(250 mg, 0.58 mmol) in acetic acid (6 mL) and water (10 mL) was added asolution of sodium nitrite (40 mg, 0.58 mmol) in water (1 mL), dropwiseover several minutes at room temperature. The resulting mixture wasstirred at room temperature for 30 min, then cooled to 0° C. A mixtureof ammonium hydroxide and water (1:1, 15 mL) was added to adjust pH to11. The mixture was extracted with ethyl acetate twice. The organiclayers washed with brine and dried over sodium sulfate. Afterfiltration, solvents were removed in vacuo and the residue was purifiedby flash column chromatography (1:1 ethyl acetate/hexanes) on silica gelto afford the title compound as a tan solid (155 mg, 72% yield). ¹H-NMR(CDCl₃, 300 MHz) δ 7.34 (s, 1H), 7.32-7.28 (m, 6H), 6.93 (s, 1H), 5.40(d, J=8.1 Hz, 1H), 5.13-5.02 (m, 2H), 4.76-4.69 (m, 1H), 3.73 (s, 3H),3.28 (dd, J=13.9, 5.5 Hz, 1H), 3.16 (dd, J=13.9, 6.2 Hz, 1H), 2.64 (s,3H). LC/MS: t_(R)=2.30 min, 369 (MH)⁺.

(R)-Methyl 2-amino-3-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoate

Benzyl(R)-1-(methoxycarbonyl)-2-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)ethylcarbamate(146 mg, 0.40 mmol) was dissolved in 12 mL of a solution of 4.4% formicacid in methanol. The reaction flask containing this solution wasequipped with a magnetic stirbar and then flushed with nitrogen overseveral minutes. To the solution was added palladium on carbon (10%, 200mg) and the reaction was stirred for 16 h at room temperature undernitrogen atmosphere. The reaction mixture was filtered through a pad ofCelite® washing the pad several times with methanol. The filtrate wasevaporated to give the title compound (quantitative yield). ¹H-NMR(CDCl₃, 300 MHz) δ 8.40 (bs, 1H), 7.55 (s, 1H), 7.14 (s, 1H), 4.29-4.24(m, 1H), 3.78 (s, 3H), 3.39-3.19 (m, 2H), 2.69 (s, 3H). LC/MS:t_(R)=1.18 min, 235 (MH)⁺.

(R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoate

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.LC/MS: t_(R)=2.17 min, 492 (MH)⁺.

(R)-2-(4-(1,2-dihydro-2,4-dioxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoicacid. LC/MS: t_(R)=2.11 min, 492 (MH)⁺.

Example 2374-(1,2-dihydro-2,4-dioxoquinazolin-3(4H)-yl)-N—((R)-3-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide

Prepared as described above for Example 231. ¹H-NMR (CD₃OD, 300 MHz) δ8.01 (d, J=8.1 Hz, 1H), 7.63 (t, J=7.5 Hz, 1H), 7.28-7.11 (m, 4H),5.06-5.00 (m, 1H), 4.70-4.60 (m, 1H), 4.31-4.17 (m, 2H), 3.50-3.44 (m,1H), 3.20-2.82 (m, 7H), 2.75-2.47 (m, 6H), 2.12-2.02 (m, 2H), 1.93-1.67(m, 11H), 1.37-1.28 (m, 2H, 0.97-0.79 (m, 2H), 0.23-0.09 (m, 1H). Massspec.: 642 (MH)⁺.

(R)-2-Benzyloxycarbonylamino-3-(4-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

A mixture of(R)-2-benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (373 mg, 1.01 mmol), N-chlorosuccinimide (168 mg, 1.26mmol), silica gel (EM Scientific, 230-400 mesh, 3.73 g) indichloroethane (20 mL) was heated at 90° C. for 16 h. After cooling downto room temperature, the solvents were removed in vacuo. The residue wassubjected to silica gel chromatography using ethyl acetate/hexanes (1:2)as eluent to afford the title compound (40 mg, 9.8%), also2-benzyloxycarbonylamino-3-(5-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (78 mg, 19%). The structure was confirmed by 2D NMRand by comparison with that of2-benzyloxycarbonylamino-3-(5-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester prepared by the reaction shown below. ¹H-NMR(CD₃COCD₃, 500 MHz) δ 7.37-7.27 (m, 5H), 7.18 (d, J=1.0 Hz, 1H), 7.16(s, 1H), 6.76 (d, J=8.5 hz, 1H), 5.06 (d, J=12.5 Hz, 1H), 5.02 (d,J=12.5 Hz, 1H), 4.55-4.51 (m, 1H), 3.72 (s, 3H), 3.26 (dd, J=14.0, 5.0Hz, 1H), 3.04 (dd, J=14.0, 9.5 Hz, 1H); ¹³C-NMR (CD₃COCD₃, 125 MHz) δ172.2, 156.4, 154.0, 144.8, 137.6, 133.3, 128.7, 128.2, 128.0, 127.9,125.0, 66.3, 55.9, 52.0, 37.3; Mass spec. 405 (MH⁺).

(R)-2-Benzyloxycarbonylamino-3-(5-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

N-Chlorosuccinimide (315 mg, 2.36 mmol) was added to a solution of(R)-2-benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (700 mg, 1.89 mmol) in acetic acid (50 mL) at roomtemperature. The mixture was heated at 100° C. for 16 h. After it wascooled down to room temperature, solvents were removed in vacuo. Theresidue was subjected to silica gel chromatography using ethylacetate/hexanes (4:6) then (1:1) as eluent to afford the title compoundas an off-yellow solid (242 mg, 32%). The structure of the product wasconfirmed by 2D NMR. ¹H-NMR (CD₃COCD₃, 500 MHz) δ 10.47 (s, 1H),7.36-7.28 (m, 6H), 7.20 (s, 1H), 6.80 (d, J=8.5 Hz, 1H), 5.05 (d, J=12.5Hz, 1H), 5.00 (d, J=12.5 Hz, 1H), 4.65-4.60 (m, 1H), 3.73 (s, 3H), 3.43(dd, J=14.0, 5.0 Hz, 1H), 3.08 (dd, J=14.0, 10.5 Hz, 1H); ¹³C-NMR(CD₃COCD₃, 125 MHz) δ 172.2, 156.5, 154.5, 143.1, 137.5, 130.8, 129.0,128.9, 128.7, 128.2, 128.0, 112.8, 110.9, 66.3, 54.3, 52.1, 35.8; Massspec. 405 (MH⁺).

(R)-2-Benzyloxycarbonylamino-3-(4-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

A mixture of(R)-2-benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (418 mg, 1.13 mmol), N-bromosuccinimide (221 mg, 1.24mmol), silica gel (EM Scientific, 230-400 mesh, 2.51 g) and methylenechloride (70 mL) was stirred at room temperature for 16 h. Solvents wereremoved in vacuo and the residue was subjected to silica gelchromatography using ethyl acetate/hexanes (2:3) as eluent to afford thetitle compound. ¹H-NMR (CD₃COCD₃, 500 MHz) δ 10.71 (s, 1H), 7.35-7.28(m, 6H), 7.21 (s, 1H), 6.75 (d, J=7.5 Hz, 1H), 5.06 (d, 12.5 Hz, 1H),5.02 (d, J=12.5 Hz, 1H), 4.56-4.51 (m, 1H), 3.73 (s, 3H), 3.26 (dd,J=14.0, 5.0 Hz, 1H), 3.03 (dd, J=14.0, 10.0 Hz, 1H); ¹³C-NMR (CD₃COCD₃,125 MHz) δ 172.2, 156.4, 153.8, 144.4, 137.6, 133.7, 129.8, 128.7,128.2, 128.0, 127.8, 110.1, 100.9, 66.3, 55.9, 52.0, 37.3; Mass spec.448.03 (MH⁺).

(R)-2-Benzyloxycarbonylamino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

A mixture of(R)-2-benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (1.07 g, 2.89 mmol), N-bromosuccinimide (643 mg, 3.61mmol), and acetic acid (150 mL) was heated at 105° C. for 14 h. Aftercooling to room temperature, the solvents were removed in vacuo. Theresidue was subjected to silica gel chromatography using ethylacetate/hexanes (2:3), then (1:1) as eluent to afford the title compound(446 mg, 34%). The structure of the title compound was confirmed by 2DNMR. ¹H-NMR (CD₃COCD₃, 500 MHz) δ 10.46 (s, 1H), 7.36-7.28 (m, 7H), 6.82(d, J=8.5 Hz, 1H), 5.05 (d, J=12.5 Hz, 1H), 5.00 (d, J=12.5 Hz, 1H),4.67-4.62 (m, 1H), 3.73 (s, 3H), 3.43 (dd, J=14.0, 5.0 Hz, 1H), 3.10(dd, J=14.0, 10.5 Hz, 1H); ¹³C-NMR (CD₃COCD₃, 125 MHz) δ 172.2, 156.4,154.2, 143.7, 137.6, 131.1, 130.6, 128.7, 128.2, 128.0, 118.2, 113.9,112.9, 66.2, 54.3, 52.1, 38.3; Mass spec. 448.03 (MH⁺).

(R)-2-Benzyloxycarbonylamino-3-(4-iodo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

A mixture of(R)-2-benzyloxycarbonylamino-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (324 mg, 0.87 mmol), I(PyH)₂BF₄ (409 mg, 1.08 mmol),silica gel (EM Scientific, 230-400 mesh, 3.24 g) and dichloroethane (20mL) was heated at 90° C. for 6 h. After cooling to room temperature thesolvents were removed in vacuo. The residue was subjected to silica gelchromatography using ethyl acetate/hexanes (1:2) as eluent to afford thetitle compound (175 mg, 40%). The structure of the title compound wasconfirmed by 2D NMR. ¹H-NMR (CD₃COCD₃, 500 MHz) δ 10.47 (s, 1H), 7.46(s, 1H), 7.37-7.29 (m, 5H), 7.22 (s, 1H), 6.74 (d, J=8.5 Hz, 1H), 5.07(d, J=12.5 Hz, 1H), 5.02 (d, J=12.5 Hz, 1H), 4.54-4.49 (m, 1H), 3.72 (s,3H), 3.23 (dd, J=14.0, 5.0 Hz, 1H), 3.01 (dd, J=14.0, 9.5 Hz, 1H);¹³C-NMR (CD₃COCD₃, 125 MHz) δ 172.2, 156.4, 153.4, 143.3, 137.6, 134.1,133.64, 133.60, 128.7, 128.2, 128.0, 110.7, 71.1, 66.3, 56.0, 52.0,37.1; Mass spec. 496.01 (MH⁺).

(R)-2-Amino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

Trimethylsilyliodide (73 mL, 0.73 mmol) was added to a solution ofazotropically dried(R)-2-benzyloxycarbonylamino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester (146 mg, 0.33 mmol) in acetonitrile (10 mL) at roomtemperature, and the resulting mixture was stirred at room temperaturefor 2 h. Triethylamine (0.12 mL) was added and the mixture was stirredat room temperature for 15 min. The solvents were removed in vacuo, andthe residue was extracted with ethyl acetate. The combined organics werewashed with sodium bicarbonate and brine, dried over sodium sulfate andfiltered. Solvents were removed and the residue was used directly in thenext step. Mass spec. 315.10 (MH)⁺.

(R)-2-Amino-3-(4-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

Prepared as described above for(R)-2-amino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester. Mass spec. 315.06 (MH)⁺.

(R)-2-Amino-3-(5-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

Prepared as described above for(R)-2-amino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester. Mass spec. 271.10 (MH)⁺.

(R)-2-Amino-3-(4-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester

Prepared as described above for(R)-2-amino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester. Mass spec. 271.16 (MH)⁺.

(R)-2-Amino-3-(4-iodo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionic acidmethyl ester

Prepared as described above for(R)-2-Amino-3-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-propionicacid methyl ester. Mass spec. 363.04 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 481.20 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 480.24 (MH)⁺.

(R)-3-(4-Chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 528.16 (MH)⁺.

(R)-3-(5-Chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 528.20 (MH)⁺.

(R)-3-(4-Bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 572.20 (MH)⁺.

(R)-3-(5-Bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 572.15 (MH)⁺.

(R)-3-(4-Iodo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid methyl ester

Prepared as described above for (R)-methyl2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)propanoate.Mass spec. 620.20 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 467.18 (MH)⁺.

(R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carbonyl]-amino}-propionic acid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 466.20 (MH)⁺.

(R)-3-(4-Chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 514.20 (MH)⁺.

(R)-3-(5-Chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 514.24 (MH)⁺.

(R)-3-(4-Bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 558.30 (MH)⁺.

(R)-3-(5-Bromo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 558.25 (MH)⁺.

(R)-3-(4-Iodo-2-oxo-2,3-dihydro-benzooxazol-6-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid

Prepared as described above for(R)-2-(4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxamido)-3-(2-(trifluoromethyl)-1H-benzo[dimidazol-5-yl)propanoic acid. Mass spec. 606.10 (MH)⁺.

Example 238(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(4-cyclohexyl-piperazin-1-yl)-2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.80 min,630.37 (MH)⁺.

Example 239(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(4-isopropyl-piperazin-1-yl)-2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.71 min,590.34 (MH)⁺.

Example 240(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.64 min,617.34 (MH)⁺.

Example 241(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(cyclohex-1-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.69 min,617.35 (MH)⁺.

Example 242(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(prop-2-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.57 min,577.32 (MH)⁺.

Example 243(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.74 min,616.37 (MH)⁺.

Example 244(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(cyclohex-1-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carboxamide

Prepared as above. LC/MS: t_(R)=1.79 min, 616.36 (MH)⁺.

Example 245(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(prop-2-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carboxamide

Prepared as described above for Example 231. LC/MS: t_(R)=1.67 min,576.34 (MH)⁺.

Example 246(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-chloro-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.91 min,664.35 (MH)⁺.

Example 247(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(5-chloro-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.91 min,664.34 (MH)⁺.

Example 248(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-bromo-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.96 min,708.31 (MH)⁺.

Example 249(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(5-bromo-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.96 min,708.31 (MH)⁺.

Example 250(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-iodo-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 231. LC/MS: t_(R)=1.97 min,756.36 (MH⁺).

Example 251(±)—N-(1-Benzyl-2-hydroxy-ethyl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyramide

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.38 min, 596 (MH)⁺.

Example 252(±)—N-(1-Benzyl-2-hydroxy-ethyl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyramide

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.50 min, 609 (MH)⁺. ¹H NMR (400 MHz, CD₃OD) δ 7.90 (1H,s), 7.64-7.84 (1H, m), 6.71-7.42 (11H, m), 4.58 (1H, m), 3.82-4.50 (6H,m), 2.21-3.52 (13H, m), 1.42-1.87 (4H, m).

Example 253 (±)-Phenyl-acetic acidN′-{2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-hydrazide

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.43 min, 630 (M+Na)⁺.

Example 254(±)-1-[1,4′]Bipiperidinyl-1′-yl-4-[4-(8-fluoro-2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-2-(7-methyl-1H-indazol-5-ylmethyl)-butane-1,4-dione

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.18 min, 644 (MH)⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (1H,s), 6.82-7.40 (6H, m), 4.48-4.70 (3H, m), 4.31 (2H, s), 3.85-4.11 (2H,m), 3.65 (1H, m), 2.70-3.16 (5H, m), 2.53 (3H, s), 0.72-2.52 (23H, m).

Example 255(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline]-butane-1,4-dione

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.09 min, 612 (MH)⁺.

2-Oxo-2,3-dihydro-benzooxazole-6-carbaldehyde

A solution of 6-bromo-3H-benzooxazol-2-one (0.9236 g, 4.31 micromoles)in anhydrous tetrahydrofuran (25 mL) and dimethylformamide (3 mL) undernitrogen was cooled to −78° C. before addition of n-butyllithium (2.5Min hexane) (3.8 mL, 2.2 equiv). After stirring for 10 min at −78° C., 24mL of sec-butyllithium (1.4 M in cyclohexane, 8 equiv) was added. Thereaction was stirred while slowly warming to −40° C. When thistemperature was reached, the reaction was quenched by addition ofmethanol. The reaction mixture was concentrated in vacuo and water wasadded. The aqueous layer was acidified with 1N HCl (ca. pH 5) andextracted with ethyl acetate (3×50 mL), dried over sodium sulfate,filtered and concentrated to give the product, 0.6402 g (91%). MS (ESI)164 (MH)⁺. ¹H NMR (400 MHz, DMSO-d6) δ 9.90 (1H, s), 7.79 (1H, d, J=8.0Hz), 7.74 (1H, s), 7.28 (1H, d, J=8.0 Hz).

3-(2-Oxo-2,3-dihydro-benzooxazol-6-ylmethylene)-pentanedioic acidmonomethyl ester

Prepared as described above for2-(7-methyl-1H-indazol-5-ylmethylene)-succinic acid 1-methyl ester (1.4g, 90% yield). MS (ESI) 300 (M+Na)⁺.

(±)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-pentanedioic acidmonomethyl ester

Prepared as described above for(±)-2-(7-methyl-1H-indazol-5-ylmethyl)-succinic acid 1-methyl ester (1.4g, 99% yield). MS (ESI) 302 (M+Na)⁺.

(±)-4-Oxo-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid methyl ester

Prepared as described above for(±)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid methyl ester. MS (ESI) 493 (MH)⁺.

(±)-4-Oxo-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butyricacid methyl ester

Prepared as described above for(±)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid methyl ester. MS (ESI) 479 (MH)⁺.

(±)-4-Oxo-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butyricacid

Prepared as described above for(±)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid. MS (ESI) 465 (MH)⁺.

(±)-4-Oxo-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyricacid

Prepared as described above for(±)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid. MS (ESI) 479 (MH)⁺.

Example 256(±)-1-(4-Cyclohexyl-piperazin-1-yl)-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.10 min, 629 (MH)⁺.

Example 257(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.08 min, 629 (MH)⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.89 (1H,s), 8.28 (1H, d, J=11.2 Hz), 6.90-7.25 (5H, m), 6.75 (1H, d, J=8.0 Hz),4.40-4.79 (3H, m), 4.35 (2H, s), 2.27-3.98 (19H,m), 1.46-2.10 (9H, m),1.36 (1H, m), 1.08 (1H, m), 0.12 (1H, m).

Example 258(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butane-1,4-dione

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.02 min, 615 (MH)⁺.

Example 259(±)-1-(4-cyclohexyl-piperazin-1-yl)-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butane-1,4-dione

Prepared as described above for(±)-1-[1,4′]bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione.LC/MS: t_(R)=1.04 min, 615 (MH)⁺.

Example 260(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(4-cyclohexyl-piperazin-1-yl)-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 16. ¹H-NMR (CD₃OD, 500 MHz) δ0.81 (1H, m), 0.89 (1H, m), 1.02 (1H, m), 1.1-2.0 (12H, m), 2.23 (1H,d), 2.47 (1H, d), 2.61 (3H, s), 2.90 (4H, t), 3.08 (4H, m), 3.2-3.5 (4H,m), 3.82 (1H, m), 4.14 (2H, d), 4.29 (2H, s), 4.40 (1H, t), 6.80 (1H,d), 6.95 (1H, t), 7.12 (3H, m), 7.47 (1H, s), 8.01 (1H, s). Mass spec.:627.47 (MH)⁺.

Example 261(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[4-(4-fluoro-phenyl)-piperazin-1-yl]-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

Prepared as described above for Example 16. LC/MS: t_(R)=2.34 min,621.42 (MH)⁺.

Example 262(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid tert-butyl ester

A solution of(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid (50 mg, 0.105 mmol) and dicyclohexylcarbodiimide (25 mg, 0.12 mmol)in dimethylformamide was stirred for 30 min at room temperature, andthen pentafluorophenol (26 mg, 1.3 mmol) was added. Stirring wascontinued at room temperature overnight, and then the solvent wasremoved, the residue was dried under high vacuum for 4 h. The crudepentafluorophenyl ester was used without further purification in thenext step.

To a solution of tert-butyl alcohol (10 equiv.) in tetrahydrofuran at−78° C. under nitrogen was added 1.4M sec-butyllithium in cyclohexane(10 equiv.). After 10-15 min, a solution of pentafluorophenol ester (1equiv.) in tetrahydrofuran was added. The reaction mixture was stirredat room temperature overnight. The solvents were removed in vacuo, andthe residue was purified by preparative-HPLC to give the desiredcompound. ¹H-NMR(CD₃OD) δ 1.40 (s, 9H) 1.56 (m, 4H), 2.54 (s, 3H) 2.85(m, 2H) 3.05 (m, 1H) 3.19 (m, 1H) 4.14 (m, 4H) 4.44 (m, 2H) 6.76 (d,J=7.68 Hz, 1H) 6.93 (t, J=7.5 Hz, 1H) 7.10 (m, 3H) 7.14 (s, 1H) 7.97 (s,1H). LC/MS: t_(R=)2.19 min, 533.36 (MH)⁺.

Example 263(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-methyl cyclohexyl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid tert-butyl ester. LC/MS: t_(R=)2.47 min, 574.39 (MH)⁺.

Example 264(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-aza-bicyclo[2.2.2]oct-3-yl ester

To a solution of(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid (50 mg, 0.105 mmol), EDCI (100 mg), and 4-dimethylaminopyridine(0.2 equiv.) in dimethylformamide was added aza-bicyclo[2.2.2]oct-3-ylalcohol (0.525 mmol, 5 equiv.). The mixture was stirred at roomtemperature overnight. The solvent was removed in vacuo and the residuewas dissolved in ethyl acetate, washed with brine, dried over magnesiumsulfate, and purified by preparative HPLC to yield the desired compound.LC/MS: t_(R)=1.62 min, 586.41 (MH)⁺.

Example 265(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid piperidin-4-yl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-aza-bicyclo[2.2.2]oct-3-yl ester. LC/MS: t_(R)=1.58 min, 560.37(MH)⁺.

Example 266(±)-4-(3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionyloxy)-piperidine-1-carboxylicacid tert-butyl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-aza-bicyclo[2.2.2]oct-3-yl ester. LC/MS: t_(R=)2.38 min, 660.42(MH)⁺.

Example 267(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-aza-bicyclo[2.2.2]oct-3-yl ester. LC/MS: t_(R)=1.67 min, 637.43(MH)⁺.

Example 268(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid 1-diethylamino-1-methyl-ethyl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-aza-bicyclo[2.2.2]oct-3-yl ester. LC/MS: t_(R)=1.66 min, 590.44(MH)⁺.

Example 269(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1,1-dimethyl-2-phenyl-ethyl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid t-butyl ester. LC/MS: t_(R)=2.52 min, 609.46 (MH)⁺.

Example 270(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1,1-dimethyl-3-phenyl-propyl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid t-butyl ester. LC/MS: t_(R)=2.61 min, 623.48 (MH)⁺.

Example 271(±)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid ethyl ester

Prepared as described above for(±)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid t-butyl ester. LC/MS: t_(R)=1.98 min, 505.32 (MH)⁺.

Example 272(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1-pyridin-4-yl-methyl]-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide

Prepared as described above for Example 16. LC/MS: t_(R)=1.49 min,553.12 (MH)⁺.

Example 273(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1-pyridin-4-yl-piperazinyl]-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide

Prepared as described above for Example 16. LC/MS: t_(R)=1.56 min,608.18 (MH)⁺.

Example 274(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[(2-dimethylamino-ethyl-ethylcarbamoyl)-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide

Prepared as described above for Example 16. LC/MS: t_(R)=1.58 min,561.20 (MH)⁺.

Example 275(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1-pyridin-4-yl-piperazinyl]-2-oxoethyl]-11′,2′-dihydro-2′-oxospiro-[4H-3′1-benzoxazine-4,4′-piperidine]-1-carboxamide

Prepared as described above for Example 16. LC/MS: t_(R)=1.56 min,609.14 (MH)⁺.

Example 276(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1-pyridin-2-yl-piperazinyl]-2-oxoethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide

Prepared as described above for Example 16. LC/MS: t_(R)=1.57 min,609.17 (MH)⁺.

Example 277(R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3yl)-piperidine-1d-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-ethyl]amide

Prepared as described above for Example 16. ¹H-NMR (CD₃OD, 500 MHz) δ−0.27 (1H, m), 0.75 (1H, m), 1.1-2.0 (12H, m), 2.10 (2H, m), 2.4-2.5(3H, m), 2.57 (3H, s), 2.68 (2H, m), 2.92 (4H, m), 3.10 (4H, m), 3.9-5.1(4H, several m), 6.82 (1H, d), 6.96 (1H, t), 7.18 (3H, m), 7.50 (1H, s),8.05 (1H, s). LC/MS: t_(R)=1.68 min, 627.42 (MH)⁺.

Example 278(R)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide

Prepared as descr ibed above for Example 16. LC/MS: t_(R)=1.63 min,613.36 (MH)⁺.

Among other compounds envisaged within the present invention and capableof being made according to the description provided herein or thosemethods known to those skilled in the art include the followingprophetic examples:

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-bromo-1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-piperidin-1-yl-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(4-methyl-piperazin-1-yl)-2-oxo-1-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-methyl-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(4-methyl-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-2-piperidin-1-yl-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(4-chloro-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-2-piperidin-1-yl-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-dimethylcarbamoyl-2-(4-methyl-2-oxo-2,3-dihydro-benzooxazol-6-yl)-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(4-chloro-2-oxo-2,3-dihydro-benzooxazol-6-yl)-1-dimethylcarbamoyl-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(4-methyl-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[1-(4-chloro-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(4-ethyl-2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-methyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-chloro-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-ethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(3-methyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(3,7-dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-[1,4′]bipiperidinyl-1′-yl-1-(7-ethyl-3-methyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethyl)-2-oxo-ethyl]-amide

3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid isopropyl ester

3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid isopropyl ester

3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid isopropyl ester

3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid tert-butyl ester

3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid tert-butyl ester

3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid cyclohexyl ester

3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid cyclohexyl ester

3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-methyl-piperidin-4-yl ester

3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-methyl-piperidin-4-yl ester

3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-methyl-cyclohexyl ester

3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 1-methyl-cyclohexyl ester

3-(7-Chloro-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 4-phenyl-cyclohexyl ester

3-(7-Ethyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionicacid 4-phenyl-cyclohexyl ester

CGRP Binding Assay

Tissue Culture. SK-N-MC cells were grown at 37° C. in 5% CO₂ as amonolayer in medium consisting of MEM with Earle's salts and L-glutamine(Gibco) supplemented with 10% fetal bovine serum (Gibco).

Cell Pellets. The cells were rinsed twice with phosphate-buffered saline(155 mM NaCl, 3.3 mM Na₂HPO₄, 1.1 mM KH₂PO₄, pH 7.4), and incubated for5-10 min. at 4° C. in hypotonic lysis buffer consisting of 10 mM Tris(pH 7.4) and 5 mM EDTA. The cells were transferred from plates topolypropylene tubes (16×100 mm) and homogenized using a polytron.Homogenates were centrifuged at 32,000×g for 30 min. The pellets wereresuspended in cold hypotonic lysis buffer with 0.1% mammalian proteaseinhibitor cocktail (Sigma) and assayed for protein concentration. TheSK-N-MC homogenate was then aliquoted and stored at −80° C. untilneeded.

Radioligand Binding Assay. The compounds of invention were solubilizedand carried through serial dilutions using 100% DMSO. Aliquots from thecompound serial dilutions were further diluted 25 fold into assay buffer(50 mM Tris-Cl pH 7.5, 5 mM MgCl₂, 0.005% Triton X-100) and transferred(volume 50 μl) into 96 well assay plates. [¹²⁵I]-CGRP (AmershamBiosciences) was diluted to 60 pM in assay buffer and a volume of 50 μlwas added to each well. SK-N-MC pellets were thawed, diluted in assaybuffer with fresh 0.1% mammalian protease inhibitor cocktail (Sigma),and homogenized again. SK-N-MC homogenate (5 μg/well) was added in avolume of 100 μl. The assay plates were then incubated at roomtemperature for 2 h. Assays were stopped by addition of excess cold washbuffer (20 mM Tris-Cl pH 7.5, 0.1% BSA) immediately followed byfiltration over glass fiber filters (Whatman GF/B) previously soaked in0.5% PEI. Non-specific binding was defined with 1 μM beta-CGRP. Proteinbound radioactivity was determined using a gamma or scintillationcounter. The IC₅₀ was defined as the concentration of a compound ofinvention required to displace 50% of radioligand binding.

In the table below, results are denoted as follows: A≦10 nM; 10 nM<B≦100 nM; 100 nM<C≦1000 nM; D>1000 nM. TABLE 4 CGRP Binding, cAMPFunction and Ex Vivo Human Cerebral Artery Data cAMP Cerebral CGRPbinding¹ Function² Artery³ Example # IC₅₀ (nM) IC₅₀ (nM) EC₅₀ (nM)  1C * *  2 A A A  3 B B B  4 B B *  5 A A *  6 A A A  7 C C *  8 C C *  9B B *  10 C B *  11 B B *  12 B C *  13 C * *  14 D * *  15 C C *  16 AA A  17 A A A  18 A B A  19 A A A  20 A A A  21 A A A  22 A A *  23 A AA  24 B B *  25 A A A  26 B B *  27 B C *  28 C * *  29 A * *  30 B * * 31 A A *  32 C * *  33 C * *  34 A A *  35 B B *  36 B B *  37 A B * 38 B B *  39 C C *  40a A A *  40b B * *  40c D * *  40d C * *  40eD * *  40f D * *  40g D * *  40h D * *  40i B * *  40j D * *  40k D * * 41a B * *  41b A * *  41c A * *  41d B * *  41e A * *  41f B * *  42C * *  43 A A A  44 C * *  45 A * *  46 B B *  47 A A A  48 D * *  49A * *  50 A * *  51 D * *  52 D * *  53 D * *  54 B C A  55 C * *  56 AA *  57 C * *  58 D * *  59 C * *  60 C * *  61 C C *  62 B B *  63 CC *  64 B * B  65 A B B  66 C * *  67 B C B  68 A A A  69 A A A  70 A AA  71 A A A  72 A A A  73 B B *  74 A A A  75 A B *  76 B B A  77 B B * 78 A A *  79 B C *  80 C * *  81 B C *  82 B C *  83 B C *  84 B B * 85 C * *  86 C B C  87 B B *  88 C B *  89 C B *  90 B * *  91 C * * 92 B C *  93 C * *  94 C C *  95 C * *  96 D * *  97 D * *  98 D * * 99 D D * 100 C * * 101 D * * 102 C * * 103 C * * 104 C * * 105 C * *106 C * * 107 C * * 108 C * * 109 C * * 110 C * * 111 C * * 112 C * *113 C * * 114 C * * 115 C * * 116 C * * 117 C * * 118 C * * 119 C * *120 C * * 121 C * * 122 C * * 123 B * * 124 C * * 125 C * * 126 C * *127 C * * 128 C * * 129 C * * 130 C * * 131 C * * 132 C * * 133 C * *134 C * * 135 C * * 136 C * * 137 C * * 138 C * * 139 C * * 140 B * *141 C * * 142 C * * 143 C * * 144 C * * 145 C * * 146 B * * 147 C * *148 B * * 149 B * * 150 B * * 151 C * * 152 C * * 153 C * * 154 C * *155 C * * 156 C * * 157 C * * 158 B * * 159 B * * 160 C * * 161 B * *162 C * * 163 C * * 164 C * * 165 C * * 166 C * * 167 C * * 168 C * *169 C * * 170 C * * 171 B * * 172 B * * 173 C * * 174 C * * 175 C * *176 B * * 177 B * * 178 B * * 179 C * * 180 C * * 181 C * * 182 C * *183 C * * 184 B * * 185 C * * 186 C * * 187 C * * 188 C * * 189 C * *190 C * * 191 C * * 192 C * * 193 B * * 194 C * * 195 C * * 196 B * *197 C * * 198 C * * 199 B * * 200 B * * 201 C * *Cyclic AMP Assay

Functional Antagonism. Antagonism of the compounds of invention wasdetermined by measuring the formation of cyclic AMP (adenosine3′5′-cyclic monophosphate) in SK-N-MC cells that endogenously expressthe human CGRP receptor. CGRP receptor complex is coupled with Gsprotein and CGRP binding to this complex leads to the cyclic AMPproduction via Gs-dependent activation of an adenylate cyclase (JuanedaC et al., TiPS, 2000; 21:432-438; incorporated by reference herein).Consequently, CGRP receptor antagonists inhibit CGRP-induced cyclic AMPformation in SK-N-MC cells (Doods H et al., Br J Pharmacol, 2000;129(3):420-423); incorporated by reference herein). For cyclic AMPmeasurements SK-N-MC cells were incubated with 0.3 nM CGRP alone or inthe presence of various concentrations of the compounds of invention for30 min at room temperature. Compounds of invention were pre-incubatedwith SK− N-MC cells for 15 min before the addition of CGRP to allowreceptor occupancy (Edvinsson et al., Eur J Pharmacol, 2001, 415:39-44;incorporated by reference herein). Cyclic AMP was extracted using thelysis reagent and its concentration was determined by radioimmunoassayusing RPA559 cAMP SPA Direct Screening Assay Kit (Amersham PharmaciaBiotech). IC50 values were calculated using Excel fit. The testedcompounds of invention were determined to be antagonists as theyexhibited a dose-dependent inhibition of the CGRP-induced cyclic AMPproduction. See Table 3 for summary of results.

Schild Analysis. Schild analysis can be used to characterize the natureof antagonism of the compounds of invention. The dose response of CGRPstimulated cAMP production was generated either with CGRP alone, or inthe presence of various concentrations of compounds of invention. Theantagonist dose is plotted as X against the dose ratio (defined as IC50of agonist with the presence of the compounds divided by the IC50 of theagonist alone) minus 1 as Y. Linear regression was then performed withboth X and Y axis log-transformed. A slope that does not differsignificantly from unity (1) indicates competitive antagonism. K_(b) isthe dissociation constant of the antagonist. TABLE 5 Schild AnalysisExample # K_(b)(nM) slope 2 0.16 0.94 3 55 0.96 5 3 0.92 6 0.36 0.93 161.3 17 1.1 0.92 18 1 0.8 21 0.018 0.89 43 0.018 1.2 45 1.4 47 0.1 0.9369 0.016 1 70 0.71 71 2 0.87

See FIG. 1. Schild Analysis

Ex Vivo Human Cerebral Artery Assay

Rationale and Overview. To provided direct evidence of the ability fornovel compounds to reverse CGRP-induced dilation in human cerebralvessels, an ex vivo assay was design. Briefly, isolated vessel ringswere mounted in a tissue bath where vessels were pre-contracted withpotassium chloride (KCl) and fully dilated with hCGRP, then thisrelaxation was reversed by the cumulative addition of CGRP-receptorantagonists (complete details follow).

Tissue Samples. Autopsy samples of human arteries were obtained fromvendors (ABS Inc. or NDRI). All vessels were transported on ice-coldHEPES buffer (composition in mM: NaCl 130, KCl 4, KH2PO4 1.2, MgSO4 1.2,CaCl2 1.8, Glucose 6, NaHCO3 4, HEPES 10, EDTA 0.025). Upon receipt, thevessels were placed in cold Kreb's buffer (composition in mM: NaCl118.4, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 1.8, Glucose 10.1, NaHCO325) saturated with carbogen (5% CO₂ and 95% oxygen).

Isolated Tissue Baths. The vessels were cleaned of connective tissuesand cut into cylindrical segments of 4-5 mm in length. The vessels werethen mounted in tissue baths between two stainless steel hooks; one ofwhich is fixed and the other of which was connected to a forcedisplacement transducer. The vessel tension was continuously recordedusing a data acquisition system (Powerlab, ADInstruments, Mountain View,Calif.) connected to the transducer. The tissue baths containing Krebsbuffer and mounted vessels were temperature (37° C.) and pH (7.4)controlled with continuous bubbling of carbogen. The artery segmentswere allowed to equilibrate for about 30-45 min until a stable restingtone was achieved. Prior to the assay, vessels were primed (conditioned)with 100 mM KCl and subsequently washed. The vessels were pre-contractedwith 10 mM KCl and fully dilated with 1 nM hCGRP. Concentration-responsecurves to CGRP-receptor antagonists were performed by the cumulativeaddition of drugs in half log units in fully dilated vessels. At eachconcentration, the effects of the drugs were expressed as % reversal ofCGRP-induced relaxation in each vessel. The actual assay and dataanalysis were performed for each vessel individually, fitting theconcentration-response data to a four parameter logistic function bynon-linear regression analysis, to estimate the EC50 values. A summaryof results is provided in Table 3.

Non-Terminal Method for Assessing In Vivo Efficacy of Small MoleculeCGRP-receptor Antagonists in Mammals

Overview. Blocking cerebral artery dilation induced by calcitoningene-related peptide (CGRP) has been proposed as a treatment formigraine headache, however, novel small molecule CGRP-receptorantagonists have shown species-specific differences with relatively pooractivity in rodents (Mallee et al. J Biol Chem 2002 277:14294) requiringnew models for assessment of in vivo efficacy. Non-human primates (e.g.,marmosets) are the only animals known to have human-like CGRP receptorpharmacology conferred by the presence of the specific amino acidresidue (Trp74) in their RAMP1 sequence which is responsible for thephenotype of the human receptor (Mallee et al. J Biol Chem 2002277:14294). Since current migraine models primarily use rats (Escott etal. Brain Res 1995 669:93; Williamson et al. Cephalalgia 1997 17:525),or are invasive, terminal procedures in primates (Doods et al. Br JPharmacol 2000 129:420), a novel non-invasive, survival model innon-human primates for in vivo efficacy assessment of CGRP-receptorantagonists as in the present invention is a significant contribution.While it is known that trigeminal activation increases both cerebral(Goadsby & Edvinsson, 1993) and facial blood flow (Doods et al., 2000),demonstration of a direct relationship between facial blood flow andcerebral artery dilation conducted in the same animals was not known.Therefore, before initiating studies in non-human primates, laserDoppler measurement of facial blood flow was directly validated in therat as a surrogate for cerebral artery dilation in terminal studies thatmeasured both cerebral artery diameter and changes in facial blood flowin the same animals (see FIG. 2. Direct Validation of Facial Blood Flowas Surrogate for Cerebral Artery Dilation in the Rat). In both measures,comparable increases were induced by i.v. CGRP and blocked by thepeptide antagonist hαCGRP(8-37). Next, A compound of i.v. CGRP-inducedchanges in facial blood flow was validated as a recovery model inisoflurane anesthetized rats using hαCGRP(8-37). The survival method wasthen established in non-human primates and a dose-response studycharacterizing i.v. CGRP activity was completed (see FIG. 3.Dose-Response for hαCGRP in Non-Human-Primate Laser Doppler Facial BloodFlow). Peptide and small-molecule CGRP-receptor antagonists were used tovalidate the non-human primate model. Pre-treatment with small moleculeantagonists or hαCGRP(8-37) dose-dependently inhibited i.v.CGRP-stimulated increases in primate facial blood flow (see FIG. 4.Inhibitition of CGRP-Induced Changes in Non-Human Primate Facial BloodFlow), without altering blood pressure (see FIG. 5. Effect of CGRPAntagonist on Non-Human Primate Blood Pressure). Post-treatment ofantagonists also reversed CGRP-induced increases in facial blood flow(not shown). This survival model provides a novel, non-invasive recoveryprocedure for evaluating prophylactic and abortive effects ofCGRP-receptor antagonists in non-human primates, or in transgenicanimals with humanized RAMP1 (Trp74) which have similar CGRP receptorpharmacology, as a surrogate marker for activity in cerebral vesseldiameter.

Animals. Adult male and female common marmosets (Callithrix jacchus)purchased from Harlan and weighing 350-550 g served as subjects. Othermammals endogenously expressing RAMP1 having Trp 74 or transgenicmammals with humanized RAMP1 having Trp 74 can also be employed in Acompound described herein.

Anesthesia & Surgical Preparation. Animals are anesthetized byisoflurane inhalation in an induction chamber (4-5% rapid induction,maintained with 1-2.5%; Solomon et al., 1999). Anesthesia is maintainedby delivering a constant supply of air:oxygen (50:50) and isoflurane viaface mask, or by intubation and ventilation (with blood gas monitoring).Body temperature is maintained at 38±0.5° C. by placement on anautomated temperature controlled surface with rectal probe. A small areaof fur (approx. 1.5 cm square) is removed from one or both sides of theface by application of a depilatory cream and/or shaving. Surgical areasare clipped and prepared with betadine. An i.v. line is placed in anyaccessible vein for the administration of test compounds andCGRP-receptor agonist and, if needed, withdrawal of blood samples (max2.5 ml, 10%) for blood gas monitoring and content analysis. A solutionof 5% dextrose is administered i.v. in order to maintain blood sugarlevels. Anesthesia depth is monitored by measuring blood pressure andheart rate using a non-invasive arm cuff method and a pulse oximeter,respectively. Guanethidine 5-10 mg/kg i.v., supplemented with 5 mg/kgi.v. as needed, may be given to stabilize the peak flux in facial bloodflow seen with repeated stimulation-induced changes in blood flow(Escott et al., 1999; incorporated by reference herein). Microvascularblood flow is monitored by attaching a self adhesive laser Doppler flowprobe to the facial skin.

Compound Administration Test compounds may be administered i.v. (0.01-5ml/kg), i.m. (0.01-0.5 ml/kg), s.c. (0.01-5 ml/kg) or p.o. (0.1-10ml/kg) (Diehl et al., 2001; incorporated by reference herein).CGRP-receptor agonists may be delivered i.v. (0.01-5 ml/kg), i.d.(10-100 μl/site) or s.c. (10-100 μl/site).

Laser Doppler Flowmetry A control increase in facial blood flow isinduced by administration of a vasodilator, such as CGRP (0.05-100 μg/kgi.v.) or 2-20 pmol/site i.d) or adrenomedullin (ADM, 0.05-5 mg/kg i.v.or 10-100 pmol/site i.d.). Test compound or vehicle is administeredeither before (pre-treatment) or after (post-treatment) subsequentrepeat administration of the vasodilating agent, providing the abilityto assess prophylactic or therapeutic actions. Blood pressure ismonitored continuously to ensure adequate depth of anesthesia, andanesthetic is adjusted to maintain stable levels that matchpre-treatment values. During collection of laser Doppler flowmetry data,isoflurane may be reduced to 0.25-0.75% as previous electrophysiologicstudies in marmosets found that recordings were sensitive to isofluraneconcentration (Solomon, 1999; incorporated by reference herein). Toreduce the number of animals used, the effect of test compound on i.v.vasodilator-induced changes in blood flow may be repeated up to 6 timesin a single session.

Recovery Animals are returned to the transport cage which is placed on atemperature controlled surface to keep the animals warm until fullyawake and ambulatory. Animals may be tested again after 7-14 days rest,and may be tested repeatedly at 7-14 day intervals depending on thehealth of the animal.

See Diehl K H, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D,Vidal J M, van de Vorstenbosch C. A good practice guide to theadministration of substances and removal of blood, including routes andvolumes. J Appl Toxicol. 2001 January-February;21(1):15-23; Doods H,Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W.Pharmacological profile of BIBN4096BS, the first selective smallmolecule CGRP-receptor antagonist. Br J Pharmacol. 2000February;129(3):420-3; Edvinsson L. Calcitonin gene-related peptide(CGRP) and the pathophysiology of headache: therapeutic implications.CNS Drugs 2001; 15(10):745-53; Escott K J, Beattie D T, Connor H E,Brain S D. Trigeminal ganglion stimulation increases facial skin bloodflow in the rat: a major role for calcitonin gene-related peptide. BrainRes. 1995 Jan. 9; 669(1):93-9; Goadsby P J, Edvinsson L. Thetrigeminovascular system and migraine: studies characterizingcerebrovascular and neuropeptide changes seen in humans and cats. AnnNeurol. 1993 January;33(1):48-56; Lassen L H, Haderslev P A, Jacobsen VB, Iversen H K, Sperling B, Olsen J. CGRP may play a causative role inmigraine. Cephalalgia, 2002, 22, 54-61; Mallee J J, Salvatore C A,LeBourdelles B, Oliver K R, Longmore J, Koblan K S, Kane S A. RAMP1determines the species selectivity of non-peptide CGRP receptorantagonists. J Biol Chem. 2002 Feb. 14 [epub ahead of print]; Solomon SG, White A J, Martin P R. Temporal contrast sensitivity in the lateralgeniculate nucleus of a New World monkey, the marmoset Callithrixjacchus. J Physiol. 1999 Jun. 15; 517 (Pt 3):907-17; all incorporated byreference herein.

Departures from Other Migraine Models. This invention represents a novelmigraine model and is remarkably distinct from other migraine models.Some of the distinguishing characteristics of A compound of the presentinvention include: (i) the only survival model of migraine in anyspecies; (ii) the only model to demonstrate the abortive(post-treatment) effects of CGRP antagonists on active induced increasesin blood flow; (iii) the only demonstration of a direct relationshipbetween facial blood flow and intracranial artery dilation carried outin the same animals; (iv) the only model to use non-invasive surgicaltechniques, and does not require catheter placement, intubation, orneuromuscular blockade; (v) the only primate model to use exogenous CGRPas the stimulus and demonstrate pretreatment blockade by CGRP antagonismand post-treatment reversal by CGRP antagonism; (vi) the only migrainemodel to use isoflurane anesthesia in spontaneously breathing animals.The models described in Williamson et al., Sumatriptan inhibitsneurogenic vasodilation of dural blood vessels in the anaesthetizedrat-intravital microscope studies. Cephalalgia. 1997 June; 17(4):525-31;Williamson D J, Hargreaves R J, Hill R G, Shepheard S L. Intravitalmicroscope studies on the effects of neurokinin agonists and calcitoningene-related peptide on dural vessel diameter in the anaesthetized rat.Cephalalgia. 1997 June;17(4):518-24; Escott K J et al., Trigeminalganglion stimulation increases facial skin blood flow in the rat: amajor role for calcitonin gene-related peptide. Brain Res. 1995 Jan. 9;669(1):93-9; Chu D Q et al., The calcitonin gene-related peptide (CGRP)antagonist CGRP(8-37) blocks vasodilatation in inflamed rat skin:involvement of adrenomedullin in addition to CGRP. Neurosci Lett. 2001Sep. 14; 310(2-3):169-72; Escott K J, Brain S D. Effect of a calcitoningene-related peptide antagonist (CGRP8-37) on skin vasodilatation andoedema induced by stimulation of the rat saphenous nerve. Br JPharmacol. 1993 October; 110(2):772-6; Hall J M, Siney L, Lippton H,Hyman A, Kang-Chang J, Brain S D. Interaction of human adrenomedullin13-52 with calcitonin gene-related peptide receptors in themicrovasculature of the rat and hamster. Br J Pharmacol. 1995 February;114(3):592-7; Hall J M, Brain S D. Interaction of amylin with calcitoningene-related peptide receptors in the microvasculature of the hamstercheek pouch in vivo. Br J Pharmacol. 1999 January; 126(1):280-4; andDoods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, EberleinW. Pharmacological profile of BIBN4096BS, the first selective smallmolecule CGRP-receptor antagonist. Br J Pharmacol. 2000February;129(3):420-3 fail to possess the remarkable features of Acompound of the present invention.

In the table below, results are denoted as follows: W≦25%; 25%<X≦50%;50%<Y≦75%; Z>75%. TABLE 6 Inhibition of CGRP-Induced Increase in LaserDoppler Facial Blood Flow in the Non-Human Primate (e.g., CommonMarmoset) Non-Human Primate (% Inhibition) of CGRP-induced (10 μg/kg,iv) increase in laser Doppler facial blood flow 0.01 0.03 mg/kg, 0.1mg/kg, 0.3 mg/kg, 1 mg/kg, Example # mg/kg, iv iv iv iv iv  2 W X X Y Z 6 Z 16 Y 69 Y Z hαCGRP Z (8-37) W ≦ 25%; 25% < X ≦ 50%; 50% < Y ≦ 75%;Z > 75%.

See FIG. 5. Effect of CGRP Antagonist on Non-Human Primate BloodPressure.

1. A compound according to Formula (I)

or a pharmaceutically acceptable salt thereof wherein V is —N(R¹)(R²) orOR¹; R⁴ is H, C₁₋₆alkyl, C₁₋₄haloalkyl or (C₁₋₄alkylene)₀₋₁R^(4′) R^(4′)is C₃₋₇cycloalkyl, phenyl, adamantyl, quinuclidyl,azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl,dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl,pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl, pyridyl,pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, piperidinyl,piperazinyl, morpholino, thiomorpholino or dioxolanyl; and R^(4′) isoptionally substituted with 1 or 2 of the same or different substituentsselected from the group consisting of halo, cyano, C₁₋₄alkyl,C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy, amino, C₃₋₇cycloalkyl, C₁₋₃alkylamino, C₁₋₃dialkylamino, (C₁₋₃alkyl)₀₋₂ureido, phenyl and benzyl;and R^(4′) optionally contains 1 or 2 carbonyls wherein the carbon atomof said carbonyl is a member of the ring structure of R^(4′); R¹ and R²are each independently L¹, wherein L¹ is selected from the groupconsisting of H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl,—C₁₋₆alkylene-amino(C₁₋₃alkyl)₂, C₃₋₇cycloalkyl, phenyl, azetidinyl,adamantyl, tetrahydrofuranyl, furanyl, dioxolanyl, thienyl,tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl,imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl,thiadiazolyl, triazolyl, pyranyl, pyridyl, pyrimidinyl, pyrazinyl,pyridazinyl, triazinyl, piperidinyl, piperazinyl, morpholino,thiomorpholino and dioxolanyl; and R¹ and R² are each optionally andindependently substituted with 1 or 2 of the same or differentsubstituents selected from the group consisting of halo, cyano,C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, hydroxy, amino, C₃₋₇cycloalkyl,C₁₋₃alkylamino, C₁₋₃dialkylamino, (C₁₋₃alkyl)₀₋₂ureido, phenyl andbenzyl; R¹ and R² optionally and independently contain 1 or 2 carbonylswherein the carbon atom of said carbonyl is a member of the heterocyclescomprising R¹ and R²; wherein L¹ is optionally and independentlyinterrupted from the nitrogen to which it is attached by L², wherein L²is independently C₁₋₃alkylene or C₁₋₃ alkylidene; or R¹ and R² togetherwith the nitrogen to which they are attached form X, wherein X isazetidinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolinyl,imidazolidinyl, pyrazolinyl, pyrazolidinyl, azepinyl, diazepinyl,piperazinyl, piperidinyl, morpholino or thiomorpholino; wherein X isoptionally substituted with Y, wherein Y is dioxolanyl, C₁₋₉alkyl,C₂₋₉alkenyl, C₂₋₉ alkynyl, C₁₋₄alkylamino, C₁₋₄dialkylamino, C₁₋₄alkoxy,C₃₋₇cycloalkyl, phenyl, azetidinyl, furanyl, thienyl, pyrrolyl,pyrrolinyl, pyrrolidinyl, pyrrolidinonyl, imidazolyl, imidazolinyl,imidazolidinyl, imidazolidinonyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,azepinyl, diazepinyl, pyridyl, pyrimidinyl, dihydrobenzimidazolonyl,piperazinyl, piperidinyl, morpholino, benzothiazolyl, benzisothiazolylor thiomorpholino; and wherein X and Y are  optionally interrupted withZ, wherein Z is —NHC(O)O—, —NHC(O)NH—, NC(O)NH₂, —NH—, —C₁₋₃alkylene-,C₁₋₃ alkenylene-NHC(O)O—C₁₋₃ alkylene-; and  optionally andindependently substituted with 1 or 2 of the same or differentsubstituents selected from the group consisting of C₁₋₄alkyl, amino,C₁₋₃alkylamino, —C₁₋₆alkylene-amino(C₁₋₃ alkyl)₂, (C₁₋₃alkyl)₀₋₂ureido,phenyl and benzyl;  X and Y optionally and independently contain 1 or 2carbonyls wherein the carbon atom of said carbonyl is a member of theheterocycles comprising X and Y; provided that if X is substituted withY, and if X and Y are not interrupted with Z, then  X and Y optionallyshare one carbon atom and together form a spirocyclic moiety; Q is Q′ orQ″; wherein Q′ is (S^(y))_(s)R³; and Q″ is NH(S^(y))_(s)R³,NHC(O)(S^(y))_(s)R³, NHC(O)O(S^(y))_(s)R³, NHC(O)NH(S^(y))_(s)R³,O(S^(y))_(s)R³, (S^(y))_(s)NHR³, (S^(y))_(s)NHC(O)R³,(S^(y))_(s)NHC(O)OR³, (S^(y))_(s)NHC(O)NHR³ or (S^(y))_(s)OR³; whereinS^(y) is C₁₋₃alkylene or C₁₋₃alkylidene and s is 0 or 1; U is CH₂ or NH;provided that if Q is Q″, then U is CH₂; R³ is R^(3a) or R^(3b) whereinR^(3a) is (i) a heterocycle having two fused rings with 5 to 7 membersin each of said rings, said heterocycle containing one to five of thesame or different heteroatoms selected from the group consisting of O, Nand S and said heterocycle optionally containing 1 or 2 carbonylswherein the carbon atom of said carbonyl is a member of said fusedrings; (ii) a 4 to 6 membered heterocycle containing one to three of thesame or different heteroatoms selected from the group consisting of O, Nand S, optionally containing 1 to 2 carbonyls, wherein the carbon atomof said carbonyl is a member of said 4 to 6 membered heterocycle; (iii)C₃₋₇cycloalkyl; (iv) carbazolyl, fluorenyl, phenyl, —O-phenyl, —O—C₁₋₄alklylene-phenyl, or napthyl; or (v) C₁₋₈alkyl, C₂₋₇alkenyl,—C(O)R^(3′), CHC(O)O—R^(3′), CH(CH₃)C(O)O—R^(3′), —C(O)O—R^(3′) orC₂₋₇alkynyl; and wherein R^(3a) is optionally substituted with 1 to 3 ofthe same or different substituents selected from the group consisting ofbenzyl, phenyl, —O-phenyl, —O—C₁₋₃alkylenephenyl,—C₁₋₃alkylene-OC(O)-phenyl, cyano, amino, nitro, halo, C₁₋₆alkyl,C₁₋₃mono-bi-tri-haloalkyl, C₁₋₃mono-bi-tri-haloalkyloxy, (C₁₋₃alkyl)₁₋₂amine, —OR^(3′), —C(O)R^(3′), —C(O)O—R^(3′),—O—C(O)R^(3′)—N(R^(3′))₂, —C(O)N(R^(3′))₂, —N(R^(3′))C(O)(R^(3′))₂,—N(R^(3′))C(O)N(R^(3′))₂, —N(R^(3′))C(O)OR^(3′), —O—C(O)N(R^(3′))₂,—N(R^(3′))SO₂R^(3′), —SO₂N(R^(3′))₂ and —SO₂R^(3′); R^(3′) is H or—C₁₋₆alkyl; provided that if R^(3a) is, —C(O)R^(3′), CHC(O)O—R^(3′),CH(CH₃)C(O)O—R^(3′) or —C(O)O—R^(3′), then said —C(O)R^(3′),CHC(O)O—R^(3′), CH(CH₃)C(O)O—R^(3′) or —C(O)O—R^(3′) are unsubstituted;R^(3b) is R^(3a) but is not phenyl, 1-naphthyl, 2-naphthyl,1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl,1-formyl-1H-indol-3-yl, 1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl,4-imidazolyl, 1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl,1H-indazol-3-yl, 1-methyl-1H-indazol-3-yl, benzo[b]fur-3-yl,benzo[b]thien-3-yl, pyridinyl, quinolinyl or isoquinolinyl; optionallysubstituted in the carbon skeleton with mono-, di- or trisubstituted byfluorine, chlorine or bromine atoms or by branched or unbranched alkylgroups, C₃₋₈-cycloalkyl groups, phenylalkyl groups, alkenyl, alkoxy,phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonylalkyl,carboxyalkyl, alkoxycarbonyl, carboxy, dialkylaminoalkyl,dialkylaminoalkoxy, hydroxy, nitro, amino, acetylamino, propionylamino,benzoyl, benzoylamino, benzoylmethylamino, methylsulphonyloxy,aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl,cyano, tetrazolyl, phenyl, pyridinyl, thiazolyl, furyl,trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- ortrifluoromethylsulphonyl groups; wherein said substituents may be thesame or different and the above-mentioned benzoyl, benzoylamino- andbenzoylmethylamino groups may in turn additionally be substituted in thephenyl moiety by a fluorine, chlorine or bromine atom, or by an alkyl,trifluoromethyl, amino or acetylamino group; D is O, NCN orNSO₂C₁₋₃alkyl; A is C; m and n are each 1; E is N, CH or C; p is 0; G, Jand E together form A^(x); A^(x) is a fused heterocycle having two fusedrings with 5 to 7 members in each of said rings, said heterocyclecontaining one to four of the same or different heteroatoms selectedfrom the group consisting of O, N and S; and optionally containing 1 or2 carbonyls wherein the carbon atom of said carbonyl is a member of saidfused heterocycle; and further provided that if Q is Q″, then R³ isR^(3a); and if Q is Q′, then R³ is R^(3b).
 2. A compound according toclaim 1, or a pharmaceutically acceptable salt thereof, wherein Q is Q′and R³ is R^(3b).
 3. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein Q is Q″.
 4. A compoundaccording to claim 3, or a pharmaceutically acceptable salt thereof,wherein Q″ is NH(S^(y))_(s)R³.
 5. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ isNHC(O)(S^(y))_(s)R³.
 6. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ isNHC(O)O(S^(y))_(s)R³.
 7. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ isNHC(O)NH(S^(y))_(s)R³.
 8. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ is O(S^(y))_(s)R³.9. A compound according to claim 3, or a pharmaceutically acceptablesalt thereof, wherein Q″ is (S^(y))_(s)NHR³.
 10. A compound according toclaim 3, or a pharmaceutically acceptable salt thereof, wherein Q″ is(S^(y))_(s)NHC(O)R³.
 11. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ is(S^(y))_(s)NHC(O)OR³.
 12. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ is(S^(y))_(s)NHC(O)NHR³.
 13. A compound according to claim 3, or apharmaceutically acceptable salt thereof, wherein Q″ is (S^(y))_(s)OR³.14. A compound according to claim 1, or a pharmaceutically acceptablesalt thereof, wherein V is OR⁴.
 15. A compound according to claim 1, ora pharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²). 16.A compound according to claim 1, or a pharmaceutically acceptable saltthereof, wherein R⁴ is H, C₁₋₆alkyl or (C₁₋₄alkylene)₀₋₁R^(4′) andR^(4′) is C₃₋₇cycloalkyl.
 17. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²) and R¹and R² are each independently L¹, wherein L¹ is selected from the groupconsisting of H, C₁₋₆alkyl, —C₁₋₆alkylene-amino(C₁₋₃alkyl)₂,C₃₋₇cycloalkyl, phenyl, azetidinyl, adamantyl, tetrahydrofuranyl,furanyl, dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl,pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl, pyridyl,pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, piperidinyl,piperazinyl, morpholino, thiomorpholino and dioxolanyl; or R¹ and R²together with the nitrogen to which they are attached form X, wherein Xis azetidinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl,pyrazolinyl, pyrazolidinyl, azepinyl, diazepinyl, piperazinyl,piperidinyl, morpholino or thiomorpholino; wherein X is substituted withY, wherein Y is dioxolanyl, C₁₋₄alkyl, C₁₋₄alkoxy, C₃₋₇ cycloalkyl,phenyl, azetidinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrrolidinonyl,imidazolyl, imidazolinyl, imidazolidinyl, imidazolidinonyl, pyrazolyl,pyrazolinyl, pyrazolidinyl, azepinyl, diazepinyl, pyridyl, pyrimidinyl,dihydrobenzimidazolonyl, piperazinyl, piperidinyl, morpholino,benzothiazolyl, benzisothiazolyl or thiomorpholino; and wherein X and Yoptionally share one carbon atom and together form a spirocyclic moiety.18. A compound according to claim 1, or a pharmaceutically acceptablesalt thereof, wherein V is —N(R¹)(R²) and R¹ and R² are eachindependently L¹, wherein L¹ is selected from the group consisting of H,C₁₋₆alkyl, or R¹ and R² together with the nitrogen to which they areattached form X, wherein X is piperidinyl or morpholino; wherein X issubstituted with Y, wherein Y is dioxolanyl, C₁₋₄alkyl or piperidinyl;and wherein X and Y optionally share one carbon atom and together form aspirocyclic moiety.
 19. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²) andwherein R¹ and R² are each independently L¹, wherein L¹ is selected fromthe group consisting of H, C₁₋₆alkyl.
 20. A compound according to claim1, or a pharmaceutically acceptable salt thereof, wherein V is—N(R¹)(R²) and wherein R¹ and R² together with the nitrogen to whichthey are attached form X, wherein X is piperidinyl or morpholino;wherein X is substituted with Y, wherein Y is dioxolanyl, C₁₋₄alkyl orpiperidinyl; and wherein X and Y optionally share one carbon atom andtogether form a spirocyclic moiety.
 21. A compound according to claim 1,or a pharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²)and wherein R¹ and R² together with the nitrogen to which they areattached form X, wherein X is piperidinyl; wherein X is substituted withY, wherein Y is piperidinyl.
 22. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²) andwherein R¹ and R² together with the nitrogen to which they are attachedform X, wherein X is morpholino; wherein X is substituted with Y,wherein Y is C₁₋₄ alkyl.
 23. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²) andwherein R¹ and R² together with the nitrogen to which they are attachedform X, wherein X is piperidinyl; wherein X is substituted with Y,wherein Y is C₁₋₄ alkyl.
 24. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein V is —N(R¹)(R²) andwherein R¹ and R² together with the nitrogen to which they are attachedform X, wherein X is piperidinyl; wherein X is substituted with Y,wherein Y is dioxolanyl; and wherein X and Y share one carbon atom andtogether form a spirocyclic moiety.
 25. A compound according to claim 1,or a pharmaceutically acceptable salt thereof, wherein R³ is R^(3a) andR^(3a) is substituted or unsubstituted phenyl, hydroxyphenyl,azetidinyl, napthyl, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆alkynl,dihydroquinolinonyl, hydroquinolinonyl, quinolinyl,dihydroisoquinolinonyl, hydroisoquinolinonyl, isoquinolinyl,dihydroquinazolinonyl, hydroquinazolinonyl, quinazolinyl,dihydroquinoxalinonyl, hydroquinoxalinonyl, quinoxalinyl,benzimidazolyl, indazolyl, dihydrobenzimidazolonyl,hydrobenzimidazolonyl, benzimidazolinyl, dihydro-benzthiazolonyl,hydrobenzthiazolonyl, benzthiazolyl, dihydrobenzoxazolyl,benzotriazolyl, dihydrobenzothiophenonyl, hydrobenzothiophenonyl,benzothienyl, dihydrobenzofuranonyl, hydrobenzofuranonyl, benzofuranyl,benzdioxolanyl, dihydroindolonyl, hydroindolonyl, indolyl, indolizinyl,isoindolyl, indolinyl, indazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,furanyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl,imidazolinyl, imidazolidinyl, pyridyl, purinyl, carbazolyl, pyrimidinyl,piperidinyl, triazolopyrimidinyl, tetrahydropyrazolopyridinyl,piperazinyl or morpholino.
 26. A compound according to claim 1, or apharmaceutically acceptable salt thereof, wherein R³ is R^(3b) andR^(3b) is substituted or unsubstituted dihydrobenzimidazolonyl,hydrobenzimidazolonyl, benzimidazolinyl, dihydro-benzthiazolonyl,hydrobenzthiazolonyl, benzthiazolyl, dihydrobenzothiophenonyl,hydrobenzothiophenonyl, dihydrobenzofuranonyl, hydrobenzofuranonyl,1H-indazol-5-yl, benzdioxolanyl, dihydrobenzoxazolyl, benzotriazolyl,dihydroindolonyl, hydroindolonyl, indolizinyl, isoindolyl, indolinyl,pyrazolyl, pyrazolinyl, pyrazolidinyl, furanyl, pyrrolyl, pyrrolinyl,pyrrolidinyl, imidazolinyl, imidazolidinyl, purinyl, carbazolyl,pyrimidinyl, piperidinyl, piperazinyl or morpholino.
 27. A compoundaccording to claim 1, or a pharmaceutically acceptable salt thereof,wherein D is O and m and n are each
 1. 28. A compound according to claim1, or a pharmaceutically acceptable salt thereof, wherein p is 1; and G,J and E together form A^(x).
 29. A compound according to claim 1 whereinR³ is R^(3b) and R^(3b) is 1H-Indol-5-yl

1H-Indazol-5-yl

1H-Benzotriazol-5-yl

1,3-Dihydro-indol-2-on-5-yl

3H-Benzooxazol-2-on-6-yl

1,3-Dihydro-benzoimidazol-2-on-5-yl

1-Methyl-1,3-dihydro-benzoimidazol-2-on-6-yl

3,4-Dihydro-1H-quinolin-2-on-6-yl

1,4-Dihydro-benzo [d][1,3]oxazin-2-on-6-yl

3,4-Dihydro-1H-quinazolin-2-on-6-yl

3-Methyl-3,4-dihydro-1H-quinazolin-2-on-6-yl

4H-Benzo[1,4]oxazin-3-on-7-yl

wherein T^(y) is H, C₁₋₄alkyl, F, Cl, Br or nitrile.
 30. A compoundaccording to claim 1, or a pharmaceutically acceptable salt thereof,wherein V is —N(R¹)(R²); R¹ and R² together with the nitrogen to whichthey are attached form X, wherein X is piperazinyl; wherein X issubstituted with Y, wherein Y is piperidinyl; Q is Q′; wherein Q′ is(S^(y))_(s)R³; wherein S^(y) is C₁₋alkylene and s is 1; U is NH; R³ isR^(3b) wherein R^(3b) is 3H-Benzooxazol-2-on-6-yl

wherein T^(y) is H; D is O; A is C; m and n are each 1; E is N; p is 1;G, J and E together form A^(x); A^(x) is a fused heterocycle having twofused rings with 6 members in each of said rings, said heterocyclecontaining two nitrogen atoms; and containing 1 carbonyl wherein thecarbon atom of said carbonyl is a member of said fused heterocycle. 31.A compound according to claim 1, or a pharmaceutically acceptable saltthereof wherein V is —N(R¹)(R²); R¹ and R² together with the nitrogen towhich they are attached form X, wherein X is piperazinyl; wherein X issubstituted with Y, wherein Y is piperidinyl; Q is Q′; wherein Q′is(S^(y))_(s)R³; wherein S^(y) is C₁₋alkylene and s is 1; U is NH; R³ isR^(3b) wherein R^(3b) is 1H-Benzotriazol-5-yl

wherein T^(y) is H; D is O; A is C; m and n are each 1; E is N; p is 0;G, J and E together form A^(x); A^(x) is a fused heterocycle having twofused rings with 6 members in each of said rings, said heterocyclecontaining two nitrogen atoms; and containing 1 carbonyl wherein thecarbon atom of said carbonyl is a member of said fused heterocycle. 32.A compound according to claim 1, or a pharmaceutically acceptable saltthereof wherein V is —N(R¹)(R²); R¹ and R² together with the nitrogen towhich they are attached form X, wherein X is piperazinyl; wherein X issubstituted with Y, wherein Y is piperidinyl; and wherein X and Y are optionally and independently substituted with 1 or 2 of the same ordifferent substituents selected from the group consisting of C₁₋₄alkyl;Q is Q′; wherein Q′ is (S^(y))_(s)R³; wherein S^(y) is C₁₋alkylene and sis 1; U is NH; R³ is R^(3b) wherein R^(3b) is 1H-Indazol-5-yl

wherein T^(y) is C₁₋₄alkyl; D is O; A is C; m and n are each 1; E is C;p is 0; G, J and E together form A¹; A^(x) is a fused heterocycle havingtwo fused rings with 6 members in each of said rings, said heterocyclecontaining one nitrogen atom; and containing 1 carbonyl wherein thecarbon atom of said carbonyl is a member of said fused heterocycle. 33.A compound or a pharmaceutically acceptable salt thereof selected fromthe group consisting of(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid{2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-2-oxo-1-[1-(2-trimethylsilanyl-ethanesulfonyl)-1H-indol-5-ylmethyl]-ethyl}-amide;(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide;(±)-4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid[2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide;(±)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid[2-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(1H-indazol-5-ylmethyl)-2-oxo-ethyl]-amide;3-(7-Methyl-1H-indazol-5-yl)-2-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinazoline)carbonylamino]-propionic acid methyl ester;3-(7-Methyl-1H-indazol-5-yl)-2-(1,2-dihydro-2-oxospiro-4H-3,1-dihydro-benzoxazine-4′4-piperidine-carbonylamino)-propionicacid methyl ester; 3-(7-Methyl-1H-indazol-5-yl)-2{3′,4′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinolinecarbonylamino}-propionic acid methyl ester;3-(7-Methyl-1H-indazol-5-yl)-2-[2′-phenyl-1′,3′,8′-triaza-spiro(4′,5′)deo-1-ene-8-carbonyl amino]-propionic acid methylester;3-(7-Methyl-1H-indazol-5-yl)-2-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinazolinecarbonylamino]-propionic acid;3-(7-Methyl-1H-indazol-5-yl)-2-(1,2-dihydro-2-oxospiro-4H-3,1-dihydro-benzoxazine-4′4-piperidine-carbonylamino)-propionicacid methyl ester; 3-(7-Methyl-1H-indazol-5-yl)-2{3′,4′-dihydro-2′-oxospiro-(piperidine-4,4′-(1H)-quinoline-carbonylamino}-propionic acid; 3-(7-Methyl-1H-indazol-5-yl)-2-[2′-phenyl-1′,3′,8′-triaza-spiro(4′,5′)deo-1-ene-8-carbonyl amino]-propionic acid;(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-2′,3′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide;(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-(1-piperidinyl)-2-oxoethyl]-2′,3-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinazoline]-1-carboxamide;(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide;(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-(1-piperidinyl)-2-oxoethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide;(±)-[1-Dimethylcarbamoyl-2-(7-methyl-1H-indazol-5-yl)-ethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide;(±)-[1-(2-adamantyl-carbamoyl)-2-(7-methyl-1H-indazol-5-yl)-ethyl]-1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine]-1-carboxamide;(±)-1′,2′-Dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine-1-carboxylicacid[1-(7-methyl-1H-indazol-5-ylmethyl)-2-oxo-2-(4-pyridin-4-yl-piperazin-1-yl)-ethyl]-amide;(±)-1′,2′-Dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidine-1-carboxylicacid{2-(7-methyl-1H-indazol-5-yl)-1-[(pyridin-4-ylmethyl)-carbamoyl]-ethyl}-amide;(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]3′,4′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinoline]-1-carboxamide;(±)-1-(7-Methyl-1H-indazol-5-ylmethyl)-2-[1-piperidinyl]-2-oxoethyl]3′,4′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinoline]-1-carboxamide;(±)-[1-Dimethylcarbmoyl-2-(7-methyl-1H-indazol-5-yl)-ethy]1-3′,4′-dihydro-2′-oxospiro-[piperidine-4,4′-(1H)-quinoline]-1-carboxamide;(R)-1-Oxo-3,4-benzo-2,9-diaza-spiro[5.5]undec-3-ene-9-carboxylic acid(1-benzo[b]thiophen-3-ylmethyl-2-[1,4′]bipiperidinyl-1′-yl-2-oxo-ethyl)-amide;N-[(1R)-1-(Benzo[b]thien-3-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-3′,4′-dihydro-2-oxospiro-[piperidine-4,4′(1H)-quinoline]-1-carboxamide;N-[(1R)-1-(Benzo[b]thien-3-ylmethyl)-2-[1,4-bipiperidin]-1-yl-2-oxoethyl]-2′,3′-dihydro-1-oxospiro-[piperidine-4,4′(1H)-isoquinoline]-1-carboxamide;N-[(1R)-1-(Benzo[b]thien-3-ylmethyl)-2-[1,4′-bipiperidin]-1′-yl-2-oxoethyl]-1,2-dihydro-2-oxospiro-[4H-3,1-benzoxazine-4,4′-piperidine]-1′-carboxamide;1-[1,4′]Bipiperidinyl-1′-yl-2-(3(S)-Benzo[b]thiophen-3-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione;(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid methyl ester;(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyricacid;(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione;(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione;(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione;(±)-N,N-Dimethyl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyramide;(±)-2-(7-Methyl-1H-indazol-5-ylmethyl)-1-(piperidin-1-yl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione;(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione;(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(1H-indazol-5-ylmethyl)-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butane-1,4-dione;(±)-1-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-(1H-indazol-5-ylmethyl)-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butane-1,4-dione;(±)—N-(3-(7-Ethyl-3-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)-1-carboxamide;(±)—N-(3-(7-Ethyl-3-methyl1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide;(±)—N-(3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-8′-fluoro-2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)-1-carboxamide;N—((R)-3-(2,3-dihydro-2-oxo-1H-benzo [d]imidazol-6-yl)-1-oxo-1(4-piperidin-1-yl)piperidine-1-yl)propan-2-yl)-4-(2′,3′-dihydro-2′-oxospiro(piperidine-4,4′-(1H)-quinazoline)carboxamide;(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide;(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(cyclohex-1-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide;(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(prop-2-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-benzo[d][1,3]oxazine)-1-carboxamide;(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carboxamide;(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(cyclohex-1-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carboxamide;(R)—N—((R)-3-(2-Oxo-2,3-dihydro-benzooxazol-6-yl)-1-oxo-1-(4-(prop-2-yl)piperazin-1-yl)propan-2-yl)-2,4-dihydro-2′-oxospiro-(piperidine-4,4′-1H-quinazoline)-1-carboxamide;(±)—N-(1-Benzyl-2-hydroxy-ethyl)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1′,2′-dihydro-2′-oxospiro-[4H-3′,1-benzoxazine-4,4′-piperidinyl]-butyramide;(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(7-methyl-1H-indazol-5-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline]-butane-1,4-dione;(±)-4-Oxo-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butyricacid methyl ester;(±)-4-Oxo-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butyricacid; and(±)-1-[1,4′]Bipiperidinyl-1′-yl-2-(2-oxo-2,3-dihydro-benzooxazol-6-ylmethyl)-4-[2′,3′-dihydro-2′-oxospiro-(piperidine-4,4′-quinazoline)]-butane-1,4-dione.34. A pharmaceutical composition comprising a compound according toclaim 1 or a pharmaceutically acceptable salt thereo.
 35. A method oftreating headache, circulatory shock, pain, flushing associated withmenopause or airway inflammatory diseases by the administration to apatient in need thereof an effective amount of a pharmaceuticalcomposition comprising a compound according to claim
 1. 36. The methodaccording to claim 35, wherein said headache is migraine and said airwayinflammatory disease is asthma.